




Innovative solutions
Sound science

September 30, 2021

Office of Food Additive Safety (HFS-200)
Center for Food Safety and Applied Nutrition
Food and Drug Administration
5001 Campus Drive
College Park, MD 20740-3835



Subject: GRAS Notification – Allulose

Dear Sir:

On behalf of Tate & Lyle., ToxStrategies, Inc. (its agent) is submitting, for FDA review, a copy of the GRAS notification as required. The enclosed document provides notice of a claim that the food ingredient, allulose, described in the enclosed notification is exempt from the premarket approval requirement of the Federal Food, Drug, and Cosmetic Act because it has been determined to be generally recognized as safe (GRAS), based on scientific procedures, for addition to food. This is a resubmission of GRN 893 that was withdrawn on May 6, 2020.

In addition, non-safety related data and information (marked as confidential; Exhibit 2) are attached to the GRAS notice that are to be shared with the Food Safety Inspection Service (FSIS) of the U.S. Department of Agriculture (USDA).

If you have any questions or require additional information, please do not hesitate to contact me at 630-352-0303, or dschmitt@toxstrategies.com.

Sincerely,



Donald F. Schmitt, M.P.H.
Senior Managing Scientist

GRAS Determination of Allulose for Use as an Ingredient in Human Food

SEPTEMBER 29, 2021

ToxStrategies

Innovative solutions
Sound science

GRAS Determination of Allulose for Use as an Ingredient in Human Food

SUBMITTED BY:

Tate & Lyle
5450 Prairie Stone Parkway
Hoffman Estates, IL 60192

SUBMITTED TO:

U.S. Food and Drug Administration
Center for Food Safety and Applied Nutrition
Office of Food Additive Safety
HFS-200
5001 Paint Branch Parkway
College Park MD 20740-3835

CONTACT FOR TECHNICAL OR OTHER INFORMATION

Donald F. Schmitt, MPH
ToxStrategies, Inc.
931 W. 75th St., Suite 137, PMB 255
Naperville, IL 60565

September 29, 2021

Table of Contents

§ 170.225 Part 1, GRAS Notice: Signed Statements and Certification	6
(1) GRAS Notice Submission	6
(2) Name and Address	6
(3) Name of Notified Substance	6
(4) Intended Use in Food	6
(5) Statutory Basis for GRAS Determination	6
(6) Premarket Approval Statement	7
(7) Availability of Information	7
(8) Data and Information Confidentiality Statement	7
(9) GRAS Certification	7
(10) Name/Position of Notifier	7
(11) FSIS Statement	7
§ 170.230 Part 2, Identity, Method of Manufacture, Specifications, and Physical or Technical Effect	8
A. Identity	8
C. CAS Registry Number	8
D. Trade Name	8
E. Empirical Formula and Chemical Structure of Allulose	8
F. Allulose Composition	8
G. Manufacturing Process	9
H. Product Specifications	12
I. Stability Data	15
§ 170.235 Part 3, Dietary Exposure	16
Current Uses	16
Proposed Uses	17
§ 170.240 Part 4, Self-Limiting Levels of Use	10
§ 170.245 Part 5, Experience Based on Common Use in Food	11
§ 170.250 Part 6, GRAS Narrative	12
History of Use and Regulatory Approval	12
Safety	12
Introduction	12
Absorption, Distribution, Metabolism, and Excretion (ADME)	12
Animal Studies	15
Acute Toxicity	15
Subchronic toxicity	15
Chronic toxicity	16
Reproductive toxicity	17
Mutagenicity/genotoxicity	17
Human Studies	18
Effect on Insulinemic and Glycemic Response	22
Safety Summary	24
Basis for the GRAS Determination	25
Introduction	25
Safety Determination	26
General Recognition of the Safety of Allulose	26

§ 170.255 Part 7, Supporting Data and Information 30
References30

Appendix A Pariza and Johnson Decision Tree
Appendix B COAs and Other Analytical Data
Appendix C Stability Testing Data
Appendix D Intake Assessment Report
Appendix E Epimerase Enzyme Data/Information
Exhibit I Report of the GRAS Panel
Exhibit 2 USDA/FSIS Data Package

List of Acronyms

ADME	absorption, distribution, metabolism, and excretion
AUC	area under the curve
bw	body weight
CDC	Centers for Disease Control and Prevention
cGMP	current Good Manufacturing Practice
CAS	Chemical Abstracts Service
CEDI	cumulative estimated daily intake
CFR	Code of Federal Regulations
CFU	colony-forming units
COA	Certificate of Analysis
dpm	disintegrations per minute
FDA	U.S. Food and Drug Administration
GRAS	Generally Recognized as Safe
GRN	Generally Recognized as Safe Notification
LD ₅₀	lethal dose
NHANES	US National Health and Nutrition Examination Survey
NOAEL	no-observed-adverse-effect level
SCFA	short-chain fatty acid
USDA	United States Department of Agriculture
WWEIA	What We Eat in America

§ 170.225 Part 1, GRAS Notice: Signed Statements and Certification

(1) GRAS Notice Submission

Tate & Lyle (T&L), through its agent, ToxStrategies, Inc., hereby notifies the U.S. Food and Drug Administration (FDA) of the submission of a Generally Recognized as Safe (GRAS) notice for the use of allulose in selected foods for human consumption, in accordance with Subpart E of 21 CFR § 170.

(2) Name and Address

Tate & Lyle
5450 Prairie Stone Parkway
Hoffman Estates, IL 60192

(3) Name of Notified Substance

The name of the substance that is the subject of this GRAS determination is the monosaccharide allulose.

(4) Intended Use in Food

The allulose ingredient is proposed for use in nine new food types including (1) nutritional beverages; (2) nutritional beverages intended for children; (3) sweetened alcoholic malt beverages; (4) alcoholic premixed cocktails; (5) grain-free, no sugar, high protein RTE cereals; (6) nutrition bars; (7) ketchup and barbecue sauces; (8) dried cranberries; and (9) meat- and poultry-based jerky, in addition to those foods included in GRNs 400, 498, 693 and 828 (i.e., select low calorie, reduced calorie, or sugar-free foods including bakery products, beverages, cereals, chewing gums, confections and frostings, frozen dairy desserts, yogurt and frozen yogurt, dressings for salads, gelatins, pudding and fillings, hard and soft candies, jams and jellies, sugar, sugar substitutes, sweet sauces and syrups, fat based creams, medical foods and coffee mix). Higher use levels are also proposed for existing categories for ready-to-eat (RTE) and cooked cereals including regular and low calorie, reduced calorie, and sugar-free RTE and cooked cereals; (see Table 9). Allulose has 70% of the sweetness of sugar but provides negligible energy, and therefore is an excellent substitute for sugar to reduce sugar and energy intake.

(5) Statutory Basis for GRAS Determination

T&L, through its agent, ToxStrategies, confirms that the allulose ingredient, which meets the specifications described herein, has been determined to be GRAS through scientific procedures in accordance with 21 CFR § 170.30(a) and (b).

(6) Premarket Approval Statement

T&L further asserts that the use of the allulose ingredient, as described herein, is exempt from the pre-market approval requirements of the Federal Food, Drug, and Cosmetic Act, based on a conclusion that the substance is GRAS under the conditions of its intended use.

(7) Availability of Information

The data and information that serve as the basis for this GRAS determination, as well any information that has become available since the GRAS determination, will be sent on request, or are available for the FDA's review and copying during customary business hours from ToxStrategies, Inc., Naperville, IL.

(8) Data and Information Confidentiality Statement

None of the data and information in the GRAS notice are exempt from disclosure under the Freedom of Information Act, 5 U.S.C. 552.

(9) GRAS Certification

To the best of our knowledge, the GRAS determination is a complete, representative, and balanced document. T&L is not aware of any information that would be inconsistent with a finding that the proposed uses and use levels of the allulose ingredient in food, meeting the appropriate specifications described herein, and used according to current Good Manufacturing Practice (cGMP), is GRAS. Recent reviews of the scientific literature revealed no potential adverse health concerns.

(10) Name/Position of Notifier


Donald F. Schmitt, M.P.H.
Senior Managing Scientist
ToxStrategies, Inc.
Agent for Tate & Lyle

Sept. 30, 2021
Date

(11) FSIS Statement

The allulose ingredient will be used as a sweetener in selected meat/poultry products at a maximum use level of 15% under the jurisdiction of USDA/SFSIS. Allulose adds a sweet flavor to meat and/or decreases saltiness.

§ 170.230 Part 2, Identity, Method of Manufacture, Specifications, and Physical or Technical Effect

A. Identity

Allulose is produced from corn glucose by enzymatic epimerization. It contains negligible residual amounts of other related monosaccharides and impurities (Table 2 and Appendix A).

B. Common or Usual Name

D-Allulose or D-psicose. The names D-allulose and D-psicose are used interchangeably in literature but refer to the same substance. The ingredient will be referred to as allulose throughout this document.

C. CAS Registry Number

CAS No. 551-68-8

D. Trade Name

The trade name of T&L's allulose product is DOLCIA PRIMA® allulose.

E. Empirical Formula and Chemical Structure of Allulose

The empirical formula for allulose is $C_6H_{12}O_6$. The chemical names are D-ribo-2-hexulose, D-ribo-2-ketohexose. The molecular weight of allulose is 180.16 g/mol. The chemical structure of allulose is represented in Figure 1.




Figure 1. Structural formula of allulose

F. Allulose Composition

DOLCIA PRIMA® allulose is obtained from starch derived from corn (*Zea mays* L.); see Table 1.

Table 1. Taxonomic classification of the raw material source of allulose

Classification	Corn
Kingdom	Plantae
Phylum	Magnoliophyta
Class	Liliopsida
Order	Poales
Family	Poaceae
Genus	<i>Zea</i>
Species	<i>Zea mays</i> L.

DOLCIA PRIMA® Allulose is composed predominantly of allulose (> 95% in syrup version, or > 99.1% in crystalline version), with the remainder being composed of only a small quantity of fructose and other di- and tri-saccharides typically found in carbohydrate syrups (Table 2).

Table 2. Composition of allulose

Components	Liquid Syrup	Crystalline
Allulose	>95%, dry basis	>99.1%, dry basis
Non-allulose saccharides	<5%, dry basis	<2%, dry basis

G. Manufacturing Process

A process flow diagram for the allulose product is shown below (Figure 2).

The starting material is typical corn (U.S. Grade #2 Dent Corn [dried grain]), and the intermediate products are monosaccharides (glucose and fructose). All enzymes used in the process are safe and suitable for food uses and consistent with enzymes identified in previous GRAS notifications (including their sources). The allulose ingredient is produced in two forms: syrup and crystalline powder. The manufacturing process is conducted under Good Manufacturing Practices (GMP) for both end products and is identical in every step but the last.

- U.S. Grade #2 Dent Corn (dried grain) is subjected to traditional wet-milling processes to produce germ, fiber, protein, and starch fractions. For the production of allulose, the starch fraction is used.
- The starch fraction (polymeric glucose; amylose and amylopectin) is converted to corn syrup (maltose and higher oligosaccharides) and ultimately to D-glucose by enzymatic hydrolysis using standard manufacturing techniques.

- D-glucose is isomerized to D-fructose using safe and suitable glucoisomerases.
- D-fructose is separated from the bulk of D-glucose by chromatography to greater than 85% (w/w) purity.
- Fructose is then epimerized to D-allulose using D-psicose 3-epimerase.
- The resulting mixture of D-allulose and D-fructose is separated by chromatography to $\geq 95\%$ D-allulose and $\leq 5\%$ non-allulose saccharides (including fructose, glucose).
- This enriched D-allulose stream concentrated and passed through activated granular carbon and an ion exchange resin.


For the syrup form, the final step consists of:

Using an evaporator, the solution is concentrated to a final density of 71%–78% solids.

For the crystalline form, the final step consists of:

The solution is concentrated, crystallized, centrifuged, washed, and dried.

Figure 2. Allulose manufacturing process



All processing aids employed in the manufacturing process are safe and suitable for use in the production of food ingredients (see Table 3).

Table 3. Processing aids

Processing aid	CAS Number	Purpose	21 CFR Citations/GRN Numbers
Alpha-amylase from <i>Aspergillus oryzae</i>	9001-19-8	Hydrolysis of starch	21 CFR 172.892; 21 CFR 184.1012; GRN Nos. 22, 24, 79, 126, 594, 664, 751
Glucoamylase from <i>Aspergillus niger</i>	977031-46-1	Hydrolysis of starch	21 CFR 172.892; GRN Nos. 372, 657

Glucosiomerase from a genetically modified strain of <i>Streptomyces rubiginosus</i> (strain DP-Pzn37)	9005-00-9	Conversion of D-glucose to D-fructose	21 CFR 184.1372
D-psicose 3-epimerase from a genetically modified strain of <i>E. coli</i> K12	1219591-85-1	Conversion of D-fructose to allulose	See footnote*
Activated carbon	64365-11-3	Purification	21 CFR 175.250; 21 CFR 172.615

* The *E. coli* production microorganism is derived from the wild-type *E. coli* K12 strain. *E. coli* K-12 has a documented history of safe use. Its derivatives are currently used in a large number of drugs, specialty chemicals, and large-scale industrial applications including in the production of amino acids for use as food ingredients. *E. coli* K12 is a nonpathogenic and nontoxigenic host organism and belongs to risk group 1 in the classification of human etiologic agents (NIH, 2002). It is one of the most extensively studied bacteria and has been used in genetic studies and biotechnology research in laboratories worldwide. A synthetic gene was designed and used to assure that no extraneous donor DNA was transferred to the production organism. (NIH 2002) Department of Health and Human Services, National Institutes of Health. Guidelines for Research involving Recombinant DNA Molecules, April 2002. In addition, the safety of the enzyme was based on the Pariza and Johnson Decision Tree (2001) that clearly showed that it is safe for the intended use (see Appendix A; Pariza, MW and Johnson, EA, 2001). Evaluating the safety of microbial enzyme preparations used in food processing: update for a new century. Regul Toxicol Pharmacol 33:173-186).

All enzymes, reagents, and processing aids used in the production of allulose are safe and suitable, food grade, and in conformity with US regulations (i.e., alpha-amylase, glucoamylase, glucoisomerases, epimerase, activated carbon). They are commonly used in food ingredient manufacturing processes and all production processes used are processes traditionally used in food manufacturing. The epimerase enzyme is purchased from CODEXIS. The enzyme never comingles with the final product but the possible presence of the enzyme in the allulose product has been evaluated (see Appendix E; analytical results for the presence of epimerase enzyme in the allulose product and the ELISA analytical method employed). The epimerase enzyme was self-determined as GRAS in 2014. The conclusion and signature page of the GRAS Panel that evaluated the safety and GRAS status (based on scientific procedures) of the epimerase enzyme is also attached in Appendix E.

H. Product Specifications

Specifications for the allulose product are presented in Table 4. A comparison of non-consecutive lots of product to the specifications below can be found in Tables 5 and 6. Results of analyses for additional microbiological parameters are presented in Table 7. All analytical methods used to analyze batches of allulose against its specifications have been validated for that purpose.

Table 4. Specifications for allulose

Parameter	Liquid Syrup	Crystalline Granules
Appearance	Colorless to slightly yellow	Off white
Allulose (% dry basis)	>95	>99.1
Total non-allulose saccharides (%)	<5	<0.9
Dry solids (%)	70-78	n/a
Moisture (%)	n/a	<0.5
pH	3.0 – 4.5	n/a
Ash (%)	n/a	<0.5
SO ₂ (ppm)	<10	<10
Total plate count (cfu/10g)	<200	<200
Yeast (cfu/10g)	≤10	≤10
Mold (cfu/10g)	≤10	≤10
Arsenic (ppm)	<0.1	<0.1
Cadmium (ppm)	<0.1	<0.1
Lead (ppm)	<0.1	<0.1
Mercury (ppm)	<0.01	<0.01

n/a = not applicable

Table 5. Analytical results for three non-consecutive lots of allulose syrup

Specification		Lot No. YP19DO3774	Lot No. YP19G01863	Lot No. YP18D03177
Allulose (% dry basis)	>95	96.2	96.3	96.3
Total non-allulose saccharides (%)	<5	2.6	2.9	2.4
Dry solids (%)	70-78	70.8	70.5	71.0
pH	3.0 – 4.5	4.2	3.9	4.3
Sulfur dioxide (ppm)	<10	<10	<10	<10
Total plate count (cfu/10g)	<200	<10	<10	<10
Yeast (cfu/10g)	≤10	<10	<10	<10
Mold (cfu/10g)	≤10	<10	<10	<10
Arsenic (ppm)	<0.1	0.016	0.011	0.024

Cadmium (ppm)	<0.1	<0.005	<0.005	<0.005
Lead (ppm)	<0.1	<0.005	<0.005	0.006
Mercury (ppm)	<0.01	<0.005	<0.005	<0.005

Table 6. Analytical results for three non-consecutive lots of crystalline allulose

Specification		Lot No. LO18J90596	Lot No. LO19F90351	Lot No. LO18J90294
Allulose (% dry basis)	>99.1	99.4	99.8	99.2
Total non-allulose saccharides (%)	<0.9	0.27	0.06	0.29
Moisture (%)	<0.5	0.14	0.12	0.10
Ash (%)	<0.5	<0.1	<0.1	<0.1
Sulfur dioxide (ppm)	<10	<10	<10	<10
Total plate count (cfu/10g)	<200	<10	10	10
Yeast (cfu/10g)	≤10	<10	10	<10
Mold (cfu/10g)	≤10	<10	10	<10
Arsenic (ppm)	<0.1	<0.005	<0.005	<0.005
Cadmium (ppm)	<0.1	<0.005	<0.005	<0.005
Lead (ppm)	<0.1	<0.005	<0.005	<0.005
Mercury (ppm)	<0.01	<0.005	<0.005	<0.005

Table 7. Other microbiological criteria for three non-consecutive lots of liquid syrup and crystalline allulose

Microbiological Criteria				
Allulose Syrup		Lot No. YP19DO3774	Lot No. YP19G01863	Lot No. YP18D03177
<i>E. coli</i> (cfu/10g)	ND	ND	ND	ND
<i>Salmonella</i> (cfu/25g)	Negative	Negative	Negative	Negative
Crystalline Allulose		Lot No. LO18J90596	Lot No. LO19F90351	Lot No. LO18J90294
<i>E. coli</i> (cfu/10g)	ND	ND	ND	ND
<i>Salmonella</i> (cfu/25g)	Negative	Negative	Negative	Negative

ND = not detected

The analytical results for the allulose ingredient summarized in the above tables and included in the Certificates of Analysis (COAs) in Appendix B confirm that the finished product meets the analytical specifications. The results also demonstrate that T&L's manufacturing process results in a consistently reproducible product and confirm the lack of significant levels of impurities and/or contaminants (e.g., heavy metals, microbiological contaminants). In addition, the corn starting material is periodically analyzed for the presence of pesticides and mycotoxins as part of Tate & Lyle's standard Quality Assurance processes.

Regarding heavy metals analyses, the method employed for the analysis of arsenic is a validated internal Tate & Lyle method designated as R method 2837 and is based upon AOAC 2011.19 and AOAC 993.14 (modified). The method employed for the analysis of cadmium is a validated internal Tate & Lyle method designated as R method 2837 and is based upon AOAC 2011.19 and AOAC 993.14 (modified). The method employed for the analysis of mercury is a validated internal Tate & Lyle method designated as R method 2832 and is based upon AOAC 2011.19 and AOAC 993.14 (modified). The method employed for analysis of *E.coli* is TN10512L, is an internal method, which references ISO21528-1:2017. The method TN10512L is validated for the intended use. The method employed for analysis of *Salmonella* is TN10547, is an internal validated method for the intended use that references ISO6579-1:2017.

I. Stability Data

The results of stability testing conducted using liquid allulose, DOLCIA PRIMA® LS brand, at temperatures of 4°C, 25°C, and 35°C demonstrate its stability through the end of the product's shelf-life in the syrup version up to 9 months. In contrast, stability studies on DOLCIA PRIMA® DS crystalline allulose show that this material is stable for up to 30 months. See Appendix C for stability testing data.

§ 170.235 Part 3, Dietary Exposure

Current Uses

Allulose is naturally present in small quantities in many common foods, such as in dried fruits (e.g., figs, raisins, fried dough, brown sugar and ketchup). Allulose amounts are usually below 1%. Table 8 describes the quantities of naturally occurring allulose in foods (Oshima et al., 2006).

Table 8. D-allulose content in foods

Item	mg/100 g food
Bakery products	
Sponge cake	11.0
Corn snack	47.0
Rice cracker	27.3
Cookie	26.7
Brown sugar drop	76.5
Fried dough cake	95.6
Chocolate chip cookies	6.4
Cereal	2.2
Dishes	
Fish broiled with soy	39.1
Simmered dishes of dried radish strips	8.1
Fermented soybeans	7.8
Seasonings and beverages	
Caramel sauce	83.0
Brown sugar	71.1
Meat sauce	15.8
Demiglaze	16.3
Maple syrup	57.9
Ketchup	39.8
Worcester sauce	130.6
Coke® (sic)	38.3
Coffee	0.5
Fruit juice	21.5
Tomato juice	2.4

Item	mg/100 g food
Fruits	
Dried fig	29.6
Dried kiwi fruit	9.4
Raisin	38.7
Canned peaches	1.5
Can of mandarin oranges	8.4
Canned cherries	2.0

Allulose is added to select foods as a sweetener, per previous GRAS notifications, and these foods include bakery products, chewing gum, hard candies, frozen dairy desserts, carbonated beverages, non-carbonated beverages, soft candies, yogurt, ready-to-eat cereals, coffee mix, jams/jellies, confections and frostings, dressings for salads, gelatins, pudding and fillings, sweet sauces/syrups, and fat-based creams. Intake assessments of allulose in US populations were conducted as part of GRAS notification nos. 400, 498, 693, and 828.

Proposed Uses

The focus of this GRAS determination is for the use of allulose as a sweetener in additional food categories including those in the publicly available GRN's in which FDA has issued "no questions" letters. Higher use levels are also proposed in two existing food categories covered in prior GRAS notifications.

Table 9 below summarizes the food categories and associated use levels. An intake assessment was conducted to estimate the mean and 90th percentile daily intakes of allulose based on its intended use in foods as shown in Appendix D.

The EDI of allulose were generated from dietary recalls collected as part of the *What We Eat in America* (WWEIA) component of the combined 2015-2018 National Health and Nutrition Examination Surveys (NHANES) data files (NCHS 2018, 2020). Exponent developed allulose EDIs on a per capita and per user basis for the U.S. population ages 2 years (y) and older and the following five subpopulations: (1) infants and young children <2 y, (2) children 2-12 y, (3) adolescents 13-18 y, (4) adult females 19 y and older, and (5) adult males 19 y and older. Estimates were generated in units of grams allulose per day (g/day) and grams allulose per kilogram body weight per day (g/kg-bw/day). The sections below summarize the data, methods, and results.

Background dietary intake of allulose was determined based on the existing food uses and use levels of allulose as described in U.S. GRAS Notices (GRNs) 400 (CJ Cheiljedang, 2011), 498 (Matsutani Chemical Industry Company, Ltd 2013), 693 (Samyang Corporation, 2017), and 828 (Samyang Corporation, 2018). These uses of allulose are summarized in Table 9 by food category and corresponding use levels. For the purpose of estimating

background allulose intake from existing food uses, the maximum use level from all GRNs for a given food type was used in the assessment.

Table 9. Maximum allulose use levels by food type of foods and beverages

	Food Category	Description of Foods Selected for Analysis	Maximum Allulose Use Level, %		
			Proposed New Uses	Existing GRAS Uses*	Combined existing GRAS and proposed uses **
1	Baked products (bread, muffin, cake and cookies, pastries), dietetic, low calorie, reduced calorie, sugar-free	Sweetened bread/rolls, muffin, and cakes and cookies – all identified as low calorie, reduced calorie, sugar-free, or NFS†.	NA	10	10
2	Beverages				
2a	Non-alcoholic beverages, low calorie, reduced calorie, sugar-free	Sweetened coffees, teas, soft drinks, energy drinks, juice drinks, fruit drinks, fruit flavored drinks, flavored/carbonated waters, and enhanced/fortified waters – all identified as low calorie, reduced calorie, or sugar-free.	NA	3.5	3.5
2b	Nutritional beverages	Nutritional beverages within the “nutritional beverages” and “protein and nutritional powders”WWEIA categories not included as part of the existing GRAS uses in medical foods	2.5	NA	2.5
2c	Nutritional beverages intended for children (i.e., PediaSure)	PediaSure	3.5	NA	3.5
2d	Alcoholic malt beverage, sweetened	Sweetened alcoholic malt beverage (food code 93106000), which includes products such as hard lemonade, hard punch, hard tea, etc.	3.5	NA	3.5
2e	Alcoholic premixed cocktails	All cocktails with added sugar	3.0	NA	3.0
3	Candy, hard and soft				
3a	Hard candy (includes pressed candy and mints), low calorie, reduced calorie, sugar-free	Hard candy – low calorie, reduced calorie, sugar-free, or NFS†.	NA	70	70
3b	Soft candy, low calorie, reduced calorie, sugar-free	Soft candy – low calorie, reduced calorie, sugar-free.	NA	25	25

	Food Category	Description of Foods Selected for Analysis	Maximum Allulose Use Level, %		
			Proposed New Uses	Existing GRAS Uses*	Combine existing GRAS and proposed uses **
4	Chewing gum	Regular and sugar-free chewing gum.	NA	50	50
5	Cereals, ready-to-eat (RTE) and cooked				
5a	RTE and cooked, regular	RTE and cooked cereals identified as containing added sugar.	12	2	12
5b	RTE and cooked, low calorie, reduced calorie, sugar-free	RTE and cooked cereals identified as low calorie, reduced sugar, or sugar-free.	12	5	12
5c	RTE cereals with <5% sugar	RTE cereals with <5% added sugar excluding cereals with no added sugar.	NA	10	10
5d	Grain-free, no sugar, high protein RTE cereal	No grain-free, no sugar, high protein RTE cereals were reported consumed, hence, zero-sugar added RTE cereals were selected as surrogates.	20	NA	20
6	Coffee mix	Sweetened non-reconstituted coffee mixes.	NA	30	30
7	Confections & Frostings	Frostings and icings and marshmallows.	NA	5	5
8	Dressings for salads	Salad dressings including mayonnaise.	NA	5	5
9	Frozen dairy (ice cream, soft serve, sorbet), low calorie, reduced calorie, sugar-free	Desserts including ice cream, soft serve, sorbet - all identified as low calorie, reduced calorie, sugar-free, or NFS†.	NA	5	5
10	Gelatins, pudding & fillings				
10a	Gelatins, pudding & fillings, low calorie, reduced calorie, sugar-free	Gelatins and puddings - all identified as low calorie, reduced calorie, sugar-free, or NFS†.	NA	10	10
10b	Fat-based cream (used in modified fat/calorie cookies, cakes, pastries, pie)	Fat-based cream filling in cookies, cakes, pastries, pies.	NA	10	10
11	Nutrition bars	Meal replacement bars, protein bars, energy bars, etc.	25	NA	25
12	Jams & Jellies	Jams, jellies, and pastes, all types.	NA	10	10

	Food Category	Description of Foods Selected for Analysis	Maximum Allulose Use Level, %		
			Proposed New Uses	Existing GRAS Uses*	Combine existing GRAS and proposed uses **
13	Sugar	Sugar added in home preparations including white sugar, brown sugar, cinnamon sugar, raw sugar, honey, molasses, and not specified.	NA	10	10
14	Sugar substitutes	Sugar substitutes.	NA	100	100
15	Sweet sauces & syrups, low calorie, reduced calorie, sugar-free	Sweet sauces & syrups - all identified as low calorie, reduced calorie, sugar-free, dietetic or NFS†.	NA	10	10
16	Ketchup and barbecue sauces	Ketchup and barbecue sauces.	10	NA	10
17	Yogurt and frozen yogurt, low calorie, reduced calorie, sugar-free	Yogurt and frozen yogurt - all identified as low calorie, reduced calorie, sugar-free, or NFS†.	NA	5	5
18	Medical foods	Nutritional drinks such as Boost, Ensure, and Glucerna to provide a surrogate for medical foods.	NA	15	15
19	Cranberries, dried	Dried cranberries (i.e., Craisins).	25	NA	25
20	Jerky (meat or poultry based)	Jerky (meat or poultry based).	15	NA	15

* Based on current food uses and use levels of allulose as described in U.S. GRNs 400 (CJ Cheiljedang, 2011), 498 (Matsutani Chemical Industry Company, Ltd2013), 693 (Samyang Corporation, 2017), and 828 (Samyang Corporation, 2018).

† NFS refers to food codes described as “not-further-specified;” providing a generic description to the food reported consumed (i.e., dietetic topping).NA: Not applicable.

** Maximum use levels applied in estimating cumulative intake from proposed and existing GRAS uses

Food Consumption Data

Estimated food intakes of allulose were based on food consumption records collected in the WWEIA component of NHANES conducted in 2015-2016 and 2017-2018 (NHANES 2015-2018). This continuous survey uses a complex multistage probability sample designed to be representative of the civilian U.S. population (NCHS 2018, 2020). The NHANES datasets provide nationally representative nutrition and health data and prevalence estimates for nutrition and health status measures in the USA. Statistical weights are provided by the National Center for Health Statistics (NCHS) to adjust for the differential probabilities of selection.

As part of the examination, trained dietary interviewers collected detailed information on all foods and beverages consumed by respondents in the previous 24-hour time period (midnight to midnight). A second dietary recall was administered by telephone three to ten days after the first dietary interview, but not on the same day of the week as the first interview. The dietary component of the survey is conducted as a partnership between the U.S. Department of Agriculture (USDA) and the U.S. Department of Health and Human Services (DHHS). DHHS is responsible for the sample design and data collection, and USDA is responsible for the survey's dietary data collection methodology, maintenance of the databases used to code and process the data, and data review and processing. A total of 13,666 individuals in the survey period 2015- 2018 provided 2 complete days of dietary recalls.

Selection of Representative Food Codes

Food codes corresponding to each of the food categories to which allulose can currently be added to or is proposed to be added were identified in the WWEIA, NHANES 2015-2018. Foods in which only a component is of interest for the addition of allulose (e.g., dressing as part of a salad, jelly in a sandwich, icing on a cake) were also identified. Food descriptions and the "additional description" details provided for some food codes were reviewed as part of the process to select representative foods and food mixtures to include in the analysis.

For relevant food mixtures, the proportion of the food code (as a percentage of total weight) corresponding to the component of interest was identified and only this portion of the food weight was used to determine the amount of allulose that may be added. Exponent used USDA's Food and Nutrient Database for Dietary Studies (FNDDS)2017-2018 (USDA, 2018) to translate the food as consumed into its corresponding ingredients based on percent weight. Additional details on the identification of the portion of food mixtures assumed to contain allulose are presented in sections below. The list of the food codes included in the analysis is provided in Appendix D.

Confection & Frosting and Gelatins, Pudding & Fillings

The average proportion of frosting/icing in baked goods was assumed to be 30% for cakes/cupcakes, 25% for brownies, 30% for cookies, and 20% for pastries. Likewise, the

average filling proportion was assumed to be 30% for cookies and 15% for pastries. These proportions were based on frosting/icing or filling contribution between baked goods with and without icing/frosting or filling using portion weight information from the FNDDS.

Sugar and Sugar Substitutes

Food codes for sugar and sugar substitutes were identified and assigned the maximum use levels of allulose as specified in Table 1. The WWEIA food codes also include food mixtures that may contain a sweetener added during home preparation. To capture these potential existing uses of allulose as a sugar substitute assumed to occur at the consumer level, food descriptions containing “homemade”, “home recipe”, “prepared with”, “made with”, “made from”, “with sugar”, “sugar added”, “sweetened”, or “presweetened” were identified and reviewed. When the food was assumed to represent a home preparation, the sugar or sugar substitute portion of the mixture was identified and included in the analysis. The Food Patterns Equivalent Database (FPED) was used to identify the concentration of added sugars in these mixtures (USDA, 2020). For example, sugar portions of the food codes for “Cornbread, made from home recipe” and “Apple, dried, cooked, with sugar” were assumed to contain allulose in the analysis.

For beverage food codes identified as presumably sweetened by the consumer, Exponent used USDA’s FPED database to determine the proportion of sugar in the beverage mixtures. This proportion was included in the analysis for the sugar and sugar substitute existing uses.

Analysis

For each WWEIA NHANES respondent on each day of dietary recall, intake of allulose was calculated as the amount of the select food or food ingredient (g) corresponding to either background existing GRAS uses or proposed uses and multiplied by the maximum allulose use level of that food as shown in Table 9. Contributions from all foods consumed during the two days of recall were summed and the resulting value was divided by two to result in an estimate of 2-day average allulose intake for each respondent. Intakes of allulose derived on a body weight (bw) basis were calculated using each participant’s measured body weight.

Summaries of the estimated allulose intake by the population ages 2 y and older and subpopulations of infants and children <2 y, children 2-12 y, adolescents 13-18 y, adult females 19 y and older, and adult males 19 y and older were derived from the allulose intakes calculated for each respondent. Estimates of intake for the population groups were calculated on a *per user* basis and a *per capita* basis, in units of gram allulose per day (g/day) and gram allulose per kilogram body weight per day (g/kg-bw/day). In this analysis, a “user” is anyone who reported consuming a food with allulose added on either of the survey days. The resulting values represent estimates of allulose intake assuming the maximum use level of allulose.

The 2-day average intakes by each individual were estimated using Exponent's Foods Analysis and Residue Evaluation Program (FARE® version 14.06) software, which uses the statistically weighted values from the survey in its analyses. The statistical weights compensate for variable probabilities of selection, adjust for non-response, and provide intake estimates that are representative of the U.S. population.

Cumulative EDI (CEDI)

To estimate the CEDI for allulose, food uses of allulose from background food uses and proposed uses together were considered. Specifically, intake of allulose was calculated as the amount of the select food or food ingredient (in grams) from either background existing GRAS and/or proposed uses and multiplied by the maximum allulose level associated with the combined GRAS and proposed uses of that food as shown in Table 9.

Results

The two-day average intake estimates of allulose at the mean and 90th percentile of intake was derived using dietary records from NHANES 2015-2018 for the U.S. population 2+ years of age and subpopulations of infants and young children, children, adolescents, adult females, and adult males. The EDI of allulose from background and proposed uses are summarized in Tables 10 and 11, respectively. The allulose CEDI from the combined background and proposed uses are summarized in Table 12.

Background EDI

Among the U.S. population 2+ y, 92% consumed one or more foods containing allulose from background uses (i.e., GRAS uses from GRNs 400, 498, 693, and 828; Table 10). The estimated daily intake of allulose from background uses at the per user mean and 90th percentile of intake among this population is 6.69 g/day (0.09 g/kg-bw/day) and 16.39 g/day (0.23 g/kg-bw/day), respectively. Per user mean intake of allulose from background uses ranged from 1.50 g/day among infants <2 y to 8.68 g/day among males 19+ y. On a per body weight basis, the highest per user mean intake was among infants <2 y at 0.14 g/kg-bw/day allulose. The per user 90th percentile intake estimates of allulose ranged from 3.63 g/day among infants <2 y to 22.71 g/day among males 19+ y. The highest per user 90th percentile of intake on a body weight basis was among infants <2 y at 0.34 g/kg-bw/day allulose.

The total per user mean and 90th percentile intake estimates of allulose based on NHANES data and reported for the U.S. population by GRNs 400, 498, 693 and 828 ranged from 9-12.55 g/day and 24.8-30 g/day, respectively. The per user mean and 90th percentile intake estimates in the present analysis are approximately 26% and 34% lower, respectively, than those estimates in the GRNs. In order to understand the downward shift of allulose intake observed in the more recent NHANES data, Exponent generated and compared two sets of allulose intake estimates using NHANES 2015- 2018 and NHANES 2007-2010 for the food uses reported in GRN 498 (see Appendix C of Exponent Intake Assessment Report; Appendix D of this GRN). Lower allulose intake

estimates in the present analysis appear to be due to a shift in dietary patterns of non-alcoholic low calorie, reduced calorie, sugar-free beverages. Specifically, the percent users and intake of non-alcoholic beverages (low calorie, reduced calorie, sugar-free) have decreased from 32% in NHANES 2007-2010 to 21% in NHANES 2015-2018 with a decreased intake among consumers of non-alcoholic beverages in NHANES 2015-2018. A trend analysis conducted by Bleich et al.(2018) similarly reported an observed decline in beverage and sugar-sweetened beverage consumption for children and adults from 2003 to 2014. There was also a reduction in intake of regular cereal contributing to lower allulose intakes, i.e., a decrease in percent users (46% in NHANES 2007-2010 versus 33% in NHANES 2015-2018) and lower intake amounts in NHANES 2015-2018. This reduction, however, did not result from changes in dietary patterns but instead was due to differences in the food selection methodology between GRN 498 and the current assessment. The food selection of regular cereals in the present analysis was limited to cereals with added sugar since allulose would not be added to cereals with no added sugar, whereas all cereals excluding low calorie, reduced calorie, and sugar-free cereals were included in the assessment for GRN 498 under regular cereals. The estimated allulose intake from existing background uses in this analysis relies on the most currently available dietary data from NHANES (2015-2018) and shows a lower allulose intake as compared to previously reported allulose EDIs from GRNs 400, 498, 693, and 828.

Table 10. Two-day average EDI of allulose from background uses by the U.S. population 2+ years and subpopulations

	N*	% User	Per Capita		Per User	
			Mean	90 th Percentile	Mean	90 th Percentile
Background Allulose EDIs (g/day)						
U.S. 2+ y	11650	92	6.18	15.15	6.69	16.39
Infants <2 y	391	48	0.72	1.94	1.50	3.63
Children 2-12 y	2566	95	2.89	6.71	3.04	6.98
Adolescents 13-18 y	1257	88	3.27	7.62	3.70	8.33
Males 19+ y	3696	92	7.97	20.70	8.68	22.71
Females 19+ y	4131	93	6.30	16.44	6.79	17.45
Background Allulose EDIs (g/kg-bw/day)						
U.S. 2+ y	11650	92	0.09	0.22	0.09	0.23
Infants <2 y	391	48	0.07	0.16	0.14	0.34
Children 2-12 y	2566	95	0.11	0.27	0.12	0.28
Adolescents 13-18 y	1257	88	0.05	0.12	0.06	0.14
Males 19+ y	3696	92	0.09	0.23	0.10	0.25
Females 19+ y	4131	93	0.08	0.21	0.09	0.22

*Unweighted number of users; % user, *per capita*, and *per user* estimates were based on NHANES 2015-2018 and derived using the statistical weights provided by the NCHS.

Proposed Uses EDI

Among the U.S. population 2+ y, 64% consumed one or more foods containing allulose from proposed uses (Table 11). The estimated daily intake of allulose from proposed

uses at the per user mean and 90th percentile of intake among this population is 5.92 g/day (0.10 g/kg-bw/day) and 13.47 g/day (0.22 g/kg-bw/day), respectively. Per user mean intake of allulose from proposed uses ranged from 3.61 g/day among infants <2 y to 6.94 g/day among males 19+ y. On a per body weight basis, the highest per user mean intake was among infants <2 y at 0.32 g/kg-bw/day allulose. The per user 90th percentile intake estimates of allulose ranged from 7.74 g/day among infants <2 y to 16.34 g/day among males 19+ y. The highest per user 90th percentile of intake on a body weight basis was among infants <2 y at 0.66 g/kg-bw/day allulose.

Table 11. Two-day average EDI of allulose from all intended uses by the U.S. population 2+ years and subpopulations

	N*	% User	Per Capita		Per User		
			Mean	90 th Percentile	Mean	90 th Percentile	
Allulose EDIs from Proposed Uses (g/day)							
U.S. 2+ y	7831	64	3.78	10.35	5.92	13.47	
Infants <2 y	252	31	1.13	2.64	3.61	7.74	
Children 2-12 y	2078	75	3.16	7.88	4.20	8.58	
Adolescents 13-18 y	942	67	3.40	9.58	5.09	11.00	
Males 19+ y	2316	63	4.37	12.39	6.94	16.34	
Females 19+ y	2495	60	3.54	10.33	5.89	13.91	
Allulose EDIs from Proposed Uses (g/kg-bw/day)							
U.S. 2+ y	7831	64	0.06	0.17	0.10	0.22	
Infants <2 y	252	31	0.10	0.23	0.32	0.66	
Children 2-12 y	2078	75	0.13	0.30	0.17	0.34	
Adolescents 13-18 y	942	67	0.05	0.15	0.08	0.17	
Males 19+ y	2316	63	0.05	0.14	0.08	0.19	
Females 19+ y	2495	60	0.05	0.15	0.08	0.19	

* Unweighted number of users; % user, *per capita*, and *per user* estimates were based on NHANES 2015-2018 and derived using the statistical weights provided by the NCHS.

Cumulative EDI (CEDI)

In the U.S. population 2+ y, 95% consumed one or more foods containing allulose from background and/or proposed uses. The allulose CEDI at the per user mean and 90th percentile of intake among this population is 10.09 g/day (0.15 g/kg-bw/day) and 23.53 g/day (0.35 g/kg-bw/day), respectively (Table 4). Per user mean allulose CEDI ranged from 3.33 g/day among infants <2 y to 12.61 g/day among males 19+ y. On a per body weight basis, the highest per user mean intake was among infants <2 y at 0.30 g/kg-bw/day allulose. The per user 90th percentile intake estimates of allulose ranged from 7.18 g/day among infants <2 y to 29.86 g/day among males 19+ y. The highest per user 90th percentile of intake on a body weight basis was among infants <2 y at 0.65 g/kg-bw/day allulose.

Table 12. Two-day average CEDI of allulose from background uses and all proposed uses combined by the U.S. population 2+ y and subpopulations

	N *	% User	Per Capita		Per User	
			Mean	90 th Percentile	Mean	90 th Percentile
Allulose CEDIs (g/day)						
U.S. 2+ y	12017	95	9.60	22.65	10.09	23.53
Infants <2 y	409	50	1.66	4.75	3.33	7.18
Children 2-12 y	2632	97	5.63	12.04	5.83	12.36
Adolescents 13-18 y	1320	92	6.28	13.39	6.79	13.55
Males 19+ y	3828	95	12.00	28.84	12.61	29.86
Females 19+ y	4237	95	9.48	23.27	9.99	24.05
Allulose CEDIs (g/kg-bw/day)						
U.S. 2+ y	12017	95	0.14	0.34	0.15	0.35
Infants <2 y	409	50	0.15	0.40	0.30	0.65
Children 2-12 y	2632	97	0.22	0.48	0.23	0.49
Adolescents 13-18 y	1320	92	0.10	0.22	0.11	0.22
Males 19+ y	3828	95	0.13	0.32	0.14	0.33
Females 19+ y	4237	95	0.13	0.30	0.14	0.32

* Unweighted number of users; % user, *per capita*, and *per user* estimates were based on NHANES 2015-2018 and derived using the statistical weights provided by the NCHS.

§ 170.240 Part 4, Self-Limiting Levels of Use

The use of allulose in foods is considered to be self-limiting, for technological reasons such as product flavor profile, which could affect consumer acceptability.

§ 170.245 Part 5, Experience Based on Common Use in Food

The statutory basis for our conclusion of the GRAS status of allulose for the proposed food uses in the notice is based on scientific procedures and not common use in food.

§ 170.250 Part 6, GRAS Narrative

History of Use and Regulatory Approval

Allulose is considered GRAS for use in selected foods for human consumption (FDA, 2012, 2014, 2017, 2020; Table 13). Extensive published information and data have been submitted to and reviewed by FDA as part of the various GRNs for allulose ingredients.

Table 13. Regulatory approvals for use of allulose in human food

Year Approved	Country	Submission
2012	USA	GRN 400; D-psicose
2014	USA	GRN 498; D-psicose
2017	USA	GRN 693; D-psicose
2020	USA	GRN 828; D-psicose
2015	Mexico	Allulose as a non-nutritive sweetener
2015	Chile	Allulose as an ingredient
2017	Colombia	Allulose as an ingredient
2017	Costa Rica	Allulose as a food ingredient
2017	South Korea	Allulose as a “processed saccharide product”
2017	Singapore	Allulose as a food ingredient

Safety

Introduction

Allulose has been added to food as an alternative sweetener and has a history of safe use. Multiple GRAS “no questions” letters have been issued (GRNs 400, 498, 693, and 828) with respect to the conclusion regarding the safety of the intended uses and use levels of allulose in foods in which it serves as a sugar replacer/sweetener at levels up to 100% (FDA, 2012, 2014, 2017, 2020). Clinical and preclinical studies with allulose have been conducted to examine its general toxicity and gastrointestinal tolerance and are summarized in the following sections, many similar references and discussion can also be found in the GRNs noted above (Tables 14 and 15).

Absorption, Distribution, Metabolism, and Excretion (ADME)

GRN Nos. 400, 498, 693, and 828 have previously reviewed and summarized the ADME properties of allulose. Human studies have reported that allulose is rapidly absorbed in

the small intestine and is mostly excreted in urine within 48 hours, although it is not significantly metabolized (Iida et al., 2010). Additionally, several rodent studies indicate that allulose is absorbed after oral administration and eliminated after both oral and intravenous administration (Matsuo et al., 2003; Tsukamoto et al., 2014; Whistler et al., 1974).

Animal studies

Whistler et al. (1974) conducted a study with intravenous administration of 15 mg of ¹⁴C-labeled allulose to rats (150–200 g bodyweight), collecting urine samples and carbon dioxide exhaled for six hours following the intervention for analysis. It was demonstrated that only 0.6% of the monosaccharide was excreted through respiration; the vast majority (97%–98%) was eliminated through the urine (35.4%), which suggests that the allulose is metabolized in small quantities and eliminated very quickly through the kidneys. In the same study, following oral administration of the monosaccharide, about 70% was excreted in the urine in the first 7 hours, demonstrating that allulose passed through the wall of the small intestine and as in the intravenous administration, entered the bloodstream and was eliminated primarily by the kidneys (Whistler et al., 1974).

Following oral administration to Wistar rats, Matsuo et al. (2003) investigated the absorption, excretion, and fermentation of allulose. In the absorption test, 18 animals (6 weeks old; average weight 140 ± 4 g) were given a single dose of 5 g/kg bw of allulose, then divided into three groups for the collection of blood samples and quick removal of the organs at 1, 3, and 7 hours after ingestion (Matsuo et al., 2003). A progressive reduction in the serum concentration of allulose was observed, with a more pronounced drop after the first hour, as well as in the level contained in the small intestine, with quantities of the monosaccharide being detected at 6%–10% after 1 hour, 2%–3% after 3 hours, and 1%–3% after 7 hours. In the stomach, levels of 26%–37% were found after 1 hour, 0.4%–0.6% after 3 hours, and nothing after 7 hours post-intervention. By comparison, in the cecum, despite not having been detected after the first hour, there was an increase in the concentration of the monosaccharide after 3 (11% to 18%) and 7 hours (10% to 19%) (Matsuo et al., 2003).

Tsukamoto et al. (2014) administered ¹⁴C-labeled D-psicose intravenously and by oral gavage at a dose of 100 mg/kg bw to Wistar rats. After oral administration, D-psicose appeared rapidly in the bloodstream, while peak liver and kidney concentrations occurred 60 minutes post-administration. At 120 minutes, D-psicose concentrations decreased in the liver and kidney and were highest in urine, indicating rapid elimination (Figure 3). Seven days after oral administration, the appearance of D-psicose in the body was less than 1% of the original dose. Following intravenous administration, the D-psicose concentration in the blood was decreased with a half-life of 57 minutes, and the excretion in urine was approximately 50% within 1 hour. Similar to the results obtained following oral administration, accumulation in organs was primarily in the liver (Tsukamoto et al., 2014).

In an excretion test conducted by Matsuo et al. (2003), samples of urine and feces were collected at 24-hour intervals for three days from eight Wistar rats, six weeks old, and having an average weight of 138 ± 4 g, that had been given a single dose of 5 g/kg bw of allulose. Twenty-four hours after administration, 11%–15% of the quantity ingested was detected in the urine, and 8%–13% in the feces. In the following two periods (48 and 72 hours), no additional residual monosaccharide was found, thus suggesting that practically all of the allulose was eliminated during the first hour.

Human studies

In a study by Iida et al. (2010), following oral ingestion of 0.08, 0.17, or 0.33 g/kg bw of D-psicose, excretion rates in urine were measured for up to 48 hours in 14 humans. In the first 12 hours, urine excretion rates ranged from 54% to 63%, depending on dose, then decreased to 3% to 6% by 24 to 48 hours following administration. Cumulative excretion rate measured at 48 hours for the lowest dose (0.08 g/kg bw) was $78.8\% \pm 11.7\%$, whereas the 0.33-g/kg bw dose was $66.2\% \pm 12.6\%$ (Iida et al., 2010).

To evaluate the absorption, distribution, metabolism, and excretion (ADME) of allulose in humans, a single dose containing 15 g Dolcia Prima® allulose containing a defined quantity of marked [$^{14}\text{C}(\text{U})$] allulose was administered to eight healthy male adult individuals (Atiee, 2015; unpublished). In the first 6 hours after ingestion, exhaled air, as well as samples of blood, urine, and feces, were collected at previously established times over the course of the first 7 days. Analytical results from the blood samples showed that the monosaccharide was absorbed quickly, with the maximum mean plasma concentrations reached in the first hour after ingestion (Atiee, 2015; unpublished).

Work in humans by Atiee, 2015 (unpublished), suggested further that allulose is not metabolized for energy in humans as only 6% of a total of 80 samples of exhaled air collected following the administration of ^{14}C -labeled allulose showed detectable levels of measurable $^{14}\text{CO}_2$. Levels above the minimum detection limit of the equipment (50 disintegrations per minute [dpm]) were detected and reported. Of the five samples with detectable levels of measurable $^{14}\text{CO}_2$, the highest concentration found was only 79.29 dpm which indicated that allulose is not metabolized for energy in humans (Atiee, 2015; unpublished).

After analysis of human samples of urine and feces, collected following the administration of ^{14}C -labeled allulose, Atiee, 2015 (unpublished) confirmed that the urinary tract represents the primary route of allulose elimination. For seven participants, 84% to 93% of the ingested dose was recovered in the urine and feces samples. Only one individual showed very low recovery in the urine, less than 50% of the marked ^{14}C , when compared to all of the other participants. This was most likely due to incomplete urine collection by this subject who was therefore considered to be an outlier of the group studied (Atiee, 2015; unpublished).

The ADME studies described above demonstrate that there are similarities in how allulose is absorbed, metabolized, and eliminated from the body in both animals and humans.

Animal Studies

Acute Toxicity

The acute toxicity of allulose was investigated by Matsuo et al. (2002a). Five groups of eight male Wistar rats each were administered a single oral dose of allulose (8, 11, 14, 17, or 20 g/kg bw). Three rats receiving 14 g/kg bw, three rats receiving 17 g/kg bw, and eight rats receiving 20 g/kg of allulose died within 2 days of allulose administration. The authors calculated the LD₅₀ value of 16.3 g/kg by the Behrens-Karber method and 15.8 g/kg by the Litchfield-Wilcoxon method.

These LD₅₀ values are of the same magnitude as for other commonly consumed carbohydrates (e.g., fructose [14.7 g/kg-bw] and erythritol [15.3 g/kg-bw]). Compounds with LD₅₀ values of >5 g/kg bw in rats are classified as “practically non-toxic,” and compounds with LD₅₀ values of >15 g/kg bw as “relatively harmless” (Altug, 2003).

Nishi et al. (2016) conducted a study in dogs, reporting that a single oral dose of 1 or 4 g/kg bw allulose did not cause any treatment-related abnormalities in dogs. All dogs were active and had good appetites throughout the study period. Blood glucose concentrations decreased slightly, without a rise in plasma insulin concentration 2 hours after D-allulose administration. Plasma alkaline phosphatase activities showed a mild and transient increase between 12 and 48 hours after D-allulose administration. The data suggest that a single oral dose of up to 4 g/kg bw of D-allulose does not result in severe toxicity in dogs.

Subchronic toxicity

A 90-day oral sub-chronic toxicity study was undertaken with allulose (Matsuo et al., 2012). In this study, male Wistar rats (3 weeks old) were fed diets containing either 3% allulose or sucrose for 90 days. The body-weight gain and intra-abdominal adipose tissue weight did not differ between the sucrose and the allulose groups. The weights of the liver and kidneys were significantly higher in the allulose group than in the sucrose group. However, no gross pathological findings were evident at dietary doses of 3% allulose or were correlated with hypertrophy of the liver and kidney. The erythrocyte and leukocyte counts were observed to be statistically higher in the allulose group, but the authors concluded that the differences from the control group were small and considered not toxicologically significant. Therefore, the authors concluded that no adverse effects were shown, and the authors derived a NOAEL for allulose as 3% of the diet (equivalent to 1,670 mg/kg bw/day) which was the highest level tested.

Another 90-day oral sub-chronic toxicity study was undertaken to investigate a high allulose syrup (85%) in male Wistar rats (Matsuo and Ishii, 2011), as compared to the previous study diet containing 3% of allulose (see above Matsuo et al., 2012). The body weight gain and intra-abdominal adipose tissue weight did not differ between the control and allulose group. Also, weights of the tissues did not differ. In clinical chemistry and hematological analyses, no differences were found. No gross pathological findings were evident at dietary doses of 4.3% allulose syrup (approximately 2,000 mg/kg bw/day). The

authors conclude that similar to the 3% allulose (powder) diet, a diet containing 85% concentrated allulose syrup (average 3.7% allulose) did not induce any adverse effects.

Sub-chronic toxicity was assessed in a 34-day feeding study in 4-week-old Wistar rats (Matsuo et al., 2002a). Eight groups of seven male Wistar rats/group were fed a diet containing 0 (control), 10%, 20%, 30%, and 40% allulose. One rat on the 30% allulose diet and five rats on the 40% allulose diet died during the experimental period. It should be noted that the 30 and 40% dietary levels administered were extremely high, resulted in the deaths described above, and can be considered inappropriate for a toxicity study of this design. Higher concentrations of allulose resulted in decreased body weight gain and food efficiency. The authors concluded that the decreases in body weight gain in the 10% and 20% groups were attributable to a decrease in food intake and were not considered to be of toxicological significance. A laxative effect was noted but was transient and was not observed after 4 days. Rats fed the 30% and 40% allulose diet were able to regain body weight and food intake during the first 7 days of the feeding period, suggesting that the effects may have been transitory. The authors reported that allulose concentrations of up to 20% of the diet did not show adverse effects.

Chronic toxicity

Long-term toxicity of allulose was investigated by Yagi and Matsuo (2009) in male Wistar rats receiving a diet containing 3% allulose (or 1,280 mg/kg bw/d) or 3% sucrose (1,220 mg/kg bw/day) for 12–18 months. The authors found that allulose administration resulted in a lower body weight gain and lower intra-abdominal adipose tissue weight than in rats fed the sucrose diet. Relative weights of liver and kidney were significantly higher in the allulose group than in the sucrose group, but this was not considered toxicologically significant. General hematology or serum chemistry tests were within the normal ranges for all animals and did not differ between the sucrose and allulose groups. Hemoglobin (Hb) and mean corpuscular volume (MCV) at 18 months were significantly greater in the allulose group than in the sucrose group, but no differences were observed in any of the related hematology values. The histopathological data demonstrated that there were no toxicologically significant findings in rats fed 3% allulose. The authors concluded that administration of allulose at 3% in the diet for 12–18 months (1,280 mg/kg bw/day) did not result in any adverse effects in rats.

Table 14. *Summary of the toxicity studies supporting the safety of allulose*

Animals	Doses	Duration	Endpoints Evaluated	Results Found	Reference
Dogs	1 and 4 g/kg bw	One day by gavage	Acute toxicity-food intake and selected clinical chemistry	Safe up to the tested dose of 4 g/k bw	Nishi et al. (2016)
Male <i>Wistar</i> rats	8, 11, 14, 17 & 20 g/kg bw	One day by gavage	Acute toxicity	LD ₅₀ = 16.3 g/kg bw	Matsuo et al. (2002a)
Young <i>Wistar</i> rats	10%, 20%, 30% and 40% in the diet	34 days	Food intake, weight gain, and organ weights	No adverse effects reported up to 20% in diet	Matsuo et al. (2002b)

Male <i>Wistar</i> rats	3.0% or 4.3% in the diet	90 days	Serum biochemistry, hematology, histology, and macroscopic exams	Safe up to the tested dose of 4.3% (estimated to be approx. 2 g/kg bw/d)	Matsuo and Ishii (2011)
Male <i>Wistar</i> rats	3.0% (1.67 g/kg bw/d) in the diet	90 days	Serum biochemistry, hematology, histology, and macroscopic exams	Safe at the tested dose of 3% (1.67 g/kg bw/d)	Matsuo et al (2012)
Male <i>Wistar</i> rats	3.0% (1,280 mg/kg bw/d) in the diet	12-18 months	Food intake, weight gain, organ weights; serum biochemistry, hematology, histology	Safe at the tested dose (NOAEL >1,280 mg/kg bw/d)	Yagi and Matsuo (2009)

Reproductive toxicity

Kim et al. (2019) evaluated the reproductive toxicity of D-allulose in rats. They assessed reproduction and offspring growth following gavage administration of D-allulose to parental rats at dosage levels of 0, 500, 1000, and 2000 mg/kg-bw. Female rats were dosed continuously from 2 weeks prior to mating until day 21 of lactation, while males were dosed for the 10-week period before mating. No direct toxicity or mortality was evident following D-allulose administration, and no changes in body weight or food consumption were observed in the test article or control groups. No significant alterations in precoital time, copulation index, fertility index (male), or pregnancy index (male) were observed between groups. Relative to the control group, there was also no effect of D-allulose treatment on pregnancy rates, implantation, pregnancy length, gender ratios, viability indexes, lactation indexes, prenatal death rates, or the number of live young at time of birth. Organ weights and associated indexes were also comparable between groups at the time of sacrifice, and treatment with D-allulose was not linked to any obvious manifestations on necropsy or histopathological examination. In the F1 generation offspring, the body weights of pups born to parents administered D-allulose (500, 1000, and 2000 mg/kg-bw) were slightly higher on days 1–9 postnatally, relative to controls ($p < 0.05$); however, after day 9, the body-weight effects were no longer evident. The NOAEL for D-allulose was considered to be 2000 mg/kg-bw, the highest dose level tested, for both parental animals and their offspring.

Mutagenicity/genotoxicity

GRN 400 included the results of an Ames test that did not find evidence of mutagenic potential, and also reported on both a micronucleus test and chromosomal aberration test that found no evidence of genetic toxicity following exposure to allulose.

As yet unpublished studies of mutagenicity and genotoxicity were conducted *in vitro* and are considered supportive of the lack of genotoxicity of allulose as demonstrated in previous allulose GRNs (Nos. 400, 498, 693). The results of an Ames assay and micronucleus test did not show any evidence of mutagenic or genotoxic potential (Li, 2015-unpublished; Neft, 2015-unpublished).

Human Studies

Clinical studies conducted in humans have also evaluated the tolerability and occurrence of adverse effects related to consumption of allulose by healthy populations.

In general, the studies demonstrated the acceptability of different quantities of allulose. Like other ingredients, such as polyols and other monosaccharides (e.g., fructose, tagatose), or fibers and some digestion-resistant oligosaccharides, the consumption of large quantities of the ingredient can cause gastrointestinal discomfort, this effect being a temporary symptom of the adaptation of the gut flora and therefore without toxicological significance.

Previously, and even at the beginning of the 20th century, it was very common to consume greater quantities of raw, whole foods and foods rich in non-digestible fiber and carbohydrates, and the gastrointestinal systems of the population were better adapted to dealing with high concentrations of such compounds without presenting any temporary symptoms or discomfort through the ingestion of high doses (e.g., 120–160 g/day; Leach and Sobolik, 2010; Shoemaker, 1927). Over time, due to changes in eating habits and lifestyle, and with a significant reduction in the ingestion of fiber and other non-digestible carbohydrates, there has been a proportional reduction in the tolerance levels of the gut flora to the consumption of non-digestible ingredients.

More recent studies have demonstrated the ability of the gut flora to adapt to various levels of allulose over time, such as the clinical study of Iida et al. (2007) summarized below, which observed good tolerability for daily consumption of up to 31.0–33.3 g/day of allulose in healthy individuals.

Han et al. (2018) investigated gastrointestinal tolerance in 30 healthy adults (15 males and 15 females), ages 21–30 years old. Two experiments were conducted. In the first experiment, the study participants were given daily single doses of allulose starting at 0.1 g/kg bw/day and increasing by 0.1 g/kg bw/day every week until gastrointestinal symptoms were observed, at which time the study was terminated. In the fifth week, some participants developed gastrointestinal symptoms, and the study was stopped. The maximum tolerated dose in this study was 0.4 g/kg bw/day (when all of the allulose was consumed as a single dose). This maximum tolerated single dose was then used by Han et al. (2018) to conduct a second study in which the same protocol was followed as the first study, with the difference that, this time, the allulose was consumed in portions throughout the day, similar to how meals and snacks are consumed by people. In this case, the maximum tolerated dose was 0.9 g/kg bw/day, or about 54 g/day for a 60-kg adult.

Iida et al. (2007) investigated the effects of the use of allulose on gastrointestinal symptoms in five healthy men and five healthy women, aged between 20 and 30 years. For this purpose, all of the volunteers were given, at the beginning, 0.4 g/kg bw/day of allulose, increasing 0.1 g/kg bw/day up to a maximum of 0.9 g/kg bw/day, for six days. All of the test sample was consumed by the participants in a single sitting during the day. While two participants did not report any adverse effects, even at the highest doses, some

cases of diarrhea were reported with the administration of doses between 0.6 and 0.8 g/kg bw/day: one man ingesting 0.6 g/kg bw/day, two women at 0.7 g/kg bw/day, and two men and three women at 0.8 g/kg bw/day. The study concluded that the maximum tolerance levels were 0.5 g/kg bw/day (or 33.3 g/day), for men, and 0.6 g/kg bw/day (or 31.0 g/day), for women.

This clinical study of Iida et al. (2007) established a dose-response relationship for the onset of diarrhea in humans, showing that in men the maximum tolerated dose was 0.5 g/kg bw, whereas in women, it was 0.6 g/kg bw (above these doses, gastrointestinal effects such as abdominal pain, gas formation, and diarrhea occurred). Thus, it was established that, for humans, the NOAEL for allulose is 0.5 g/kg bw (33.3 g/day) for men and 0.6 g/kg bw (31 g/day) for women (Iida et al., 2007; FDA, 2012, 2014, 2017).

It is noteworthy that these no-effect levels for human subjects from Iida et al. (2007) are based on single doses of allulose, where the daily dose was consumed completely in one sitting. The actual threshold is even higher if the allulose was consumed in portions throughout the day, as one would when consuming meals and snacks daily (Han et al., 2018).

Another clinical safety study of long-term use was performed with 17 healthy volunteers, evaluating the effects of consuming 15 g/day of allulose (n=8) or glucose (n=9) for 12 consecutive weeks. According to the results observed, there were no adverse effects or changes in several hematological and biochemical parameters used in clinical toxicology studies (Hayashi et al., 2010). Four years later, a randomized, double-blind clinical trial in 34 individuals (n=17 each for allulose and control groups) evaluated the effect of 30 g/day of syrup containing 6% allulose (i.e., 1.8 g/day of allulose) and various amounts of other sugars for 12 weeks. During the treatment phase, the subjects consumed either a test drink or a control drink 30 minutes before breakfast on a daily basis. No adverse effects were found in relation to hepatic and renal function, nor any alterations in the biochemical and hematological parameters of the group consuming 1.8 g/day of allulose (Hayashi et al., 2014).

A typical dose of allulose (0.35 g/kg bw, in 100 mL solution) during a clinical study with healthy volunteers revealed that intestinal absorption may range from 66.2% to 80% of the dose initially ingested, while not being converted to energy. The absorption rate of different types of sugars correlates well with the provided laxative effect and the consequent no-observed-effect level. This is because the lower the absorption rate, the greater the intestinal fermentation and, consequently, the laxative effect, hence, lowering the no-effect level. For sorbitol, for example, which has a low intestinal absorption rate, the NOAEL is 0.15–0.17 g/kg bw for men, and 0.24–0.30 g/kg bw for women. For erythritol, which is better absorbed in the small intestine (90%), the NOAEL for tolerance is 0.66 g/kg bw for men, and 0.8 g/kg bw for women. Therefore, with an absorption rate slightly lower than that of erythritol, allulose would also be expected to have a slightly lower threshold for GI intolerance. This is reflected in the previously reported NOAEL of 0.5 g/kg bw (33.3 g/day) for men and 0.6 g/kg bw (31 g/day) for women (Iida et al., 2007; FDA, 2012, 2014, 2017).

In summary, the studies (Table 17) demonstrated the tolerability of different quantities of allulose. Like other ingredients, such as polyols and other monosaccharides (e.g., fructose, tagatose), or fibers and some digestion-resistant oligosaccharides, the consumption of large quantities of the ingredient can cause certain gastrointestinal discomfort; this effect is a temporary symptom of the organism adapting and therefore is without toxicological significance.

Table 15. Clinical trials conducted with administration of Dolcia Prima® allulose

References	Main Characteristics of the Human Studies on Allulose	Doses with No Adverse Effects in Human Subjects
Human Studies on Allulose		
Iida et al. (2008)	<ul style="list-style-type: none"> - Total combined n=28; - Doses 0, 2.5, 5.0, and 7.5 g; - Ages 20–39; - Healthy individuals (male and female). 	7.5 g (highest single dose tested)
Hayashi et al. (2010)	<ul style="list-style-type: none"> - n=17; - Healthy individuals-men and women-given allulose (n=8) or glucose (n=9); - Dose 15 g/day, for 12 weeks. 	15 g/day (one dose level tested)
Iida et al. (2007)	<ul style="list-style-type: none"> - n=10 (5 males and 5 females); - Age 20-30 years; - Given 0.4–0.9 g/kg bw/day in increments of 0.1 g/kg bw/day; - Dosing was once a day at 10 am, followed by 1 week of no allulose ingestion, and then the higher dose was consumed; - 6 treatment days, over 6–7 weeks. 	Up to 0.5 g/kg bw/day was tolerated well by men, and 0.6 g/kg bw/day was tolerated well by women, when consumed as a single dose. This equates to up to 33.3 g/serving, for men and 31 g/serving for women (based on the study participants, or about 30-36 g/serving for 60-kg bw adults in general)
Hayashi et al. (2014)	<ul style="list-style-type: none"> - N=34 (males and females; 17 in allulose group and 17 in control group) - Given 1.8 g/day of allulose in 30 g of syrup, over 12 weeks. 	1.8 g/day (one dose level tested)
Han et al. (2018)	<ul style="list-style-type: none"> - n=30 (15 males and 15 females); - Age 21-30 years; - Given daily doses of allulose increasing every week until gastrointestinal symptoms observed; - Study duration about 8 weeks, for allulose consumption throughout the day, and about 5 weeks, for single daily dose exposures. 	0.9 g/kg bw/day, or 54 g/day, for a 60-kg bw adult, when allulose is consumed in portions throughout the day. 0.4 g/kg bw/day, or 24 g, for a 60-kg bw adult well-tolerated, as a single bolus dose consumed at one time.
Human Studies on Dolcia Prima® Allulose		
Kendall et al. (2014)	<ul style="list-style-type: none"> - n=10; - Healthy subjects given allulose or glucose. 	25 g (single dose tested)
Wolever et al. (2014)	<ul style="list-style-type: none"> - n=12 healthy adults; N=12 adults with type II diabetes - Given allulose or glucose. 	25 g (single dose tested)
Noronha et al. (2018)	<ul style="list-style-type: none"> - n=24; - Given single doses of 0, 5.0 or 10 g allulose, in a solution containing 75 g glucose. 	10 g (highest dose tested)

Effect on Insulinemic and Glycemic Response

In addition to the more classical ADME studies, other clinical studies and experiments on animals have been conducted to observe the effects of allulose on glycemia and/or insulinemia.

Animal studies

Matsuo and Izumori (2009) conducted a research study on the effects of allulose on the postprandial glycemic response in 6-month-old male Wistar rats. Animals were given 2.0 g/kg bw of sucrose, maltose, or soluble starch supplemented with 0.2 g/kg bw of allulose or fructose. An inhibitory effect of allulose was observed on the glycemic response of the other sugars, significantly suppressing the increase in glycemia that normally occurs after the ingestion of carbohydrates. In the case of starch, while not statistically significant, a trend was observed indicating the same inhibitory effect of a reduction in the glycemic response by allulose. Based on the findings of Matsuo and Izumori (2009), it can be concluded that allulose does not induce a glycemic response per se, and also suppresses the glycemic response of other carbohydrates.

Baek et al. (2010) reported the results of a comparative study on the effects of ingesting different types of carbohydrates on glycemic response, the release of insulin, and lipid profiles using as a model diabetic *C57BL/6J* rats. Rats were orally administered 200 mg/kg bw of allulose, glucose, fructose, or water (control), for 28 days. In addition to no adverse effects being observed that were associated with the intervention with the monosaccharide used, they also demonstrated that allulose was capable of maintaining the initial glycemic level between 276 and 305 mg/dL for the entire intervention period, whereas all of the other test groups showed glycemia that was twice as high ($p < 0.05$). Moreover, allulose was demonstrated to be safe, significantly increasing the tolerance to glucose ($p < 0.05$) and even reversing the hepatic concentrations of triglycerides (37.9%) and total cholesterol (62.9%) without any effect on the serum insulin concentration (Baek et al., 2010).

Human studies

Iida et al. (2008) published the results of their study on the effects of ingesting allulose on glycemic and insulinemic response in healthy individuals. In this blind, crossover, and randomized study, eleven men and nine women aged between 20 and 39 years consumed a single dose of four test beverages containing 75 g of maltodextrin and supplemented with 0 g, 2.5 g, 5 g, or 7.5 g of allulose, with minimum intervals of one week between the different forms of intervention. In parallel, eight participants were given 7.5 g of allulose in isolated form to evaluate the effect of consuming the pure monosaccharide on the concentration of plasma insulin and glucose (Iida et al., 2008). Blood samples were collected before initiation of the intervention and also at an interval of 30 minutes, up to 2 hours after the interventions. The results showed that, besides the absence of adverse effects related to the intervention, the independent consumption of the monosaccharide did not influence the glycemic and insulinemic levels of the individuals (Iida et al., 2008).

Another clinical research study was conducted by Hayashi et al. (2010) to investigate the safety and effect of allulose on postprandial blood glucose levels in adult men and women, including borderline diabetic patients. A randomized double-blind, placebo-controlled, crossover experiment of single ingestion was conducted on 26 subjects who consumed 0 or 5 g of allulose in tea with a standard meal. Blood glucose levels at fasting and 30, 60, 90, and 120 min after the meal were compared. The blood glucose level was significantly lower 30 and 60 min after the meal with allulose ($p < 0.01$, $p < 0.05$), and a significant decrease was also shown in the area under the curve ($p < 0.01$). The results suggest that allulose had the effect of suppressing the postprandial blood glucose elevation, mainly in borderline diabetic cases. Another randomized double-blind placebo-controlled parallel-group experiment of long-term ingestion was conducted on 17 normal subjects who ingested 5 g of allulose ($n=8$) or D-glucose ($n=9$) with meals three times a day (total 15 g/day) for 12 continuous weeks. No adverse effects or clinical problems from the continuous ingestion of allulose were reported (Hayashi et al., 2010).

In a double-blind, randomized, multi-center, controlled study that evaluated and tested the effect of single doses of 0 (control), 5.0, or 10 g of allulose, added in a solution containing 75 g of glucose, at glycemia up to 120 minutes in 24 subjects (12 males and 12 females aged 66 ± 1.2 years; BMI 27.0 ± 0.9 kg/m²; diabetes duration 11.3 ± 1.7 years; HbA1c 50.0 ± 1.3 mmol/mol [$6.7 \pm 0.1\%$] with type-2 diabetes (Noronha et al., 2018). The study showed that allulose is able to reduce significantly the plasma glucose iAUC by 8% at 10 g, when compared with the control (717.4 ± 38.3 versus 777.5 ± 39.9 mmol·min/L, $p=0.015$) with a linear dose-response gradient between the reduction in plasma glucose iAUC and dose ($p=0.016$). Allulose also significantly reduced several related secondary and exploratory outcome measures at 5.0 g (plasma glucose absolute mean and total AUC) and at 10 g (plasma glucose absolute mean, absolute and incremental maximum concentration [C_{max}], and total AUC) ($p < 0.0125$). There was no effect of fructose at any dose. Although allulose showed statistically significant reductions in plasma glucose iAUC compared with fructose at both 5.0 g, 10 g, and pooled doses, these reductions were within the prespecified equivalence margins of $\pm 20\%$.

Two unpublished clinical studies were conducted to evaluate the glycemic response of Dolcia Prima® allulose in healthy individuals and diabetics (Kendall et al., 2014-unpublished; Wolever et al., 2014-unpublished).

While the first study evaluated the effects on glycemia in 10 healthy adult individuals, the second study measured the glycemia and insulinemia of 12 healthy adults and 12 patients with type-2 diabetes. In both studies, beverages supplemented with 25 g of Dolcia Prima® allulose, or 25 g of glucose (control) were administered, with the glycemic and/or the insulinemic response measured before and 15, 30, 45, 60, 90, and 120 minutes after the intervention. It was demonstrated that the ingestion of 25 g of the allulose did not cause a glycemic or insulinemic peak above fasting levels in either the healthy or diabetic population (Kendall et al., 2014-unpublished; Wolever et al., 2014-unpublished).

After reviewing the effects of allulose on glycemia and insulinemia, Chung et al. (2012) concluded that the monosaccharide contributed to maintaining appropriate levels of plasma glucose and insulin, characterizing it as a safe and strategic alternative ingredient for substitution of the sugars in the diet of individuals who are at high risk of developing type-2 diabetes.

Safety Summary

Based on the preclinical and clinical safety studies summarized above, the following can be concluded:

- Regulatory authorities have reviewed the safety of allulose and found it to be safe for use in human food. Numerous studies and publications support the safety of allulose, including *in vitro* studies, *in vivo* animal studies, and clinical studies in humans.
- A summary of the most relevant studies on allulose ADME, acute and subchronic toxicity, reproductive and developmental toxicity, mutagenicity and genotoxicity, and chronic toxicity in animals along with clinical studies have been summarized and reviewed. The compositional profile of allulose presents no obvious safety concerns. As a result, allulose has been reviewed and approved in several countries for addition to food for human consumption.
- ADME data on allulose are available in both animals and humans, and the data are similar for both.
- Allulose is rapidly absorbed such that large bolus doses are more likely to have an impact on laxation than smaller cumulative doses. As such, clinical studies have demonstrated that the tolerability of allulose is highly dependent on the mode and timeline of ingestion. Individual tolerance develops with continued ingestion over time. Mild GI intolerance is considered a physiological response to osmotic loading, is of no toxicological significance, is generally self-limiting, and not severe or indicative of toxicity per se but is a short-term individual tolerability issue similar to other foods (dried fruit) or food ingredients (fructose), and other sweeteners such as polyols like sorbitol, mannitol, erythritol, and xylitol.
- No adverse effects attributable to allulose were observed in multiple animal studies including in 90-day studies (1670 - 2000 mg/kg bw/day) and in a chronic study (approximately 1300 mg/kg bw/day).
- Data are available from a number of human studies in both sexes, healthy individuals, and sensitive subpopulations such as diabetics.
- No effects were observed in multiple human studies, except gastrointestinal intolerance at very high dose levels. Gastrointestinal intolerance is related to the presence of excess indigestible material in the gastrointestinal tract and is

temporary and reversible. This type of symptom is usually transient and is not considered to be of toxicological significance (IOM, 2002). It is not unique to allulose; similar effects are observed with other sweeteners, such as polyols like sorbitol, mannitol, and xylitol.

- Allulose can be considered safe for human consumption at up to 63 g/day, when consumed in portions throughout the day as one would typically, based on multiple meals or snacks throughout the day (Han et al., 2018), and up to 24–36 g (0.4 – 0.6 g/kg/day for a 60 kg individual) can be consumed in one sitting (Han et al., 2018; Iida et al., 2007).
- In summary, the published study data, additional unpublished supporting data, and previous reviews by regulatory authorities (e.g., GRN Nos. 400, 498, 693, 828), support the conclusion that Tate & Lyle’s allulose ingredient is safe for its intended use as a sweetener, at the proposed use levels in specified foods.

Basis for the GRAS Determination

Introduction

The regulatory framework for determining whether a substance can be considered GRAS in accordance with section 201(s) (21 U.S.C. § 321(s)) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et. Seq.) (“the Act”) is set forth at 21 CFR 170.30, which states:

General recognition of safety may be based only on the view of experts qualified by scientific training and experience to evaluate the safety of substances directly or indirectly added to food. The basis of such views may be either (1) scientific procedures or (2) in the case of a substance used in food prior to January 1, 1958, through experience based on common use in food. General recognition of safety requires common knowledge about the substance throughout the scientific community knowledgeable about the safety of substances directly or indirectly added to food.

General recognition of safety based upon scientific procedures shall require the same quantity and quality of scientific evidence as is required to obtain approval of a food additive regulation for the ingredient. General recognition of safety through scientific procedures shall ordinarily be based upon published studies, which may be corroborated by unpublished studies and other data and information.

These criteria are applied in the analysis below to determine whether the use of allulose in selected human food that is the subject of this GRAS determination is GRAS based on scientific procedures. All data relied upon in this GRAS determination are publicly available and generally known, and therefore meet the “general recognition” standard

under the Federal Food, Drug, and Cosmetic Act. Unpublished study data are included only as supportive and corroborative of the publicly available data and information.

Safety Determination

The subject of this GRAS determination is the use of allulose as a sweetener in selected foods. Allulose is currently marketed for use in food for human consumption. This GRAS determination supports additional new uses. Regulatory authorities have reviewed the extensive safety database on allulose and found no issues of concern with respect to its use in human food at the proposed use levels. Numerous studies have been conducted and published and unpublished data are available that provide support for the safety of the intended uses of allulose, including *in vitro* studies and *in vivo* animal studies (i.e., acute and subchronic toxicity, mutagenicity and genotoxicity, chronic toxicity), as well as clinical studies in adults.

Allulose is considered GRAS for use in food for human consumption (GRNs 400, 498, 693, 828) (FDA, 2012, 2014, 2017, 2020). To date, Tate & Lyle's allulose ingredient has been approved for direct use in foods by the U.S. FDA, and regulatory bodies in Mexico, Chile, Columbia, Costa Rica, Singapore, and South Korea.

The safety of orally administered allulose has been characterized extensively in the publicly available preclinical and clinical study literature. The compositional profiles and specifications for both Tate & Lyle's proposed allulose syrup and crystalline products present no obvious safety concerns. Finally, similar allulose products have been reviewed and approved around the world for addition to food.

General Recognition of the Safety of Allulose

The intended use of the allulose ingredient in human food has been determined to be safe through scientific procedures set forth in 21 CFR§170.3(b), thus satisfying the so-called "technical" element of the GRAS determination, based on the following:

- Allulose is manufactured from corn, following current cGMP for food (21 CFR § Part 110). The raw materials and processing aids used in the manufacturing process are food grade and/or approved for use in food. The allulose ingredient has been characterized appropriately, contains a minimum of 95%–98% allulose (syrup and crystalline forms, respectively), and meets appropriate food-grade specifications.
- There is a body of common knowledge of historical human consumption of allulose from foods containing allulose. Allulose is naturally present in small quantities in many common foods, such as in dried fruits (e.g., figs, raisins, fried dough, brown sugar, and ketchup). The additional intended uses will be in sweetened alcoholic malt beverages; alcoholic premixed cocktails; ready-to-eat (RTE) and cooked cereals including regular and low calorie, reduced calorie, and sugar-free RTE and cooked cereals; grain-free, no sugar, high protein RTE

cereals; nutrition bars; ketchup and barbecue sauces; dried cranberries; meat- and poultry-based jerky, and nutritional beverages.

- Allulose is rapidly absorbed such that large bolus doses are more likely to have an impact on laxation than smaller cumulative doses. As such, clinical studies have demonstrated that the tolerability of allulose is highly dependent on the mode and timeline of ingestion. Individual tolerance develops with continued ingestion over time. Mild GI intolerance is considered a physiological response to osmotic loading of no toxicological significance, is generally self-limiting, and not severe or indicative of toxicity per se, but is a short-term individual tolerability issue as with other foods (dried fruit) or food ingredients (fructose), and other sweeteners such as polyols like sorbitol, mannitol, and xylitol.
- Allulose is currently added to food, and multiple GRAS “no-questions” letters have been issued (GRNs 400, 498, 693, 828) that support the safe use of allulose in foods in which it serves as a sugar replacement/sweetener at 90th percentile daily intake levels for ages 2+ of up to approximately 30 g/day. GRN 498 stated the following, *“A potential side effect of D-allulose is gastrointestinal discomfort when ingested in large quantities. It is well-known that this type of side effect is transient. As consumption levels of non-digestible carbohydrates decreased throughout the 20th century, human tolerance levels also decreased. This tolerance and loss of tolerance suggests that the gastrointestinal symptoms associated with high intakes of non-digestible carbohydrates are likely transient and can improve over time. This type of symptom is usually transient and is not considered to be of toxicological significance”*.
- The clinical study of Iida et al. (2007) established a dose-response relationship for the onset of diarrhea in humans, showing that in men the maximum tolerated dose was 0.5 g/kg bw, whereas in women, it was 0.6 g/kg bw (above these doses, gastrointestinal effects such as abdominal pain, gas formation, and diarrhea occurred). Thus, it was established that, for humans, the NOAEL for the onset of diarrhea in humans from consuming allulose is 0.5 g/kg bw (33.3 g/day) for men and 0.6 g/kg bw (31 g/day) for women (Iida et al., 2007; FDA, 2012, 2014, 2017).
- Among the U.S. population 2+ y, 95% consumed one or more foods containing allulose from background and/or proposed uses. The allulose CEDI at the per user mean and 90th percentile of intake among this population is 10.09 g/day (0.15 g/kg-bw/day) and 23.53 g/day (0.35 g/kg-bw/day), respectively. Per user mean allulose CEDI ranged from 3.33 g/day among infants <2 y to 12.61 g/day among males 19+ y. On a per body weight basis, the highest per user mean intake was among infants <2 y at 0.30 g/kg-bw/day allulose. The per user 90th percentile intake estimates of allulose ranged from 7.18 g/day among infants <2 y to 29.86 g/day among males 19+ y. The highest per user 90th percentile of intake on a body weight basis was among infants <2y at 0.65 g/kg-bw/day allulose.
- In the current analysis, a downward shift of allulose intake was observed

using more recent NHANES data (i.e., NHANES 2015-2018) as compared to total allulose intakes reported by GRNs 400, 498, 693, and 828. The total per user mean and 90th percentile intake estimates of allulose based on older NHANES 2007-2010 data and reported for the U.S. population by GRNs 400, 498, 693 and 828 ranged from 9 - 12.55 g/day and 24.8 - 30 g/day, respectively. Allulose intake estimates from background uses in the present analysis (NHANES 2015-2018) at the per user mean and 90th percentile are 6.69 g/day and 16.39 g/day, respectively. These estimates at the per user mean and 90th percentile are at least 26% and 34% lower, respectively, than those estimates in the previous GRNs.

- Lower allulose intake estimates in the present analysis appear to be due to a shift in dietary patterns of non-alcoholic low calorie, reduced calorie, sugar-free beverages. Specifically, the percent users and intake of non-alcoholic beverages (low calorie, reduced calorie, sugar-free) have decreased from 32% in NHANES 2007-2010 to 21% in NHANES 2015-2018 with a decreased intake among consumers of non- alcoholic beverages in NHANES 2015-2018. A trend analysis conducted by Bleich et al.(2018) similarly reported an observed decline in beverage and sugar-sweetened beverage consumption for children and adults from 2003 to 2014. There was also a reduction in intake of regular cereal contributing to lower allulose intakes, i.e., a decrease in percent users (46% in NHANES 2007-2010 versus 33% in NHANES 2015-2018) and lower intake amounts in NHANES 2015-2018. This reduction, however, did not result from changes in dietary patterns but instead was due to differences in the food selection methodology between GRN 498 and the current assessment. The food selection of regular cereals in the present analysis was limited to cereals with added sugar since allulose would not be added to cereals with no added sugar, whereas all cereals excluding low calorie, reduced calorie, and sugar-free cereals were included in the assessment for GRN 498 under regular cereals. The estimated allulose intake from existing background uses in this analysis relies on the most currently available dietary data from NHANES (2015-2018) and shows a lower allulose intake as compared to previously reported allulose EDIs from GRNs 400, 498, 693, and 828 (see Exponent intake assessment report Appendix C).
- Allulose can be considered safe for human consumption up to 24–36 g (0.4 – 0.6 g/kg/day for a 60 kg individual) when consumed in one sitting. As summarized above, the 90th percentile estimated total daily intake for the US population, ages 2+ is 23.53 g/day; this is likely an overestimate of intake as it assumes allulose is used in all intended foods at the maximum intended use level.
- No safety/toxicity concerns related to consumption of allulose are evident, beyond that of gastrointestinal intolerance at high bolus doses. Even at the 90th percentile, the estimated total daily intake for the US population, ages 2+ of 23.53 g/day is conservative, and as such, tolerability should be of limited concern.

- Regulatory authorities have reviewed the extensive safety study database for allulose and found no issues of concern with respect to its use in human food at the proposed use levels. Numerous studies have been conducted and published in support of the safety of allulose, including *in vitro* studies and *in vivo* animal studies (i.e., acute and subchronic toxicity, mutagenicity and genotoxicity, chronic toxicity), as well as clinical studies in adults. No adverse effects attributable to allulose were observed in multiple animal studies; in 90-day studies (1670 - 2000 mg/kg bw/day) and in a chronic study (approximately 1300 mg/kg bw/day).
- The body of publicly available scientific literature on the consumption and safety of allulose is sufficient to support the safety and GRAS determination to support the proposed new uses of the allulose ingredient.

Because this safety evaluation was based on generally available and widely accepted data and information, it also satisfies the so-called “common knowledge” element of a GRAS determination.

Determination of the safety and GRAS status of this allulose ingredient for the specified uses that is the subject of this self-determination has been made through the deliberations of a GRAS Panel of qualified experts convened by Tate & Lyle and comprised of Michael Carakostas, DVM, Ph.D., Stanley M. Tarka, Jr., Ph.D., F.A.T.S., and Thomas A. Vollmuth, Ph.D. These individuals are qualified by scientific training and experience to evaluate the safety of substances intended to be added to food. They have critically reviewed and evaluated the publicly available information summarized in this document and have individually and collectively concluded that the allulose ingredient, produced in a manner consistent with cGMP and meeting the specifications described herein, is safe under its intended conditions of use.

The Panel further unanimously concluded that use of this allulose ingredient in these additional specified human foods described herein is GRAS based on scientific procedures, and that other experts qualified to assess the safety of food and food ingredients for human consumption would concur with these conclusions. The Panel’s GRAS opinion is included as Exhibit I to this document.

It is also Tate & Lyle’s opinion that other qualified scientists reviewing the same publicly available toxicological and safety information would reach the same conclusion. Tate & Lyle has concluded that the allulose ingredient is GRAS under the intended conditions of use on the basis of scientific procedures; and therefore, it is excluded from the definition of a food additive and may be marketed and sold for its intended purpose in the U.S. without the promulgation of a food additive regulation under Title 21 of the CFR.

Tate & Lyle is not aware of any information that would be inconsistent with a finding that the use of the allulose ingredient in food for human consumption, meeting appropriate specifications, and used according to GMP, is GRAS. Recent reviews of the scientific literature revealed no potential adverse health concerns.

§ 170.255 Part 7, Supporting Data and Information

References

Altug T. 2003. Introduction to toxicology and food. CRC Press, Boca Raton, FL; ISBN 0-8493-1456-9.

Atiee G. 2015. An open-label, single-dose, nonrandomized microtracer study to determine the mass balance of orally administered, ¹⁴C-labeled sweetener product with 15 g sweetener in healthy adult subjects. Worldwide Clinical Trials-unpublished.

Baek SH, Park SJ, Lee HG. 2010. D-psicose, a sweet monosaccharide, ameliorate hyperglycemia, and dyslipidemia in C57BL/6J db/db mice. *J Food Sci* 75:H49–H53.

Bleich SN, Vercammen KA, Wyatt Komma J, Li Z. 2018. Trends in beverage consumption among children and adults, 2003-2014. *Obesity* 26(2):432-441.

Chung MY, Oh DK, Lee KW. 2012. Hypoglycemic health benefits of D-psicose. *J Agric Food Chem* 60:863–869.

FDA. 2012. GRAS Notification No. 400. D-psicose.
<http://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=400>.

FDA. 2014. GRAS Notification No. 498. D-psicose.
<http://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=498>.

FDA 2017. GRAS Notification No. 693
<http://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=693>.

Han Y, Choi BR, Kim SY. 2018. Gastrointestinal tolerance of d-allulose in healthy and young adults. a non-randomized controlled trial. *Nutrition* 10(12), 2010-2021.

Hayashi N, Iida T, Yamada T, Okuma K, Takehara I, Yamamoto T, Yamada K, Tokuda M. 2010. Study on the postprandial blood glucose suppression effect of D-psicose in borderline diabetes and the safety of long-term ingestion by normal human subjects. *Biosci Biotechnol Biochem* 74(3):510–519.

Hayashi N, Yamada T, Takamine S. 2014. Weight reducing effect and safety evaluation of rare sugar syrup by a randomized double-blind, parallel-group study in human. *J Funct Foods* 11:152–159.

Iida T, Kishimoto Y, Yoshikawa Y, Okuma K, Yagi K, Matsuo T, Izumori K. 2007. Estimation of maximum non-effective level of D-psicose in causing diarrhea in human subjects. *J Advanced Food Ingrid* 10(1):15–19.

Iida T, Kishimoto Y, Yoshikawa Y, Hayashi N, Okuma K, Tobi M, Yagi K, Matsuo T, Izumori K. 2008. Acute D-psicose administration decreases the glycemic responses to an oral maltodextrin tolerance test in normal adults. *J Nutr Sci Vitaminol* 54:511–514.

Iida T, Hayashi N, Yamada T, Yoshikawa Y, Miyazato S, Kishimoto Y, Okuma K, Tokuda M, Izumori K. 2010. Failure of D-psicose absorbed in the small intestine to metabolize into energy and its low large intestinal fermentability in humans. *Metabolism Clinical and Experimental* 59:206-214.

IOM (Institute of Medicine). 2005. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. Washington, DC: The National Academies Press.

Kendall CWC, Wolever T, Vuksan V. 2014. Final Report - Comparison of glycemic responses elicited by: 25g glucose 25g allulose. Glycemia Consulting Inc, May 27- unpublished.

Kim H, Park C, Sa S, Case I, Chunmei L, Gao Y, Wang H, Tian J. 2019. A study of D-allulose-associated reproductive toxicity in rats. *Food Chem Toxicol* 131:115048.

Laerke, FN, Jensen BB. 1999. D-Tagatose has low small intestinal digestibility but high large intestinal fermentability in pigs. *J Nutr* 129:1002–1009.

Lambe, J, Kearney, J, Leclercq, C, Zunft, HFJ, De Henauw, S, Lamberg-Allardt, CJE, Dunne, A, Gibney, MJ. 2000. The influence of survey duration on estimates of food intakes and its relevance for public health nutrition and food safety issues. *Eur J Clin Nutr*. 54: 166-173.

Leach JD, Sobolik KD. 2010. High dietary intake of prebiotic inulin-type fructans in the prehistoric Chihuahuan Desert. *Br J Nutr* 103:1558–1561.

Li Y. 2015 (unpublished). Final Report - Bacterial reverse mutation assay. Covance Laboratories, Inc. March 30.

Matsuo, T, Tanaka T, Hashiguchi M, Izumori K, Suzuki H. 2002a. Effects of oral acute administration and subchronic feeding of several levels of D-psicose in rats. *J Nutr Sci Vitaminol* 48:512–516.

Matsuo T, Suzuki H, Hashiguchi M, Izumori K. 2002b. D-psicose is a rare sugar that provides no energy to growing rats. *J Nutr Sci Vitaminol* 48:77–80.

Matsuo T, Tanaka T, Hashiguchi M, Izumori K, Suzuki H. 2003. Metabolic effects of D-allulose in rats: studies on fecal and urinary excretion and cecal fermentation. *Asia Pac J Clin Nutr* 12(2):225–231.

Matsuo T, Izumori K. 2009. D-psicose inhibits intestinal alpha-glucosidase and suppresses the glycemic response after ingestion of carbohydrates in rats. *J Clin Biochem Nutr* 45:202–206.

Matsuo T, Ishii R. 2011. The effects of 90-day feeding of D-psicose syrup in male Wistar rats. *Open J Prevent Med* 1(2):66–71.

Matsuo T, Ishii R, Shirai Y. 2012. The 90-day oral toxicity of D-allulose in male Wistar rats. *J Clin Biochem Nutr* 50(2):158–161.

Neft R. 2015. In vitro micronucleus assay in human peripheral blood lymphocytes. Covance Laboratories, Inc.-unpublished.

NIH. 2002. NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines; April, 2002). Bethesda (MD): National Institutes of Health (U.S.).

Nishi N, Nomizo T, Takashima S, Matsubara T, Tokuda M, Kitagawa H. 2016. Single oral dose safety of D-allulose in dogs. *J Vet Med Sci* 78:1079–1083.

Noronha JC, Braunstein CR, Glenn A. 2018. Effect of small dose of fructose and allulose on postprandial glucose metabolism in type 2 diabetes: A double-blind, randomized, controlled, acute feeding equivalence trial. *Diabetes Obes Metab* 20:2361–2370.

Oshima H, Kimura I, Izumori K. 2006. Psicose contents in various food products and its origin. *Food Sci Technol Res* 12(2):137–143.

Pariza MW, Jonson EA. 2001. Evaluating the safety of microbial enzyme preparations used in food processing: update for a new century. *Regul Toxicol Pharmacol* 45(2):144–158.

Shoemaker DN. 1927. The Jerusalem artichoke as a crop plant. Technical Bulletin No. 33. U.S. Department of Agriculture, Washington, DC.

Tsukamoto I, Hossain A, Yamaguchi F, Hirata Y. 2014. Intestinal absorption, organ distribution, and urinary excretion of the rare sugar D-psicose. *Drug Design Devel Ther* 8:1955–1964.

Whistler RL, Singh PP, Lake WC. 1974. D-allulose metabolism in the rat. *Carbohydr Res* 34:200–202.

Wolever T, Jenkins A, Campbell J. 2014. Final GR Report - A randomized, controlled, crossover study to assess the effects of a sweetener on postprandial glucose and insulin excursions in subjects with and without diabetes. GI Labs, December 5-unpublished.

Yagi K, Matsuo T. 2009. The study on long-term toxicity of D-psicose in rats. *J Clin Biochem Nutr* 45:271–277.

APPENDIX A

**Pariza and Johnson
Decision Tree**

Appendix 4 - Analysis of Safety Based on Pariza/Johnson Decision Tree

Guidelines have been published for the safety assessment of microbial enzyme preparations (Pariza and Johnson, 2001). The guidelines have proven to be a useful tool in safety assessments for the production and use of numerous food enzymes. The safety assessment of a given enzyme preparation is based upon an evaluation of the toxigenic potential of the production organism. The responses below follow the pathway indicated in the decision tree. The outcome of this analysis is that the epimerase enzyme preparation is accepted as safe for its intended use.

1. Is the production strain genetically modified? Yes, go to 2.
2. Is the production strain modified using rDNA techniques? Yes, go to 3a.
3. a. Does the expressed enzyme product which is encoded by the introduced DNA have a history of safe use? This epimerase enzyme is novel but the epimerase enzyme has been used previously to make a food sweetener that was the subject of a GRAS Notification that has been reviewed by FDA (GRN 400); Yes, go to 3c.
- c. Is the test article free of transferable antibiotic resistance gene DNA? No, go to 3d.
- d. Does the resistance gene(s) code for resistance to a drug substances used in the treatment of disease agents in man or animal? Due to its toxicity characteristics, chloramphenicol is not a clinically important antibiotic. No, go to 3e.

- e. Is all other introduced DNA well characterized and free of attributes that would render it unsafe for constructing microorganisms to be used to produce food-grade products? Yes, go to 4.
4. Is the introduced DNA randomly integrated into the chromosome? No, go to 6.
6. Is the production strain derived from a safe lineage, as previously demonstrated by repeated assessment via this evaluation procedure? Yes, *E. Coli* K-12 is a well established strain with a history of safe use. Accept.

APPENDIX B

**COAs and Other
Analytical Data**

TATE & LYLE

CONSISTENTLY FIRST IN RENEWABLE INGREDIENTS
ICD CERTIFICATE OF ANALYSIS

PRODUCT: Dolcia Prima LS	PO# : N.A
Report Date: 09/22/2019	Order # : NA
Sent to: N.A	Date Shipped:
Product: N.A	NA


Analytical Data

Sample Number: Dolcia Prima LS YP19D03774

Manufacture Date May 6, 2019

Analysis	Unit	Result	Specification	Methods
Color	n/a	Colorless	Off white	Visual inspection
Allulose	% dsb	96.2	≥95%	Saccharide distribution – TN67435
Total non allulose saccharides	% dsb	2.6	≤5%	Saccharide distribution – TN67435
pH		4.2	3.0-4.5	pH – TN60710
Dry solids	%	70.8	70% to 78%	DS RI M – TN27501
Total plate count	CFU/10 g	<10	≤200 CFU/10 g	Total Plate Count – TN10565; TN10560
E. Coli.	CFU/10 g	None detected	None detected	E. coli – TN 10512L
Salmonella	CFU/ 25 g	Negative	Negative	Salmonella – TN 10547
Yeast	CFU/10 g	<10	≤10 CFU/10 g	Mold & Yeast – TN10600
Mold	CFU/10 g	<10	≤10 CFU/10 g	Mold & Yeast – TN10600
SO2	ppm	<10	<10 ppm	Sulphur dioxide – TN80055
Arsenic	ppb	15.8	<0.10 ppm	Elemental Analysis of Heavy Metals - R 2837
Lead	ppb	5.6	<0.10 ppm	Elemental Analysis of Heavy Metals - R 2837
Cadmium	ppb	<5	<0.1 ppm	Elemental Analysis of Heavy Metals – R method 2837
Mercury	ppb	<5	<0.01 ppm	Elemental Analysis of Mercury - R method 2832

Item Signed by



Shana Bender – Manager Analytical

3/25/2020

Date

TATE & LYLE

CONSISTENTLY FIRST IN RENEWABLE INGREDIENTS
ICD CERTIFICATE OF ANALYSIS

PRODUCT: Dolcia Prima LS	PO# : N.A
Report Date: 09/22/2019	Order # : NA
Sent to: N.A	Date Shipped:
Contact: N.A	N.A

Analytical Data

Sample Number: Dolcia Prima LS YP19G01863

Manufacture Date: April 27, 2019

Analysis	Unit	Result	Specification	Methods
Color	n/a	Colorless	Colourless to slightly yellow	Visual inspection
Allulose	% dsb	96.34	≥95%	Saccharide distribution – TN67435
Total non allulose saccharides	% dsb	2.87	≤5%	Saccharide distribution – TN67434
pH	%	3.9	3.0-4.5	pH – TN60710
Dry solids	%	70.5	70% to 78%	DS RI – TN27501
Total plate count	CFU/10 g	<10	≤200 CFU/10 g	Total Plate Count – TN10565; TN10560
E. Coli.	CFU/10 g	None detected	None detected	<i>E. coli</i> TN 10512L
Salmonella	CFU/ 25 g	Negative	negative	<i>Salmonella</i> – TN 10547
Yeast	CFU/10 g	<10	≤10 CFU/10 g	Mold & Yeast – TN10600
Mold	CFU/10 g	<10	≤10 CFU/10 g	Mold&Yeast – TN10600
SO ₂	ppm	<10	<10 ppm	Sulphur dioxide – TN80055
Arsenic	ppb	11.4	<0.10 ppm	Elemental Analysis of Heavy Metals - R method 2837
Lead	ppb	<5	<0.10 ppm	Elemental Analysis of Heavy Metals - R method 2837
Cadmium	ppb	<5	<0.1 ppm	Elemental Analysis of Heavy Metals – R method 2837
Mercury	ppb	<5	<0.01 ppm	Elemental Analysis of Mercury - R method 2832


 Shana Bender – Manager Analytical

3/25/2020

Date

TATE & LYLE

CONSISTENTLY FIRST IN RENEWABLE INGREDIENTS
ICD CERTIFICATE OF ANALYSIS

PRODUCT: Dolcia Prima LS	PO# : N.A
Report Date: 09/22/2019	Order# : NA
Sent to: N.A	Date Shipped:
Contact: N.A	NA

Analytical Data

Sample Number: Dolcia Prima LS YP18D03177

Manufacture Date April 13, 2018

Analysis	Unit	Result	Specification	Methods
Color	n/a	Colorless	Colourless to slightly yellow	Visual inspection
Allulose	% dsb	96.3	≤95%	Saccharide distribution -- TN67435
Total non allulose saccharides	% dsb	2.4	≤5%	Saccharide distribution -- TN67435
pH		4.3	3.0-4.5	pH -- TN60710
Dry solids	%	71	70% to 78%	DS RI -- TN27501
Total plate count	CFU/10 g	<10	≤200 CFU/10 g	Total Plate Count -- TN10565; TN10560
E. Coli.	CFU/10 g	None detected	None detected	E. Coli - TN 10512L
Salmonella	CFU/ 25 g	Negative	Negative	Salmonella -- TN 10547
Yeast	CFU/10 g	<10	≤10 CFU/10 g	Mold & Yeast -- TN10600
Mold	CFU/10 g	<10	≤10 CFU/10 g	Mold & Yeast -- TN10600
SO2	ppm	<10	<10 ppm	Sulphur dioxide -- TN80055
Arsenic	ppb	23.8	<0.10 ppm	Elemental Analysis of Heavy Metals - R method 2837
Lead	ppb	6	<0.10 ppm	Elemental Analysis of Heavy Metals - R method 2837
Cadmium	ppb	<5	<0.1 ppm	Elemental Analysis of Heavy Metals -- R method 2837
Mercury	ppb	<5	<0.01 ppm	Elemental Analysis of Mercury - R method 2832

Investigated by

 Shana Bender -- Manager Analytical

3/25/2020

Date

TATE & LYLE

CONSISTENTLY FIRST IN RENEWABLE INGREDIENTS
ICD CERTIFICATE OF ANALYSIS

Product: Dolcia Prima DS	PO# : N.A
Report Date: 09/22/2019	Order # : NA
Sent to:	Date Shipped: N.A

Analytical Data

Sample Number: Dolcia Prima DS LO18J90596

Manufacture Date November 15, 2018

Analysis	Unit	Result	Specification	Methods
Color	n/a	Off white	Off white	Visual inspection
Screen	%	0.1	<5%	
screen	%	7	<10%	
Allulose	% dsb	99.35	≥99.10%	Saccharide distribution – TN67450
Total non allulose saccharides	% dsb	0.27	≤0.90%	Saccharide distribution TN67435
moisture	% dsb	0.14	≤0.50%	Moisture – TN46040
Ash	% dsb	<0.1%	<0.5%	Ash – TN 09580
Total plate count	CFU/g	<10	≤200 CFU/g	Total Plate Count – TN10565
E. Coli.	CFU/ g	None detected	None detected	<i>E. coli</i> – TN 10412L
Salmonella	CFU/ 25 g	Negative	Negative	<i>Salmonella</i> TN 10510
Yeast	CFU/ g	<10	≤10 CFU/g	Mold & Yeast – TN47010
Mold	CFU/10 g	<10	≤10 CFU/g	Mold & Yeast – TN47010
SO ₂	ppm	<10	<10 ppm	Sulphur dioxide – TN80055
Arsenic ¹	ppb	<5	<0.10 ppm	Elemental Analysis of Heavy Metals – R method 2837
Lead	ppb	<5	<0.10 ppm	Elemental Analysis of Heavy Metals – R method 2837
Cadmium	ppb	<5	<0.1 ppm	Elemental Analysis of Heavy Metals – R method 2837
Mercury	ppb	<5	<0.01 ppm	Elemental Analysis of Mercury - R method 2832

DocuSign Envelope ID: 4E274058-E978-4296-AF39-0A07025CBA65

Shana Bender

Shana Bender – Manager Analytical

3/25/2020

Date

TATE & LYLE

CONSISTENTLY FIRST IN RENEWABLE INGREDIENTS
ICD CERTIFICATE OF ANALYSIS

PRODUCT: Dolcia Prima DS	PO# : N.A
Report Date: 09/22/2019	Order# : NA
Sent to: N.A	Date Shipped:
Contact: N.A	NA

Analytical Data

Sample Number: Dolcia Prima DS LO19F90351

Manufacture Date: June 3, 2019

Analysis	Unit	Result	Specification	Methods
Color	n/a	Off white	Off white	Visual inspection
Screen	# 10	0.1	<5%	
screen	# 200	3	<10%	
Allulose	% dsb	99.74	≥99.1%	Saccharide distribution - TN67450
Total non allulose saccharides	% dsb	0.06	≤0.9%	Saccharide distribution - TN67434
moisture	%dsb	0.12	≤0.5%	Moisture - TN46040
Ash	% dsb	<0.1%	<0.5%	Ash - TN 09580
Total plate count	CFU/ g	10	≤200 CFU/g	Total Plate Count - TN10565; TN10560
E. Coli.	CFU/10 g	None detected	None detected	<i>E. Coli</i> TN10512L
Salmonella	CFU/ 25 g	Negative	Negative	<i>Salmonella</i> TN 10547
Yeast	CFU/g	10	≤10 CFU/ g	Mold & Yeast - TN47010
Mold	CFU/10 g	10	≤10 CFU/ g	Mold & Yeast - TN47010
SO2	ppm	<10	<10 ppm	Sulphur dioxide - TN80055
Arsenic	ppb	<5	<0.10 ppm	Elemental Analysis of Heavy Metals - R method 2837
Lead	ppb	<5	<0.10 ppm	Elemental Analysis of Heavy Metals - R method 2837
Cadmium	ppb	<5	<0.1 ppm	Elemental Analysis of Heavy Metals - R method 2837
Mercury	ppb	<5	<0.01 ppm	Elemental Analysis of Mercury - R method 2832

This is signed by

Shana Bender

Shana Bender - Manager Analytical

3/25/2020

Date

TATE & LYLE

CONSISTENTLY FIRST IN RENEWABLE INGREDIENTS
ICD CERTIFICATE OF ANALYSIS

Product: Dolcia Prima DS	PO# : N.A
Report Date: 09/22/2019	Order# : NA
Sent to: N.A	Date Shipped:
Contact: N.A	N.A

Analytical Data

Sample Number: Dolcia Prima DS LO18J90294

Manufacture Date October 3, 2019

Analysis	Unit	Result	Specification	Methods
Color	n/a	Colorless	Off white	Visual inspection
Screen US#10	%	0.1	<5%	
Screen US #200	%	6.6	<10%	
Allulose	% dsb	99.19	≥99.1%	Saccharide distribution -- TN67450
Total non allulose saccharides	% dsb	0.29	<0.9%	Saccharide distribution -- TN67435
moisture	%dsb	0.1	≤0.5%	Moisture -- TN46040
Ash	% dsb	<0.1%	<0.5%	Ash -- TN 09580
Total plate count	CFU/g	10	≤200 CFU/g	Total Plate Count --TN10560
<i>E. Coli.</i>	CFU/g	None detected	None detected	<i>E. Coli</i> - TN10512
<i>Salmonella</i>	CFU/ g	Negative	Negative	<i>Salmonella</i> TN 10547
Yeast	CFU/g	<10	≤10 CFU/g	Mold & Yeast -- TN47010
Mold	CFU/g	<10	≤10 CFU/g	Mold & Yeast -- TN47010
SO2	ppm	<10	<10 ppm	Sulphur dioxide -- TN80055
Arsenic	ppb	<5	<0.10 ppm	Elemental Analysis of Heavy Metals -- R method 2837
Lead	Ppb	<5	<0.10 ppm	Elemental Analysis of Heavy Metals - R method 2837
Cadmium	Ppb	<5	<0.1 ppm	Elemental Analysis of Heavy Metals -- R method 2837
Mercury	ppb	<5	<0.01 ppm	Elemental Analysis of Mercury - R method 2832

Authorized by:

 Shana Bender - Manager Analytical

3/25/2020

Date

APPENDIX C

Stability Testing Data

Shelf Life Stability DOLCIA PRIMA® LS Allulose Syrup DOLCIA PRIMA® DS Crystalline Allulose


Based on the studies summarized below, the shelf life of DOLCIA PRIMA® LS Allulose Syrup is shown to be at least 9 months when stored at the recommended storage temperature, i.e. 25° C. In this study, the test samples were stored in tightly sealed glass jars in a dark chamber at ambient humidity.

The shelf life of DOLCIA PRIMA® DS Crystalline Allulose is shown to be at least 26 months when stored at the recommended storage conditions of 25° C, <50% RH. In this study, the samples were heat sealed in pouches made from the plastic bag liner which provides a moisture barrier in the DOLCIA PRIMA® DS bag. These pouches were stored in a dark chamber with humidity controlled to <50% RH.

A. pH Stability

The pH of DOLCIA PRIMA® Allulose Syrup decreased gradually throughout shelf-life study at all temperatures tested (Figure 1). The material remained within specification for duration of the 9 month period at 25°C and below.

Figure 1. pH Stability of DOLCIA PRIMA® LS Allulose Syrup



TATE & LYLE

B. Color Stability of DOLCIA PRIMA® LS Allulose Syrup

One of the key factors that define the end of shelf life for a syrup is color development. As shown in Figure 2, the rate of color development is strongly influenced by temperature. No color generation was seen at 4°C, and only a mild color increase was seen at 25°C over 6 months. Based on color, the syrup should be kept at 25°C for any storage beyond 1 month. Extended storage at these recommended conditions is shown in Figure 3.

Figure 2. Color Stability of DOLCIA PRIMA® Allulose Syrup 4°C – 35°C





Figure 3. Color Stability of DOLCIA PRIMA® LS Allulose Syrup at 15°C, 20°C, and 25°C




TATE & LYLE

C. Composition Stability of DOLCIA PRIMA® LS Allulose Syrup

The main component of DOLCIA PRIMA® LS Allulose Syrup is allulose. The allulose did not change significantly during the 9 month storage (Figure 4).

Figure 4. Composition Stability of DOLCIA PRIMA® Allulose Syrup



TATE & LYLE

D. Microbial Stability of DOLCIA PRIMA® Allulose Syrup

The DOLCIA PRIMA® Allulose Syrup tested has a water activity of approximately 0.66 which is very similar to other corn syrups and HFCS products. Microbial growth is not supported in these products due to the low water activity as demonstrated in Table 1. In addition, Tate & Lyle has conducted a challenge study on DOLCIA PRIMA® Allulose Syrup with Salmonella and E. Coli which showed that these microorganisms died off after 1 day at room temperature.

Table 1. Microbial Stability of DOLCIA PRIMA® Allulose Syrup

Temp (°C)	Month	E Coli	Salmonella	Total Plate Count	Mold	Yeast
4	0	NEGATIVE	NEGATIVE	<10	<10	<10
	3	NEGATIVE	NEGATIVE	20	<10	<10
	6	NEGATIVE	NEGATIVE	<10	<10	<10
	9	NEGATIVE	NEGATIVE	<10	<10	<10
25	0	NEGATIVE	NEGATIVE	<10	<10	<10
	3	NEGATIVE	NEGATIVE	<10	<10	<10
	6	NEGATIVE	NEGATIVE	<10	<10	<10
	9	NEGATIVE	NEGATIVE	<10	<10	<10
35	0	NEGATIVE	NEGATIVE	<10	<10	<10
	3	NEGATIVE	NEGATIVE	20	<10	<10
	6	NEGATIVE	NEGATIVE	<10	<10	<10

TATE & LYLE

E. Stability of DOLCIA PRIMA® DS Crystalline Allulose

Stability studies on DOLCIA PRIMA® DS Crystalline Allulose are currently underway. Allulose composition and moisture are unchanged after 30 months (2.5 years) when stored in original packaging at the recommended storage conditions of 77 degrees Fahrenheit (25°C) or lower and 50% or less relative humidity. This is similar to other crystalline saccharides such as crystalline fructose or crystalline glucose. DOLCIA PRIMA® DS Crystalline Allulose is an anhydrous crystalline product with moisture <0.5% and therefore does not support microbial growth.

Figure 5. Composition Stability of DOLCIA PRIMA® DS Crystalline Allulose at 25°C




Figure 6. Moisture uptake of DOLCIA PRIMA® DS Crystalline Allulose at 25°C, <50% RH

TATE & LYLE



Brian Pohrte, Research Chemist

The information contained in this bulletin should not be construed as recommending the use of our product in violation of any patent, or as warranties (expressed or implied) of internal use only or its fitness for any particular purpose. Prospective purchasers are invited to conduct their own tests, studies and regulatory review to determine the fitness of Tate & Lyle products for their particular purposes product claims or specific applications.

APPENDIX D

Intake Assessment Report

Exponent[®]

*Center for Chemical Regulation and Food
Safety*

**ESTIMATED DAILY INTAKE
OF ALLULOSE FROM
PROPOSED USES**

ESTIMATED DAILY INTAKE OF ALLULOSE FROM PROPOSED USES

Prepared for

Lore Kolberg
Director, Regulatory and Scientific Affairs
Innovation and Commercial Development
Tate & Lyle
222 Walelu Trail
Vonore, TN 37885

Prepared by

Exponent, Inc.
1150 Connecticut Avenue, NW
Suite 1100
Washington, DC 20036

August 30, 2021

© Exponent, Inc.

Contents

	<u>Page</u>
List of Tables	iii
List of Acronyms	iv
Introduction	1
Data and Methods	2
Background Use	2
Proposed Use	2
Food Consumption Data	4
Selection of Representative Food Codes	4
Confection & Frosting and Gelatins, Pudding & Fillings	5
Sugar and Sugar Substitutes	5
Analysis	6
Cumulative EDI (CEDI)	6
Results	7
Background EDI	7
Proposed Uses EDI	8
Cumulative EDI (CEDI)	9
References	11
Appendix A. Existing Food Uses of Allulose	13
Appendix B. Food Codes Included In Analysis	15
Appendix C. Allulose Intake Comparison to GRN 498	38

List of Tables

	<u>Page</u>
Table 1. Maximum allulose use levels by types of foods and beverages	1
Table 2. Two-day average EDI of allulose from background uses by the U.S. population 2+ y and subpopulations	8
Table 3. Two-day average EDI of allulose from all intended uses by the U.S. population 2+ y and subpopulations	9
Table 4. Two-day average CEDI of allulose from background uses and all proposed uses combined by the U.S. population 2+ y and subpopulations	10

List of Acronyms

bw	Body weight
CEDI	Cumulative Estimated Daily Intake
DHHS	Department of Health and Human Services
EDI	Estimated Daily Intake
FARE®	Foods Analysis and Residue Evaluation® Program
FDA	U.S. Food and Drug Administration
FNDDS	Food and Nutrient Database for Dietary Studies
FPED	Food Patterns Equivalent Database
g	gram
GRAS	Generally Recognized As Safe
GRN	GRAS Notice
kg	kilogram
NA	Not applicable
NCHS	National Center for Health Statistics
NFS	Not-further-specified
NHANES	National Health and Nutrition Examination Survey
RTE	Ready-to-eat
U.S.	United States
USDA	United States Department of Agriculture
WWEIA	What We Eat in America

Introduction

At the request of Tate & Lyle, Exponent, Inc. (Exponent) conducted an intake assessment to estimate the estimated daily intake (EDI) of allulose among the United States (U.S.) population from proposed uses in a total of ten food types. The background intake of allulose was also assessed based on existing Generally Recognized As Safe (GRAS) uses in several food and beverage types in order to derive the cumulative estimated daily intake (CEDI) from the combined background and proposed new uses.

The EDI of allulose were generated from dietary recalls collected as part of the *What We Eat in America* (WWEIA) component of the combined 2015-2018 National Health and Nutrition Examination Surveys (NHANES) data files (NCHS 2018, 2020). Exponent developed allulose EDIs on a per capita and per user basis for the U.S. population ages 2 years (y) and older and the following five subpopulations: (1) infants and young children <2 y, (2) children 2-12 y, (3) adolescents 13-18 y, (4) adult females 19 y and older, and (5) adult males 19 y and older. Estimates were generated in units of grams allulose per day (g/day) and grams allulose per kilogram body weight per day (g/kg-bw/day). The sections below summarize the data, methods, and results.

Data and Methods

Background Use

Background dietary intake of allulose was determined based on the existing food uses and use levels of allulose as described in U.S. GRAS Notices (GRNs) 400 (CJ Cheiljedang, 2011), 498 (Matsutani Chemical Industry Company, Ltd 2013), 693 (Samyang Corporation, 2017), and 828 (Samyang Corporation, 2018). These uses of allulose are summarized in Table 1 by food category and corresponding use levels. For the purpose of estimating background allulose intake from existing food uses, the maximum use level from all GRNs for a given food type was used in the assessment. The existing food uses and corresponding use level of allulose from each of the four GRNs (i.e., GRNs 400, 498, 693, and 828) to which the U.S. Food and Drug Administration (FDA) issued a no questions letter (FDA 2012, 2014, 2017, 2020) are summarized and presented in Appendix A.

Proposed Use

Allulose is proposed for use in ten food types including (1) nutritional beverages intended for the general population; (2) nutritional beverages intended for children (i.e., PediaSure); (3) sweetened alcoholic malt beverages; (4) alcoholic premixed cocktails; (5) ready-to-eat (RTE) and cooked cereals including regular and low calorie, reduced calorie, and sugar-free RTE and cooked cereals; (6) grain-free, no sugar, high protein RTE cereals; (7) nutrition bars; (8) ketchup and barbecue sauces; (9) dried cranberries; and (10) meat- and poultry-based jerky. The categories of food to which allulose is proposed for use, descriptions of the general types of foods within each category, and the maximum proposed use of allulose are also summarized in Table 1.

Table 1. Maximum allulose use levels by types of foods and beverages

	Food Category	Description of Foods Selected for Analysis	Maximum Allulose Use Level, %		
			Proposed New Uses	Existing GRAS Uses*	Combined existing GRAS and proposed uses **
1	Baked products (bread, muffin, cake and cookies, pastries), dietetic, low calorie, reduced calorie, sugar-free	Sweetened bread/rolls, muffin, and cakes and cookies – all identified as low calorie, reduced calorie, sugar-free, or NFS†.	NA	10	10
2	Beverages				
2a	Non-alcoholic beverages, low calorie, reduced calorie, sugar-free	Sweetened coffees, teas, soft drinks, energy drinks, juice drinks, fruit drinks, fruit flavored drinks, flavored/carbonated waters, and enhanced/fortified waters – all identified as low calorie, reduced calorie, or sugar-free.	NA	3.5	3.5
2b	Nutritional beverages	Nutritional beverages within the “nutritional beverages” and “protein and nutritional powders” WWEIA categories not included as part of the existing GRAS uses in medical foods	2.5	NA	2.5
2c	Nutritional beverages intended for children (i.e., PediaSure)	PediaSure	3.5	NA	3.5
2d	Alcoholic malt beverage, sweetened	Sweetened alcoholic malt beverage (food code 93106000), which includes products such as hard lemonade, hard punch, hard tea, etc.	3.5	NA	3.5
2e	Alcoholic premixed cocktails	All cocktails with added sugar	3.0	NA	3.0
3	Candy, hard and soft				
3a	Hard candy (includes pressed candy and mints), low calorie, reduced calorie, sugar-free	Hard candy – low calorie, reduced calorie, sugar-free, or NFS†.	NA	70	70
3b	Soft candy, low calorie, reduced calorie, sugar-free	Soft candy – low calorie, reduced calorie, sugar-free.	NA	25	25

	Food Category	Description of Foods Selected for Analysis	Maximum Allulose Use Level, %		
			Proposed New Uses	Existing GRAS Uses*	Combined existing GRAS and proposed uses **
4	Chewing gum	Regular and sugar-free chewing gum.	NA	50	50
5	Cereals, ready-to-eat (RTE) and cooked				
5a	RTE and cooked, regular	RTE and cooked cereals identified as containing added sugar.	12	2	12
5b	RTE and cooked, low calorie, reduced calorie, sugar-free	RTE and cooked cereals identified as low calorie, reduced sugar, or sugar-free.	12	5	12
5c	RTE cereals with <5% sugar	RTE cereals with <5% added sugar excluding cereals with no added sugar.	NA	10	10
5d	Grain-free, no sugar, high protein RTE cereal	No grain-free, no sugar, high protein RTE cereals were reported consumed, hence, zero-sugar added RTE cereals were selected as surrogates.	20	NA	20
6	Coffee mix	Sweetened non-reconstituted coffee mixes.	NA	30	30
7	Confections & Frostings	Frostings and icings and marshmallows.	NA	5	5
8	Dressings for salads	Salad dressings including mayonnaise.	NA	5	5
9	Frozen dairy (ice cream, soft serve, sorbet), low calorie, reduced calorie, sugar-free	Desserts including ice cream, soft serve, sorbet - all identified as low calorie, reduced calorie, sugar-free, or NFS†.	NA	5	5
10	Gelatins, pudding & fillings				
10a	Gelatins, pudding & fillings, low calorie, reduced calorie, sugar-free	Gelatins and puddings - all identified as low calorie, reduced calorie, sugar-free, or NFS†.	NA	10	10
10b	Fat-based cream (used in modified fat/calorie cookies, cakes, pastries, pie)	Fat-based cream filling in cookies, cakes, pastries, pies.	NA	10	10
11	Nutrition bars	Meal replacement bars, protein bars, energy bars, etc.	25	NA	25
12	Jams & Jellies	Jams, jellies, and pastes, all types.	NA	10	10

	Food Category	Description of Foods Selected for Analysis	Maximum Allulose Use Level, %		
			Proposed New Uses	Existing GRAS Uses*	Combined existing GRAS and proposed uses **
13	Sugar	Sugar added in home preparations including white sugar, brown sugar, cinnamon sugar, raw sugar, honey, molasses, and not specified.	NA	10	10
14	Sugar substitutes	Sugar substitutes.	NA	100	100
15	Sweet sauces & syrups, low calorie, reduced calorie, sugar-free	Sweet sauces & syrups - all identified as low calorie, reduced calorie, sugar-free, dietetic or NFS†.	NA	10	10
16	Ketchup and barbecue sauces	Ketchup and barbecue sauces.	10	NA	10
17	Yogurt and frozen yogurt, low calorie, reduced calorie, sugar-free	Yogurt and frozen yogurt - all identified as low calorie, reduced calorie, sugar-free, or NFS†.	NA	5	5
18	Medical foods	Nutritional drinks such as Boost, Ensure, and Glucerna to provide a surrogate for medical foods.	NA	15	15
19	Cranberries, dried	Dried cranberries (i.e., Craisins).	25	NA	25
20	Jerky (meat or poultry based)	Jerky (meat or poultry based).	15	NA	15

* Based on current food uses and use levels of allulose as described in U.S. GRNs 400 (CJ Cheiljedang, 2011), 498 (Matsutani Chemical Industry Company, Ltd 2013), 693 (Samyang Corporation, 2017), and 828 (Samyang Corporation, 2018).

† NFS refers to food codes described as "not-further-specified;" providing a generic description to the food reported consumed (i.e., dietetic topping).

NA: Not applicable.

** Maximum use levels applied in estimating cumulative intake from proposed and existing GRAS uses

Food Consumption Data

Estimated food intakes of allulose were based on food consumption records collected in the WWEIA component of NHANES conducted in 2015-2016 and 2017-2018 (NHANES 2015-2018). This continuous survey uses a complex multistage probability sample designed to be representative of the civilian U.S. population (NCHS 2018, 2020). The NHANES datasets provide nationally representative nutrition and health data and prevalence estimates for nutrition and health status measures in the U.S. Statistical weights are provided by the National Center for Health Statistics (NCHS) to adjust for the differential probabilities of selection.

As part of the examination, trained dietary interviewers collected detailed information on all foods and beverages consumed by respondents in the previous 24-hour time period (midnight to midnight). A second dietary recall was administered by telephone three to ten days after the first dietary interview, but not on the same day of the week as the first interview. The dietary component of the survey is conducted as a partnership between the U.S. Department of Agriculture (USDA) and the U.S. Department of Health and Human Services (DHHS). DHHS is responsible for the sample design and data collection, and USDA is responsible for the survey's dietary data collection methodology, maintenance of the databases used to code and process the data, and data review and processing. A total of 13,666 individuals in the survey period 2015-2018 provided 2 complete days of dietary recalls.

Selection of Representative Food Codes

Food codes corresponding to each of the food categories to which allulose can currently be added to or is proposed to be added to were identified in the WWEIA, NHANES 2015-2018. Foods in which only a component is of interest for the addition of allulose (e.g., dressing as part of a salad, jelly in a sandwich, icing on a cake) were also identified. Food descriptions and the "additional description" details provided for some food codes were reviewed as part of the process to select representative foods and food mixtures to include in the analysis.

For relevant food mixtures, the proportion of the food code (as a percentage of total weight) corresponding to the component of interest was identified and only this portion of the food weight was used to determine the amount of allulose that may be added. Exponent used USDA's Food and Nutrient Database for Dietary Studies (FNDDS) 2017-2018 (USDA, 2018) to translate the food as consumed into its corresponding

ingredients based on percent weight. Additional details on the identification of the portion of food mixtures assumed to contain allulose are presented in sections below. The list of the food codes included in the analysis is provided in Appendix B.

Confection & Frosting and Gelatins, Pudding & Fillings

The average proportion of frosting/icing in baked goods was assumed to be 30% for cakes/cupcakes, 25% for brownies, 30% for cookies, and 20% for pastries. Likewise, the average filling proportion was assumed to be 30% for cookies and 15% for pastries. These proportions were based on frosting/icing or filling contribution between baked goods with and without icing/frosting or filling using portion weight information from the FNDDS.

Sugar and Sugar Substitutes

Food codes for sugar and sugar substitutes were identified and assigned the maximum use levels of allulose as specified in Table 1. The WWEIA food codes also include food mixtures that may contain a sweetener added during home preparation. To capture these potential existing uses of allulose as a sugar substitute assumed to occur at the consumer level, food descriptions containing “homemade”, “home recipe”, “prepared with”, “made with”, “made from”, “with sugar”, “sugar added”, “sweetened”, or “presweetened” were identified and reviewed. When the food was assumed to represent a home preparation, the sugar or sugar substitute portion of the mixture was identified and included in the analysis. The Food Patterns Equivalent Database (FPED) was used to identify the concentration of added sugars in these mixtures (USDA, 2020). For example, sugar portions of the food codes for “Cornbread, made from home recipe” and “Apple, dried, cooked, with sugar” were assumed to contain allulose in the analysis.

For beverage food codes identified as presumably sweetened by the consumer, Exponent used USDA’s FPED database to determine the proportion of sugar in the beverage mixtures. This proportion was included in the analysis for the sugar and sugar substitute existing uses.

Analysis

For each WWEIA NHANES respondent on each day of dietary recall, intake of allulose was calculated as the amount of the select food or food ingredient (g) corresponding to either background existing GRAS uses or proposed uses, and multiplied by the maximum allulose use level of that food as shown in Table 1. Contributions from all foods consumed during the two days of recall were summed and the resulting value was divided by two to result in an estimate of 2-day average allulose intake for each respondent. Intakes of allulose derived on a body weight (bw) basis were calculated using each participant's measured body weight.

Summaries of the estimated allulose intake by the population ages 2 y and older and subpopulations of infants and children <2 y, children 2-12 y, adolescents 13-18 y, adult females 19 y and older, and adult males 19 y and older were derived from the allulose intakes calculated for each respondent. Estimates of intake for the population groups were calculated on a *per user* basis and a *per capita* basis, in units of gram allulose per day (g/day) and gram allulose per kilogram body weight per day (g/kg-bw/day). In this analysis, a "user" is anyone who reported consuming a food with allulose added on either of the survey days. The resulting values represent estimates of allulose intake assuming the maximum use level of allulose.

The 2-day average intakes by each individual were estimated using Exponent's Foods Analysis and Residue Evaluation Program (FARE® version 14.06) software, which uses the statistically weighted values from the survey in its analyses. The statistical weights compensate for variable probabilities of selection, adjust for non-response, and provide intake estimates that are representative of the U.S. population.

Cumulative EDI (CEDI)

To estimate the CEDI for allulose, food uses of allulose from background food uses and proposed uses together were considered. Specifically, intake of allulose was calculated as the amount of the select food or food ingredient (in grams) from either background existing GRAS and/or proposed uses, and multiplied by the maximum allulose level associated with the combined GRAS and proposed uses of that food as shown in Table 1.

Results

The two-day average intake estimates of allulose at the mean and 90th percentile of intake was derived using dietary records from NHANES 2015-2018 for the U.S. population 2+ y and subpopulations of infants and young children, children, adolescents, adult females, and adult males. The EDI of allulose from background and proposed uses are summarized in Tables 2 and 3, respectively. The allulose CEDI from the combined background and proposed uses are summarized in Table 4.

Background EDI

Among the U.S. population 2+ y, 92% consumed one or more foods containing allulose from background uses (i.e., GRAS uses from GRNs 400, 498, 693, and 828; Table 2). The estimated daily intake of allulose from background uses at the per user mean and 90th percentile of intake among this population is 6.69 g/day (0.09 g/kg-bw/day) and 16.39 g/day (0.23 g/kg-bw/day), respectively. Per user mean intake of allulose from background uses ranged from 1.50 g/day among infants <2 y to 8.68 g/day among males 19+ y. On a per body weight basis, the highest per user mean intake was among infants <2 y at 0.14 g/kg-bw/day allulose. The per user 90th percentile intake estimates of allulose ranged from 3.63 g/day among infants <2 y to 22.71 g/day among males 19+ y. The highest per user 90th percentile of intake on a body weight basis was among infants <2 y at 0.34 g/kg-bw/day allulose.

The total per user mean and 90th percentile intake estimates of allulose based on NHANES data and reported for the U.S. population by GRNs 400, 498, 693 and 828 ranged from 9-12.55 g/day and 24.8-30 g/day, respectively. The per user mean and 90th percentile intake estimates in the present analysis are approximately 26% and 34% lower, respectively, than those estimates in the GRNs. In order to understand the downward shift of allulose intake observed in the more recent NHANES data, Exponent generated and compared two sets of allulose intake estimates using NHANES 2015-2018 and NHANES 2007-2010 for the food uses reported in GRN 498 (see Appendix C). Lower allulose intake estimates in the present analysis appear to be due to a shift in dietary patterns of non-alcoholic low calorie, reduced calorie, sugar-free beverages. Specifically, the percent users and intake of non-alcoholic beverages (low calorie, reduced calorie, sugar-free) have decreased from 32% in NHANES 2007-2010 to 21% in NHANES 2015-2018 with a decreased amount intake among consumers of non-alcoholic beverages in NHANES 2015-2018. A trend analysis conducted by Bleich et al. (2018) similarly reported an observed decline in beverage and sugar-sweetened beverage consumption for children and adults from 2003 to 2014. There was also a

reduction in intake of regular cereal contributing to lower allulose intakes, i.e., a decrease in percent users (46% in NHANES 2007-2010 versus 33% in NHANES 2015-2018) and lower intake amounts in NHANES 2015-2018. This reduction, however, did not result from changes in dietary patterns but instead was due to differences in the food selection methodology between GRN 498 and the current assessment. The food selection of regular cereals in the present analysis was limited to cereals with added sugar since allulose would not be added to cereals with no added sugar, whereas all cereals excluding low calorie, reduced calorie, and sugar-free cereals were included in the assessment for GRN 498 under regular cereals. The estimated allulose intake from existing background uses in this analysis relies on the most currently available dietary data from NHANES (2015-2018) and shows a lower allulose intake as compared to previously reported allulose EDIs from GRNs 400, 498, 693, and 828.

Table 2. Two-day average EDI of allulose from background uses by the U.S. population 2+ y and subpopulations

	N*	% User	Per Capita		Per User	
			Mean	90 th Percentile	Mean	90 th Percentile
Background Allulose EDIs (g/day)						
U.S. 2+ y	11650	92	6.18	15.15	6.69	16.39
Infants <2 y	391	48	0.72	1.94	1.50	3.63
Children 2-12 y	2566	95	2.89	6.71	3.04	6.98
Adolescents 13-18 y	1257	88	3.27	7.62	3.70	8.33
Males 19+ y	3696	92	7.97	20.70	8.68	22.71
Females 19+ y	4131	93	6.30	16.44	6.79	17.45
Background Allulose EDIs (g/kg-bw/day)						
U.S. 2+ y	11650	92	0.09	0.22	0.09	0.23
Infants <2 y	391	48	0.07	0.16	0.14	0.34
Children 2-12 y	2566	95	0.11	0.27	0.12	0.28
Adolescents 13-18 y	1257	88	0.05	0.12	0.06	0.14
Males 19+ y	3696	92	0.09	0.23	0.10	0.25
Females 19+ y	4131	93	0.08	0.21	0.09	0.22

* Unweighted number of users; % user, *per capita*, and *per user* estimates were based on NHANES 2015-2018 and derived using the statistical weights provided by the NCHS.

Proposed Uses EDI

Among the U.S. population 2+ y, 64% consumed one or more foods containing allulose from proposed uses (Table 3). The estimated daily intake of allulose from proposed uses at the per user mean and 90th percentile of intake among this population is 5.92 g/day (0.10 g/kg-bw/day) and 13.47 g/day (0.22 g/kg-bw/day), respectively. Per user mean intake of allulose from proposed uses ranged from 3.61 g/day among infants < 2 y

to 6.94 g/day among males 19+ y. On a per body weight basis, the highest per user mean intake was among infants <2 y at 0.32 g/kg-bw/day allulose. The per user 90th percentile intake estimates of allulose ranged from 7.74 g/day among infants <2 y to 16.34 g/day among males 19+ y. The highest per user 90th percentile of intake on a body weight basis was among infants <2 y at 0.66 g/kg-bw/day allulose.

Table 3. Two-day average EDI of allulose from all intended uses by the U.S. population 2+ y and subpopulations

	N*	% User	Per Capita		Per User	
			Mean	90 th Percentile	Mean	90 th Percentile
Allulose EDIs from Proposed Uses (g/day)						
U.S. 2+ y	7831	64	3.78	10.35	5.92	13.47
Infants <2 y	252	31	1.13	2.64	3.61	7.74
Children 2-12 y	2078	75	3.16	7.88	4.20	8.58
Adolescents 13-18 y	942	67	3.40	9.58	5.09	11.00
Males 19+ y	2316	63	4.37	12.39	6.94	16.34
Females 19+ y	2495	60	3.54	10.33	5.89	13.91
Allulose EDIs from Proposed Uses (g/kg-bw/day)						
U.S. 2+ y	7831	64	0.06	0.17	0.10	0.22
Infants <2 y	252	31	0.10	0.23	0.32	0.66
Children 2-12 y	2078	75	0.13	0.30	0.17	0.34
Adolescents 13-18 y	942	67	0.05	0.15	0.08	0.17
Males 19+ y	2316	63	0.05	0.14	0.08	0.19
Females 19+ y	2495	60	0.05	0.15	0.08	0.19

* Unweighted number of users; % user, *per capita*, and *per user* estimates were based on NHANES 2015-2018 and derived using the statistical weights provided by the NCHS.

Cumulative EDI (CEDI)

Among the U.S. population 2+ y, 95% consumed one or more foods containing allulose from background uses and/or proposed uses. The allulose CEDI at the per user mean and 90th percentile of intake among this population is 10.09 g/day (0.15 g/kg-bw/day) and 23.53 g/day (0.35 g/kg-bw/day), respectively (Table 4). Per user mean allulose CEDI ranged from 3.33 g/day among infants <2 y to 12.61 g/day among males 19+ y. On a per body weight basis, the highest per user mean intake was among infants <2 y at 0.30 g/kg-bw/day allulose. The per user 90th percentile intake estimates of allulose ranged from 7.18 g/day among infants <2 y to 29.86 g/day among males 19+ y. The highest per user 90th percentile of intake on a body weight basis was among infants <2 y at 0.65 g/kg-bw/day allulose.

Table 4. Two-day average CEDI of allulose from background uses and all proposed uses combined by the U.S. population 2+ y and subpopulations

	N*	% User	Per Capita		Per User	
			Mean	90 th Percentile	Mean	90 th Percentile
Allulose CEDIs (g/day)						
U.S. 2+ y	12017	95	9.60	22.65	10.09	23.53
Infants <2 y	409	50	1.66	4.75	3.33	7.18
Children 2-12 y	2632	97	5.63	12.04	5.83	12.36
Adolescents 13-18 y	1320	92	6.28	13.39	6.79	13.55
Males 19+ y	3828	95	12.00	28.84	12.61	29.86
Females 19+ y	4237	95	9.48	23.27	9.99	24.05
Allulose CEDIs (g/kg-bw/day)						
U.S. 2+ y	12017	95	0.14	0.34	0.15	0.35
Infants <2 y	409	50	0.15	0.40	0.30	0.65
Children 2-12 y	2632	97	0.22	0.48	0.23	0.49
Adolescents 13-18 y	1320	92	0.10	0.22	0.11	0.22
Males 19+ y	3828	95	0.13	0.32	0.14	0.33
Females 19+ y	4237	95	0.13	0.30	0.14	0.32

* Unweighted number of users; % user, *per capita*, and *per user* estimates were based on NHANES 2015-2018 and derived using the statistical weights provided by the NCHS

References

Bleich SN, Vercammen KA, Wyatt Komma J, and Li Z. 2018. Trends in Beverage Consumption Among Children and Adults, 2003-2014. *Obesity* (Silver Spring) 26(2):432-441.

CJ Cheiljedang, Inc. 2011. GRAS Notice No. GRN 000400. Available via: <https://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices&id=400>.

Matsutani Chemical Industry Company, Ltd. 2013. GRAS Notice No. GRN 000498. Available via: <https://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices&id=498>.

National Center for Health Statistics (NCHS). 2020. National Health and Nutrition Examination Survey Data 2017-2018. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Available via: <https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/default.aspx?BeginYear=2017>.

National Center for Health Statistics (NCHS). 2018. National Health and Nutrition Examination Survey Data 2015-2016. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Available via: <https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/default.aspx?BeginYear=2015>.

Samyang Corporation. 2017. GRAS Notice No. GRN 000693. Available at: <https://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices&id=693>.

Samyang Corporation. 2018. GRAS Notice No. GRN 000828. Available at: <https://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices&id=828>.

US Department of Agriculture (USDA). 2018. USDA Food and Nutrient Database for Dietary Studies 2017-2018. Available via: <https://www.ars.usda.gov/northeast-area/beltsville-md-bhnrc/beltsville-human-nutrition-research-center/food-surveys-research-group/docs/fndds-download-databases/>.

US Department of Agriculture (USDA). 2020. USDA Food Patterns Equivalent Database 2017-2018. Beltsville, MD: US Department of Agriculture, Agricultural Research Service, Food Surveys Research Group. Available via: <https://www.ars.usda.gov/northeast-area/beltsville-md/beltsville-human-nutrition-research-center/food-surveys-research-group/docs/fped-databases/>.

US Food and Drug Administration (FDA). 2012. Agency Response Letter GRAS Notice No. GRN 000400. Available via: <https://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices&id=400>.

US Food and Drug Administration (FDA). 2014. Agency Response Letter GRAS Notice No. GRN 000498. Available via:

<https://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices&id=498>.

US Food and Drug Administration (FDA). 2017. Agency Response Letter GRAS Notice No. GRN 000693. Available at:

<https://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices&id=693>.

US Food and Drug Administration (FDA). 2020. Agency Response Letter GRAS Notice No. GRN 000828. Available at:

<https://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices&id=828>.

Appendix A. Existing Food Uses of Allulose

Food Category	Allulose Use Level (%)				
	Maximum use level from existing GRAS uses	GRN 828 (Samyang Corporation, 2018)	GRN 693 (Samyang Corporation, 2017)	GRN 498 (Matsutani Chemical Industry Company Ltd, 2013)	GRN 400 (CJ Cheiljedang, 2011)
Baked products (bread, muffin, cake/cookies, pastries, dietetic, low calorie, reduced calorie, sugar-free)	10	10	10	-	10
Beverages, non-alcoholic, low calorie, red calorie, sugar free	3.5	3.5	3.5	3.5	2.1
Candy, hard & soft					
(a) Hard candy includes pressed candy and mints, low calorie, reduced calorie, sugar-free	70	50	50	50	70
(b) Soft candy, low calorie, reduced calorie, sugar-free	25	25	25	25	25
Chewing gum	50	50	50	50	50
Cereals, ready to eat and cooked					
(a) RTE and cooked, regular	2	2	2	2	-
(b) RTE and cooked, low calorie, reduced calorie, sugar-free	5	5	5	5	-
(c) RTE cereals with <5% sugar	10	-	-	-	10
Coffee mix	30	-	-	-	30
Confections & Frostings	5	5	5	5	-
Dressing for salads	5	5	5	5	-
Frozen dairy (ice cream, soft serve, sorbet), low calorie, reduced calorie, sugar-free	5	5	5	5	5
Gelatins, pudding & fillings					
(a) Gelatins, pudding & fillings, low calorie, reduced calorie, sugar-free	10	10	10	10	-
(b) Fat-based cream (used in modified fat/calorie cookies, cakes, pastries, pie)	10	5	5	-	10
Jams & Jellies	10	10	10	10	-

Food Category	Allulose Use Level (%)				
	Maximum use level from existing GRAS uses	GRN 828 (Samyang Corporation, 2018)	GRN 693 (Samyang Corporation, 2017)	GRN 498 (Matsutani Chemical Industry Company Ltd, 2013)	GRN 400 (CJ Cheiljedang, 2011)
Sugar	10	10	10	10	-
Sugar Substitutes	100	100	100	100	100
Sweet sauces & syrups, low calorie, reduced calorie, sugar-free	10	10	10	10	-
Yogurt and frozen yogurt, low calorie, reduced calorie, sugar-free	5	5	5	5	5
Medical foods	15	-	-	-	15

Appendix B. Food Codes Included In Analysis

Food Category

1	Baked products (bread, muffin, cake and cookies, pastries), dietetic, low calorie, reduced calorie, sugar-free
	Food code Food description
	51121015 Garlic bread, NFS
	51122000 Bread, reduced calorie and/or high fiber, white or NFS
	51122100 Bread, reduced calorie and/or high fiber, white or NFS, with fruit and/or nuts
	51122110 Bread, reduced calorie and/or high fiber, white or NFS, with fruit and/or nuts, toasted
	51183990 Breadsticks, NFS
	51184200 Breadsticks, soft, NFS
	51301510 Bread, wheat or cracked wheat, reduced calorie and/or high fiber
	51602020 Bread, multigrain, reduced calorie and/or high fiber, toasted
	53109220 Snack cake, not chocolate, with icing or filling, reduced fat and calories
	53201000 Cookie, NFS
	53260030 Cookie, chocolate chip, sugar free
	53260200 Cookie, oatmeal, sugar free
	53260300 Cookie, sandwich, sugar free
	53260400 Cookie, sugar or plain, sugar free
	53260500 Cookie, sugar wafer, sugar free
	53260600 Cookie, peanut butter, sugar free
2	Beverages
2a	Non-alcoholic beverages, low calorie, reduced calorie, sugar-free
	Food code Food description
	64134100 Fruit smoothie, light
	92101901 Coffee, Latte, nonfat
	92101911 Coffee, Latte, decaffeinated, nonfat
	92101921 Frozen coffee drink, nonfat
	92101926 Frozen coffee drink, nonfat, with whipped cream
	92102010 Frozen mocha coffee drink, nonfat
	92102040 Frozen mocha coffee drink, nonfat, with whipped cream
	92102501 Coffee, Iced Latte, nonfat
	92130005 Coffee, pre-lightened and pre-sweetened with low calorie sweetener
	92130010 Coffee, pre-lightened
	92130011 Coffee, decaffeinated, pre-lightened
	92130030 Coffee, pre-sweetened with low calorie sweetener
	92130031 Coffee, decaffeinated, pre-sweetened with low calorie sweetener
	92171010 Coffee, bottled/canned, light
	92305090 Tea, iced, instant, black, pre-sweetened with low calorie sweetener
	92305110 Tea, iced, instant, black, decaffeinated, pre-sweetened with low calorie sweetener
	92305920 Tea, iced, instant, green, pre-sweetened with low calorie sweetener
	92307510 Iced Tea / Lemonade juice drink, light
	92307520 Iced Tea / Lemonade juice drink, diet
	92308010 Tea, iced, brewed, black, pre-sweetened with low calorie sweetener
	92308040 Tea, iced, brewed, black, decaffeinated, pre-sweetened with low calorie sweetener
	92308510 Tea, iced, brewed, green, pre-sweetened with low calorie sweetener
	92308540 Tea, iced, brewed, green, decaffeinated, pre-sweetened with low calorie sweetener
	92309020 Tea, iced, bottled, black, diet

92309030	Tea, iced, bottled, black, decaffeinated, diet
92309510	Tea, iced, bottled, green, diet
92400100	Soft drink, NFS, diet
92410250	Carbonated water, sweetened, with low-calorie or no-calorie sweetener
92410315	Soft drink, cola, reduced sugar
92410320	Soft drink, cola, diet
92410350	Soft drink, cola, decaffeinated, diet
92410370	Soft drink, pepper type, diet
92410400	Soft drink, pepper type, decaffeinated, diet
92410420	Soft drink, cream soda, diet
92410520	Soft drink, fruit flavored, diet, caffeine free
92410560	Soft drink, fruit flavored, caffeine containing, diet
92410620	Soft drink, ginger ale, diet
92410720	Soft drink, root beer, diet
92411610	Soft drink, cola, fruit or vanilla flavored, diet
92513010	Slush frozen drink, no sugar added
92550030	Fruit juice drink, with high vitamin C, light
92550035	Fruit juice drink, light
92550040	Fruit juice drink, diet
92550110	Cranberry juice drink, with high vitamin C, light
92550200	Grape juice drink, light
92550350	Orange juice beverage, 40-50% juice, light
92550360	Apple juice beverage, 40-50% juice, light
92550370	Lemonade, fruit juice drink, light
92550380	Pomegranate juice beverage, 40-50% juice, light
92550400	Vegetable and fruit juice drink, with high vitamin C, diet
92550405	Vegetable and fruit juice drink, with high vitamin C, light
92550610	Fruit flavored drink, with high vitamin C, diet
92550620	Fruit flavored drink, diet
92552000	Fruit flavored drink, with high vitamin C, powdered, reconstituted, diet
92552010	Fruit flavored drink, powdered, reconstituted, diet
92552020	Fruit juice drink, reduced sugar (Sunny D)
92552030	Fruit juice drink (Capri Sun)
92900200	Fruit flavored drink, powdered, not reconstituted, diet**
93301183	Whiskey and diet cola*
93301191	Rum and diet cola*
93301215	Vodka and diet cola*
94100200	Water, bottled, sweetened, with low calorie sweetener
94220215	Water, bottled, flavored, sugar free (Glaceau Vitamin Water)
94220310	Water, bottled, flavored, sugar free (SoBe)
95312400	Energy drink, low calorie (Monster)
95312410	Energy drink, sugar free (Monster)
95312600	Energy drink, sugar-free (Red Bull)
95312700	Energy drink, sugar free (Rockstar)
95313200	Energy drink, sugar free
95322200	Sports drink, low calorie (Gatorade G2)
95322500	Sports drink, low calorie (Powerade Zero)
95323000	Sports drink, low calorie
2b	Nutritional beverages
	Food code Food description*.**
11553120	Fruit smoothie, with whole fruit and dairy, added protein***

64134020	Fruit smoothie, with whole fruit, no dairy, added protein**
78101110	Fruit and vegetable smoothie, added protein**
78101118	Fruit and vegetable smoothie, non-dairy, added protein**
95102000	Nutritional drink or shake, ready-to-drink (Carnation Instant Breakfast)
95105000	Nutritional drink or shake, ready-to-drink (Kellogg's Special K Protein)
95106000	Nutritional drink or shake, ready-to-drink (Muscle Milk)
95106010	Nutritional drink or shake, ready-to-drink, light (Muscle Milk)
95110000	Nutritional drink or shake, ready-to-drink (Slim Fast)
95110010	Nutritional drink or shake, ready-to-drink, sugar free (Slim Fast)
95110020	Nutritional drink or shake, high protein, ready-to-drink (Slim Fast)
95120000	Nutritional drink or shake, ready-to-drink, NFS
95120010	Nutritional drink or shake, high protein, ready-to-drink, NFS
95120020	Nutritional drink or shake, high protein, light, ready-to-drink, NFS
95201000	Nutritional powder mix (Carnation Instant Breakfast)**
95201010	Nutritional powder mix, sugar free (Carnation Instant Breakfast)**
95201200	Nutritional powder mix (EAS Whey Protein Powder) **
95201300	Nutritional powder mix (EAS Soy Protein Powder)**
95201500	Nutritional powder mix, high protein (Herbalife)**
95201600	Nutritional powder mix (Isopure)**
95201700	Nutritional powder mix (Kellogg's Special K20 Protein Water)**
95202000	Nutritional powder mix (Muscle Milk)**
95210000	Nutritional powder mix (Slim Fast)**
95210020	Nutritional powder mix, high protein (Slim Fast)**
95220000	Nutritional powder mix, NFS**
95220010	Nutritional powder mix, high protein, NFS**
95230000	Nutritional powder mix, whey based, NFS**
95230010	Nutritional powder mix, protein, soy based, NFS**
95230020	Nutritional powder mix, protein, light, NFS**
95230030	Nutritional powder mix, protein, NFS**
2c	Nutritional beverages intended for children (i.e., PediaSure)
	Food code Food description
	11710800 Infant formula, NS as to form (PediaSure)
	11710801 Infant formula, ready-to-feed (PediaSure)
	11710806 Infant formula, with fiber, ready-to-feed (PediaSure Fiber)
2d	Alcoholic malt beverage, sweetened
	Food code Food description
	93106000 Alcoholic malt beverage, sweetened
2e	Alcoholic premixed cocktails
	Food code Food description
	93301000 Cocktail, NFS
	93301010 Alexander
	93301020 Bacardi cocktail
	93301032 Cape Cod
	93301040 Daiquiri
	93301050 Gimlet
	93301060 Gin and Tonic
	93301083 Jagerbomb
	93301085 Kamikaze
	93301100 Margarita
	93301111 Martini, flavored
	93301125 Mojito

93301130	Old fashioned
93301132	Orange Blossom
93301141	Seabreeze
93301142	Seven and Seven
93301150	Tom Collins
93301160	Whiskey sour
93301170	Whiskey and soda
93301182	Whiskey and cola
93301183	Whiskey and diet cola
93301184	Whiskey and ginger ale
93301190	Rum and cola
93301191	Rum and diet cola
93301200	Pina Colada
93301205	Brandy and cola
93301211	Vodka and soda
93301213	Vodka and lemonade
93301214	Vodka and cola
93301215	Vodka and diet cola
93301216	Vodka and energy drink
93301218	Vodka and tonic
93301240	Black Russian
93301250	White Russian
93301270	Fruit punch, alcoholic
93301310	Mai Tai
93301320	Tequila Sunrise
93301360	Long Island iced tea
93301400	Irish Coffee
93301450	Liqueur with cream
93301500	Frozen daiquiri
93301510	Frozen margarita
93301550	Eggnog, alcoholic
93404000	Wine cooler
93504100	Rum cooler
3	Candy, hard and soft
3a	Hard Candy (includes pressed candy and mints), low calorie, reduced calorie, sugar-free
	Food code Food description
	91700010 Candy, NFS
	91770020 Dietetic or low calorie hard candy
3b	Soft Candy, low calorie, reduced calorie, sugar-free
	Food code Food description
	91770010 Dietetic or low calorie gumdrops
	91770030 Dietetic or low calorie candy, chocolate covered
4	Chewing gum
	Food code Food description
	91800100 Chewing gum, NFS
	91801000 Chewing gum, regular
	91802000 Chewing gum, sugar free
5	Cereals, ready-to-eat (RTE) and cooked
5a	RTE and cooked, regular
	Food code Food description
	56201360 Grits, instant, made with non-dairy milk, fat added

56201540	Corrmeal, Puerto Rican Style
56202905	Oatmeal, from fast food, maple flavored
56202910	Oatmeal, from fast food, fruit flavored
56202920	Oatmeal, from fast food, other flavors
56203075	Oatmeal, regular or quick, made with non-dairy milk, NS as to fat
56203076	Oatmeal, regular or quick, made with non-dairy milk, no added fat
56203077	Oatmeal, regular or quick, made with non-dairy milk, fat added
56203106	Oatmeal, instant, plain, made with non-dairy milk, no added fat
56203125	Oatmeal, instant, maple flavored, NS as to fat
56203130	Oatmeal, instant, maple flavored, no added fat
56203135	Oatmeal, instant, maple flavored, fat added
56203150	Oatmeal, instant, fruit flavored, NS as to fat
56203155	Oatmeal, instant, fruit flavored, no added fat
56203160	Oatmeal, instant, fruit flavored, fat added
56203175	Oatmeal, instant, other flavors, no added fat
56203180	Oatmeal, instant, other flavors, fat added
56205080	Rice, creamed, made with milk and sugar, Puerto Rican style
56207027	Cream of wheat, regular or quick, made with non-dairy milk, fat added
56207030	Cream of wheat, instant, made with water, no added fat
56207060	Cream of wheat, instant, made with water, fat added
56207094	Cream of wheat, instant, made with milk, fat added
56207095	Cream of wheat, instant, made with milk, no added fat
56207102	Cream of wheat, instant, made with non-dairy milk, no added fat
57100100	Cereal, ready-to-eat, NFS
57101000	Cereal (Kellogg's All-Bran)
57103000	Cereal (Post Alpha-Bits)
57103100	Cereal (General Mills Cheerios Apple Cinnamon)
57104000	Cereal (Kellogg's Apple Jacks)
57106050	Cereal (Post Great Grains Banana Nut Crunch)
57106060	Cereal (General Mills Cheerios Banana Nut)
57106100	Cereal (General Mills Basic 4)
57106250	Cereal (General Mills Kix Berry Berry)
57106260	Cereal (General Mills Cheerios Berry Burst)
57107000	Cereal (General Mills Boo Berry)
57110000	Cereal (Kellogg's All-Bran Bran Buds)
57117000	Cereal (Quaker Cap'n Crunch)
57117500	Cereal (Quaker Christmas Crunch)
57119000	Cereal (Quaker Cap'n Crunch's Crunchberries)
57120000	Cereal (Quaker Cap'n Crunch's Peanut Butter Crunch)
57124030	Cereal (General Mills Chex Chocolate)
57124050	Cereal (General Mills Chex Cinnamon)
57124100	Cereal (General Mills Cheerios Chocolate)
57124200	Cereal, chocolate flavored, frosted, puffed corn
57124300	Cereal (General Mills Lucky Charms Chocolate)
57125000	Cereal (General Mills Cinnamon Toast Crunch)
57125900	Cereal (General Mills Honey Nut Clusters)
57126000	Cereal (Kellogg's Cocoa Krispies)
57127000	Cereal (Post Cocoa Pebbles)
57128000	Cereal (General Mills Cocoa Puffs)
57130000	Cereal (General Mills Cookie Crisp)
57132000	Cereal (General Mills Chex Corn)

57134000 Cereal, corn flakes
57135000 Cereal (Kellogg's Corn Flakes)
57137000 Cereal, corn puffs
57139000 Cereal (General Mills Count Chocula)
57143000 Cereal (Kellogg's Cracklin' Oat Bran)
57143500 Cereal (Post Great Grains, Cranberry Almond Crunch)
57148000 Cereal (Kellogg's Crispix)
57148500 Cereal, crispy brown rice
57151000 Cereal, crispy rice
57201900 Cereal (General Mills Dora The Explorer)
57206710 Cereal (General Mills Fiber One Honey Clusters)
57206715 Cereal (General Mills Fiber One Raisin Bran Clusters)
57207000 Cereal, bran flakes
57208000 Cereal (Kellogg's All-Bran Complete Wheat Flakes)
57209000 Cereal (Post Bran Flakes)
57211000 Cereal (General Mills Frankenberry)
57213000 Cereal (Kellogg's Froot Loops)
57213010 Cereal (Kellogg's Froot Loops Marshmallow)
57213850 Cereal (General Mills Cheerios Frosted)
57214000 Cereal (Kellogg's Frosted Mini-Wheats)
57218000 Cereal (Kellogg's Frosted Krispies)
57221700 Cereal, fruit rings
57221810 Cereal (General Mills Cheerios Fruity)
57223000 Cereal (Post Fruity Pebbles)
57224000 Cereal (General Mills Golden Grahams)
57227000 Cereal, granola
57228000 Granola, homemade
57229000 Cereal (Kellogg's Low Fat Granola)
57229500 Cereal (Kellogg's Low Fat Granola with Raisins)
57231000 Cereal (Post Grape-Nuts Flakes)
57231200 Cereal (Post Great Grains Raisins, Dates, and Pecans)
57231250 Cereal (Post Great Grains Double Pecan Whole Grain Cereal)
57237100 Cereal (Post Honey Bunches of Oats Honey Roasted)
57237200 Cereal (Post Honey Bunches of Oats with Vanilla Bunches)
57237300 Cereal (Post Honey Bunches of Oats with Almonds)
57237900 Cereal (Post Honey Bunches of Oats Just Bunches)
57238000 Cereal (Post Honeycomb)
57240100 Cereal (General Mills Chex Honey Nut)
57241000 Cereal (General Mills Cheerios Honey Nut)
57241200 Cereal (Post Shredded Wheat Honey Nut)
57243000 Cereal (Kellogg's Honey Smacks)
57301505 Cereal (Kashi Autumn Wheat)
57301510 Cereal (Kashi GOLEAN)
57301511 Cereal (Kashi GOLEAN Crunch)
57301512 Cereal (Kashi GOLEAN Crunch Honey Almond Flax)
57301530 Cereal (Kashi Heart to Heart Honey Toasted Oat)
57303100 Cereal (General Mills Kix)
57303105 Cereal (General Mills Honey Kix)
57303200 Cereal (Kellogg's Krave)
57304100 Cereal (Quaker Life)
57305100 Cereal (General Mills Lucky Charms)

57305150 Cereal, frosted oat cereal with marshmallows
57305160 Cereal (Malt-O-Meal Blueberry Muffin Tops)
57305165 Cereal (Malt-O-Meal Cinnamon Toasters)
57305170 Cereal (Malt-O-Meal Coco-Roos)
57305174 Cereal (Malt-O-Meal Colossal Crunch)
57305175 Cereal (Malt-O-Meal Cocoa Dyno-Bites)
57305180 Cereal (Malt-O-Meal Corn Bursts)
57305200 Cereal (Malt-O-Meal Crispy Rice)
57305210 Cereal (Malt-O-Meal Frosted Flakes)
57305215 Cereal (Malt-O-Meal Frosted Mini Spooners)
57305300 Cereal (Malt-O-Meal Fruity Dyno-Bites)
57305400 Cereal (Malt-O-Meal Honey Graham Squares)
57305500 Cereal (Malt-O-Meal Honey Nut Toasty O's)
57305600 Cereal (Malt-O-Meal Marshmallow Mateys)
57306130 Cereal (Malt-O-Meal Raisin Bran)
57306500 Cereal (Malt-O-Meal Golden Puffs)
57306800 Cereal (Malt-O-Meal Tootie Fruities)
57308190 Cereal, muesli
57308400 Cereal (General Mills Cheerios Multigrain)
57309100 Cereal (Nature Valley Granola)
57316300 Cereal (Health Valley Oat Bran Flakes)
57316380 Cereal (General Mills Cheerios Oat Cluster Crunch)
57316385 Cereal (General Mills Cheerios Protein)
57316450 Cereal (General Mills Oatmeal Crisp with Almonds)
57316710 Cereal (Quaker Honey Graham Oh's)
57320500 Cereal (Quaker Granola with Oats, Honey, and Raisins)
57321900 Cereal (Nature's Path Organic Flax Plus)
57326000 Cereal (Barbara's Puffins)
57327450 Cereal (Quaker Toasted Oat Bran)
57327500 Cereal (Quaker Oatmeal Squares)
57329000 Cereal, raisin bran
57330000 Cereal (Kellogg's Raisin Bran)
57330010 Cereal (Kellogg's Raisin Bran Crunch)
57331000 Cereal (Post Raisin Bran)
57332050 Cereal (General Mills Total Raisin Bran)
57332100 Cereal (General Mills Raisin Nut Bran)
57335550 Cereal (General Mills Reese's Puffs)
57336000 Cereal (General Mills Chex Rice)
57337000 Cereal, rice flakes
57339000 Cereal (Kellogg's Rice Krispies)
57339500 Cereal (Kellogg's Rice Krispies Treats Cereal)
57341200 Cereal (Kellogg's Smart Start Strong)
57341300 Cereal (Kellogg's Smorz)
57344000 Cereal (Kellogg's Special K)
57344001 Cereal (Kellogg's Special K Blueberry)
57344005 Cereal (Kellogg's Special K Chocolatey Delight)
57344007 Cereal (Kellogg's Special K Low Fat Granola)
57344010 Cereal (Kellogg's Special K Red Berries)
57344015 Cereal (Kellogg's Special K Fruit & Yogurt)
57344020 Cereal (Kellogg's Special K Vanilla Almond)
57344025 Cereal (Kellogg's Special K Cinnamon Pecan)

	57347000	Cereal (Kellogg's Corn Pops)
	57348000	Cereal, frosted corn flakes
	57349000	Cereal (Kellogg's Frosted Flakes)
	57355000	Cereal (Post Golden Crisp)
	57406100	Cereal (General Mills Total)
	57407100	Cereal (General Mills Trix)
	57411000	Cereal (General Mills Chex Wheat)
	57416010	Cereal, puffed wheat, sweetened
	57418000	Cereal (General Mills Wheaties)
5b	RTE and cooked, low calorie, reduced calorie, sugar-free	
	Food code	Food description
	56203510	Oatmeal, reduced sugar, plain, no added fat
	56203550	Oatmeal, reduced sugar, flavored, NS as to fat
	56203555	Oatmeal, reduced sugar, flavored, no added fat
	56203560	Oatmeal, reduced sugar, flavored, fat added
	57125010	Cereal (General Mills 25% Less Sugar Cinnamon Toast Crunch)
	57128005	Cereal (General Mills 25% Less Sugar Cocoa Puffs)
	57407110	Cereal (General Mills 25% Less Sugar Trix)
5c	RTE cereals with <5% sugar	
	Food code	Food description
	57000100	Cereal, oat, NFS
	57123000	Cereal (General Mills Cheerios)
	57306700	Cereal (Malt-O-Meal Toasted Oat Cereal)
	57401100	Cereal, toasted oat
	57410000	Cereal (Weetabix Whole Grain)
5d	Grain-free, no sugar, high protein RTE cereal	
	Food code	Food description
	57206700	Cereal (General Mills Fiber One)
	57230000	Cereal (Post Grape-Nuts)
	57301500	Cereal (Kashi 7 Whole Grain Puffs)
	57307500	Cereal, millet, puffed
	57340000	Cereal, puffed rice
	57341000	Cereal (Post Shredded Wheat'n Bran)
	57408100	Cereal (Uncle Sam)
	57416000	Cereal, puffed wheat, plain
	57417000	Cereal (Post Shredded Wheat)
6	Coffee mix	
	Food code	Food description
	92121000	Coffee, instant, pre-lightened and pre-sweetened with sugar, reconstituted*
	92121001	Coffee, instant, decaffeinated, pre-lightened and pre-sweetened with sugar, reconstituted*
	92121010	Coffee, instant, pre-sweetened with sugar, reconstituted*
	92121020	Coffee, mocha, instant, pre-lightened and pre-sweetened with sugar, reconstituted*
	92121030	Coffee, mocha, instant, pre-lightened and pre-sweetened with low calorie sweetener, reconstituted*
	92121040	Coffee, instant, pre-lightened and pre-sweetened with low calorie sweetener, reconstituted*
	92121041	Coffee, instant, decaffeinated, pre-lightened and pre-sweetened with low calorie sweetener, reconstituted*
	92191400	Coffee, instant, pre-sweetened with sugar, not reconstituted
	92193000	Coffee, instant, pre-lightened and pre-sweetened with sugar, not reconstituted

7	Confections & Frostings
	Food code Food description
	51160110 Roll, sweet, cinnamon bun, frosted*
	51161020 Roll, sweet, with fruit, frosted*
	51161050 Roll, sweet, frosted*
	51161270 Pan Dulce, with sugar topping*
	51161280 Pan Dulce, with raisins and icing*
	51165000 Coffee cake, yeast type*
	53100100 Cake or cupcake, NS as to type*
	53101200 Cake, angel food, with icing or filling*
	53101250 Cake, angel food, with fruit and icing or filling*
	53102200 Cake or cupcake, applesauce, with icing or filling*
	53102700 Cake or cupcake, banana, with icing or filling*
	53102800 Cake or cupcake, Black Forest*
	53104260 Cake or cupcake, carrot, with icing or filling*
	53104400 Cake or cupcake, coconut, with icing or filling*
	53105270 Cake or cupcake, chocolate, devil's food or fudge, with icing or filling*
	53105300 Cake or cupcake, German chocolate, with icing or filling*
	53108200 Snack cake, chocolate, with icing or filling*
	53109200 Snack cake, not chocolate, with icing or filling*
	53111000 Cake or cupcake, gingerbread*
	53114100 Cake or cupcake, lemon, with icing or filling*
	53115200 Cake or cupcake, marble, with icing or filling*
	53115320 Cake or cupcake, nut, with icing or filling*
	53115410 Cake or cupcake, oatmeal*
	53115450 Cake or cupcake, peanut butter*
	53116020 Cake, pound, with icing or filling*
	53116270 Cake, pound, chocolate*
	53116510 Cake or cupcake, pumpkin, with icing or filling*
	53117200 Cake or cupcake, spice, with icing or filling*
	53118200 Cake, sponge, with icing or filling*
	53118300 Cake, sponge, chocolate*
	53118500 Cake, torte*
	53118550 Cake, tres leche*
	53120270 Cake or cupcake, white, with icing or filling*
	53121270 Cake or cupcake, yellow, with icing or filling*
	53124110 Cake or cupcake, zucchini*
	53204000 Cookie, brownie, NS as to icing*
	53204100 Cookie, brownie, with icing or filling*
	53204840 Cookie, brownie, reduced fat, NS as to icing*
	53204860 Cookie, brownie, fat free, NS as to icing*
	53206100 Cookie, chocolate chip sandwich*
	53208000 Cookie, marshmallow, chocolate-covered*
	53208200 Cookie, marshmallow pie, chocolate covered*
	53209005 Cookie, chocolate, with icing or coating*
	53210900 Cookie, graham cracker with chocolate and marshmallow*
	53226000 Cookie, marshmallow, with coconut*
	53226500 Cookie, marshmallow, with rice cereal, no bake*
	53226550 Cookie, marshmallow, with rice cereal and chocolate chips*
	53226600 Cookie, marshmallow and peanut butter, with oat cereal, no bake*
	53233000 Cookie, oatmeal*

53233010	Cookie, oatmeal, with raisins*
53234100	Cookie, peanut butter, with chocolate*
53238000	Cookie, sandwich-type, not chocolate or vanilla*
53239050	Cookie, shortbread, with icing or filling*
53240010	Cookie, animal, with frosting or icing*
53243000	Cookie, vanilla sandwich*
53243050	Cookie, vanilla sandwich, reduced fat*
53244010	Cookie, butter or sugar, with chocolate icing or filling*
53244020	Cookie, butter or sugar, with icing or filling other than chocolate*
53420000	Cream puff, eclair, custard or cream filled, NS as to icing*
53420200	Cream puff, eclair, custard or cream filled, iced*
53452420	Pastry, puff, custard or cream filled, iced or not iced*
53510000	Danish pastry, plain or spice*
53510100	Danish pastry, with fruit*
53520110	Doughnut, cake type*
53520120	Doughnut, chocolate*
53520135	Doughnut, cake type, with icing*
53520140	Doughnut, cake type, chocolate icing*
53520160	Doughnut, chocolate, with chocolate icing*
53520170	Doughnut holes*
53521100	Doughnut, chocolate, raised or yeast, with chocolate icing*
53521110	Doughnut, yeast type*
53521120	Doughnut, chocolate, raised or yeast*
53521130	Doughnut, yeast type, with chocolate icing*
53521230	Doughnut, custard-filled, with icing*
53530000	Breakfast tart*
53610100	Coffee cake, crumb or quick-bread type*
63402980	Fruit salad, excluding citrus fruits, with marshmallows*
63403040	Fruit salad, including citrus fruits, with marshmallows*
91304040	Topping, marshmallow
91305010	Icing, chocolate
91305020	Icing, white
91723000	Marshmallow
8	Dressings for salads
Food code	Food description
11440010	Chipotle dip, yogurt based*
11440020	Dill dip, yogurt based*
11440040	Ranch dip, yogurt based*
11440050	Spinach dip, yogurt based*
11440070	Vegetable dip, yogurt based*
12350010	Dip, NFS*
12350200	Chipotle dip, regular*
12350210	Dill dip, regular*
12350220	Onion dip, regular*
12350225	Onion dip, light*
12350230	Ranch dip, regular*
12350235	Ranch dip, light*
12350240	Spinach dip, regular*
12350245	Spinach dip, light*
12350250	Vegetable dip, regular*
12350255	Vegetable dip, light*

14620110	Artichoke dip*
14620115	Spinach and artichoke dip*
14620130	Seafood dip*
14640026	Cheese sandwich, American cheese, on white bread, with mayonnaise*
14640028	Cheese sandwich, American cheese, on wheat bread, with mayonnaise*
14640030	Cheese sandwich, American cheese, on whole wheat bread, with mayonnaise*
14640032	Cheese sandwich, Cheddar cheese, on white bread, with mayonnaise*
14640034	Cheese sandwich, Cheddar cheese, on wheat bread, with mayonnaise*
14640036	Cheese sandwich, Cheddar cheese, on whole wheat bread, with mayonnaise*
14640042	Cheese sandwich, reduced fat American cheese, on whole wheat bread, with mayonnaise*
14640046	Cheese sandwich, reduced fat Cheddar cheese, on wheat bread, with mayonnaise*
14640048	Cheese sandwich, reduced fat Cheddar cheese, on whole wheat bread, with mayonnaise*
14670000	Mozzarella cheese, tomato, and basil, with oil and vinegar dressing*
27220080	Ham croquette*
27246300	Chicken or turkey cake, patty, or croquette*
27250040	Crab cake*
27250070	Salmon cake or patty*
27250160	Tuna cake or patty*
27250400	Shrimp cake or patty*
27416250	Beef salad*
27420020	Ham or pork salad*
27446200	Chicken or turkey salad, made with mayonnaise*
27446205	Chicken or turkey salad with nuts and/or fruits*
27446220	Chicken or turkey salad with egg*
27446225	Chicken or turkey salad, made with light mayonnaise*
27446230	Chicken or turkey salad, made with mayonnaise-type salad dressing*
27446235	Chicken or turkey salad, made with light mayonnaise-type salad dressing*
27446240	Chicken or turkey salad, made with creamy dressing*
27446245	Chicken or turkey salad, made with light creamy dressing*
27446260	Chicken or turkey salad, made with any type of fat free dressing*
27450010	Crab salad*
27450020	Lobster salad*
27450060	Tuna salad, made with mayonnaise*
27450061	Tuna salad, made with light mayonnaise*
27450062	Tuna salad, made with mayonnaise-type salad dressing*
27450063	Tuna salad, made with light mayonnaise-type salad dressing*
27450064	Tuna salad, made with creamy dressing*
27450066	Tuna salad, made with Italian dressing*
27450068	Tuna salad, made with any type of fat free dressing*
27450070	Shrimp salad*
27450080	Seafood salad*
27450090	Tuna salad with cheese*
27450100	Tuna salad with egg*
27450130	Crab salad made with imitation crab*
27500050	Sandwich, NFS*
27500100	Meat sandwich, NFS*
27510000	Beef sandwich, NFS*
27510145	Cheeseburger, 1 miniature patty, with condiments, on miniature bun, from fast food / restaurant*

- 27510165 Cheeseburger, 1 small patty, with condiments, on bun, from fast food / restaurant*
- 27510171 Whopper Jr with cheese (Burger King)*
- 27510175 Cheeseburger, 1 small patty, with condiments, on bun, from fast food / restaurant (Wendy's Jr. Cheeseburger Deluxe)*
- 27510205 Cheeseburger, 1 small patty, with condiments, on white bun*
- 27510206 Cheeseburger, 1 small patty, with condiments, on wheat bun*
- 27510207 Cheeseburger, 1 small patty, with condiments, on whole wheat bun*
- 27510225 Cheeseburger, 1 medium patty, with condiments, on bun, from fast food / restaurant*
- 27510251 Cheeseburger, 1 medium patty, with condiments, on white bun*
- 27510252 Cheeseburger, 1 medium patty, with condiments, on wheat bun*
- 27510253 Cheeseburger, 1 medium patty, with condiments, on whole wheat bun*
- 27510266 Cheeseburger, 1 large patty, with condiments, on bun, from fast food / restaurant*
- 27510276 Bacon cheeseburger, 1 small patty, with condiments, on bun, from fast food / restaurant*
- 27510312 Bacon cheeseburger, 1 medium patty, with condiments, on bun, from fast food / restaurant*
- 27510341 Bacon cheeseburger, 1 medium patty, with condiments, on white bun*
- 27510342 Bacon cheeseburger, 1 medium patty, with condiments, on wheat bun*
- 27510343 Bacon cheeseburger, 1 medium patty, with condiments, on whole wheat bun*
- 27510346 Bacon cheeseburger, 1 large patty, with condiments, on bun, from fast food / restaurant*
- 27510376 Double cheeseburger, 2 small patties, with condiments, on bun, from fast food / restaurant*
- 27510406 Double cheeseburger, 2 medium patties, with condiments, on bun, from fast food / restaurant*
- 27510431 Double bacon cheeseburger, 2 small patties, with condiments, on bun, from fast food / restaurant (Burger King Bacon Double Cheeseburger)*
- 27510451 Double bacon cheeseburger, 2 medium patties, with condiments, on bun, from fast food / restaurant*
- 27510465 Double bacon cheeseburger, 2 medium patties, with condiments, on bun, from fast food / restaurant (Wendy's Baconator)*
- 27510475 Double bacon cheeseburger, 2 large patties, with condiments, on bun, from fast food / restaurant*
- 27510486 Triple cheeseburger, 3 medium patties, with condiments, on bun, from fast food / restaurant*
- 27510506 Hamburger, 1 miniature patty, with condiments, on miniature bun, from fast food / restaurant*
- 27510511 Hamburger, 1 miniature patty, on miniature bun, from school*
- 27510536 Hamburger, 1 small patty, with condiments, on bun, from fast food / restaurant*
- 27510552 Whopper Jr (Burger King)*
- 27510555 Hamburger, 1 small patty, with condiments, on bun, from fast food / restaurant (Wendy's Jr. Hamburger)*
- 27510565 Hamburger, from school cafeteria*
- 27510585 Hamburger, 1 small patty, with condiments, on white bun*
- 27510587 Hamburger, 1 small patty, with condiments, on whole wheat bun*
- 27510606 Hamburger, 1 medium patty, with condiments, on bun, from fast food / restaurant*
- 27510641 Hamburger, 1 medium patty, with condiments, on white bun*
- 27510642 Hamburger, 1 medium patty, with condiments, on wheat bun*
- 27510643 Hamburger, 1 medium patty, with condiments, on whole wheat bun*
- 27510667 Double hamburger, 2 small patties, with condiments, on bun, from fast food / restaurant*

27510676	Double hamburger, 2 medium patties, with condiments, on bun, from fast food / restaurant*
27510681	Double hamburger, 2 medium patties, with condiments, on bun, from fast food / restaurant (Burger King Double WHOPPER)*
27510682	Double hamburger, 2 medium patties, with condiments, on bun, from fast food / restaurant (Wendy's 1/2 lb Double)*
27510950	Reuben sandwich, corned beef sandwich with sauerkraut and cheese, with spread*
27513040	Roast beef submarine sandwich, with lettuce, tomato and spread*
27513041	Roast beef submarine sandwich, with cheese, lettuce, tomato and spread*
27520150	Bacon, lettuce, and tomato sandwich with spread*
27520155	Bacon, lettuce, and tomato submarine sandwich, with spread*
27520156	Bacon, lettuce, tomato, and cheese submarine sandwich, with spread*
27520160	Bacon, chicken, and tomato club sandwich, on multigrain roll with lettuce and spread*
27520166	Bacon, breaded fried chicken fillet, and tomato club sandwich with cheese, lettuce and spread*
27520310	Ham sandwich with lettuce and spread*
27520320	Ham and cheese sandwich, with lettuce and spread*
27520350	Ham and cheese sandwich, with spread, grilled*
27520370	Hot ham and cheese sandwich, on bun*
27540110	Sliced chicken sandwich, with spread*
27540111	Sliced chicken sandwich, with cheese and spread*
27540120	Chicken salad or chicken spread sandwich*
27540170	Chicken patty sandwich, miniature, with spread*
27540240	Chicken fillet, broiled, sandwich, on whole wheat roll, with lettuce, tomato and spread*
27540295	Buffalo chicken submarine sandwich*
27540296	Buffalo chicken submarine sandwich with cheese*
27540310	Turkey sandwich, with spread*
27540360	Turkey and bacon submarine sandwich, with lettuce, tomato and spread*
27540361	Turkey and bacon submarine sandwich, with cheese, lettuce, tomato and spread*
27541000	Turkey, ham, and roast beef club sandwich, with lettuce, tomato and spread*
27545010	Turkey or chicken burger, with condiments, on bun, from fast food / restaurant*
27545200	Turkey or chicken burger, with condiments, on white bun*
27545210	Turkey or chicken burger, with condiments, on wheat bun*
27545220	Turkey or chicken burger, with condiments, on whole wheat bun*
27550110	Crab cake sandwich*
27550120	Salmon cake sandwich*
27550720	Tuna salad sandwich, on bread*
27550730	Tuna salad sandwich, on bread, with cheese*
27550740	Tuna salad sandwich, on bun*
27550745	Tuna salad sandwich, on bun, with cheese*
27550750	Tuna salad submarine sandwich, with lettuce and tomato*
27550751	Tuna salad submarine sandwich, with cheese, lettuce and tomato*
27550755	Tuna salad wrap sandwich*
27550800	Seafood salad sandwich*
27560120	Bologna and cheese sandwich, with spread*
27560500	Pepperoni and salami submarine sandwich, with lettuce, tomato and spread*
32102000	Egg, deviled*
32103000	Egg salad, made with mayonnaise*
32103015	Egg salad, made with light mayonnaise*
32103020	Egg salad, made with mayonnaise-type salad dressing*
32103025	Egg salad, made with light mayonnaise-type salad dressing*

32103050	Egg Salad, made with any type of fat free dressing*
32202025	Egg, cheese and ham on bagel*
41203030	Black bean salad*
41420100	Miso sauce*
58127500	Vegetable submarine sandwich, with fat free spread*
58134640	Tortellini, cheese-filled, meatless, with vinaigrette dressing*
58148110	Macaroni or pasta salad, made with mayonnaise*
58148111	Macaroni or pasta salad, made with light mayonnaise*
58148112	Macaroni or pasta salad, made with mayonnaise-type salad dressing*
58148114	Macaroni or pasta salad, made with Italian dressing*
58148117	Macaroni or pasta salad, made with light creamy dressing*
58148118	Macaroni or pasta salad, made with any type of fat free dressing*
58148120	Macaroni or pasta salad with egg*
58148130	Macaroni or pasta salad with tuna*
58148150	Macaroni or pasta salad with shrimp*
58148160	Macaroni or pasta salad with tuna and egg*
58148170	Macaroni or pasta salad with chicken*
58148180	Macaroni or pasta salad with cheese*
58148550	Macaroni or pasta salad with meat*
63401010	Apple salad with dressing*
63402950	Fruit salad, excluding citrus fruits, with salad dressing or mayonnaise*
63402980	Fruit salad, excluding citrus fruits, with marshmallows*
63403040	Fruit salad, including citrus fruits, with marshmallows*
71600950	Potato salad with egg, from restaurant*
71601010	Potato salad with egg, made with mayonnaise*
71601015	Potato salad with egg, made with light mayonnaise*
71601020	Potato salad with egg, made with mayonnaise-type salad dressing*
71601025	Potato salad with egg, made with light mayonnaise-type salad dressing*
71601035	Potato salad with egg, made with light creamy dressing*
71601050	Potato salad with egg, made with any type of fat free dressing*
71602010	Potato salad, German style*
71602950	Potato salad, from restaurant*
71603010	Potato salad, made with mayonnaise*
71603015	Potato salad, made with light mayonnaise*
71603020	Potato salad, made with mayonnaise-type salad dressing*
71603050	Potato salad, made with any type of fat free dressing*
73101110	Carrots, raw, salad*
73101210	Carrots, raw, salad with apples*
74701000	Tomato sandwich*
75140500	Broccoli salad with cauliflower, cheese, bacon bits, and dressing*
75140510	Broccoli slaw salad*
75140990	Cabbage salad or coleslaw, from fast food / restaurant*
75141000	Cabbage salad or coleslaw, made with coleslaw dressing*
75141005	Cabbage salad or coleslaw, made with light coleslaw dressing*
75141020	Cabbage salad or coleslaw, made with Italian dressing*
75141025	Cabbage salad or coleslaw, made with light Italian dressing*
75141030	Cabbage salad or coleslaw, made with creamy dressing*
75141035	Cabbage salad or coleslaw, made with light creamy dressing*
75141040	Cabbage salad or coleslaw, made with any type of fat free dressing*
75141100	Cabbage salad or coleslaw with apples and/or raisins, with dressing*
75141200	Cabbage salad or coleslaw with pineapple, with dressing*

75142500	Cucumber salad, made with sour cream dressing*
75142550	Cucumber salad, made with Italian dressing*
75142600	Cucumber salad made with cucumber and vinegar*
75302080	Bean salad, yellow and/or green string beans*
75416600	Pea salad with cheese*
81308100	Fry sauce*
83100100	Salad dressing, NFS, for salads
83100200	Salad dressing, NFS, for sandwiches
83101000	Blue or roquefort cheese dressing
83102000	Caesar dressing
83103000	Coleslaw dressing
83104000	French or Catalina dressing
83105500	Honey mustard dressing
83106000	Italian dressing, made with vinegar and oil
83107000	Mayonnaise, regular
83108000	Vegan mayonnaise
83109000	Russian dressing
83110000	Mayonnaise-type salad dressing
83112000	Avocado dressing
83112500	Creamy dressing
83112950	Poppy seed dressing
83112990	Sesame dressing
83114000	Thousand Island dressing
83115000	Yogurt dressing
83200100	Salad dressing, light, NFS
83201000	Blue or roquefort cheese dressing, light
83202020	French or Catalina dressing, light
83203000	Caesar dressing, light
83204000	Mayonnaise, light
83204030	Mayonnaise, reduced fat, with olive oil
83204050	Mayonnaise-type salad dressing, light
83204500	Honey mustard dressing, light
83205450	Italian dressing, light
83206500	Sesame dressing, light
83207000	Thousand Island dressing, light
83210100	Creamy dressing, light
83300100	Blue or roquefort cheese dressing, fat free
83300200	Caesar dressing, fat free
83300300	Creamy dressing, fat free
83300400	French or Catalina dressing, fat free
83300500	Honey mustard dressing, fat free
83300600	Italian dressing, fat free
83300700	Mayonnaise, fat free
83300900	Salad dressing, fat free, NFS
83301000	Thousand Island dressing, fat free
9	Frozen dairy (ice cream, soft serve, sorbet), low calorie, reduced calorie, sugar-free
	Food code Food description
	13110000 Ice cream, NFS
	13110320 Ice cream, no sugar added, flavors other than chocolate
	13110330 Ice cream, no sugar added, chocolate
	13120740 Ice cream cone, NFS

13121000	Ice cream sundae, NFS
13130300	Light ice cream, vanilla
13130310	Light ice cream, chocolate
13130320	Light ice cream, no sugar added, NS as to flavor
13130330	Light ice cream, no sugar added, flavors other than chocolate
13130340	Light ice cream, no sugar added, chocolate
13135000	Light ice cream sandwich, vanilla
13135010	Light ice cream sandwich, chocolate
13136000	Ice cream sandwich, made with light, no sugar added ice cream
13140000	Light ice cream bar, vanilla
13140100	Light ice cream bar, vanilla, chocolate coated
13140115	Light ice cream bar, chocolate
13140575	Light ice cream, no sugar added, cone, flavors other than chocolate
13140580	Light ice cream, no sugar added, cone, chocolate
13142100	Light ice cream cone, vanilla, prepackaged
13142110	Light ice cream cone, chocolate, prepackaged
13160160	Fat free ice cream, no sugar added, flavors other than chocolate
13161600	Fudgesicle, light
13161630	Light ice cream, bar or stick, with low-calorie sweetener, chocolate coated
10	Gelatins, pudding & fillings
10a	Gelatins, pudding & fillings, low calorie, reduced calorie, sugar-free
	Food code Food description
	13200110 Pudding, chocolate, NFS
	13210250 Pudding, chocolate, low calorie, containing artificial sweetener, NS as to from dry mix or ready-to-eat
	13210280 Pudding, flavors other than chocolate, NFS
	13210290 Pudding, flavors other than chocolate, low calorie, containing artificial sweetener, NS as to from dry mix or ready-to-eat
	13210520 Pudding, tapioca, made from dry mix
	13220210 Pudding, flavors other than chocolate, made from dry mix, sugar free
	13220220 Pudding, chocolate, made from dry mix, sugar free
	13230120 Pudding, flavors other than chocolate, ready-to-eat, sugar free
	13230140 Pudding, chocolate, ready-to-eat, sugar free
	13230500 Pudding, tapioca, ready-to-eat
	91511010 Gelatin dessert, sugar free
	91511020 Gelatin dessert, sugar free, with fruit*
	91511030 Gelatin dessert, dietetic, with whipped topping, sweetened with low calorie sweetener*
	91511060 Gelatin dessert, dietetic, with sour cream, sweetened with low calorie sweetener*
10b	Fat-based cream (used in modified fat/calorie cookies, cakes, pastries, pie)
	Food code Food description
	53209010 Cookie, sugar wafer, chocolate-covered*
	53209015 Cookie, chocolate sandwich*
	53209020 Cookie, chocolate sandwich, reduced fat*
	53209100 Cookie, chocolate, sandwich, with extra filling*
	53209500 Cookie, chocolate and vanilla sandwich*
	53210000 Cookie, chocolate wafer*
	53233050 Cookie, oatmeal sandwich, with creme filling*
	53237010 Cookie, raisin sandwich, cream-filled*
	53242000 Cookie, sugar wafer*
	53344200 Mixed fruit tart filled with custard or cream cheese*
	53420000 Cream puff, eclair, custard or cream filled, NS as to icing*

	53420100	Cream puff, eclair, custard or cream filled, not iced*
	53420200	Cream puff, eclair, custard or cream filled, iced*
	53430000	Crepe, NS as to filling*
	53430100	Crepe, chocolate filled*
	53452420	Pastry, puff, custard or cream filled, iced or not iced*
	53521210	Doughnut, custard-filled*
	53521230	Doughnut, custard-filled, with icing*
	54102200	Graham crackers, sandwich, with filling*
11	Nutrition bars	
	Food code	Food description
	53710800	Cereal or granola bar (Kashi Chewy)
	53710802	Cereal or granola bar (Kashi Crunchy)
	53720100	Nutrition bar (Balance Original Bar)
	53720200	Nutrition bar (Clif Bar)
	53720210	Nutrition bar (Clif Kids Organic Zbar)
	53720300	Nutrition bar (PowerBar)
	53720400	Nutrition bar (Slim Fast Original Meal Bar)
	53720500	Nutrition bar (Snickers Marathon Protein Bar)
	53720600	Nutrition bar (South Beach Living Meal Bar)
	53720610	Nutrition bar (South Beach Living High Protein Bar)
	53720700	Nutrition bar (Tiger's Milk)
	53720800	Nutrition bar (Zone Perfect Classic Crunch)
	53729000	Nutrition bar or meal replacement bar, NFS
12	Jams & Jellies	
	Food code	Food description
	42203000	Peanut butter and jelly*
	42302010	Peanut butter and jelly sandwich, NFS*
	42302015	Peanut butter and jelly sandwich, with regular peanut butter, regular jelly, on white bread*
	42302020	Peanut butter and jelly sandwich, with regular peanut butter, regular jelly, on wheat bread*
	42302025	Peanut butter and jelly sandwich, with regular peanut butter, regular jelly, on whole wheat bread*
	42302055	Peanut butter and jelly sandwich, with reduced fat peanut butter, regular jelly, on white bread*
	42302060	Peanut butter and jelly sandwich, with reduced fat peanut butter, regular jelly, on wheat bread*
	42302065	Peanut butter and jelly sandwich, with reduced fat peanut butter, regular jelly, on whole wheat bread*
	42302105	Peanut butter and jelly sandwich, with regular peanut butter, reduced sugar jelly, on white bread*
	42302110	Peanut butter and jelly sandwich, with regular peanut butter, reduced sugar jelly, on wheat bread*
	42302115	Peanut butter and jelly sandwich, with regular peanut butter, reduced sugar jelly, on whole wheat bread*
	42302155	Peanut butter and jelly sandwich, with reduced fat peanut butter, reduced sugar jelly, on white bread*
	42302160	Peanut butter and jelly sandwich, with reduced fat peanut butter, reduced sugar jelly, on wheat bread*
	42302165	Peanut butter and jelly sandwich, with reduced fat peanut butter, reduced sugar jelly, on whole wheat bread*

42303100	Peanut butter and jelly sandwich, frozen commercial product without crusts*
53233080	Cookie, oatmeal sandwich, with peanut butter and jelly filling*
53344200	Mixed fruit tart filled with custard or cream cheese*
53344300	Dessert pizza*
53521140	Doughnut, jelly*
58201005	Jelly sandwich, regular jelly, on white bread*
58201015	Jelly sandwich, regular jelly, on wheat bread*
58201025	Jelly sandwich, regular jelly, on whole wheat bread*
58201035	Jelly sandwich, reduced sugar jelly, on white bread*
58201045	Jelly sandwich, reduced sugar jelly, on wheat bread*
91401000	Jelly, all flavors
91402000	Jam, preserve, all flavors
91403000	Fruit butter, all flavors
91404000	Marmalade, all flavors
91405000	Jelly, sugar free, all flavors
91405500	Jelly, reduced sugar, all flavors
91406000	Jam, preserve, marmalade, sugar free, all flavors
91406500	Jam, preserve, marmalade, sweetened with fruit juice concentrates, all flavors
91406600	Jam, preserve, marmalade, reduced sugar, all flavors
91407100	Guava paste
91407120	Sweet potato paste
91407150	Bean paste, sweetened

13

Sugar

Food code	Food description
11541110	Milk shake, home recipe, chocolate*
11541120	Milk shake, home recipe, flavors other than chocolate*
11541130	Milk shake, home recipe, chocolate, light*
11541135	Milk shake, home recipe, flavors other than chocolate, light*
13210500	Pudding, tapioca, made from home recipe, made with milk*
28340310	Chicken or turkey gumbo soup, home recipe, canned or ready-to-serve*
41601030	Black bean soup, home recipe, canned or ready-to-serve*
51000180	Bread, made from home recipe or purchased at a bakery, NS as to major flour*
51101050	Bread, white, made from home recipe or purchased at a bakery*
51101060	Bread, white, made from home recipe or purchased at a bakery, toasted*
51161270	Pan Dulce, with sugar topping*
51300140	Bread, whole wheat, made from home recipe or purchased at bakery*
51300150	Bread, whole wheat, made from home recipe or purchased at bakery, toasted*
51301040	Bread, wheat or cracked wheat, made from home recipe or purchased at bakery*
51301050	Bread, wheat or cracked wheat, made from home recipe or purchased at bakery, toasted*
52104010	Biscuit, home recipe*
52202060	Cornbread, made from home recipe*
52206060	Cornbread muffin, stick, round, made from home recipe*
53206020	Cookie, chocolate chip, made from home recipe or purchased at a bakery*
55801000	Funnel cake with sugar*
55801010	Funnel cake with sugar and fruit*
58146222	Pasta with tomato-based sauce, home recipe*
58146302	Pasta with tomato-based sauce, and added vegetables, home recipe*
58146322	Pasta with tomato-based sauce and meat, home recipe*
58146332	Pasta with tomato-based sauce, meat, and added vegetables, home recipe*
58146342	Pasta with tomato-based sauce and poultry, home recipe*

58146352	Pasta with tomato-based sauce, poultry, and added vegetables, home recipe*
58146362	Pasta with tomato-based sauce and seafood, home recipe*
58146372	Pasta with tomato-based sauce, seafood, and added vegetables, home recipe*
58146602	Pasta, whole grain, with tomato-based sauce, home recipe*
58146612	Pasta, whole grain, with tomato-based sauce and added vegetables, home recipe*
58146622	Pasta, whole grain, with tomato-based sauce and meat, home recipe*
58146632	Pasta, whole grain, with tomato-based sauce, meat, and added vegetables, home recipe*
58146642	Pasta, whole grain, with tomato-based sauce and poultry, home recipe*
58146652	Pasta, whole grain, with tomato-based sauce, poultry, and added vegetables, home recipe*
58146662	Pasta, whole grain, with tomato-based sauce and seafood, home recipe*
58146672	Pasta, whole grain, with tomato-based sauce, seafood, and added vegetables, home recipe*
58401010	Barley soup, home recipe, canned, or ready-to-serve*
62101230	Apple, dried, cooked, with sugar*
63101130	Applesauce, stewed apples, with sugar*
63101330	Apple, baked, with sugar*
63135630	Peach, frozen, with sugar*
63147620	Rhubarb, frozen, with sugar*
63223620	Strawberries, frozen, with sugar*
91101000	Sugar, NFS
91101010	Sugar, white, granulated or lump
91101020	Sugar, white, confectioner's, powdered
91102010	Sugar, brown
91104100	Sugar, cinnamon
91302010	Honey
91302020	Agave liquid sweetener
91303000	Molasses
92101820	Coffee, macchiato, sweetened*
92101850	Coffee, cafe con leche*
92101851	Coffee, cafe con leche, decaffeinated*
92102450	Iced Coffee, pre-lightened and pre-sweetened*
92130000	Coffee, pre-lightened and pre-sweetened with sugar*
92130020	Coffee, pre-sweetened with sugar*
92130021	Coffee, decaffeinated, pre-sweetened with sugar*
92305040	Tea, iced, instant, black, pre-sweetened with sugar*
92305050	Tea, iced, instant, black, decaffeinated, pre-sweetened with sugar*
92305910	Tea, iced, instant, green, pre-sweetened with sugar*
92307400	Tea, iced, instant, black, pre-sweetened, dry*
92308000	Tea, iced, brewed, black, pre-sweetened with sugar*
92308030	Tea, iced, brewed, black, decaffeinated, pre-sweetened with sugar*
92308500	Tea, iced, brewed, green, pre-sweetened with sugar*
92308530	Tea, iced, brewed, green, decaffeinated, pre-sweetened with sugar*
14	Sugar substitutes
	Food code Food description
	91106010 Sugar substitute and sugar blend
	91107000 Sugar substitute, sucralose, powder
	91108000 Sugar substitute, stevia, powder
	91108010 Sugar substitute, stevia, liquid
	91108020 Sugar substitute, monk fruit, powder

	91200000	Sugar substitute, powder, NFS
	91200005	Sugar substitute, liquid, NFS
	91200040	Sugar substitute, saccharin, powder
	91200110	Sugar substitute, saccharin, liquid
	91201010	Sugar substitute, aspartame, powder
15	Sweet sauces & syrups, low calorie, reduced calorie, sugar-free	
	Food code	Food description
	11513801	Chocolate milk, made from light syrup with whole milk*
	11513802	Chocolate milk, made from light syrup with reduced fat milk*
	11513803	Chocolate milk, made from light syrup with low fat milk*
	11513804	Chocolate milk, made from light syrup with fat free milk*
	91300010	Syrup, NFS
	91301081	Chocolate syrup, light
	91301082	Chocolate syrup, thin type, sugar free
	91301510	Pancake syrup, light
	91306025	Caramel dip, light
	91351010	Syrup, dietetic
16	Ketchup and barbecue sauces	
	Food code	Food description
	21304210	Beef, shortribs, barbecued, with sauce, lean and fat eaten*
	21304220	Beef, shortribs, barbecued, with sauce, lean only eaten*
	22701030	Pork, spareribs, barbecued, with sauce, NS as to fat eaten*
	22701040	Pork, spareribs, barbecued, with sauce, lean and fat eaten*
	22701050	Pork, spareribs, barbecued, with sauce, lean only eaten*
	24103070	Chicken, NS as to part, grilled with sauce, NS as to skin eaten*
	24103075	Chicken, NS as to part, grilled with sauce, skin eaten*
	24103080	Chicken, NS as to part, grilled with sauce, skin not eaten*
	24123310	Chicken breast, grilled with sauce, skin eaten*
	24123311	Chicken breast, grilled with sauce, skin not eaten*
	24134150	Chicken leg, drumstick and thigh, grilled with sauce, skin eaten*
	24134151	Chicken leg, drumstick and thigh, grilled with sauce, skin not eaten*
	24142510	Chicken drumstick, grilled with sauce, skin eaten*
	24142511	Chicken drumstick, grilled with sauce, skin not eaten*
	24154020	Chicken thigh, grilled with sauce, skin eaten*
	24154021	Chicken thigh, grilled with sauce, skin not eaten*
	24164010	Chicken wing, grilled with sauce*
	24168001	Chicken "wings" with other sauces or seasoning, from fast food / restaurant*
	24168011	Chicken "wings" with other sauces or seasoning, from precooked*
	24168021	Chicken "wings" with other sauces or seasoning, from other sources*
	24168030	Chicken "wings", boneless, with hot sauce, from fast food / restaurant*
	24168031	Chicken "wings", boneless, with hot sauce, from other sources*
	24209000	Turkey with barbecue sauce, skin eaten*
	24209001	Turkey with barbecue sauce, skin not eaten*
	27111500	Beef sloppy joe, no bun*
	27116200	Beef with barbecue sauce*
	27116300	Beef with sweet and sour sauce*
	27120030	Ham or pork with barbecue sauce*
	27120060	Sweet and sour pork*
	27146011	Chicken, shredded or pulled, with barbecue sauce*
	27150170	Sweet and sour shrimp*
	27160010	Meat with barbecue sauce, NS as to type of meat*

27315250	Stuffed cabbage rolls with beef and rice*
27510145	Cheeseburger, 1 miniature patty, with condiments, on miniature bun, from fast food / restaurant*
27510165	Cheeseburger, 1 small patty, with condiments, on bun, from fast food / restaurant*
27510170	Cheeseburger (Burger King)*
27510171	Whopper Jr with cheese (Burger King)*
27510175	Cheeseburger, 1 small patty, with condiments, on bun, from fast food / restaurant (Wendy's Jr. Cheeseburger Deluxe)*
27510205	Cheeseburger, 1 small patty, with condiments, on white bun*
27510206	Cheeseburger, 1 small patty, with condiments, on wheat bun*
27510207	Cheeseburger, 1 small patty, with condiments, on whole wheat bun*
27510225	Cheeseburger, 1 medium patty, with condiments, on bun, from fast food / restaurant*
27510251	Cheeseburger, 1 medium patty, with condiments, on white bun*
27510252	Cheeseburger, 1 medium patty, with condiments, on wheat bun*
27510253	Cheeseburger, 1 medium patty, with condiments, on whole wheat bun*
27510266	Cheeseburger, 1 large patty, with condiments, on bun, from fast food / restaurant*
27510276	Bacon cheeseburger, 1 small patty, with condiments, on bun, from fast food / restaurant*
27510312	Bacon cheeseburger, 1 medium patty, with condiments, on bun, from fast food / restaurant*
27510341	Bacon cheeseburger, 1 medium patty, with condiments, on white bun*
27510342	Bacon cheeseburger, 1 medium patty, with condiments, on wheat bun*
27510343	Bacon cheeseburger, 1 medium patty, with condiments, on whole wheat bun*
27510346	Bacon cheeseburger, 1 large patty, with condiments, on bun, from fast food / restaurant*
27510376	Double cheeseburger, 2 small patties, with condiments, on bun, from fast food / restaurant*
27510386	Double cheeseburger (Burger King)*
27510406	Double cheeseburger, 2 medium patties, with condiments, on bun, from fast food / restaurant*
27510431	Double bacon cheeseburger, 2 small patties, with condiments, on bun, from fast food / restaurant (Burger King Bacon Double Cheeseburger)*
27510451	Double bacon cheeseburger, 2 medium patties, with condiments, on bun, from fast food / restaurant*
27510465	Double bacon cheeseburger, 2 medium patties, with condiments, on bun, from fast food / restaurant (Wendy's Baconator)*
27510475	Double bacon cheeseburger, 2 large patties, with condiments, on bun, from fast food / restaurant*
27510486	Triple cheeseburger, 3 medium patties, with condiments, on bun, from fast food / restaurant*
27510506	Hamburger, 1 miniature patty, with condiments, on miniature bun, from fast food / restaurant*
27510511	Hamburger, 1 miniature patty, on miniature bun, from school*
27510536	Hamburger, 1 small patty, with condiments, on bun, from fast food / restaurant*
27510551	Hamburger (Burger King)*
27510552	Whopper Jr (Burger King)*
27510555	Hamburger, 1 small patty, with condiments, on bun, from fast food / restaurant (Wendy's Jr. Hamburger)*
27510565	Hamburger, from school cafeteria*
27510585	Hamburger, 1 small patty, with condiments, on white bun*
27510587	Hamburger, 1 small patty, with condiments, on whole wheat bun*

	27510606	Hamburger, 1 medium patty, with condiments, on bun, from fast food / restaurant*
	27510641	Hamburger, 1 medium patty, with condiments, on white bun*
	27510642	Hamburger, 1 medium patty, with condiments, on wheat bun*
	27510643	Hamburger, 1 medium patty, with condiments, on whole wheat bun*
	27510667	Double hamburger, 2 small patties, with condiments, on bun, from fast food / restaurant*
	27510676	Double hamburger, 2 medium patties, with condiments, on bun, from fast food / restaurant*
	27510681	Double hamburger, 2 medium patties, with condiments, on bun, from fast food / restaurant (Burger King Double WHOPPER)*
	27510682	Double hamburger, 2 medium patties, with condiments, on bun, from fast food / restaurant (Wendy's 1/2 lb Double)*
	27520500	Pork sandwich, on white roll, with onions, dill pickles and barbecue sauce*
	27520510	Pork barbecue sandwich or Sloppy Joe, on bun*
	27545010	Turkey or chicken burger, with condiments, on bun, from fast food / restaurant*
	27545200	Turkey or chicken burger, with condiments, on white bun*
	27545210	Turkey or chicken burger, with condiments, on wheat bun*
	27545220	Turkey or chicken burger, with condiments, on whole wheat bun*
	28110620	Beef short ribs, boneless, with barbecue sauce, potatoes, vegetable, frozen meal*
	28160650	Stuffed green pepper, frozen meal*
	74401010	Ketchup
	74406010	Barbecue sauce
	81308100	Fry sauce*
17	Yogurt and frozen yogurt, low calorie, reduced calorie, sugar-free	
	Food code	Food description
	11400000	Yogurt, NFS
	11459990	Frozen yogurt, NFS
	11460400	Yogurt, frozen, chocolate, nonfat milk, with low-calorie sweetener
	11460410	Yogurt, frozen, flavors other than chocolate, nonfat milk, with low-calorie sweetener
18	Medical foods	
	Food code	Food description
	95101000	Nutritional drink or shake, ready-to-drink (Boost)
	95101010	Nutritional drink or shake, ready-to-drink (Boost Plus)
	95103000	Nutritional drink or shake, ready-to-drink (Ensure)
	95103010	Nutritional drink or shake, ready-to-drink (Ensure Plus)
	95104000	Nutritional drink or shake, ready-to-drink, sugar free (Glucerna)
	95120050	Nutritional drink or shake, liquid, soy-based
19	Cranberries, dried	
	Food code	Food description
	42500000	Trail mix, NFS*
	42501000	Trail mix with nuts and fruit*
	42501500	Trail mix with chocolate*
	42502100	Trail mix with pretzels, cereal, or granola*
	53710810	Cereal or granola bar (KIND Fruit and Nut Bar)*
	53713010	Cereal or granola bar, fruit and nut*
	62101000	Fruit, dried, NFS, uncooked
	62101050	Fruit mixture, dried*
	62109100	Cranberries, dried
20	Jerky (meat or poultry based)	
	Food code	Food description
	21602100	Beef jerky

22002800 Pork jerky

23321900 Venison/deer jerky

* Only the component of the food (by weight) with existing or proposed use of allulose was included in the analysis

** Non-reconstituted dry powder was adjusted to the reconstituted/prepared amount.

Appendix C. Allulose Intake Comparison to GRN 498

In the current analysis, a downward shift of allulose intake was observed using the more recent NHANES data (i.e., NHANES 2015-2018) as compared to total allulose intakes reported by GRNs 400, 498, 693, and 828. The total per user mean and 90th percentile intake estimates of allulose based on older NHANES data and reported for the U.S. population by GRNs 400, 498, 693 and 828 ranged from 9-12.55 g/day and 24.8-30 g/day, respectively. Allulose intake estimates from background uses in the present analysis at the per user mean and 90th percentile is 6.69 g/day and 16.39 g/day, respectively. These estimates at the per user mean and 90th percentile is at least 26% and 34% lower, respectively, than those estimates in the GRNs.

In order to understand the downward shift of allulose intake observed using more recent NHANES data, Exponent generated and compared two sets of allulose intake estimates based on NHANES 2015-2018 and NHANES 2007-2010 for the food uses reported in GRN 498 as shown in Table C-1 below. Estimates based on NHANES 2015-2018 account for new food codes that have emerged since NHANES 2007-2010.

Table C-1. Two-day average allulose intake by GRN 498 food use categories from NHANES 2007-2010 and NHANES 2015-2018 for the U.S. population 2+ y

Proposed Food Category		U.S. 2+ y Allulose Intake (g/day)											
		NHANES 2007-2010*						NHANES 2015-2018					
		N-user†	% User	Per Capita		Per User		N-user†	% User	Per Capita		Per User	
		Mean	90th	Mean	90th	Mean	90th	Mean	90th	Mean	90th	Mean	90th
1	Beverages (non-alcoholic), low calorie, reduced calorie, sugar-free	4,136	32	5.5	18.6	17.3	39.4	2,191	21	3.3	10.3	15.8	34.8
2	Cereals, low calorie, reduced calorie, sugar-free‡	15‡	<1.0	NA	NA	NA	NA	57‡	<1.0	0.02	0	5.5	12.1
	Cereals, regular	7,399	46	0.6	1.8	1.3	3.2	4,389	33	0.3	1.0	0.9	1.9
3	Chewing gum	662	4	0.1	0.0	1.7	3.5	379	3	<0.05	0	1.4	2.0
4	Confections & frostings	1,655	13	0.1	0.2	0.6	1.3	3,408	26	0.2	0.6	0.7	1.5
5	Frozen dairy desserts (ice cream, soft serve, sorbet), low calorie, reduced calorie, sugar-free	223	1	<0.05	0.0	2.6	5.5	195	2	0.1	0	3.7	7.2
6	Yogurt and frozen yogurt, low calorie, reduced calorie, sugar-free	487	4	0.2	0.0	5.2	8.9	24‡	0	<0.05	0	3.0	6.1
7	Dressings for salads	4,557	36	0.4	1.2	1.0	2.0	6,100	54	0.5	1.6	1.0	2.1
8	Gelatins, pudding & fillings, low calorie, reduced calorie, sugar-free	201	1	0.1	0.0	7.3	12.1	126	1	0.1	0	8.7	13.0
9	Hard candy, low calorie, reduced calorie, sugar-free	11‡	<1.0	NA	NA	NA	NA	35‡	<1.0	<0.05	0	7.8	17.4
10	Soft candy, low calorie, reduced calorie, sugar-free	26‡	<1.0	<0.05	0.0	2.0	4.5	13‡	<1.0	<0.05	0	2.9	5.2
11	Jams & jellies	2,083	14	0.2	0.5	1.2	2.2	1,506	13	0.2	0.5	1.2	2.0
12	Sugar	5,801	39	0.6	1.8	1.5	3.7	5,618	43	0.7	2.0	1.6	3.7
13	Sugar substitutes	1,660	12	0.3	0.5	2.2	4.5	974	8	0.2	0	2.3	5.0
14	Sweet sauces & syrups, low calorie, reduced calorie, sugar-free	238	2	<0.05	0.0	1.7	4.0	168	1	<0.05	0	2.4	6.0

* Estimates reported in GRN 498.

† Unweighted number of users; % user, per capita, and per user estimates were based on statistical weights provided by the National Center for Health Statistics (NCHS).

‡ The estimated per user mean and 90th percentile daily intakes associated with the unweighted number of users are likely not statistically reliable due to small user sample size.

NA Not available, sample sizes too small to provide intake estimates.

APPENDIX E

Epimerase Enzyme Data/Information

Appendix E: 8 pages redacted, (b)(4), and removed

GRAS PANEL ENZYME CDX-032 EPIMERASE
August 29, 2014

Conclusion

We, the members of the Expert Panel, have independently and collectively critically evaluated the information summarized above and conclude that Codexis' CDX-032 D-psicose-3-epimerase enzyme preparation produced by fermentation from recombinant *Escherichia coli* expressing an engineered synthetic epimerase gene, meeting appropriate food-grade specifications and manufactured in accordance with current Good Manufacturing Practice, is safe, suitable, and Generally Recognized as Safe (GRAS) (based on scientific procedures) for its intended use in the production of D-psicose.

It is our opinion that other qualified experts would concur with these conclusions.



Stanley M. Tarka Ph.D.
The Pennsylvania State University College of Medicine

29 August 2014

Date



Michael W. Pariza Ph.D.
Emeritus Professor, Food Science
Emeritus Director, Food Research Institute
University of Wisconsin

29 Aug 2014

Date



Ashley Roberts Ph.D.
Intertek Health Sciences Consultancy

29 August 2014

Date

EXHIBIT 1

Report of the Expert Panel

OPINION OF THE GRAS PANEL ON THE SAFETY AND GENERALLY RECOGNIZED AS SAFE (GRAS) STATUS OF ALLULOSE FOR USE IN FOOD

Introduction

An independent panel of experts (the GRAS Panel), qualified by scientific training and experience to evaluate the safety of food and food ingredients, was requested by Tate & Lyle to determine the safety and Generally Recognized as Safe (GRAS) status of the use of allulose in select foods for human consumption. The allulose ingredient is proposed for use in nine new food types including (1) nutritional beverages; (2) nutritional beverages intended for children; (3) sweetened alcoholic malt beverages; (4) alcoholic premixed cocktails; (5) grain-free, no sugar, high protein RTE cereals; (6) nutrition bars; (7) ketchup and barbecue sauces; (8) dried cranberries; and (9) meat- and poultry-based jerky, in addition to those foods included in GRNs 400, 498, 693 and 828 (i.e., select low calorie, reduced calorie, or sugar-free foods including bakery products, beverages, cereals, chewing gums, confections and frostings, frozen dairy desserts, yogurt and frozen yogurt, dressings for salads, gelatins, pudding and fillings, hard and soft candies, jams and jellies, sugar, sugar substitutes, sweet sauces and syrups, fat based creams, medical foods and coffee mix). Higher use levels are also proposed for existing categories for ready-to-eat (RTE) and cooked cereals including regular and low calorie, reduced calorie, and sugar-free RTE and cooked cereals. The allulose ingredient is manufactured in accordance with current Good Manufacturing Practice (cGMP) and meets the proposed specifications.

A detailed review based on the existing scientific literature on the safety of allulose was conducted by ToxStrategies, Inc. (ToxStrategies) and is summarized in the attached dossier. The GRAS Panel members independently reviewed the dossier prepared by ToxStrategies and other pertinent information and first convened on October 24, 2019 via teleconference. Based on their independent, critical evaluation of all of the available information and discussions during the October 24, 2019 teleconference and reviews again in May 2020 and September 2021, the GRAS Panel unanimously concluded that the intended uses described herein for Tate & Lyle's allulose ingredient, meeting appropriate food-grade specifications as described in the supporting dossier (**GRAS Determination of Allulose for Use as an Ingredient in Human Food**) and manufactured according to cGMP, are safe, suitable, and GRAS based on scientific procedures. A summary of the basis for the GRAS Panel's conclusion is provided below.

Summary and Basis for GRAS Determination

Description

Allulose is a sweetener derived from corn (*Zea mays* L.) glucose by enzymatic epimerization of corn starch in a multi-step process. It contains negligible residual amounts of other related monosaccharides and impurities. Allulose has 70% of the sweetness of sucrose but provides negligible energy, and therefore is an excellent substitute for sucrose to reduce sugar and energy intake.

Manufacturing Process

The starting material is typical corn (U.S. Grade #2 Dent Corn [dried grain]), and the intermediate products are monosaccharides (glucose and fructose). All enzymes used in the process are safe and suitable for food uses and consistent with enzymes identified in previous GRAS notifications (including their sources). The allulose ingredient is produced in two forms: syrup and crystalline powder. The manufacturing process is conducted under Good Manufacturing Practice (GMP) for both end products and is identical in every step but the last.

Analytical results for the allulose ingredient confirm that the finished product meets the analytical specifications. The results also demonstrate that T&L's manufacturing process results in a consistently reproducible product and confirm the lack of significant levels of impurities and/or contaminants (e.g., heavy metals, microbiological contaminants). In addition, the corn starting material is periodically analyzed for the presence of pesticides and mycotoxins as part of Tate & Lyle's standard Quality Assurance processes. The results of stability testing conducted using liquid allulose, Dolcia Prima[®] LS brand, at temperatures of 4°C, 25°C, and 35°C demonstrate its stability through the end of the product's shelf-life in the syrup version up to 9 months. Stability studies on Dolcia Prima[®] DS crystalline allulose show that this material is stable for up to 30 months.

History of Use

Allulose is naturally present in small quantities in many common foods, such as in dried fruits (e.g., figs, raisins), fried dough, brown sugar and ketchup. Allulose has been added to food as an alternative sweetener and has a history of safe use. Multiple GRAS "no questions" letters have been issued (GRNs 400, 498, 693) regarding the safety of the intended uses and use levels of allulose in foods in which it serves as a sugar replacer/sweetener at levels up to 100% (FDA, 2012, 2014, 2017). Allulose is added to select foods as a sweetener, per previous GRAS notifications, and these foods include bakery products, chewing gum, hard candies, frozen dairy desserts, carbonated beverages, non-carbonated beverages, soft candies, yogurt, ready-to-eat cereals, coffee mix, jams/jellies, frostings, sauces, and many others.

Intended Use and Intake Assessment

The focus of this GRAS determination is for the use of allulose as a sweetener in select foods that have not been previously identified in any of the publicly available GRN's (GRN 498, GRN 693, and GRN 828).

The following table summarizes current and proposed additional food categories and associated use levels. An intake assessment employing dietary survey data obtained from What We Eat in America (WWEIA), the dietary interview portion of the National Health and Nutrition Examination Survey (NHANES) was conducted to estimate the mean and 90th percentile daily intakes of allulose based on its intended use in foods.

	Food Category	Description of Foods Selected for Analysis	Maximum Allulose Use Level, %		
			Proposed New Uses	Existing GRAS Uses*	Combined existing GRAS and proposed uses **
1	Baked products (bread, muffin, cake and cookies, pastries), dietetic, low calorie, reduced calorie, sugar-free	Sweetened bread/rolls, muffin, and cakes and cookies – all identified as low calorie, reduced calorie, sugar-free, or NFS†.	NA	10	10
2	Beverages				
2a	Non-alcoholic beverages, low calorie, reduced calorie, sugar-free	Sweetened coffees, teas, soft drinks, energy drinks, juice drinks, fruit drinks, fruit flavored drinks, flavored/carbonated waters, and enhanced/fortified waters – all identified as low calorie, reduced calorie, or sugar-free.	NA	3.5	3.5
2b	Nutritional beverages	Nutritional beverages within the “nutritional beverages” and “protein and nutritional powders”WWEIA categories not included as part of the existing GRAS uses in medical foods	2.5	NA	2.5
2c	Nutritional beverages intended for children (i.e., PediaSure)	PediaSure	3.5	NA	3.5
2d	Alcoholic malt beverage, sweetened	Sweetened alcoholic malt beverage (food code 93106000), which includes products such as hard lemonade, hard punch, hard tea, etc.	3.5	NA	3.5
2e	Alcoholic premixed cocktails	All cocktails with added sugar	3.0	NA	3.0
3	Candy, hard and soft				
3a	Hard candy (includes pressed candy and mints), low calorie, reduced calorie, sugar-free	Hard candy – low calorie, reduced calorie, sugar-free, or NFS†.	NA	70	70
3b	Soft candy, low calorie, reduced calorie, sugar-free	Soft candy – low calorie, reduced calorie, sugar-free.	NA	25	25

	Food Category	Description of Foods Selected for Analysis	Maximum Allulose Use Level, %		
			Proposed New Uses	Existing GRAS Uses*	Combine dexisting GRAS and proposed uses **
4	Chewing gum	Regular and sugar-free chewing gum.	NA	50	50
5	Cereals, ready-to-eat (RTE) and cooked				
5a	RTE and cooked, regular	RTE and cooked cereals identified as containing added sugar.	12	2	12
5b	RTE and cooked, low calorie, reduced calorie, sugar-free	RTE and cooked cereals identified as low calorie, reduced sugar, or sugar-free.	12	5	12
5c	RTE cereals with <5% sugar	RTE cereals with <5% added sugar excluding cereals with no added sugar.	NA	10	10
5d	Grain-free, no sugar, high protein RTE cereal	No grain-free, no sugar, high protein RTE cereals were reported consumed, hence, zero-sugar added RTE cereals were selected as surrogates.	20	NA	20
6	Coffee mix	Sweetened non-reconstituted coffee mixes.	NA	30	30
7	Confections & Frostings	Frostings and icings and marshmallows.	NA	5	5
8	Dressings for salads	Salad dressings including mayonnaise.	NA	5	5
9	Frozen dairy (ice cream, soft serve, sorbet), low calorie, reduced calorie, sugar-free	Desserts including ice cream, soft serve, sorbet - all identified as low calorie, reduced calorie, sugar-free, or NFS†.	NA	5	5
10	Gelatins, pudding & fillings				
10a	Gelatins, pudding & fillings, low calorie, reduced calorie, sugar-free	Gelatins and puddings - all identified as low calorie, reduced calorie, sugar-free, or NFS†.	NA	10	10
10b	Fat-based cream (used in modified fat/calorie cookies, cakes, pastries, pie)	Fat-based cream filling in cookies, cakes, pastries, pies.	NA	10	10
11	Nutrition bars	Meal replacement bars, protein bars, energy bars, etc.	25	NA	25
12	Jams & Jellies	Jams, jellies, and pastes, all types.	NA	10	10

	Food Category	Description of Foods Selected for Analysis	Maximum Allulose Use Level, %		
			Proposed New Uses	Existing GRAS Uses*	Combine existing GRAS and proposed uses **
13	Sugar	Sugar added in home preparations including white sugar, brown sugar, cinnamon sugar, raw sugar, honey, molasses, and not specified.	NA	10	10
14	Sugar substitutes	Sugar substitutes.	NA	100	100
15	Sweet sauces & syrups, low calorie, reduced calorie, sugar-free	Sweet sauces & syrups - all identified as low calorie, reduced calorie, sugar-free, dietetic or NFS†.	NA	10	10
16	Ketchup and barbecue sauces	Ketchup and barbecue sauces.	10	NA	10
17	Yogurt and frozen yogurt, low calorie, reduced calorie, sugar-free	Yogurt and frozen yogurt - all identified as low calorie, reduced calorie, sugar-free, or NFS†.	NA	5	5
18	Medical foods	Nutritional drinks such as Boost, Ensure, and Glucerna to provide a surrogate for medical foods.	NA	15	15
19	Cranberries, dried	Dried cranberries (i.e., Craisins).	25	NA	25
20	Jerky (meat or poultry based)	Jerky (meat or poultry based).	15	NA	15

* Based on current food uses and use levels of allulose as described in U.S. GRNs 400 (C) Cheiljedang, 2011), 498 (Matsutani Chemical Industry Company, Ltd 2013), 693 (Samyang Corporation, 2017), and 828 (Samyang Corporation, 2018).

† NFS refers to food codes described as "not-further-specified;" providing a generic description to the food reported consumed (i.e., dietetic topping).NA: Not applicable.

** Maximum use levels applied in estimating cumulative intake from proposed and existing GRAS uses

The Cumulative Estimated Daily Intake (CEDI) for the extended uses of allulose in grams per day and grams per kilogram body weight per day for the following age groups in the US populations: 2 years and older, 2 to 5 years, 6 to 18 years, and 19 years and older are presented below.

	N *	% User	Per Capita		Per User	
			Mean	90 th Percentile	Mean	90 th Percentile
Allulose CEDIs (g/day)						
U.S. 2+ y	12017	95	9.60	22.65	10.09	23.53
Infants <2 y	409	50	1.66	4.75	3.33	7.18
Children 2-12 y	2632	97	5.63	12.04	5.83	12.36
Adolescents 13-18 y	1320	92	6.28	13.39	6.79	13.55
Males 19+ y	3828	95	12.00	28.84	12.61	29.86
Females 19+ y	4237	95	9.48	23.27	9.99	24.05
Allulose CEDIs (g/kg-bw/day)						
U.S. 2+ y	12017	95	0.14	0.34	0.15	0.35
Infants <2 y	409	50	0.15	0.40	0.30	0.65
Children 2-12 y	2632	97	0.22	0.48	0.23	0.49
Adolescents 13-18 y	1320	92	0.10	0.22	0.11	0.22
Males 19+ y	3828	95	0.13	0.32	0.14	0.33
Females 19+ y	4237	95	0.13	0.30	0.14	0.32

*Unweighted number of users; % user, *per capita*, and *per user* estimates were based on NHANES 2015-2018 and derived using the statistical weights provided by the NCHS.

In the U.S. population 2+ y, 95% consumed one or more foods containing allulose from background and/or proposed uses. The allulose CEDI at the per user mean and 90th percentile intakes among this population is 10.09 g/day (0.15 g/kg-bw/day) and 23.53 g/day (0.35 g/kg-bw/day), respectively. Per user mean allulose CEDI ranged from 3.33 g/day among infants <2 y to 12.61 g/day among males 19+ y. On a per body weight basis, the highest per user mean intake was among infants <2 y at 0.30 g/kg-bw/day allulose. The per user 90th percentile intake estimates of allulose ranged from 7.18 g/day among infants <2 y to 29.86 g/day among males 19+ y. The highest per user 90th percentile of intake on a body weight basis was among infants <2y at 0.65 g/kg-bw/day allulose.

The total per user mean and 90th percentile intake estimates of allulose based on NHANES data and reported for the U.S. population by GRNs 400, 498, 693 and 828 ranged from 9-12.55 g/day and 24.8-30 g/day, respectively. The per user mean and 90th percentile intake estimates in the present analysis are approximately 26% and 34% lower, respectively, than those estimates in the GRNs. In order to understand the downward shift of allulose intake observed in the more recent NHANES data, Exponent generated and compared two sets of allulose intake estimates using NHANES 2015-2018 and NHANES 2007-2010 for the food uses reported in GRN 498 (see Appendix C of Exponent Intake Assessment Report; Appendix D of this GRN). Lower allulose intake

estimates in the present analysis appear to be due to a shift in dietary patterns of non-alcoholic low calorie, reduced calorie, sugar-free beverages. Specifically, the percent users and intake of non-alcoholic beverages (low calorie, reduced calorie, sugar-free) have decreased from 32% in NHANES 2007-2010 to 21% in NHANES 2015-2018 with a decreased intake among consumers of non-alcoholic beverages in NHANES 2015-2018. A trend analysis conducted by Bleich et al.(2018) similarly reported an observed decline in beverage and sugar-sweetened beverage consumption for children and adults from 2003 to 2014. There was also a reduction in intake of regular cereal contributing to lower allulose intakes, i.e., a decrease in percent users (46% in NHANES 2007-2010 versus 33% in NHANES 2015-2018) and lower intake amounts in NHANES 2015-2018. This reduction, however, did not result from changes in dietary patterns but instead was due to differences in the food selection methodology between GRN 498 and the current assessment. The food selection of regular cereals in the present analysis was limited to cereals with added sugar since allulose would not be added to cereals with no added sugar, whereas all cereals excluding low calorie, reduced calorie, and sugar-free cereals were included in the assessment for GRN 498 under regular cereals. The estimated allulose intake from existing background uses in this analysis relies on the most currently available dietary data from NHANES (2015-2018) and shows a lower allulose intake as compared to previously reported allulose EDIs from GRNs 400, 498, 693, and 828.

The estimate of the 90th percentile *per user* consumption for the general US population (2+ years of age) of approximately 23.53 g/day, or 0.35 g/kg bw/day is extremely conservative. It is known that a 2-day survey overestimates the actual consumption. Shorter surveys are associated with misclassification of individuals, inaccurate correlation coefficients, reduced power, and overestimation of the percentages of high and low intakes. The effects of survey duration are thought to be due to the within-person and day-to-day variation. In addition, the percentage of respondents who consume a food increases as survey duration increases, because the longer duration begins to incorporate days with no consumption, thus decreasing the mean intakes among consumers over time.

Safety Data

Allulose has been added to food as an alternative sweetener and has a history of safe use. Multiple GRAS “no questions” letters have been issued (GRNs 400, 498, 693, 828) with respect to the conclusion regarding the safety of the intended uses and use levels of allulose in foods in which it serves as a sugar replacer/sweetener at levels up to 100% (FDA, 2012, 2014, 2017, 2020). Clinical and preclinical studies with allulose have been conducted to examine its general toxicity and gastrointestinal tolerance.

Regulatory authorities have reviewed the safety of allulose and found it to be safe for use in human food. Numerous studies and publications support the safety of allulose, including *in vitro* studies, *in vivo* animal studies, and clinical studies in humans. A summary of the most relevant studies on allulose absorption, distribution, metabolism, and excretion (ADME), acute and subchronic toxicity, reproductive and developmental toxicity, mutagenicity and genotoxicity, and chronic toxicity in animals along with clinical studies have been summarized and reviewed. The compositional profile of

allulose presents no obvious safety concerns. As a result, allulose has been reviewed and approved in several countries for addition to food for human consumption.

ADME data on allulose are available in both animals and humans, and the results are similar for both. Allulose is rapidly absorbed such that large bolus doses are more likely to have an impact on laxation than smaller cumulative doses. As such, clinical studies have demonstrated that the tolerability of allulose is highly dependent on the mode and timeline of ingestion. Individual tolerance develops with continued ingestion over time. Mild gastrointestinal intolerance (GI intolerance) is considered a physiological response to osmotic loading. It is of no toxicological significance, is generally self-limiting, and is not severe or indicative of toxicity per se. GI intolerance due to allulose is a short-term individual tolerability issue similar to other foods (dried fruit) or food ingredients (fructose), and other sweeteners such as polyols like sorbitol, mannitol, and xylitol.

No adverse effects attributable to allulose were observed in multiple animal studies; in a 90-day study (high dose-2000 mg/kg bw/day) and in a chronic study (approximately 1300 mg/kg bw/day).

Data are available from a number of human studies in both sexes, healthy individuals, and sensitive subpopulations such as diabetics. No effects were observed in multiple human studies, except gastrointestinal intolerance at very high dose levels. Gastrointestinal intolerance is related to the presence of excess indigestible material in the gastrointestinal tract and is temporary and reversible. It is not unique to allulose; similar effects are observed with other sweeteners, such as polyols like sorbitol, mannitol, and xylitol.

Allulose can be considered safe for human consumption at up to 63 g/day, when consumed in portions throughout the day as one would typically, based on multiple meals or snacks throughout the day (Han et al., 2018), and up to 28–42 g (0.4 – 0.6 g/kg/day for a 70 kg individual) can be consumed in one sitting (Han et al., 2018; Iida et al., 2007).

In summary, the published study data, additional unpublished supporting data, and previous reviews by regulatory authorities (e.g., GRN Nos. 400, 498, 693, 828), support the conclusion that Tate & Lyle's allulose ingredient is safe for use as a sweetener, at the proposed use levels in specified foods.

General Recognition of the Safety of Allulose

The intended use of allulose has been determined to be safe through scientific procedures as set forth in 21 CFR§170.3(b), thus satisfying the so-called “technical” element of the GRAS determination and is based on the following:

- Allulose is manufactured from corn, following current cGMP for food (21 CFR § Part 110). The raw materials and processing aids used in the manufacturing

process are food grade and/or approved for use in food. The allulose ingredient has been characterized appropriately, contains a minimum of 95%–98% allulose (syrup and crystalline forms, respectively), and meets appropriate food-grade specifications.

- There is a body of common knowledge of historical human consumption of allulose from foods containing allulose. Allulose is naturally present in small quantities in many common foods, such as in dried fruits (e.g., figs, raisins, fried dough, brown sugar, and ketchup). The additional intended uses will be in select alcoholic beverages, meat/poultry products (i.e., jerky), grain-based cereal bars, dried cranberries, and presweetened cereal as a sweetener.
- Allulose is rapidly absorbed such that large bolus doses are more likely to have an impact on laxation than smaller cumulative doses. As such, clinical studies have demonstrated that the tolerability of allulose is highly dependent on the mode and timeline of ingestion. Individual tolerance develops with continued ingestion over time. Mild GI intolerance is considered to be a physiological response to osmotic loading and is of no toxicological significance, is generally self-limiting, and not severe or indicative of toxicity per se but is a short-term individual tolerability issue similar to other foods (dried fruit) or food ingredients (fructose), and other sweeteners such as polyols like sorbitol, mannitol, and xylitol.
- Allulose is currently added to food, and multiple GRAS “no-questions” letters have been issued (GRNs 400, 498, 693, 828) that support the safe use of allulose in foods in which it serves as a sugar replacement/sweetener at 90th percentile daily intake levels for ages 2+ of up to approximately 30 g/day. GRN 498 stated the following, *“A potential side effect of D-allulose is gastrointestinal discomfort when ingested in large quantities. It is well-known that this type of side effect is transient. As consumption levels of non-digestible carbohydrates decreased throughout the 20th century, human tolerance levels also decreased. This tolerance and loss of tolerance suggests that the gastrointestinal symptoms associated with high intakes of non-digestible carbohydrates are likely transient and can improve over time. This type of symptom is usually transient and is not considered to be of toxicological significance”*.
- The clinical study of Iida et al. (2007) established a dose-response relationship for the onset of diarrhea in humans, showing that in men the maximum tolerated dose was 0.5 g/kg bw, whereas in women, it was 0.6 g/kg bw (above these doses, gastrointestinal effects such as abdominal pain, gas formation, and diarrhea occurred). Thus, it was established that, for humans, the NOAEL for allulose is 0.5 g/kg bw (33.3 g/day) for men and 0.6 g/kg bw (31 g/day) for women (Iida et al., 2007; FDA, 2012, 2014, 2017).
- The allulose CEDI at the per user mean and 90th percentile of intake among this population is 10.09 g/day (0.15 g/kg-bw/day) and 23.53 g/day (0.35 g/kg-bw/day), respectively. Per user mean allulose CEDI ranged from 3.33 g/day

among infants <2 y to 12.61 g/day among males 19+ y. On a per body weight basis, the highest per user mean intake was among infants <2 y at 0.30 g/kg-bw/day allulose. The per user 90th percentile intake estimates of allulose ranged from 7.18 g/day among infants <2 y to 29.86 g/day among males 19+ y. The highest per user 90th percentile of intake on a body weight basis was among infants <2y at 0.65 g/kg-bw/day allulose.

- Allulose can be considered safe for human consumption up to 24–36 g (0.4 – 0.6 g/kg/day for a 60 kg individual) when consumed in one sitting. As summarized above, the 90th percentile estimated total daily intake for the US population, ages 2+ is 23.53 g/day; this is likely an overestimate of intake as it assumes allulose is used in all intended foods at the maximum intended use level. The 90th percentile daily intake is at the lower end of the range of intake considered safe for human consumption in one sitting.
- No safety/toxicity concerns related to consumption of allulose are evident, beyond that of gastrointestinal intolerance at high bolus doses. The 90th percentile estimated total daily intake for the US population, ages 2+ of 23.53 g/day is conservative, and as such, tolerability should be of limited concern even at the 90th percentile total daily intake for the US population, ages 2+ of 23.53 g/day.
- Regulatory authorities have reviewed the extensive safety study database for allulose and found no issues of concern with respect to its use in human food at the proposed use levels. Numerous studies have been conducted and published in support of the safety of allulose, including *in vitro* studies and *in vivo* animal studies (i.e., acute and subchronic toxicity, mutagenicity and genotoxicity, chronic toxicity), as well as clinical studies in adults. No adverse effects attributable to allulose were observed in multiple animal studies; in 90-day studies (1670 - 2000 mg/kg bw/day) and in a chronic study (approximately 1300 mg/kg bw/day).
- The body of publicly available scientific literature on the consumption and safety of allulose is sufficient to support the safety and GRAS status of the proposed new uses of the allulose ingredient.

Conclusions of the GRAS Panel

We, the undersigned independent qualified members of the GRAS Panel, have individually and collectively, critically reviewed the published and ancillary information pertinent to the identification, use, and safety of Tate & Lyle's allulose ingredient. We unanimously conclude that the intended use of the allulose ingredient produced consistent with good manufacturing practice (cGMP) and meeting appropriate food-grade specifications as presented in the supporting dossier [**"GRAS Determination of Allulose for Use as an Ingredient in Human Food"**] is safe.

We the members of the GRAS Panel, further unanimously conclude that the intended use of Tate & Lyle's allulose ingredient, produced consistent with good manufacturing practice (cGMP) and meeting appropriate food-grade specifications as presented in the supporting dossier is Generally Recognized as Safe (GRAS) based on scientific procedures under the conditions of intended use in conventional foods and alcoholic beverages specified herein.

It is our professional opinion that other qualified experts critically evaluating the same information, would concur with this conclusion.

Michael Carakostas, DVM, PhD
Consultant
MC Scientific Consulting LLC

Date

Stanley M. Tarka, Jr., Ph.D., F.A.T.S.
Consultant
Tarka Group, Inc.

Date

Thomas A. Vollmuth, Ph.D.
Consultant
Vollmuth and Associates, LLC

Date

Conclusions of the GRAS Panel

We, the undersigned independent qualified members of the GRAS Panel, have individually and collectively, critically reviewed the published and ancillary information pertinent to the identification, use, and safety of Tate & Lyle's allulose ingredient. We unanimously conclude that the intended use of the allulose ingredient produced consistent with good manufacturing practice (cGMP) and meeting appropriate food-grade specifications as presented in the supporting dossier [**"GRAS Determination of Allulose for Use as an Ingredient in Human Food"**] is safe.

We the members of the GRAS Panel, further unanimously conclude that the intended use of Tate & Lyle's allulose ingredient, produced consistent with good manufacturing practice (cGMP) and meeting appropriate food-grade specifications as presented in the supporting dossier is Generally Recognized as Safe (GRAS) based on scientific procedures under the conditions of intended use in conventional foods and alcoholic beverages specified herein.

It is our professional opinion that other qualified experts critically evaluating the same information, would concur with this conclusion.



Michael Carakostas, DVM, PhD
Consultant
MC Scientific Consulting LLC

9-30-2021
Date

Stanley M. Tarka, Jr., Ph.D., F.A.T.S.
Consultant
Tarka Group, Inc.

Date

Thomas A. Vollmuth, Ph.D.
Consultant
Vollmuth and Associates, LLC

Date

Conclusions of the GRAS Panel


We, the undersigned independent qualified members of the GRAS Panel, have individually and collectively, critically reviewed the published and ancillary information pertinent to the identification, use, and safety of Tate & Lyle's allulose ingredient. We unanimously conclude that the intended use of the allulose ingredient produced consistent with good manufacturing practice (cGMP) and meeting appropriate food-grade specifications as presented in the supporting dossier [**"GRAS Determination of Allulose for Use as an Ingredient in Human Food"**] is safe.

We the members of the GRAS Panel, further unanimously conclude that the intended use of Tate & Lyle's allulose ingredient, produced consistent with good manufacturing practice (cGMP) and meeting appropriate food-grade specifications as presented in the supporting dossier is Generally Recognized as Safe (GRAS) based on scientific procedures under the conditions of intended use in conventional foods and alcoholic beverages specified herein.

It is our professional opinion that other qualified experts critically evaluating the same information, would concur with this conclusion.

Michael Carakostas, DVM, PhD
Consultant
MC Scientific Consulting LLC

Date


Stanley M. Tarka, Jr., Ph.D., F.A.T.S.
Consultant
Tarka Group, Inc.

29 September 2021

Date

Thomas A. Vollmuth, Ph.D.
Consultant
Vollmuth and Associates, LLC

Date

Conclusions of the GRAS Panel


We, the undersigned independent qualified members of the GRAS Panel, have individually and collectively, critically reviewed the published and ancillary information pertinent to the identification, use, and safety of Tate & Lyle's allulose ingredient. We unanimously conclude that the intended use of the allulose ingredient produced consistent with good manufacturing practice (cGMP) and meeting appropriate food-grade specifications as presented in the supporting dossier [**"GRAS Determination of Allulose for Use as an Ingredient in Human Food"**] is safe.

We the members of the GRAS Panel, further unanimously conclude that the intended use of Tate & Lyle's allulose ingredient, produced consistent with good manufacturing practice (cGMP) and meeting appropriate food-grade specifications as presented in the supporting dossier is Generally Recognized as Safe (GRAS) based on scientific procedures under the conditions of intended use in conventional foods and alcoholic beverages specified herein.


It is our professional opinion that other qualified experts critically evaluating the same information, would concur with this conclusion.

Michael Carakostas, DVM, PhD
Consultant
MC Scientific Consulting LLC

Date

Stanley M. Tarka, Jr., Ph.D., F.A.T.S.
Consultant
Tarka Group, Inc. 

Date



Thomas A. Vollmuth, Ph.D.
Consultant
Vollmuth and Associates, LLC

Date

30 Sept 2021

References

FDA. 2012. GRAS Notification No. 400. D-psicose.

<http://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=400>.

FDA. 2014. GRAS Notification No. 498. D-psicose.

<http://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=498>.

FDA 2017. GRAS Notification No. 693. D-psicose

<http://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=693>.

FDA 2020. GRAS Notification No. 828. D-psicose

https://www.cfsanappsexternal.fda.gov/scripts/fdcc/?set=GRASNotices&id=828&sort=GRN_No&order=DESC&startrow=1&type=basic&search=828

Han Y, Choi BR, Kim SY. 2018. Gastrointestinal tolerance of d-allulose in healthy and young adults. a non-randomized controlled trial. *Nutrition* 10(12), 2010-2021.

Iida T, Kishimoto Y, Yoshikawa Y, Okuma K, Yagi K, Matsuo T, Izumori K. 2007. Estimation of maximum non-effective level of D-psicose in causing diarrhea in human subjects. *J Advanced Food Ingred* 10(1):15–19.

EXHIBIT 2

USDA/FSIS Data Package

Exhibit 2: 4 pages redacted (b)(4) and removed

GRAS Notice (GRN) No. 1057 amendments

From: [Nga Tran](#)
To: [Hice, Stephanie](#)
Subject: [EXTERNAL] GRN 001057
Date: Friday, July 15, 2022 9:31:01 AM
Attachments: [Confidential -Tate+Lyle Allulose NHANES2015-2018 FILE4FDA.xlsx](#)

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Stiffy,

At the request of the submitter of GRN 001057, I am providing you with our excel file with NHANES food codes and the corresponding adjusted use levels for allulose that were used for the cumulative dietary exposure estimate from background sources, current and intended uses for allulose. Please do not hesitate to let me know if you need further details or explanation.

Best,

Nga Tran, Dr.PH, MPH

Principal Scientist

Exponent

1150 Connecticut Ave., NW

Suite 1100

Washington, DC 20036

Direct +1-202-772-4915 • Email ntran@exponent.com

www.exponent.com

CONFIDENTIALITY NOTICE: This e-mail transmission (and the attachments accompanying it) is intended only for the use of the intended recipient and may contain privileged and confidential information belonging to the sender. If you are not the intended recipient, be aware that any disclosure, copying, dissemination, distribution or use of the contents of this e-mail transmission is strictly prohibited. If you have received this transmission in error, please promptly notify the sender by reply e-mail and then destroy all copies of the transmission.

From: [Don Schmitt](#)
To: [Hice, Stephanie](#)
Subject: [EXTERNAL] Re: GRN 001057 - Request for Clarifying Information
Date: Monday, July 11, 2022 1:31:15 PM
Attachments: [image001.png](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)
[image005.png](#)
[image006.png](#)
[image007.png](#)
[image008.png](#)
[image009.png](#)
[image010.png](#)

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Stephanie,

Just heard back from Tate & Lyle and they have spoken with Nga Tran at Exponent. She indicated that Exponent (probably Nga) will send the requested data directly to you. The reason for this is that there is some proprietary information involved, so Exponent is unable to share it with Tate & Lyle and/or ToxStrategies.

Let me know if you need anything else after receiving the information from Exponent.

Don

Donald F. Schmitt, M.P.H.
Senior Managing Scientist



ToxStrategies

739 Thornapple Drive
Naperville, IL 60540
phone: 630.352.0303
email: dschmitt@toxstrategies.com

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please immediately notify ToxStrategies, Inc. at (832) 868-7729 and permanently delete the original and any copy of any e-mail and any printout thereof.

From: "Donald Schmitt, MPH" <dschmitt@toxstrategies.com>
Date: Monday, July 11, 2022 at 8:26 AM
To: "Hice, Stephanie" <Stephanie.Hice@fda.hhs.gov>
Subject: Re: GRN 001057 - Request for Clarifying Information

Good morning Stephanie,

I will get the requested information ASAP. I know several individuals are at the IFT Meeting this week, but hopefully I can provide it by the end of the week.

Don

Donald F. Schmitt, M.P.H.
Senior Managing Scientist



ToxStrategies

739 Thornapple Drive
Naperville, IL 60540
phone: 630.352.0303
email: dschmitt@toxstrategies.com

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please immediately notify ToxStrategies, Inc. at (832) 868-7729 and permanently delete the original and any copy of any e-mail and any printout thereof.

From: "Hice, Stephanie" <Stephanie.Hice@fda.hhs.gov>
Date: Monday, July 11, 2022 at 8:22 AM
To: "Donald Schmitt, MPH" <dschmitt@toxstrategies.com>
Subject: GRN 001057 - Request for Clarifying Information

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Mr. Schmitt,

Please find below a request for clarifying information needed to continue our evaluation of GRN 001057:

The notifier used USDA's Food and Nutrient Database for Dietary Studies (FNDDS) to convert the food as consumed into its corresponding ingredients based on percent weight. The notifier provided the list of the National Health and Nutrition Examination Survey (NHANES) food codes included in their analysis in Appendix D, but did not provide additional details on the adjustment of the use levels based on the FNDDS data. This information is necessary to confirm their refined exposure estimate. We ask that the notifier please provide a file with NHANES food codes and the corresponding adjusted use levels for allulose that were used for the cumulative dietary exposure estimate from background sources, current and intended uses.

Please do not include any confidential information in your response.

If you have questions or need further clarification, please feel free to contact me.

Thank you for your attention to this request.

Sincerely,

Stiffy Hice

Stephanie (Stiffy) Hice, Ph.D. (they/them/their)

Regulatory Review Scientist & Microbiology Reviewer

**Division of Food Ingredients
Office of Food Additive Safety
Center for Food Safety and Applied Nutrition
U.S. Food and Drug Administration
stephanie.hice@fda.hhs.gov**

Pronouns: They-Them-Their ([what is this?](#))



From: [Don Schmitt](#)
To: [Hice, Stephanie](#)
Cc: [Kolberg, Lore](#)
Subject: [EXTERNAL] Re: GRN 001057 - USDA/FSIS Questions for Notifier
Date: Friday, September 1, 2023 1:09:57 PM
Attachments: [image001.png](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)
[image005.png](#)
[image006.png](#)
[image007.png](#)
[image008.png](#)
[GRN 1057 USDA FSIS responses 083123.pdf](#)

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Stephanie,

Attached are Tate & Lyle's responses to the questions from USDA FSIS.

Sincerely,

Don

Donald F. Schmitt, M.P.H.
Senior Managing Scientist



ToxStrategies

739 Thornapple Drive
Naperville, IL 60540
phone: 630.352.0303
email: dschmitt@toxstrategies.com

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please immediately notify ToxStrategies, Inc. at (832) 868-7729 and permanently delete the original and any copy of any e-mail and any printout thereof.

From: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>
Date: Tuesday, August 22, 2023 at 10:13 AM
To: Don Schmitt <dschmitt@toxstrategies.com>
Subject: GRN 001057 - USDA/FSIS Questions for Notifier

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Mr. Schmitt,

During USDA/FSIS' evaluation of GRAS Notice No. 001057, they noted questions that need to be addressed and are attached to this email.

We respectfully request a response within **10 business days**. If you are unable to complete the response within that time frame, please contact me to discuss further options. Please do not include any confidential information in your response. **Please provide responses to these questions in a separate PDF from the questions asked by FDA.**

If you have questions or need further clarification, please feel free to contact me. Thank you in advance for your attention to USDA/FSIS' comments.

Sincerely,

Stiffy Hice

Stephanie (Stiffy) Hice, Ph.D. (they/them/their)

Regulatory Review Scientist & Microbiology Reviewer

Division of Food Ingredients
Office of Food Additive Safety
Center for Food Safety and Applied Nutrition
U.S. Food and Drug Administration
stephanie.hice@fda.hhs.gov

Pronouns: They-Them-Their ([what is this?](#))




GRN 1057 Items for Clarification from USDA FSIS

1. Please provide an SDS for the substance and a typical protocol of how the substance will be used when it is formulated into a product.

Response: Please see the attached SDS documents for both the crystalline and liquid allulose products. A typical protocol for use is as follows: allulose incorporation would follow typical, approved production methods where sugars and/or sugar syrups have been incorporated into seasonings, brines or marinades used in the preparation of chunked or ground, or chopped and formed, or whole muscle pieces soaked or vacuum tumbled, as may be common in industrial processing. These products would then be cured or uncured, smoked or unsmoked, as well as air dried or oven dried. The jerky products would meet USDA Food Standards and Labelling Policy requirements and would have been dried to a moisture-to-protein ratio (MPR) of 0.75:1.0 or less and allulose in finished products, as consumed, would comply to maximum permitted use levels (15% max by weight, as consumed).

An example of the whole muscle beef jerky process would consist first of slicing, then preparing the brine solution (containing allulose), curing, followed by marination/tumbling, and smokehouse processing (cooking and drying) prior to finished product packaging. The following is a flow diagram of the process:

Heat Treated-Shelf Stable Process Flow: Whole Muscle Jerky



(Reference: FSIS USDA RTE-SS Process Familiarization 11-29-16)

2. On page 21 the notifier lists the maximum use level at 15% in USDA regulated products (i.e., jerky (meat or poultry based), while the maximum use level in some FDA regulated products is up to 25%. Please confirm whether 15% is the maximum use level in jerky (meat or poultry based).

Response: Tate & Lyle requests a maximum use level of 15% in jerky (meat or poultry based).

From: [Don Schmitt](#)
To: [Hice, Stephanie](#)
Cc: [Kolberg, Lore](#)
Subject: Re: [EXTERNAL] Re: GRN 001057 - USDA/FSIS Questions for Notifier
Date: Tuesday, September 5, 2023 1:49:31 PM
Attachments: [image001.png](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)
[image005.png](#)
[image006.png](#)
[image007.png](#)
[image008.png](#)
[image009.png](#)
[image010.png](#)
[DOLCIA PRIMA DS SDS LOU 20230224.PDF](#)
[DOLCIA PRIMA LS ALLULOSE SYRUP SDS LOU TLP 20230224.PDF](#)

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Stephanie,

My apologies. Please see the attached SDS documents for both the crystalline and liquid allulose products.

Don

Donald F. Schmitt, M.P.H.
Senior Managing Scientist



ToxStrategies

739 Thornapple Drive
Naperville, IL 60540
phone: 630.352.0303
email: dschmitt@toxstrategies.com

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please immediately notify ToxStrategies, Inc. at (832) 868-7729 and permanently delete the original and any copy of any e-mail and any printout thereof.

From: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>
Date: Tuesday, September 5, 2023 at 12:37 PM
To: Don Schmitt <dschmitt@toxstrategies.com>
Cc: Kolberg, Lore <lore.kolberg@tateandlyle.com>
Subject: RE: [EXTERNAL] Re: GRN 001057 - USDA/FSIS Questions for Notifier

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good afternoon, Don –

Thank you for your responses to USDA's comments. In the amendment you provided, the response to question 1 notes that the SDS is attached; however, I do not see the SDS. Would you please provide a copy of the SDS?

Sincerely,

Stiffy Hice

Stephanie (Stiffy) Hice, Ph.D. (they/them/their)

Regulatory Review Scientist & Microbiology Reviewer

Division of Food Ingredients
Office of Food Additive Safety
Center for Food Safety and Applied Nutrition
U.S. Food and Drug Administration
stephanie.hice@fda.hhs.gov

Pronouns: They-Them-Their ([what is this?](#))



From: Don Schmitt <dschmitt@toxstrategies.com>
Sent: Friday, September 1, 2023 1:09 PM
To: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>
Cc: Kolberg, Lore <lore.kolberg@tateandlyle.com>
Subject: [EXTERNAL] Re: GRN 001057 - USDA/FSIS Questions for Notifier

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Stephanie,

Attached are Tate & Lyle's responses to the questions from USDA FSIS.

Sincerely,

Don

Donald F. Schmitt, M.P.H.
Senior Managing Scientist



ToxStrategies

739 Thornapple Drive
Naperville, IL 60540
phone: 630.352.0303
email: dschmitt@toxstrategies.com

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please immediately notify ToxStrategies, Inc. at (832) 868-7729 and permanently delete the original and any copy of any e-mail and any printout thereof.

From: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>
Date: Tuesday, August 22, 2023 at 10:13 AM
To: Don Schmitt <dschmitt@toxstrategies.com>
Subject: GRN 001057 - USDA/FSIS Questions for Notifier

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Mr. Schmitt,

During USDA/FSIS' evaluation of GRAS Notice No. 001057, they noted questions that need to be addressed and are attached to this email.

We respectfully request a response within **10 business days**. If you are unable to complete the response within that time frame, please contact me to discuss further options. Please do not include any confidential information in your response. **Please provide responses to these questions in a separate PDF from the questions asked by FDA.**

If you have questions or need further clarification, please feel free to contact me. Thank you in advance for your attention to USDA/FSIS' comments.

Sincerely,

Stiffy Hice

Stephanie (Stiffy) Hice, Ph.D. (they/them/their)

Regulatory Review Scientist & Microbiology Reviewer

**Division of Food Ingredients
Office of Food Additive Safety
Center for Food Safety and Applied Nutrition
U.S. Food and Drug Administration**
stephanie.hice@fda.hhs.gov

Pronouns: They-Them-Their ([what is this?](#))



*Safety Data Sheet***DOLCIA PRIMA® LS ALLULOSE SYRUP****SECTION 1: IDENTIFICATION OF THE SUBSTANCE/ MIXTURE AND OF THE COMPANY/UNDERTAKING****1.1 PRODUCT IDENTIFIER**

- Chemical name Allulose
- CAS number 551-68-8

1.2 RELEVANT IDENTIFIED USES OF THE SUBSTANCE AND USES ADVISED AGAINST
Liquid food ingredient.

1.3 DETAILS OF THE SUPPLIER

- Company identification Americas:
Tate & Lyle Solutions USA LLC
5450 Prairie Stone Pkwy
Hoffman Estates, IL 60192
USA

Europe:
Tate & Lyle Slovakia s.r.o.
Boleraz 114
919 08 bolezaz
Slovakia

Asia-Pacific:
Tate & Lyle
3 Biopolis Drive, #05-11 Synapse
Singapore 138623

1.4 EMERGENCY PHONE NR. CHEMTREC
Toll-Free: 1-800-424-9300 (USA and Canada)
Non Toll-Free +1-703-527-3887 (Global)

SECTION 2: HAZARDS IDENTIFICATION**2.1. CLASSIFICATION OF THE SUBSTANCE OR MIXTURE**

According with the version of the Globally Harmonized System of Classification and labeling adopted in the United States and Regulation 1272/2008/EC [CLP]: Not classified

2.2. LABEL ELEMENTS

Code :	17000001	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	21.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	1 / 8

*Safety Data Sheet***DOLCIA PRIMA® LS ALLULOSE SYRUP****SIGNAL WORD:**

Not applicable

HAZARD STATEMENTS:

Not applicable

SYMBOL:

Not applicable

PRECAUTIONARY STATEMENTS:

Not applicable

2.3. OTHER HAZARDS

This product is not considered hazardous as defined in the OSHA hazard Communication Standard (29 CFR 1910.1200) product is a liquid food ingredient.

FIRE AND EXPLOSION HAZARD:

Liquid product will not burn.

POTENTIAL ACUTE HEALTH EFFECTS FROM OCCUPATIONAL EXPOSURE:

Inhalation: No effects known or anticipated.

Skin contact: No effects known or anticipated.

Eye contact: No effects known or anticipated.

Ingestion: No effects known or anticipated.

SECTION 3 : COMPOSITION / INFORMATION OF INGREDIENTS

- Chemical name	Allulose
- CAS number	551-68-8
- EINECS number	208-999-7

SECTION 4 : FIRST AID MEASURES**4.1 DESCRIPTION OF FIRST AID MEASURES**

- General advice	Seek medical attention if irritation develops after first aid application
- Inhalation	No special treatment under normal circumstances.
- Skin contact	No special treatment under normal circumstances. Clean with soap and water.
- Eye contact	No special treatment under normal circumstances. Rinse with

Code :	1700001	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	21.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	2 / 8

*Safety Data Sheet***DOLCIA PRIMA® LS ALLULOSE SYRUP**

- Ingestion eye wash solution or clean water. If symptoms develop, obtain medical attention.
No special treatment under normal circumstances.

4.2 MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED
None Anticipated

4.3 INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED.
None Anticipated

SECTION 5: FIRE-FIGHTING MEASURES

5.1 EXTINGUISHING MEDIA
Use media appropriate for surrounding fire.

5.2 SPECIFIC HAZARDS
FIRE AND EXPLOSION HAZARD:
None, liquid product will not burn.

5.3 SPECIFIC PROTECTIVE EQUIPMENT AND PRECAUTIONS FOR FIRE-FIGHTERS
Wear self-contained breathing apparatus and full protective gear. Use water spray to cool fire exposed containers.

FLAMMABILITY CLASS (OSHA)
Not applicable

HAZARDOUS COMBUSTION PRODUCTS
Carbon dioxide and carbon monoxide

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1 PERSONAL PRECAUTIONS
None under normal conditions.

6.2 ENVIRONMENTAL PRECAUTIONS
Prevent further leakage or spillage if safe to do so. No special environmental precautions

Code :	17000001	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	21.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	3 / 8

*Safety Data Sheet***DOLCIA PRIMA® LS ALLULOSE SYRUP**

required

6.3 METHODS FOR CLEANING UP**OCCUPATIONAL SPILL:**

No specific cleaning procedure is necessary. If washing down spilled area is necessary, use copious amounts of water and control runoff. Follow local, state and federal regulations for product disposal.

6.4 REFERENCE TO OTHER SECTIONS

See Section 7 for information on safe handling

See Section 8 for information on personal protection equipment

See Section 13 for disposal information

SECTION 7: HANDLING AND STORAGE**7.1 PRECAUTIONS FOR SAFE HANDLING**

No specific handling is necessary.

7.2 CONDITIONS OF SAFE STORAGE, INCLUDING ANY INCOMPATIBILITIES

Follow the storage conditions as described in the specification sheet.

7.3 SPECIFIC END USE(S)

Not applicable

SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION**8.1 CONTROL PARAMETERS**

Not hazardous as defined in OSHA 29 CFR 1910.1200. Product is a liquid food ingredient.

Exposure limits: Not applicable

8.2 EXPOSURE CONTROLS**APPROPRIATE ENGINEERING CONTROLS:**

Ventilation: Normal industrial hygiene measures should be sufficient.

APPROPRIATE PERSONAL PROTECTIVE EQUIPMENT:

Eye protection: Safety glasses are recommended.

Emergency wash facilities: Eye wash is recommended for conditions where splashing is likely.

Special protective clothing: Not normally required.

Code :	17000001	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	21.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	4 / 8

*Safety Data Sheet***DOLCIA PRIMA® LS ALLULOSE SYRUP**

Gloves: Not normally required.
Respirator: Not normally required.

FOR FIREFIGHTING AND OTHER IMMEDIATELY DANGEROUS TO LIFE OR HEALTH CONDITIONS:
See section 5

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES**9.1 INFORMATION ON BASIC PHYSICAL AND CHEMICAL PROPERTIES**

- Physical form	Syrup
- Color	Transparent water like to light yellow
- Odor	Bland
- pH (concentration)	Data on specification sheet if available.
- Boiling point	No data
- Flash point	No data
- Melting/freezing point	No data
- Decomposition temperature	No data
- Auto-ignition temperature	No data
- Explosion properties	No data
- Oxidising properties	No data
- Vapour pressure	No data
- Vapor density	No data
- Relative density	No data
- Bulk density	No data
- Specific gravity	No data
- Viscosity	Data on specification sheet if available.
- Water solubility	Soluble
- Solubility (non aqueous)	No data
- Partition coefficient	No data
- Dissociation constant	No data
- Evaporation rate	No data

9.2 OTHER INFORMATION**SECTION 10: STABILITY AND REACTIVITY****10.1 REACTIVITY**

Stable

10.2 CHEMICAL STABILITY

Stable under normal conditions.

Code :	17000001	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	21.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	5 / 8

*Safety Data Sheet***DOLCIA PRIMA® LS ALLULOSE SYRUP**

Polymerization will not occur.

10.3 POSSIBILITY OF HAZARDOUS REACTIONS

Not applicable

10.4 CONDITIONS TO AVOID

Avoid contact with strong oxidizers.

10.5 INCOMPATIBLE MATERIALS

Oxidizing agents, strong acids

10.6 HAZARDOUS DECOMPOSITION PRODUCTS

Nothing unusual

SECTION 11: TOXICOLOGICAL INFORMATION**11.1 INFORMATION ON TOXICOLOGICAL EFFECTS**

This (these) product(s) is(are) food ingredients.

ACUTE HEALTH EFFECTS:

Inhalation: No effects known or anticipated.

Skin contact: No effects known or anticipated.

Eye contact: No effects known or anticipated.

Ingestion: No effects known or anticipated.

CHRONIC HEALTH EFFECTS: None known or anticipated.

CARCINOGEN STATUS:

OSHA: Not listed.

NTP: Not listed.

IARC: Not listed.

SECTION 12: ECOLOGICAL INFORMATION**12.1 TOXICITY**

No data

12.2 PERSISTENCE/DEGRADABILITY

Readily biodegradable

12.3 BIOACCUMULATIVE POTENTIAL

Code :	17000001	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	21.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	6 / 8

*Safety Data Sheet***DOLCIA PRIMA® LS ALLULOSE SYRUP**

Food and feed ingredient, not relevant.

12.4 MOBILITY IN SOIL

Not applicable

12.5 BPT, vPvB

The substance does not meet the criteria for PBT or vPvB.

12.6 OTHER ADVERSE EFFECTS

None known

SECTION 13: DISPOSAL CONSIDERATIONS**13.1 WASTE TREATMENT METHODS**

Follow local, state and federal regulations for product disposal. Not a hazardous waste unless contaminated with hazardous products.

SECTION 14: TRANSPORTATION INFORMATION

International regulations (RID/ADR; RTMDR; IMDG; IATA/OACI): Not classified as dangerous for transport.

DOT shipping label: Non-hazardous

SECTION 15: REGULATORY INFORMATION**15.1 SAFETY, HEALTH AND ENVIRONMENTAL REGULATIONS**

According with the version of the Globally Harmonized System of Classification and labeling adopted in the United States and Regulation 1272/2008/EC(CLP): Not classified

15.2 CHEMICAL SAFETY ASSESSMENT**US FEDERAL REGULATIONS:**

Clean Air Act:

ODS: Not applicable.

TSCA Status: Not applicable.

SARA (EPCRA) Section 313 (40 C.F.R. § 372.65): Not applicable.

STATE REPORTING REQUIREMENTS:

California Proposition 65: Not applicable.

SECTION 16: OTHER INFORMATION

Code :	17000001	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	21.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	7 / 8

*Safety Data Sheet***DOLCIA PRIMA® LS ALLULOSE SYRUP****DISCLAIMER OF LIABILITY**

The information in this SDS is collected from reliable sources. However, the information is provided without any warranty, expressed or implied. The conditions or methods of handling, storage, use or disposal of the product might be beyond our control and knowledge. For the avoidance of doubt, we shall in no such circumstances be under any liability in respect of loss, damage or expenses arising from handling, storage, use or disposal of the product by your company and/or your subcontractors. This SDS is only applicable for the product mentioned in the identification chapter and title. If the product is used as a component in another product, this SDS may not be applicable on the composite material.

Code :	17000001	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	21.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	8 / 8

*Safety Data Sheet***DOLCIA PRIMA® DS CRYSTALLINE ALLULOSE****SECTION 1: IDENTIFICATION OF THE SUBSTANCE/ MIXTURE AND OF THE COMPANY/UNDERTAKING****1.1 PRODUCT IDENTIFIER**

- Chemical name Allulose
- CAS number 551-68-8

1.2 RELEVANT IDENTIFIED USES OF THE SUBSTANCE AND USES ADVISED AGAINST
Dry food ingredient.

1.3 DETAILS OF THE SUPPLIER

- Company identification Americas:
Tate & Lyle Solutions USA LLC
5450 Prairie Stone Pkwy
Hoffman Estates, IL 60192
USA

Europe:
Tate & Lyle Slovakia s.r.o.
Boleraz 114
919 08 bolezaz
Slovakia

Asia-Pacific:
Tate & Lyle
3 Biopolis Drive, #05-11 Synapse
Singapore 138623

1.4 EMERGENCY PHONE NR.

CHEMTREC
Toll-Free: 1-800-424-9300 (USA and Canada)
Non Toll-Free +1-703-527-3887 (Global)

SECTION 2: HAZARDS IDENTIFICATION**2.1. CLASSIFICATION OF THE SUBSTANCE OR MIXTURE**

According with the version of the Globally Harmonized System of Classification and labeling adopted in the United States and Regulation 1272/2008/EC [CLP]: Not classified

2.2. LABEL ELEMENTS

Code :	17000002	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	19.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	1 / 9

*Safety Data Sheet***DOLCIA PRIMA® DS CRYSTALLINE ALLULOSE****SIGNAL WORD:**

Not applicable

HAZARD STATEMENTS:

Not applicable

SYMBOL:

Not applicable

PRECAUTIONARY STATEMENTS:

Not applicable

2.3. OTHER HAZARDS**FIRE AND EXPLOSION HAZARD:**

May form combustible dust concentrations in air. Possibility of dust explosion. It is recommended that all dust control equipment and material transport systems involved are engineered to prevent conditions contributing to dust explosions. Do not allow dust to accumulate on flat surfaces, on rafters or building structural components. Keep away from all ignition sources including heat, sparks and flame.

POTENTIAL ACUTE HEALTH EFFECTS FROM OCCUPATIONAL EXPOSURE:

Inhalation: Exposure to high airborne concentrations may cause mild respiratory irritation due to drying effects of dust.

Skin contact: Sustained exposure in a dusty manufacturing environment may result in mechanical irritation in the creases of the skin, particularly at the fingers.

No health effects known or anticipated.

Eye contact: May cause slight mechanical irritation from acute exposure.

Ingestion: No effects known or anticipated.

SECTION 3 : COMPOSITION/INFORMATION OF INGREDIENTS

- Chemical name	Allulose
- CAS number	551-68-8
- EINECS number	208-999-7

SECTION 4 : FIRST AID MEASURES**4.1 DESCRIPTION OF FIRST AID MEASURES**

- General advice	Seek medical attention if irritation develops after first aid application
- Inhalation	Move people from the exposure to fresh air.

Code :	17000002	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	19.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	2 / 9

*Safety Data Sheet***DOLCIA PRIMA® DS CRYSTALLINE ALLULOSE**

- | | |
|----------------|---|
| - Skin contact | Wash skin with soap and water. |
| - Eye contact | Remove particulates by irrigating with eye wash solution or clean water, holding eyelids apart. |
| - Ingestion | Wash mouth and flush throat upto the stomach. |

4.2 MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED
None Anticipated

4.3 INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED.
None Anticipated

SECTION 5: FIRE-FIGHTING MEASURES**5.1 EXTINGUISHING MEDIA**

Water spray, dry powder, carbon dioxide or media appropriate for surrounding fire. Use of water jet may cause explosive dust conditions.

5.2 SPECIFIC HAZARDS

FIRE AND EXPLOSION HAZARD: Possibility of dust explosion. It is recommended that all dust control equipment and material transport systems involved are engineered to prevent conditions contributing to dust explosions. Do not allow dust to accumulate on flat surfaces, on rafters or building structural components. Use of water jet may cause explosive dust conditions. SEE NFPA 61, Standard for the prevention of Fire and Dust Explosions in Agricultural and Food Processing Facilities, 2008 or later Edition, and other related standards.

5.3 SPECIFIC PROTECTIVE EQUIPMENT AND PRECAUTIONS FOR FIRE-FIGHTERS

Wear self-contained breathing apparatus and full protective gear. Use water spray to cool fire exposed containers.

FLAMMABILITY CLASS (OSHA)

Not applicable

HAZARDOUS COMBUSTION PRODUCTS

Carbon dioxide and carbon monoxide

SECTION 6: ACCIDENTAL RELEASE MEASURES**6.1 PERSONAL PRECAUTIONS**

Code :	17000002	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	19.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	3 / 9

*Safety Data Sheet***DOLCIA PRIMA® DS CRYSTALLINE ALLULOSE**

None under normal conditions. Avoid prolonged inhalation of dust.

6.2 ENVIRONMENTAL PRECAUTIONS

Prevent further leakage or spillage if safe to do so. No special environmental precautions required

6.3 METHODS FOR CLEANING UP

Vacuum or sweep spills. Minimize dust generation.
If washing down spilled area is necessary, use copious amounts of water and control runoff.
Follow local, state and federal regulations for product disposal

6.4 REFERENCE TO OTHER SECTIONS

See Section 7 for information on safe handling
See Section 8 for information on personal protection equipment
See Section 13 for disposal information

SECTION 7: HANDLING AND STORAGE**7.1 PRECAUTIONS FOR SAFE HANDLING**

See NFPA 61, Standard for the Prevention of Fire and Dust Explosions in Agricultural and Food Processing Facilities, 2008 Edition, and other related standards. Use with adequate ventilation. Minimize dust generation and accumulation; dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are disturbed.

All dust control equipment and material transport systems involved are engineered to prevent conditions contributing to dust explosions and may require explosion relief vents or an explosion suppression system or an oxygen-deficient environment. Bonding and grounding systems may be required.

Dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) should be designed to limit or prevent leakage of dust into the work area.

Do not allow dust to accumulate on flat surfaces, on rafters or building structural components. Routine housekeeping should be instituted to reduce dust accumulation. Use Avoid dispersal of dust in the air; use vacuum or wet sweeping methods. Do not use compressed air to clean surfaces.

Keep away from all ignition sources including heat, sparks, and flame. Where dust accumulations occur use non-sparking tools.

Code :	17000002	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	19.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	4 / 9

*Safety Data Sheet***DOLCIA PRIMA® DS CRYSTALLINE ALLULOSE****7.2 CONDITIONS OF SAFE STORAGE, INCLUDING ANY INCOMPATIBILITIES**

Store in a cool dry place. Store in a tightly closed container/bag.
The packaging material should have reasonable moisture and air barriers and comply with food regulations.

7.3 SPECIFIC END USE(S)

Not applicable

SECTION 8 : EXPOSURE CONTROLS / PERSONAL PROTECTION**8.1 CONTROL PARAMETERS**

Exposure limits: Nuisance dust (also called particulate not otherwise regulated (PNOR)).

OSHA PEL: 15 mg/m³ Total dust
5 mg/m³ Respirable dust

ACGIH TLV: 10 mg/m³ Inhalable dust
5 mg/m³ Respirable dust
15 mg/m³ Total dust

8.2 EXPOSURE CONTROLS**APPROPRIATE ENGINEERING CONTROLS:**

Ventilation: See NFPA 61, Standard for the Prevention of Fire and Dust Explosions in Agricultural and Food Processing Facilities, 2008 Edition, and National Fire Protection Association 650, Standard for Pneumatic Conveying Systems for Handling Combustible Materials, 1997 Edition and other related standards. Normal industrial hygiene measures should be sufficient for protection of employees from exposure to dusts. Local and mechanical exhaust is desirable when dumping bags.

APPROPRIATE PERSONAL PROTECTIVE EQUIPMENT:

Eye protection: Safety glasses are recommended. Safety goggles are desirable when dumping bags.

Emergency wash facilities: Eye wash is recommended for conditions where dust generation is likely.

Special protective clothing: Not normally required.

Gloves: Not normally required. Use ordinary work gloves if dust dries skin.

Respirator: NIOSH approved N-95 dust respirator if working in situations that could generate large amounts of airborne dust.

Code :	17000002	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	19.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	5 / 9

*Safety Data Sheet***DOLCIA PRIMA® DS CRYSTALLINE ALLULOSE**

FOR FIREFIGHTING AND OTHER IMMEDIATELY DANGEROUS TO LIFE OR HEALTH CONDITIONS:
See section 5.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES**9.1 INFORMATION ON BASIC PHYSICAL AND CHEMICAL PROPERTIES**

- Physical form	Crystalline
- Color	White to off-white
- Odor	Odorless
- pH (concentration)	Data on specification sheet if available.
- Boiling point	No data
- Flash point	No data
- Melting/freezing point	No data
- Decomposition temperature	No data
- Auto-ignition temperature	No data
- Explosion properties	No data
- Oxidising properties	No data
- Vapour pressure	No data
- Vapor density	No data
- Relative density	No data
- Bulk density	No data
- Specific gravity	No data
- Viscosity	No data
- Water solubility	Soluble
- Solubility (non aqueous)	No data
- Partition coefficient	No data
- Dissociation constant	No data
- Evaporation rate	No data

9.2 OTHER INFORMATION**SECTION 10: STABILITY AND REACTIVITY****10.1 REACTIVITY**

Stable

10.2 CHEMICAL STABILITY

Stable under normal conditions.

Polymerization will not occur.

Code :	17000002	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	19.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	6 / 9

*Safety Data Sheet***DOLCIA PRIMA® DS CRYSTALLINE ALLULOSE****10.3 POSSIBILITY OF HAZARDOUS REACTIONS**

Not applicable

10.4 CONDITIONS TO AVOID

Practices which produce dust or disperse finely divided dust in air.
See NFPA 61. Standard for the Prevention of Fire and Dust Explosions in Agricultural and Food Processing Facilities, 2008 Edition, and other related standards.

10.5 INCOMPATIBLE MATERIALS

Oxidizing agents, strong acids

10.6 HAZARDOUS DECOMPOSITION PRODUCTS

Nothing unusual

SECTION 11: TOXICOLOGICAL INFORMATION**11.1 INFORMATION ON TOXICOLOGICAL EFFECTS**

- Inhalation Exposure to high airborne concentrations may cause mild respiratory irritation due to drying effects of dust.
- Ingestion No effects known or anticipated.
- Skin irritation / corrosion Sustained exposure in a dusty manufacturing environment may result in mechanical irritation in the creases of the skin, particularly at the fingers, or other drying effects. No health effects known or anticipated.
- Eye irritation May cause slight mechanical irritation from acute exposure.
- Skin sensitisation Not sensitizing
- Chronic toxicity Not known or anticipated
- Genetic toxicity Not known or anticipated
- Carcinogenicity Not classifiable as Carcinogen.
- Reprotoxicity Not known or anticipated
- Specific effects Not applicable

SECTION 12: ECOLOGICAL INFORMATION**12.1 TOXICITY**

Starch and its breakdown products are not known to be toxic to plant and animal life.

12.2 PERSISTENCE/DEGRADABILITY

Readily biodegradable

12.3 BIOACCUMULATIVE POTENTIAL

Code :	17000002	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	19.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	7 / 9

*Safety Data Sheet***DOLCIA PRIMA® DS CRYSTALLINE ALLULOSE**

Starch and its breakdown products are not fat-soluble, and do not accumulate in plant or animal tissue.

12.4 MOBILITY IN SOIL

Not applicable

12.5 BPT, vPvB

The substance does not meet the criteria for PBT or vPvB.

12.6 OTHER ADVERSE EFFECTS

None known

SECTION 13: DISPOSAL CONSIDERATIONS**13.1 WASTE TREATMENT METHODS**

Follow local, state and federal regulations for product disposal. Not a hazardous waste unless contaminated with hazardous products.

SECTION 14: TRANSPORTATION INFORMATION

International regulations (RID/ADR; RTMDR; IMDG; IATA/OACI): Not classified as dangerous for transport.

DOT shipping label: Non-hazardous

SECTION 15: REGULATORY INFORMATION**15.1 SAFETY, HEALTH AND ENVIRONMENTAL REGULATIONS**

According with the version of the Globally Harmonized System of Classification and labeling adopted in the United States and Regulation 1272/2008/EC(CLP): Not classified

15.2 CHEMICAL SAFETY ASSESSMENT**US FEDERAL REGULATIONS:**

Clean Air Act:

ODS: Not applicable.

TSCA Status: Not applicable.

SARA (EPCRA) Section 313 (40 C.F.R. § 372.65): Not applicable.

STATE REPORTING REQUIREMENTS:

California Proposition 65: Not applicable.

Code :	17000002	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	19.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	8 / 9

*Safety Data Sheet***DOLCIA PRIMA® DS CRYSTALLINE ALLULOSE****SECTION 16: OTHER INFORMATION**

See Hazard Communication Guidance for Combustible Dusts, OSHA 3371-08 2009, U.S. Occupational Safety and Health Administration, <https://www.osha.gov/Publications/3371combustible-dust.html> (accessed 10/8/14)

NFPA 654, Standard for the Prevention of Fire and Dust Explosions from the Manufacturing, Processing, and Handling of Combustible Particulate Solids, for general safe handling and design guidance.

Safety Data Sheet according to Commission Regulation (EU) No 2020/878 amending Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)

DISCLAIMER OF LIABILITY

The information in this SDS is collected from reliable sources. However, the information is provided without any warranty, expressed or implied. The conditions or methods of handling, storage, use or disposal of the product might be beyond our control and knowledge. For the avoidance of doubt, we shall in no such circumstances be under any liability in respect of loss, damage or expenses arising from handling, storage, use or disposal of the product by your company and/or your subcontractors. This SDS is only applicable for the product mentioned in the identification chapter and title. If the product is used as a component in another product, this SDS may not be applicable on the composite material.

Code :	17000002	Effectivity date :	23.01.2023	Revision :	02
		Supersedes :	19.05.2020	Latest Revision :	02
		Printed on :	24.02.2023	Page :	9 / 9

From: [Don Schmitt](#)
To: [Hice, Stephanie](#)
Cc: [Kolberg, Lore](#)
Subject: Re: [EXTERNAL] Re: GRN 001057 - Questions for Notifier
Date: Friday, September 15, 2023 4:53:17 PM
Attachments: [image001.png](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)
[image005.png](#)
[image006.png](#)
[image007.png](#)
[image008.png](#)
[image009.png](#)
[image010.png](#)
[GRN 1057 Items for Clarification and Responses 091523.pdf](#)

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Stephanie,

Attached are Tate & Lyle's responses to FDA's questions regarding GRN 1057.

Sincerely,

Don

Donald F. Schmitt, M.P.H.
Senior Managing Scientist



ToxStrategies

739 Thornapple Drive
Naperville, IL 60540
phone: 630.352.0303
email: dschmitt@toxstrategies.com

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please immediately notify ToxStrategies, Inc. at (832) 868-7729 and permanently delete the original and any copy of any e-mail and any printout thereof.

From: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>
Date: Wednesday, August 23, 2023 at 1:07 PM
To: Don Schmitt <dschmitt@toxstrategies.com>
Cc: Kolberg, Lore <lore.kolberg@tateandlyle.com>
Subject: RE: [EXTERNAL] Re: GRN 001057 - Questions for Notifier

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Mr. Schmitt,

Thank you for the update. Yes, an extension until September 15, 2023, is fine.

Sincerely,

Stiffy Hice

Stephanie (Stiffy) Hice, Ph.D. (they/them/their)

Regulatory Review Scientist & Microbiology Reviewer

Division of Food Ingredients
Office of Food Additive Safety
Center for Food Safety and Applied Nutrition
U.S. Food and Drug Administration
stephanie.hice@fda.hhs.gov

Pronouns: They-Them-Their ([what is this?](#))



From: Don Schmitt <dschmitt@toxstrategies.com>
Sent: Wednesday, August 23, 2023 12:59 PM
To: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>
Cc: Kolberg, Lore <lore.kolberg@tateandlyle.com>
Subject: [EXTERNAL] Re: GRN 001057 - Questions for Notifier

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Stephanie,

We are working on responses to the list of questions you provided on August 14. One of the questions requires that the intake assessment be revised and this will take Exponent a few weeks to

complete, given their previous commitments. Therefore, Tate & Lyle is requesting a 3-week extension of the time to reply to all 12 questions. That would be Friday, September 15.

Thank you for considering this extension request.

Best regards,

Don

Donald F. Schmitt, M.P.H.
Senior Managing Scientist



ToxStrategies

739 Thornapple Drive
Naperville, IL 60540
phone: 630.352.0303
email: dschmitt@toxstrategies.com

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please immediately notify ToxStrategies, Inc. at (832) 868-7729 and permanently delete the original and any copy of any e-mail and any printout thereof.

From: Don Schmitt <dschmitt@toxstrategies.com>

Date: Monday, August 14, 2023 at 9:46 AM

To: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>

Subject: Re: GRN 001057 - Questions for Notifier

Hi Stephanie,

I will speak with Tate & Lyle and be back in touch shortly.

Don

Donald F. Schmitt, M.P.H.

Senior Managing Scientist



ToxStrategies

739 Thornapple Drive
Naperville, IL 60540
phone: 630.352.0303
email: dschmitt@toxstrategies.com

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please immediately notify ToxStrategies, Inc. at (832) 868-7729 and permanently delete the original and any copy of any e-mail and any printout thereof.

From: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>

Date: Monday, August 14, 2023 at 8:07 AM

To: Don Schmitt <dschmitt@toxstrategies.com>

Subject: GRN 001057 - Questions for Notifier

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Mr. Schmitt,

During our evaluation of GRAS Notice No. 001057, we noted questions that need to be addressed and are attached to this email.

We respectfully request a response within **10 business days**. If you are unable to complete the response within that time frame, please contact me to discuss further options. Please do not include any confidential information in your response.

If you have questions or need further clarification, please feel free to contact me. Thank you in advance for your attention to our comments.

Sincerely,

Stiffy Hice

Stephanie (Stiffy) Hice, Ph.D. (they/them/their)

Regulatory Review Scientist & Microbiology Reviewer

Division of Food Ingredients
Office of Food Additive Safety
Center for Food Safety and Applied Nutrition
U.S. Food and Drug Administration
stephanie.hice@fda.hhs.gov

Pronouns: They-Them-Their ([what is this?](#))



GRN 1057 Items for Clarification

1. On page 6, and in places throughout the notice, the notifier states that the intended use of D-psicose is substitutional for the intended uses described in GRNs 000400, 000498, 000693, and 000828, including medical foods, which were included in the list of intended uses described in GRN 000400. Since issuing the response letter for GRN 000400, FDA published a guidance document, entitled “Guidance for Industry: Frequently Asked Questions About Medical Foods”. This guidance states FDA’s view that the definition of medical foods constrains the types of products that fit within that category (notice of availability published on May 9, 2016, 81 FR 29867).

On page 21 of GRN 001057, the notifier includes the following in the description of medical foods: “Nutritional drinks such as Boost, Ensure, and Glucerna to provide a surrogate for medical foods”. In our guidance referenced above, FDA states, “Medical foods are distinguished from the broader category of foods for special dietary use by the requirement that medical foods be intended to meet distinctive nutritional requirements of a disease or condition, used under medical supervision, and intended for the specific dietary management of a disease or condition. Medical foods are not those simply recommended by a physician as part of an overall diet to manage the symptoms or reduce the risk of a disease or condition. Not all foods fed to patients with a disease, including diseases that require dietary management, are medical foods. Instead, medical foods are foods that are specially formulated and processed (as opposed to a naturally occurring foodstuff used in a natural state) for a patient who requires use of the product as a major component of a disease or condition’s specific dietary management.”

Based on this definition, we do not believe that the foods included in this category on page 21 of GRN 001057 meet the definition of medical foods and instead fall under the “nutritional beverages” category. For the administrative record, please provide a revised copy of Table 9 reflecting this change.

Response: See the following revised Table 9 as prepared by Exponent in revised intake assessment (September 8, 2023) and attached to this document (Question #11 attachment).

Table 9. Maximum allulose use levels by food type of foods and beverages

No.*	Food category	Description of Foods Selected for Analysis	Tate and Lyle's proposed new uses (%)
2b	Nutritional beverages	All nutritional drinks such as Camation Instant Breakfast, Muscle Milk, Slim Fast, and all other nutritional drinks or shakes	2.5
2c	PediaSure	PediaSure	3.5
5a	RTE and cooked, regular	RTE and cooked cereals identified as containing added sugar	12**
5b	RTE and cooked, low calorie, reduced calorie, sugar-free	RTE and cooked cereals identified as low calorie, reduced sugar, or sugar-free	12**
5d	Grain-free, no sugar, high protein RTE cereal	No grain-free, no sugar, high protein RTE cereals were reported consumed, hence, zero-sugar added RTE cereals were selected as surrogates.	20
9	Frozen dairy (ice cream, soft serve, sorbet), low calorie, reduced calorie, sugar-free	Desserts including ice cream, soft serve, sorbet - all identified as low calorie, reduced calorie, sugar-free, or NFS†	8**
11	Nutrition bars	Meal replacement bars, protein bars, energy bars, etc.	15
16	Ketchup and barbecue sauces	Ketchup and barbecue sauces	10
19	Cranberries, dried	Dried cranberries (i.e., Craisins)	25
20	Jerky (meat or poultry based)	Jerky (meat or poultry based)	15

* Numbering in Table 9. Maximum allulose use levels by types of foods and beverages, in Exponent's March 28, 2022 report.

** Existing Use levels from previous GRNs are below Tate & Lyle's proposed levels

- In Table 3 (pages 11-12), the notifier lists the processing aids used during the manufacture of D-psicose and provides corresponding CAS numbers. The provided CAS number for the glucoisomerase included in the table corresponds to polyoxyl stearyl ether. For the administrative record, please provide the correct CAS number for the glucoisomerase included in Table 3.

Response: The correct CAS No. is 9055-00-9.

- The notifier states that the enzyme glucoisomerase is used to convert D-glucose to D- fructose (page 12). The notifier states that this enzyme is obtained from a genetically engineered strain of *Streptomyces rubiginosus* strain "DP-Pzn37". Please indicate if this enzyme is purchased or if it is prepared by the notifier. In addition, please indicate if this enzyme is removed from the final product or if it is expected to be present in the final product. We note that this enzyme, while the subject of 21 CFR 184.1372, is not listed as being obtained from a genetically engineered strain of *S. rubiginosus*, as such please describe the genetic construction of strain "DP-Pzn37". We recommend that the notifier submit a GRAS notice for the intended use of the enzyme.

Response: On August 16, 2023, Tate & Lyle requested a clarification of FDA’s needs regarding question 3, “specifically what FDA is looking for when you say, ‘please describe the genetic construction of strain dP-Pzn37’? The DNA sequence is the most sensitive IP for enzyme suppliers, and they are typically reticent to provide it to their customers, in this case Tate & Lyle.”

The agency responded on August 17: “In response to that portion of the question, we would be looking for a description of the production strain for this enzyme (e.g., statements of pathogenicity, toxigenicity) and a general description of the construction of the production strain (e.g., which genes are inserted/excised). We would not be looking for you to supply the full genome, including any gene sequences.”

The glucoisomerase enzyme is not prepared by T&L, the notifier. The enzyme is produced by IFF (formerly Danisco) and it is purchased by Primient, the producer of fructose syrup, which T&L purchases as an intermediate material for further processing to produce d-psicose (allulose). Attached are three documents regarding the glucoisomerase enzyme and the production strain. They include a Certificate of Source and GRAS statement from IFF as well as a safety evaluation of the enzyme xylose isomerase (another name for glucoisomerase) from the genetically modified *Streptomyces rubiginosus* strain DP-Pzn37 (EFSA, 2020).

The manufacturer of the enzyme (Danisco, now IFF) submitted a dossier on their enzyme for safety evaluation by EFSA (2020) and they directed Tate & Lyle to that safety evaluation for the information and data requested by FDA in question 3. Based on the 2020 EFSA review (see attachment), the strain was considered non-toxicogenic and non-pathogenic. Information regarding the construction of the production strain can also be found in the EFSA safety evaluation document. In conclusion, EFSA (2020) found both the enzyme and production strain safe for use in the production of high fructose syrups in the EU.

Streptomyces rubiginosus is a bacterial species of the genus *Streptomyces* and isolated from soil. As stated in the EFSA safety evaluation, the glucoisomerase enzyme is produced with a genetically modified bacterium *S. rubiginosus* strain DP- Pzn37, which is deposited at the Westerdijk Fungal Biodiversity Institute (The Netherlands). The whole genome sequence of the production strain has been analyzed for the presence of antimicrobial resistance genes. Genetic stability has been demonstrated. In addition, similarity of the amino acid sequence to those of known allergens was searched and no matches were found (EFSA, 2020).

Most importantly, glucoisomerase is not expected to be present in the final product. Not only is the enzyme used in an immobilized form in the production of high-fructose corn syrup, but the purification steps applied during the production of fructose have been shown to effectively remove the food enzyme (EFSA, 2020). Based on information from the enzyme supplier, the glucoisomerase enzyme from the genetically modified *Streptomyces rubiginosus* strain DP-Pzn37 has a history of use in the U.S. in the production of high-fructose corn syrup.

As suggested by the agency, Tate & Lyle has communicated to the enzyme supplier FDA's recommendation to submit a GRAS notification for the intended use of the enzyme.

4. For the administrative record, please state whether any of the raw materials used in the production of D-psicose are allergens or are derived from allergenic sources.

Response: None of the raw materials used in the production of D-psicose are allergens or are derived from allergenic sources.

5. The content of total non-allulose saccharides in crystalline D-psicose is listed as <2%, dry basis, in Table 2 (page 9) and <0.9%, dry basis, in Table 4 (page 13). Please clarify whether the level for total non-allulose saccharides in crystalline D-psicose is <2% or <0.9%.

Response: Table 2 is incorrect. The level for total non-allulose saccharides in crystalline D-psicose is 0.9% as stated in Tables 4 and 6.

6. In Table 4 (page 13), the provided specification limit for sulfur dioxide is <10 mg/kg. We note that sulfur dioxide is not listed as a processing aid used in the manufacture of D-psicose in Table 3 (page 11). Please clarify if the sulfur dioxide is the chemical residue from corn processing and specify a technical effect for sulfur dioxide in the processing of corn.

Response: Sulfur dioxide is a chemical residue from corn processing. Sulfur dioxide is typically used in corn processing to control undesirable bacterial growth, increase corn hull permeability, and promote swelling and softening of the dense corn kernel.

7. In Table 7 (page 14), the notifier lists the following specifications:

- a. *Escherichia coli* “not detected (CFU/10 g)”. For the administrative record, please clarify the limit of detection for this specification.

Response: The limit of detection is 1 CFU/10g sample.

- b. *Salmonella* serovars “Negative (CFU/25 g)”. For the administrative record, please confirm whether this refers to a specification of “negative/25g”.

Response: Yes, this refers to a specification of negative/25g.

8. On page 15, the notifier states, “The method employed for analysis of *E. coli* is TN10512L, is an internal method, which references ISO21528-1:2017. The method TN10512L is validated for the intended use. The method employed for analysis of *Salmonella* is TN10547, is an internal validated method for the intended use that references ISO6579-1:2017”; however, on page 58, the referenced methods for *E. coli* and *Salmonella* serovars are listed as TN 10412L and TN 10510, respectively. For the administrative record, please clarify this discrepancy.

Response: The correct methods are in the COAs – TN10412L for *E. coli* and TN 10510 for *Salmonella*.

9. On pages 58-60, the listed microbiological specifications and units do not align with those provided in Table 7 (page 14). For example (but not limited to), the specification and units for total plate count is listed as ≤ 200 CFU/10 g on page 14 but is listed as ≤ 200 CFU/g on page 58. For the administrative record, please provide revised copies of the certificates of analyses presented on pages 58-60, with the corrected specifications and units.

Response: See new Tables 5 and 6 which align with the COAs in Appendix B.

Table 5. Analytical results for three non-consecutive lots of allulose syrup

Specification		Lot No. YP19DO3774	Lot No. YP19G01863	Lot No. YP18D03177
Allulose (% dry basis)	>95	96.2	96.3	96.3
Total non-allulose saccharides (%)	<5	2.6	2.9	2.4
Dry solids (%)	70-78	70.8	70.5	71.0
pH	3.0 – 4.5	4.2	3.9	4.3
Sulfur dioxide (ppm)	<10	<10	<10	<10
Total plate count	≤200 cfu/10g	<10	<10	<10
Yeast	≤10 cfu/10g	<10	<10	<10
Mold	≤10 cfu/10g	<10	<10	<10
Arsenic (ppm)	<0.1	0.016	0.011	0.024
Cadmium (ppm)	<0.1	<0.005	<0.005	<0.005
Lead (ppm)	<0.1	<0.005	<0.005	0.006
Mercury (ppm)	<0.01	<0.005	<0.005	<0.005

Table 6. Analytical results for three non-consecutive lots of crystalline allulose

Specification		Lot No. LO18J90596	Lot No. LO19F90351	Lot No. LO18J90294
Allulose (% dry basis)	>99.1	99.4	99.8	99.2
Total non-allulose saccharides (%)	<0.9	0.27	0.06	0.29
Moisture (%)	<0.5	0.14	0.12	0.10
Ash (%)	<0.5	<0.1	<0.1	<0.1
Sulfur dioxide (ppm)	<10	<10	<10	<10
Total plate count	≤200 cfu/g	<10	10	10
Yeast	≤10 cfu/g	<10	10	<10
Mold	≤10 cfu/g	<10	10	<10
Arsenic (ppm)	<0.1	<0.005	<0.005	<0.005
Cadmium (ppm)	<0.1	<0.005	<0.005	<0.005
Lead (ppm)	<0.1	<0.005	<0.005	<0.005
Mercury (ppm)	<0.01	<0.005	<0.005	<0.005

10. In Table 9 (page 19), the proposed maximum use level of D-psicose in frozen dairy products, such as ice cream and sorbets, is listed as “NA”. However, we note that the use level of 8% for D-psicose was used for the cumulative dietary exposure estimate (amendment dated July 15, 2022). Please clarify if the notifier is proposing a use level of 8% in frozen dairy products, which is higher than the current use level of 5% for frozen dairy products, or if the use level of 8% is a result of an error.

Response: The use level of 8% in the amendment dated July 15, 2022 is correct.

11. In Part 3, the notifier provides dietary exposure estimates from background uses of D- psicose (i.e., GRNs 000400, 000498, 000693, and 000828) (Table 10, page 25) as well as cumulative dietary exposure estimates (background and proposed uses of D-psicose) (Table 12, page 27).

- Considering that GRNs 001024 and 001029 submitted for the use of D-psicose recently received “no questions” letters from FDA, we request that the notifier update the dietary exposure estimates provided in Tables 10 and 12 to account for the recently notified additional uses of D-psicose.
- Specifically, GRN 001024 includes the use of D-psicose in “Alcoholic beverages (pre-mixed cocktails, wine coolers, and malt beverages, low/reduced calorie)” that the notifier should consider including in the updated background and cumulative dietary exposure estimates.
- We note that we consider the cumulative dietary exposure to D-psicose that was estimated in GRN 001024 to be 22.9 g/person (p)/d at the 90th percentile for the US population aged 2 years and older as the current dietary exposure to D-psicose. When revising the notifier’s dietary exposures, the dietary exposure presented in GRN 001024 could be used to represent the background dietary exposure to D- psicose.
- Based on human tolerance studies discussed in GRN 001057, conservative safe limits of allulose consumption are shown to be 0.5 g/kg bw/d for men and 0.6 g/kg bw/d for women. Since FDA considers 60 kg body weight as average of both males and females, the g/kg bw/d numbers translate to 30 and 36 g/person/day for males and females, respectively. The 30 g/person/day exposure appears to be safe for both males and females. Therefore, please provide a revised exposure estimate that satisfies the above conditions of safe consumption at the 90th percentile, that is, an exposure around 30 g/p/d or less.

Response: Please see the attached revised intake assessment conducted by Exponent (dated, September 8, 2023).

As per FDA’s comment, the use of allulose in alcoholic beverages (pre-mixed cocktails, wine coolers, and malt beverages, low/reduced calorie) were included in GRN 001024 and should be considered part of the background exposure and CEDI. As such, Tate and Lyle excluded alcoholic beverages from its proposed uses. Tate and Lyle also reduced the proposed use level in nutrition bars to 15% (previously 25%).

Revised estimated daily intake (EDI) for allulose from the proposed uses were based on food consumption records collected in the WWEIA component of NHANES conducted in 2017-2018 (NHANES 2017-2018). In the previous intake assessment report, Exponent used two NHANES survey cycles (NHANES 2015-2018). However, NHANES 2017-2018 was used in this update in order to be consistent with GRN 001024. The updated results from Tate and Lyle’s proposed new uses of allulose are provided in **Table 2** of the attached report.

The resulting revised per user cumulative estimated daily intake of allulose is as follows:

Sub-population	Background EDI (g/day) (GRN 001024)		EDI (g/day) from Proposed Uses	Cumulative Estimated Daily Intake (g/day)		
	% Users	Mean per capita	Mean per capita	Mean per capita	Mean per user*	Pseudo 90 ^{th**} Per user
US 2+ y	77.0	7.8	3.4	11.2	14.5	29.0
2-12 y	70.5	4.2	3.3	7.5	10.6	21.2
13-18 y	62.9	3.6	3.3	6.9	10.9	21.8
19+ y	81.2	8.9	3.4	12.3	15.1	30.2

* Mean per capita divided by % users to derive mean per user

** Pseudo 90th is derived based on 2 x mean (FDA 2006 guidance)²

As stated in question 11, based on human tolerance studies discussed in GRN 001057, conservative safe limits of allulose consumption are shown to be 0.5 g/kg bw/d for men and 0.6 g/kg bw/d for women. Since FDA considers 60 kg body weight as average of both males and females, the g/kg bw/d numbers translate to 30 and 36 g/person/day for males and females, respectively. The 30 g/person/day exposure appears to be safe for both males and females. Therefore, please provide a revised exposure estimate that satisfies the above conditions of safe consumption at the 90th percentile, that is, an exposure around 30 grams/day or less.

As shown in the above table, the CEDI for the per user US population 2+ years of age is 29.0 gram/day; below the 30 gram/day level. Only the 19+ age group intake of 30.2 grams/day is slightly above the 30 g/day level and considered not of significance.

12. Please provide an updated literature search that discusses the safety of D-psicose, including the date (month and year) the literature search was performed and discuss whether there are any study results that may be contradictory to a GRAS conclusion.

Response: Per request, please see the attached updated literature search (January 2020 – August 2023). Search terms employed are also provided. There are no study results that contradict the conclusions regarding the safety and GRAS status of allulose.

No pivotal studies that would contradict the conclusions that the proposed uses and use levels of allulose are both safe and GRAS were found. Allulose (d-psicose) has a long

history of safe use in food for consumption in the US as supported by the four GRNs summarized in Table 13 as well as the more recent GRNs 1024 and 1029 (all received letters on no objection).

GRNs 1024 and 1029 included several more recent studies not cited in GRN 1057 and are referenced here for completeness. They include the following: Teyssiere et al. (2022); Tanaka et al. (2021); Ahmed et al. (2022); Daniel et al. (2021).

We agree with the summary of the An et al. (2019) preclinical study and the conclusions of the submitters of GRN 1029 provided in the attachments to the GRN. An et al. conducted a 90-day oral toxicity study in rats and determined a NOAEL for d-allulose was 5,000 mg/kg bw/day.

As for the paper by Daniel et al. (2021) that questioned the safety of allulose because it may enhance the intestinal colonization of *Klebsiella pneumonia*, we agree with the submitters of GRN 1029. This continues to be an area of some research, but there is no conclusive evidence that this poses a safety concern to humans consuming allulose. Again, allulose (d-psicose) has a long history of safe use in food for human consumption in the US.

A few recent preclinical study publications are summarized below:

Sa et al. (2022) evaluated the teratogenicity of d-allulose in rats (modified OECD guidelines test number 414). Pregnant SD female rats received repeat doses of 1250, 2500, or 5000 mg/kg bw/day of d-allulose, or a vehicle control by gavage on gestation days 6–15. On gestation day 20, pregnant rats were weighed, anesthetized, and a laparotomy performed to remove the uterus, after which the contents were weighed. Fetuses were examined macroscopically for any soft tissue or skeletal changes. Parameters evaluated included general observations, body weight, food consumption, mortality, corpora lutea, numbers of embryonic or fetal deaths, and viable fetuses including live birth rate, fetal resorption rate, and stillbirth rate, as well as sex, body weights, and skeletal and soft tissue alterations of fetuses. No treatment-related abnormalities were observed in prenatal developmental toxicity and fetal malformation parameters. The NOAEL of d-allulose for teratogenicity was estimated to be 5000 mg/kg bw/day in pregnant SD rats.

Choi et al. (2022) studied the acute oral toxicity of D-allulose in ICR mice. Mice received a single oral dose of D-allulose (1,250, 2,500 or 5,000 mg/kg body weight). No mortality occurred and no changes were observed in clinical signs of toxicity, body weights, and blood serum chemistry. The LD50 was estimated to exceed 5,000 mg/kg.

References:

Choi, MN, Kim Y-S, Lee H, Shin K-C. 2022. A study on single-dose oral toxicity of D-allulose in ICR mice. Maejo International Journal of Science & Technology 16(3):170-178.

Sa S, Seol Y, Lee AW, Heo Y, Kim H-j, Park CJ. 2022. Teratogenicity of D-allulose. Toxicology Reports 9:821-824.

Question #3 Attachments

Date: August 17, 2023



Where science
& creativity meet

GRAS STATEMENT

RE: **GENSWEET® IGI-VHF** (A10022)¹

To Whom It May Concern,

GENSWEET® IGI-VHF consists of consists of glucose isomerase (also known as xylose isomerase) produced using a *Streptomyces rubiginosus* production strain that has been genetically engineered. The glucose isomerase protein is not protein engineered. The glucose isomerase enzyme is not a genetically modified organism (GMO).

GENSWEET® IGI-VHF is Generally Recognized as Safe (GRAS) for use as processing aid in High Fructose Corn Syrup (HFCS) manufacture when the enzyme product is used within the product dose guidelines described in IFF's product literature. The glucose isomerase enzyme produced with *Streptomyces rubiginosus* is affirmed to be Generally Recognized as Safe ('GRAS'), under 21 CFR 184.1372.

GENSWEET® IGI-VHF also meets or exceeds the Joint FAO/WHO Expert Committee on Food Additives (JECFA)/Food Chemical Codex (FCC) specifications for microbial and metal contaminants in food enzymes.

IFF is committed to help our customers maximize the benefits of our technology, and we want to ensure successful use and safety of our products. Please contact your account manager if you should have further questions.

IFF Health & Biosciences



Liane Grieco

Global Regulatory Affairs

Global Regulatory Strategy Leader, Grain Processing

liane.m.grieco@iff.com

Health & Biosciences

200 Powder Mill Road
Wilmington, DE 19803

T +1.302.332.8420

iff.com

This certificate is valid for one year from date of issue.



Where science
& creativity meet

ⁱ Copyright © 2023 International Flavors & Fragrances Inc. All rights reserved. IFF, the IFF logo and all products denoted with ® or ™ are trademarks of the affiliates of International Flavors & Fragrances Inc. The information contained herein is subject to change without further notice, is provided "as is" and without charge to our customers. This is business-to-business information and technical advice that is intended for use by persons having appropriate technical expertise and is based upon data and studies IFF believes to be reliable based upon IFF's present knowledge and experience. Conditions and methods of use of IFF's products are beyond our control, and nothing contained herein shall be construed as a representation or warranty on use or of non-infringement of intellectual property, regulatory or legal compliance. Use of the information and advice contained herein is at the recipient's sole discretion and risk and IFF assumes no liability for its use. Recipient should conduct their own tests to determine suitability of IFF products for their own specific purposes.

iff.com

Date: August 17, 2023



Where science
& creativity meet

CERTIFICATE OF SOURCE

RE: **GENSWEET® IGI-VHF** (A10022)ⁱ

To Whom It May Concern,

GENSWEET® IGI-VHF consists of consists of glucose isomerase (also known as xylose isomerase) produced by controlled fermentation in closed fermentation tanks, using a *Streptomyces rubiginosus* production strain that has been genetically engineered. The glucose isomerase protein is not protein engineered. The glucose isomerase enzyme is not a genetically modified organism (GMO).

After fermentation, the enzyme undergoes fixation and is immobilized onto an inert carrier matrix. IFF's immobilization process permanently cross-links the enzyme with matrix chemicals.

The final glucose isomerase product is available as an immobilized enzyme preparation approved for use as a processing aid in the production of high fructose corn syrup, a food ingredient.

All our enzyme products, whether obtained by genetic engineering or not, are only introduced into the market when their safety has been fully established according to internationally accepted assessments and regulatory procedures

IFF is committed to help our customers maximize the benefits of our technology, and we want to ensure successful use and safety of our products. Please contact your account manager if you should have further questions.

Health & Biosciences
200 Powder Mill Road
Wilmington, DE 19803
T +1.302.332.8420
iff.com

IFF Health & Biosciences



Liane Grieco
Global Regulatory Affairs
Global Regulatory Strategy Leader, Grain Processing
liane.m.grieco@iff.com

This certificate is valid for one year from date of issue.



Where science
& creativity meet

ⁱ Copyright © 2023 International Flavors & Fragrances Inc. All rights reserved. IFF, the IFF logo and all products denoted with ® or ™ are trademarks of the affiliates of International Flavors & Fragrances Inc. The information contained herein is subject to change without further notice, is provided "as is" and without charge to our customers. This is business-to-business information and technical advice that is intended for use by persons having appropriate technical expertise and is based upon data and studies IFF believes to be reliable based upon IFF's present knowledge and experience. Conditions and methods of use of IFF's products are beyond our control, and nothing contained herein shall be construed as a representation or warranty on use or of non-infringement of intellectual property, regulatory or legal compliance. Use of the information and advice contained herein is at the recipient's sole discretion and risk and IFF assumes no liability for its use. Recipient should conduct their own tests to determine suitability of IFF products for their own specific purposes.

iff.com

ADOPTED: 12 December 2019

doi: 10.2903/j.efsa.2020.5978

Safety evaluation of the food enzyme xylose isomerase from the genetically modified *Streptomyces rubiginosus* strain DP-Pzn37

EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP), Vittorio Silano, José Manuel Barat Baviera, Claudia Bolognesi, Pier Sandro Cocconcelli, Riccardo Crebelli, David Michael Gott, Konrad Grob, Evgenia Lampi, Alicja Mortensen, Gilles Rivière, Inger-Lise Steffensen, Christina Tlustos, Henk van Loveren, Laurence Vernis, Holger Zorn, Boet Glandorf, Lieve Herman, Karl-Heinz Engel*, Andrew Smith*, Davor Zelježić*, Margarita Aguilera-Gómez, Ana Gomes, Natália Kovalkovičová, Yi Liu, Joaquim Maia, Sandra Rainieri and Andrew Chesson

Abstract

The food enzyme is a D-xylose aldose-ketose-isomerase (EC 5.3.1.5) produced with the genetically modified *Streptomyces rubiginosus* strain DP-Pzn37 by Danisco US Inc. Although the production strain contains antibiotic resistance genes, the food enzyme was shown to be free from viable cells of the production organism and its DNA. The food enzyme is intended to be used in an immobilised form for the isomerisation of glucose for the production of high fructose syrups. Residual amounts of total organic solids (TOS) are eliminated by the use of an immobilised food enzyme and further removed by the purification steps applied during the production of high fructose syrups using the immobilised enzyme; consequently, dietary exposure was not calculated. Genotoxicity tests did not raise safety concerns. The systemic toxicity was assessed by a repeated dose 90-day oral toxicity study in rats. The Panel identified a no observed adverse effect level of 85.2 mg TOS/kg body weight (bw) per day, the highest dose tested. Similarity of the amino acid sequence to those of known allergens was searched and no match was found. The Panel considered that, under the intended conditions of use, the risk of allergic sensitisation and elicitation reactions by dietary exposure cannot be excluded, but the likelihood is considered to be low. Based on the data provided, the immobilisation process and the removal of total organic solids during the production of high fructose syrups, the Panel concluded that this food enzyme does not give rise to safety concerns under the intended conditions of use.

© 2020 European Food Safety Authority. *EFSA Journal* published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

Keywords: food enzyme, xylose isomerase, glucose isomerase, D-xylose aldose-ketose-isomerase, EC 5.3.1.5, *Streptomyces rubiginosus*

Requestor: European Commission

Question number: EFSA-Q-2016-00203

Correspondence: fip@efsa.europa.eu

* Member of the Working Group on Enzymes of the EFSA Panel Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) until 3-7-2018.

Panel members: José Manuel Barat Baviera, Claudia Bolognesi, Andrew Chesson, Pier Sandro Cocconcelli, Riccardo Crebelli, David Michael Gott, Konrad Grob, Evgenia Lampi, Alicja Mortensen, Gilles Rivière, Vittorio Silano, Inger-Lise Steffensen, Christina Tlustos, Henk Van Loveren, Laurence Vernis and Holger Zorn.

Note: The full opinion will be published in accordance with Article 12 of Regulation (EC) No 1331/2008 once the decision on confidentiality will be received from the European Commission.

Suggested citation: EFSA CEP Panel (EFSA Panel on Food Contact Materials, Enzymes and Processing Aids), Silano V, Barat Baviera JM, Bolognesi C, Cocconcelli PS, Crebelli R, Gott DM, Grob K, Lampi E, Mortensen A, Rivière G, Steffensen I-L, Tlustos C, van Loveren H, Vernis L, Zorn H, Glandorf B, Herman L, Engel K-H, Smith A, Želježić D, Aguilera-Gómez M, Gomes A, Kovalkovičová N, Liu Y, Maia J, Rainieri S and Chesson A, 2020. Scientific Opinion on the safety evaluation of the food enzyme xylose isomerase from the genetically modified *Streptomyces rubiginosus* strain DP-Pzn37. EFSA Journal 2020;18(1):5978, 12 pp. <https://doi.org/10.2903/j.efsa.2020.5978>

ISSN: 1831-4732

© 2020 European Food Safety Authority. *EFSA Journal* published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

This is an open access article under the terms of the [Creative Commons Attribution-NoDerivs](https://creativecommons.org/licenses/by/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.



The EFSA Journal is a publication of the European Food Safety Authority, an agency of the European Union.



Table of contents

Abstract.....	1
1. Introduction.....	4
1.1. Background and Terms of Reference as provided by the requestor.....	4
1.1.1. Background as provided by the European Commission	4
1.1.2. Terms of Reference	5
1.2. Interpretation of the Terms of Reference Reference	5
2. Data and methodologies.....	5
2.1. Data.....	5
2.2. Methodologies.....	5
3. Assessment.....	5
3.1. Source of the food enzyme	6
3.1.1. Characteristics of the parental and recipient microorganisms	6
3.1.2. Characteristics of the introduced sequences	6
3.1.3. Description of the genetic modification process	6
3.1.4. Safety aspects of the genetic modification.....	6
3.2. Production of the food enzyme.....	6
3.3. Characteristics of the food enzyme	7
3.3.1. Properties of the food enzyme.....	7
3.3.2. Chemical parameters	7
3.3.3. Purity	8
3.3.4. Viable cells and DNA of the production strain	8
3.4. Toxicological assessment.....	8
3.4.1. Genotoxicity.....	8
3.4.1.1. Bacterial reverse mutation test.....	8
3.4.1.2. <i>In vitro</i> mammalian chromosomal aberrations test.....	9
3.4.2. Repeated dose 90-day oral toxicity study in rodents.....	9
3.4.3. Allergenicity	9
3.5. Dietary exposure.....	10
3.5.1. Intended use of the food enzyme.....	10
3.5.2. Dietary exposure estimation.....	10
4. Conclusion	10
Documentation provided to EFSA	11
References.....	11
Abbreviations.....	11

1. Introduction

Article 3 of the Regulation (EC) No 1332/2008¹ provides definition for 'food enzyme' and 'food enzyme preparation'.

'Food enzyme' means a product obtained from plants, animals or micro-organisms or products thereof including a product obtained by a fermentation process using micro-organisms: (i) containing one or more enzymes capable of catalysing a specific biochemical reaction; and (ii) added to food for a technological purpose at any stage of the manufacturing, processing, preparation, treatment, packaging, transport or storage of foods.

'Food enzyme preparation' means a formulation consisting of one or more food enzymes in which substances such as food additives and/or other food ingredients are incorporated to facilitate their storage, sale, standardisation, dilution or dissolution.

Before January 2009, food enzymes other than those used as food additives were not regulated or were regulated as processing aids under the legislation of the Member States. On 20 January 2009, Regulation (EC) No 1332/2008 on food enzymes came into force. This Regulation applies to enzymes that are added to food to perform a technological function in the manufacture, processing, preparation, treatment, packaging, transport or storage of such food, including enzymes used as processing aids. Regulation (EC) No 1331/2008² established the European Union (EU) procedures for the safety assessment and the authorisation procedure of food additives, food enzymes and food flavourings. The use of a food enzyme shall be authorised only if it is demonstrated that:

- i) it does not pose a safety concern to the health of the consumer at the level of use proposed;
- ii) there is a reasonable technological need;
- iii) its use does not mislead the consumer.

All food enzymes currently on the European Union market and intended to remain on that market, as well as all new food enzymes, shall be subjected to a safety evaluation by the European Food Safety Authority (EFSA) and approval via an EU Community list.

The 'Guidance on submission of a dossier on food enzymes for safety evaluation' (EFSA, 2009a) lays down the administrative, technical and toxicological data required.

1.1. Background and Terms of Reference as provided by the requestor

1.1.1. Background as provided by the European Commission

Only food enzymes included in the European Union (EU) Community list may be placed on the market as such and used in foods, in accordance with the specifications and conditions of use provided for in Article 7 (2) of Regulation (EC) No 1332/2008 on food enzymes.

Five applications have been introduced by the companies "BASF Enzymes LLC1" for the authorisation of the food enzyme Alpha-amylase from a genetically modified strain of *Pseudomonas fluorescens* (BD15754), "DSM Food Specialties B.V." for the authorisation of the food enzyme Phospholipase C from a genetically modified strain of *Pichia pastoris* (PRF), and "Danisco US Inc." for the authorisation of the food enzymes Alpha-amylase from a genetically modified strain of *Bacillus licheniformis* (DP-Dzb25), Xylose isomerase from a genetically modified strain of *Streptomyces rubiginosus* (DP-Pzn37), and Alpha-amylase from a genetically modified strain of *Bacillus amyloliquefaciens* (DP-Czb53).

Following the requirements of Article 12.1 of Commission Regulation (EU) No 234/2011³ implementing Regulation (EC) No 1331/2008², the Commission has verified that the five applications fall within the scope of the food enzyme Regulation and contain all the elements required under Chapter II of that Regulation.

¹ Regulation (EC) No 1332/2008 of the European Parliament and of the Council of 16 December 2008 on Food Enzymes and Amending Council Directive 83/417/EEC, Council Regulation (EC) No 1493/1999, Directive 2000/13/EC, Council Directive 2001/112/EC and Regulation (EC) No 258/97. OJ L 354, 31.12.2008, pp. 7–15.

² Regulation (EC) No 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a common authorisation procedure for food additives, food enzymes and food flavourings. OJ L 354, 31.12.2008, pp. 1–6.

³ Commission Regulation (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the European Parliament and of the Council establishing a common authorisation procedure for food additives, food enzymes and food flavourings. OJ L 64, 11.3.2011, p. 15–24.

1.1.2. Terms of Reference

The European Commission requests the European Food Safety Authority to carry out the safety assessments on the food enzymes Alpha-amylase from a genetically modified strain of *Pseudomonas fluorescens* (strain BD15754), Phospholipase C from a genetically modified strain of *Pichia pastoris* (strain PRF), Alpha-amylase from a genetically modified strain of *Bacillus licheniformis* (strain DP-Dzb25), Xylose isomerase from a genetically modified strain of *Streptomyces rubiginosus* (strain DP-Pzn37), and Alpha-amylase from a genetically modified strain of *Bacillus amyloliquefaciens* (strain DP-Czb53) in accordance with Article 17.3 of Regulation (EC) No 1332/2008 on food enzymes.

1.2. Interpretation of the Terms of Reference

The present scientific opinion addresses the European Commission's request to carry out the safety assessment of food enzyme xylose isomerase from a genetically modified *S. rubiginosus* (strain DP-Pzn37).

2. Data and methodologies

2.1. Data

The applicant has submitted a dossier in support of the application for authorisation of the food enzyme xylose isomerase produced with a genetically modified *S. rubiginosus* strain DP-Pzn37. The dossier was updated on 28 July 2016.

Additional information was requested from the applicant during the assessment process on 29 May 2017, 28 November 2018 and 25 June 2019, and was consequently provided (see 'Documentation provided to EFSA').

Following the reception of additional data by EFSA on 26 April 2018, EFSA requested a clarification teleconference, which was held on 16 May 2018; after which the applicant provided additional data on 1 June 2018.

Following the requests for additional data sent by EFSA on 29 May 2017, 28 November 2018 and 25 June 2019, the applicant requested clarification teleconferences, which were held on 20 June 2017, 20 May 2019 and 5 July 2019.

2.2. Methodologies

The assessment was conducted in line with the principles described in the EFSA 'Guidance on transparency in the scientific aspects of risk assessment' (EFSA, 2009b) as well as in the EFSA 'Statement on the characterisation of microorganisms used for the production of food enzymes' (EFSA CEP Panel, 2019) and following the relevant existing guidance's of EFSA Scientific Committees.

The current 'Guidance on the submission of a dossier on food enzymes for safety evaluation' (EFSA, 2009a) has been followed for the evaluation of the application with the exception of the exposure assessment, which was carried out in accordance to the methodology described in the CEF Panel statement on the exposure assessment of food enzymes (EFSA CEF Panel, 2016).

3. Assessment

IUBMB nomenclature:	Xylose isomerase
Systematic name:	D-xylose aldose-ketose-isomerase
Synonyms:	Glucose isomerase; D-xylose isomerase; D-xylose ketol-isomerase
IUBMB No:	EC 5.3.1.5
CAS No:	9023-82-9
EINECS No:	232-944-6.

The xylose isomerase catalyses the conversion of D-xylose to D-xylulose and of D-glucose to D-fructose. It is intended to be used for the isomerisation of glucose for the production of high fructose syrups. The food enzyme is intended to be used only in an immobilised form.⁴ Based on its technical application, the term glucose isomerase is used throughout this dossier.

⁴ Technical dossier/Additional data April 2018.

3.1. Source of the food enzyme

The glucose isomerase is produced with a genetically modified bacterium *S. rubiginosus* strain DP-Pzn37, which is deposited at the Westerdijk Fungal Biodiversity Institute (The Netherlands) with the deposit number [REDACTED]⁴. The taxonomic identification of the production strain was performed on the basis of [REDACTED].

The whole genome sequence of the production strain was analysed for the presence of antimicrobial resistance genes. [REDACTED]⁵

3.1.1. Characteristics of the parental and recipient microorganisms

The parental microorganism is the Actinobacterium *S. rubiginosus* strain [REDACTED].

The recipient strain *S. rubiginosus* [REDACTED] was derived [REDACTED]⁶

3.1.2. Characteristics of the introduced sequences

The donor for the glucose isomerase encoding gene is [REDACTED]⁷

[REDACTED]⁸

3.1.3. Description of the genetic modification process

The production strain *S. rubiginosus* DP-Pzn37 was developed from the recipient strain [REDACTED]⁸

3.1.4. Safety aspects of the genetic modification

The technical dossier contains all necessary information on the recipient microorganism, the donor organism and the genetic modification process.

The production strain DP-Pzn37 differs from the recipient strain [REDACTED]⁷

Genetic stability was demonstrated [REDACTED]⁹

[REDACTED]⁵

3.2. Production of the food enzyme

The food enzyme is manufactured according to the Food Hygiene Regulation (EC) No 852/2004¹⁰, with food safety procedures based on hazard analysis and critical control points, and in accordance with current Good Manufacturing Practice.¹¹

⁵ Technical dossier/Additional data May 2019/Annex AH.

⁶ Technical dossier/1st submission/Annex S and T.

⁷ Technical dossier/1st submission/Annex S and Technical dossier/2nd submission/Annex U.

⁸ Technical dossier/1st submission/Annex S.

⁹ Technical dossier/2nd submission/Annex Z.

¹⁰ Regulation (EC) No. 852/2004 of the European Parliament and of the Council of 29 April 2004 on the hygiene of food additives. OJ L 226, 25.6.2004, pp. 3–21.

¹¹ Technical dossier/2nd submission/p. 40.

The production strain is grown as a pure culture using a typical industrial medium in a submerged, batch or fed-batch fermentation system with conventional process controls in place. After completion of the fermentation, the cells are lysed and the enzyme is immobilised [REDACTED]

The immobilised food enzyme preparation is then separated from the liquid fraction by filtration. Afterwards, the preparation is extruded, dried and sieved.¹² The applicant provided information on the identity of the substances used to control the fermentation and in the subsequent downstream processing of the food enzyme.⁴

The Panel considered that sufficient information has been provided on the manufacturing process and the quality assurance system implemented by the applicant to exclude issues of concern.

3.3. Characteristics of the food enzyme

3.3.1. Properties of the food enzyme

The glucose isomerase is a single polypeptide of [REDACTED] amino acids.¹³ The molecular mass, derived from the amino acid sequence, was calculated to be [REDACTED] kDa.¹⁴ The food enzyme was analysed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE). A consistent protein pattern was observed across all batches. The gels showed a single major protein band corresponding to an apparent molecular mass of about [REDACTED] kDa, consistent with the expected mass of the enzyme.¹⁵ No other enzymatic side activities were reported.

The in-house determination of free glucose isomerase activity is based on the conversion of glucose to fructose (reaction conditions: pH 6.85, 30°C, 30 min). The enzymatic activity is determined by measuring the fructose formed by high-performance liquid chromatography (HPLC). The glucose isomerase activity is quantified relative to an internal enzyme standard and expressed in glucose isomerase units (GIU)/g.¹⁶

The free food enzyme has a temperature optimum around 80–85°C (pH 7.5) and a pH optimum around pH 8.0–8.5 (60°C). Thermostability was tested after a pre-incubation of the food enzyme for 32 min at different temperatures (pH 7.5). The glucose isomerase activity decreased rapidly above 85°C, showing no residual activity above 95°C.¹⁷

3.3.2. Chemical parameters

Data on the chemical parameters of the food enzyme were provided for five food enzyme batches, three batches used for commercialisation and two batches produced for the toxicological tests (Table 1).¹⁸ The average total organic solids (TOS) of the three food enzyme batches for commercialisation was 14.4%. The average enzyme activity/TOS ratio of the three food enzyme batches for commercialisation is 21.2 GIU/mg TOS.

¹² Technical dossier/1st submission/Annex K and S and Additional data May 2019/Annex AA.

¹³ Technical dossier/1st submission/Annex G.

¹⁴ Technical dossier/Additional data May 2019.

¹⁵ Technical dossier/2nd submission/p. 30.

¹⁶ Technical dossier/1st submission/Annex C.

¹⁷ Technical dossier/2nd submission/p. 34–36.

¹⁸ Technical dossier/Additional data June 2018/Annexes F, G, H, L and M.

Table 1: Compositional data of the food enzyme prior to immobilisation and batches used for toxicological studies

Parameter	Unit	Batches				
		1	2	3	4 ^(a)	5 ^(b)
Glucose isomerase activity	GIU/g batch ^(c)	2,831	3,238	2,980	434.32	3,530
Protein	%	12.30	14.47	11.37	4.79	20.19
Ash	%	0.17	0.73	0.37	2.30	9.61
Water	%	85.77	82.26	87.48	89.18	44.00
Total organic solids (TOS) ^(d)	%	14.06	17.01	12.15	8.52	46.39
Glucose isomerase activity/mg TOS	GIU/mg TOS	20.14	19.04	24.53	5.10	7.61

(a): Batch used for the Bacterial reverse mutation test and Repeated dose 90-day oral toxicity study in rodents.

(b): Batch used for the *in vitro* chromosomal aberrations test.

(c): GIU/g: glucose isomerase units/g (see Section 3.3.1).

(d): TOS calculated as 100% – % water – % ash.

3.3.3. Purity

The lead content in the three commercial batches and in the two batches used for toxicological studies was below 0.05 mg/kg which complies with the specification for lead (< 5 mg/kg) as laid down in the general specifications and considerations for enzymes used in food processing (FAO/WHO, 2006).^{18,19}

The food enzyme complies with the microbiological criteria as laid down in the general specifications and considerations for enzymes used in food processing (FAO/WHO, 2006), which stipulate that *Escherichia coli* and *Salmonella* species are absent in 25 g of sample and total coliforms should not exceed 30 colony forming units (CFU) per gram.¹⁸ No antimicrobial activity was detected in any of these batches (FAO/WHO, 2006).²⁰

The Panel considered that the information provided on the purity of the food enzyme is sufficient.

3.3.4. Viable Cells and DNA of the production strain

The absence of the production strain has been demonstrated

²¹ The production strain was not detected

No recombinant DNA was detected

²²

3.4. Toxicological assessment

A battery of toxicological tests including a bacterial gene mutation assay (Ames test), an *in vitro* mammalian chromosomal aberration test, and a repeated dose 90-day oral toxicity study in rats has been provided. The batches 4 and 5 (Table 1) used in these studies have lower specific activity compared to the batches used for commercialisation, and thus are considered suitable for toxicological testing.

3.4.1. Genotoxicity

3.4.1.1. Bacterial reverse mutation test

A bacterial reverse mutation assay (Ames test) was performed according to Organisation for Economic Co-operation and Development (OECD) Test Guideline 471 (OECD, 1997a) and following Good Laboratory Practice (GLP).²³ Five strains of *Salmonella* Typhimurium (TA 98, TA 100, TA 102, TA

¹⁹ LoD: Pb = 0.05 mg/kg.

²⁰ Technical dossier/Additional data June 2018/Annex I.

²¹ Technical dossier/2nd submission/Annex E and Technical dossier/Additional data April 2018.

²² Technical dossier/Additional data September 2019.

²³ Technical dossier/1st submission/Annex M.

1535, TA 1537) were tested in the presence or absence of metabolic activation applying the 'treat and plate' assay. Two experiments were carried out using five different concentrations of the food enzyme for strains TA 98, TA 100, TA 102, TA 1535 (50, 166, 500, 1,660 and 5,000 µg total protein/plate, corresponding to 88.9, 295, 889, 2,953 and 8,894 µg TOS/plate), and three experiments using ten different concentrations for strain TA 1537 (0.166, 0.5, 1.66, 5, 16.6, 50, 166, 500, 1,660 and 5,000 µg total protein/plate, corresponding to 0.30, 0.89, 2.95, 8.89, 29.5, 88.9, 295, 889, 2,953 and 8,894 µg TOS/plate). Growth reductions of the background lawn were observed, in some cases severe, due to toxicity. Upon treatment with the food enzyme, there was no significant increase in revertant colony numbers above the control values in any strain with or without S9-mix.

The Panel concluded that the food enzyme glucose isomerase did not induce gene mutations under the test conditions employed in this study.

3.4.1.2. *In vitro* mammalian chromosomal aberrations test

The *in vitro* chromosomal aberrations test was carried out according to the OECD Test Guideline 473 (OECD, 1997b) and following GLP.²⁴ The food enzyme was tested for its ability to induce chromosomal aberrations in human peripheral blood lymphocytes with and without metabolic activation (S9-mix). Based on the results obtained in a dose-range finding test, the cells were treated with 1,250, 2,500 and 5,000 total protein µg/mL (corresponding to 2,872, 5,744 and 11,488 µg TOS/mL) applying a 4 + 20 h short-term treatment and recovery in the presence and absence of S9-mix, and a continuous treatment (20 + 0 h) in the absence of S9-mix. In all the tested conditions, the frequency of cells with structural and numerical chromosomal aberrations in treated cultures was comparable to the values detected in negative controls and within the range of the laboratory historical negative control data.

The Panel concluded that the food enzyme glucose isomerase did not induce chromosomal aberrations under the test conditions employed for this study.

3.4.2. Repeated dose 90-day oral toxicity study in rodents

The repeated dose 90-day oral toxicity study in rodents was performed in accordance with OECD Test Guideline 408 (OECD, 1998), and following GLP.²⁵ Groups of 10 male and 10 female Ntac:SD Sprague–Dawley rats received the food enzyme by gavage in doses corresponding to 21.3, 42.6 and 85.2 mg TOS/kg body weight (bw) per day. Controls received the vehicle (saline solution 2% NaCl).

There were three unscheduled deaths. Two deaths (one control female and one high-dose male) were related to misdosing. The third animal (low-dose male) was found dead and the cause of death could not be established at necropsy due to autolysis.

A statistically significant increase in monocytes in mid-dose females in comparison to the control group was observed. However, in the absence of a dose response and similar finding in males, this finding was considered to be incidental.

Among clinical chemistry parameters statistically significant differences to controls included increased serum sodium concentration in high-dose males and increased cholesterol and albumin concentrations in high-dose females. As these findings lacked consistency between sexes, and the values were within the historical control range (sodium and cholesterol) for the laboratory or slightly higher (albumin: 49.5 ± 2.1 g/L compared to 95% interval of historical control data of 37.89–48.7 g/L) they were considered of no toxicological significance.

Ophthalmological examination was not performed. However, no changes in the eyes were recorded during weekly clinical examinations, at necropsy and by microscopy of the eyes of control and treated groups.

No other significant effects were observed.

Overall, the Panel identified a no observed adverse effect level (NOAEL) of 85.2 mg TOS/kg bw per day, the highest dose tested.

3.4.3. Allergenicity

The allergenicity assessment considers only the food enzyme and not any carrier or other excipient, which may be used in the final formulation.

²⁴ Technical dossier/1st submission/Annex N.

²⁵ Technical dossier/1st submission/Annex O.

The potential allergenicity of the glucose isomerase produced with the genetically modified *S. rubiginosus* strain DP-Pzn37 was assessed by comparing its amino acid sequence with those of known allergens according to the scientific opinion on the assessment of allergenicity of genetically modified plants and microorganisms and derived food and feed of the Scientific Panel on Genetically Modified Organisms (EFSA GMO Panel, 2010). Using higher than 35% identity in a sliding window of 80 amino acids as the criterion, no match was found.²⁶

No information is available on oral sensitisation or elicitation reactions of this glucose isomerase. In addition, no allergic reactions upon dietary exposure to any glucose isomerase have been reported in the literature. Therefore, it can be concluded that allergic reactions upon oral ingestion of this glucose isomerase, produced with the genetically modified *S. rubiginosus* strain DP-Pzn37 cannot be excluded, but the likelihood of such a reaction to occur is considered to be low.

Quantifying the risk for allergenicity is not possible in view of the individual susceptibility to food allergens. Allergenicity can be ruled out only if the proteins are fully removed. Considering that the food enzyme is only used in immobilised form and in the glucose isomerisation for the production of high fructose syrups, experimental data showed a significant removal (below LoDs) of protein. However, traces of protein could be present in high fructose syrups.

The Panel considered that, under the intended conditions of use, the risk of allergic sensitisation and elicitation reactions upon dietary exposure to this food enzyme cannot be excluded but the likelihood of such reactions occurring is considered to be low.

3.5. Dietary exposure

3.5.1. Intended use of the food enzyme

The food enzyme is intended to be used to isomerise glucose for the production of high fructose syrup at the maximum use level proposed by the applicant of 1 mg TOS/kg glucose syrup derived from cereals,²⁷ for the immobilised food enzyme only.

As the food enzyme is intended to be used only in its immobilised form, the transfer of TOS into the final product, i.e. high fructose syrups, is expected to be negligible. Additionally, experimental data have been provided showing low ash contents (less than 0.01 g/100 g dry matter syrup), and protein, fat and fibres contents in the final high fructose syrup, after purification steps are applied (i.e. ion exchange chromatography, treatment with active carbon), are not detectable (Annex B in EFSA CEF Panel, 2016a). Amounts of [REDACTED] in the final food samples have been experimentally shown to be not detectable.^{28,29} The Panel considers that the residual amount of TOS (including substances other than proteins, such as DNA fragments) in the final high fructose syrups will be removed.

3.5.2. Dietary exposure estimation

Considering that the food enzyme is intended to be used only in its immobilised form (see Section 3.5.1), and as residual amounts of TOS are removed by the purification steps applied during the production of high fructose syrups, a dietary exposure was not calculated.

4. Conclusion

Based on the data provided, immobilisation of the food enzyme and the removal of TOS during purification steps applied during the production of high fructose syrups, the Panel concluded that the food enzyme glucose isomerase produced with the genetically modified *S. rubiginosus* strain DP-Dzn37 does not give rise to safety concerns under the intended conditions of use.

The production strain of the food enzyme contains a known antimicrobial resistance gene in a multicopy plasmid together with sequences showing homology with genes known to confer resistance to macrolides. However, based on the absence of viable cells and DNA from the production organism in the food enzyme, this is not considered to be a risk.

²⁶ Technical dossier/1st submission/Annex R.

²⁷ Technical dossier/2nd submission/p. 74 and Additional data May 2019.

²⁸ Technical dossier/1st submission/Annex W and Additional data May 2019/Annexes AB, AC and AD.

²⁹ LoDs: [REDACTED].

Documentation provided to EFSA

- 1) Technical dossier 'Application for authorisation of xylose isomerase from a genetically modified strain of *Streptomyces rubiginosus* (DP-Pzn37)'. January 2016. Submitted by Danisco US Inc.
- 2) Additional information. April 2018. Submitted by Danisco US Inc.
- 3) Additional information. June 2018. Submitted by Danisco US Inc.
- 4) Additional information. May 2019. Submitted by Danisco US Inc.
- 5) Additional information. September 2019. Submitted by Danisco US Inc.

References

- EFSA (European Food Safety Authority), 2009a. Guidance of EFSA prepared by the Scientific Panel of Food Contact Material, Enzymes, Flavourings and Processing Aids on the Submission of a Dossier on Food Enzymes. EFSA Journal 2009;7(8):1305, 26 pp. <https://doi.org/10.2903/j.efsa.2009.1305>
- EFSA (European Food Safety Authority), 2009b. Guidance of the Scientific Committee on transparency in the scientific aspects of risk assessments carried out by EFSA. Part 2: general principles. EFSA Journal 2009;7(5):1051, 22 pp. <https://doi.org/10.2903/j.efsa.2009.1051>
- EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 2016. Panel statement on the exposure assessment of food enzymes. EFSA Journal 2016;14(11):4581, 9 pp. <https://doi.org/10.2903/j.efsa.2016.4581>
- EFSA CEP Panel (EFSA Panel on Food Contact Materials, Enzymes and Processing Aids), 2019. Statement on the characterisation of microorganisms used for the production of food enzymes. EFSA Journal 2019;17(6):5741, 13 pp. <https://doi.org/10.2903/j.efsa.2019.5741>
- EFSA GMO Panel (EFSA Panel on Genetically Modified Organisms), 2010. Scientific Opinion on the assessment of allergenicity of GM plants and microorganisms and derived food and feed. EFSA Journal 2010;8(7):1700, 168 pp. <https://doi.org/10.2903/j.efsa.2010.1700>
- FAO/WHO (Food and Agriculture Organization of the United Nations/World Health Organization), 2006. General specifications and considerations for enzyme preparations used in food processing in Compendium of food additive specifications. 67th meeting. FAO JECFA Monographs, 3, 63–67. Available online: <http://www.fao.org/3/a-a0675e.pdf>
- OECD (Organisation for Economic Co-Operation and Development), 1997a. OECD Guideline for the testing of chemicals, Section 4 Health effects, Test No. 471: Bacterial reverse mutation test. 21 July 1997. 11 pp. Available online: http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en;jsessionid=9zfgzu35paaq.x-oecd-live-01
- OECD (Organisation for Economic Co-Operation and Development), 1997b. OECD Guideline for the testing of chemicals, Section 4 Health effects, Test No. 473: *In vitro* mammalian chromosomal aberration test. 21 July 1997. 10 pp. Available online: https://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-mammalian-chromosome-aberration-test_9789264071261-en
- OECD (Organisation for Economic Co-Operation and Development), 1998. OECD Guideline for the testing of chemicals, Section 4 Health effects, Test No. 408: Repeated dose 90-day oral toxicity study in rodents. 21 September 1998. 10 pp. Available online: http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90-day-oral-toxicity-study-in-rodents_9789264070707-en

Abbreviations

bw	body weight
CAS	Chemical Abstracts Service
CEF	EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CEP	EFSA Panel on Food Contact Materials, Enzymes and Processing Aids
CFU	colony forming units
EINECS	European Inventory of Existing Commercial Chemical Substances
FAO	Food and Agricultural Organisation
GIU	glucose isomerase units
GLP	Good Laboratory Practice
GMO	EFSA Panel on Genetically Modified Organisms
HPLC	high-performance liquid chromatography
IUBMB	International Union of Biochemistry and Molecular Biology

LoD	limit of detection
NOAEL	no observed adverse effect level
OECD	Organisation for Economic Cooperation and Development
SDS-PAGE	sodium dodecyl sulfate-polyacrylamide gel electrophoresis
TOS	total organic solids
WHO	World Health Organisation

Question #11 Attachment



EXTERNAL MEMORANDUM

TO: Lore Kolberg (Tate & Lyle)
FROM: Exponent
DATE: September 8, 2023
PROJECT: 2103250.000
SUBJECT: Revised Cumulative Estimated Daily Intake of Allulose

At the request of Tate and Lyle, Exponent prepared this memorandum to provide the updated cumulative estimated daily intake (CEDI) for allulose. The update was made in response to the following FDA’s review comments on the dietary exposure estimate summarized in GRN 001057:

“Considering that GRNs 001024 and 001029 submitted for the use of D-psicose recently received “no questions” letters from FDA, we request that the notifier update the dietary exposure estimates provided in Tables 10 and 12 to account for the recently notified additional uses of D-psicose...

Specifically, GRN 001024 includes the use of D-psicose in ‘Alcoholic beverages (pre-mixed cocktails, wine coolers, and malt beverages, low/reduced calorie)’ that the notifier should consider including in the updated background and cumulative dietary exposure estimates.

We note that we consider the cumulative dietary exposure to D-psicose that was estimated in GRN 001024 to be 22.9 g/person (p)/d at the 90th percentile for the US population aged 2 years and older as the current dietary exposure to D-psicose. When revising the notifier’s dietary exposures, the dietary exposure presented in GRN 001024 could be used to represent the background dietary exposure to D-psicose.”

Revised Proposed Uses

As per FDA’s comment, the use of allulose in alcoholic beverages (pre-mixed cocktails, wine coolers, and malt beverages, low/reduced calorie) were included in GRN 001024 and should be considered part of the background exposure and CEDI. As such, Tate and Lyle excluded alcoholic beverages from its proposed uses. Tate and Lyle also reduced the proposed use level in nutrition bars to 15% (previously 25%). Tate and Lyle’s revised proposed uses of allulose is provided in **Table 1**. The list of food codes included in this assessment is provided in **Appendix A**.

Revised estimated daily intake (EDI) for allulose from the proposed uses in Table 1 were based on food consumption records collected in the WWEIA component of NHANES conducted in 2017-2018 (NHANES 2017-2018). In the previous intake assessment report, Exponent used two NHANES survey cycles (NHANES 2015-2018). However, NHANES 2017-2018 was used in this update in order to be consistent with GRN 001024. The updated results from Tate and Lyle’s proposed new uses of allulose are provided in **Table 2**.

Table 1. Tate and Lyle’s revised proposed uses

No.*	Food category	Description of Foods Selected for Analysis	Tate and lye’s proposed new uses (%)
2b	Nutritional beverages	All nutritional drinks such as Carnation Instant Breakfast, Muscle Milk, Slim Fast, and all other nutritional drinks or shakes	2.5
2c	PediaSure	PediaSure	3.5
5a	RTE and cooked, regular	RTE and cooked cereals identified as containing added sugar	12**
5b	RTE and cooked, low calorie, reduced calorie, sugar-free	RTE and cooked cereals identified as low calorie, reduced sugar, or sugar-free	12**
5d	Grain-free, no sugar, high protein RTE cereal	No grain-free, no sugar, high protein RTE cereals were reported consumed, hence, zero-sugar added RTE cereals were selected as surrogates.	20
9	Frozen dairy (ice cream, soft serve, sorbet), low calorie, reduced calorie, sugar-free	Desserts including ice cream, soft serve, sorbet - all identified as low calorie, reduced calorie, sugar-free, or NFS‡	8**
11	Nutrition bars	Meal replacement bars, protein bars, energy bars, etc.	15
16	Ketchup and barbecue sauces	Ketchup and barbecue sauces	10
19	Cranberries, dried	Dried cranberries (i.e., Craisins)	25
20	Jerky (meat or poultry based)	Jerky (meat or poultry based)	15

* Numbering in Table 1. Maximum allulose use levels by types of foods and beverages, in Exponent’s March 28, 2022 report.

** Existing Use levels from previous GRNs are below Tate & Lyle’s proposed levels

Table 2. Two-day average EDI of allulose from Tate and Lyle’s revised proposed uses by the U.S. 2+ y and subpopulations (g/day); NHANES 2017-2018

Sub-population	Unweighted N	% Users	EDI of allulose (g/day)			
			Per Capita		Per User	
			Mean	90 th Percentile	Mean	90 th Percentile
US 2+ y	6184	62.3	3.4	9.6	5.4	11.9
2-12 y	1262	77.1	3.3	8.0	4.3	8.6
13-18 y	682	64.3	3.3	8.9	5.1	10.7
19+ y	4240	59.4	3.4	10.0	5.7	12.8

Revised Cumulative Estimated Daily Intake

FDA commented that the CEDI of 22.9 g/person (p)/d at the 90th percentile for the US population aged 2 years and older in GRN 001024 is the current dietary exposure to allulose. As recommended by the FDA, Exponent relied on the dietary exposure presented in GRN 001024 to represent the background dietary exposure to allulose. Specifically, Exponent relied on the data provided in **Table 1. Updated Cumulative Allulose Intake (g/day)** on page 232 of GRN 001024.¹

The revised CEDI for allulose from both Tate and Lyle’s proposed uses and background uses for the US 2+ y and sub-populations are summarized in **Table 3**.

Table 3. CEDI of allulose from background uses and Tate and Lyle’s proposed uses by the U.S. 2+ y and subpopulations (g/day); NHANES 2017-2018

Sub-population	Background EDI (g/day) (GRN 001024)		EDI (g/day) from Proposed Uses	Cumulative Estimated Daily Intake (g/day)		
	% Users	Mean per capita	Mean per capita	Mean per capita	Mean per user*	Pseudo 90 ^{th**} Per user
US 2+ y	77.0	7.8	3.4	11.2	14.5	29.0
2-12 y	70.5	4.2	3.3	7.5	10.6	21.2
13-18 y	62.9	3.6	3.3	6.9	10.9	21.8
19+ y	81.2	8.9	3.4	12.3	15.1	30.2

* Mean per capita divided by % users to derive mean per user

* Pseudo 90th is derived based on 2 x mean (FDA 2006 guidance)²

¹ Jan 19, 2023 letter from Katrina Emmel of GRAS Associations, LLC. to the US FDA, attention Stephanie Hice; Re: GRN 1024-Allulose response to questions posted in an email dated 1/4/2023.

² U.S. Food and Drug Administration (FDA), Center for Food Safety and Nutrition, Office of Food Additive Safety. 2006. Guidance for Industry: Estimating Dietary Intake of Substances in Food. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-estimating-dietary-intake-substances-food>

Appendix A. Food Codes Included In Analysis of Proposed Uses

Food Category		
2b	Nutritional beverages	
	Food code	Food description
	11553120	Fruit smoothie, with whole fruit and dairy, added protein ^{*,**}
	64134020	Fruit smoothie, with whole fruit, no dairy, added protein ^{*,**}
	78101110	Fruit and vegetable smoothie, added protein ^{*,**}
	78101118	Fruit and vegetable smoothie, non-dairy, added protein ^{*,**}
	95102000	Nutritional drink or shake, ready-to-drink (Carnation Instant Breakfast)
	95105000	Nutritional drink or shake, ready-to-drink (Kellogg's Special K Protein)
	95106000	Nutritional drink or shake, ready-to-drink (Muscle Milk)
	95106010	Nutritional drink or shake, ready-to-drink, light (Muscle Milk)
	95110000	Nutritional drink or shake, ready-to-drink (Slim Fast)
	95110010	Nutritional drink or shake, ready-to-drink, sugar free (Slim Fast)
	95110020	Nutritional drink or shake, high protein, ready-to-drink (Slim Fast)
	95120000	Nutritional drink or shake, ready-to-drink, NFS
	95120010	Nutritional drink or shake, high protein, ready-to-drink, NFS
	95120020	Nutritional drink or shake, high protein, light, ready-to-drink, NFS
	95201000	Nutritional powder mix (Carnation Instant Breakfast)**
	95201010	Nutritional powder mix, sugar free (Carnation Instant Breakfast)**
	95201200	Nutritional powder mix (EAS Whey Protein Powder)**
	95201300	Nutritional powder mix (EAS Soy Protein Powder)**
	95201500	Nutritional powder mix, high protein (Herbalife)**
	95201600	Nutritional powder mix (Isopure)**
	95201700	Nutritional powder mix (Kellogg's Special K20 Protein Water)**
	95202000	Nutritional powder mix (Muscle Milk)**
	95210000	Nutritional powder mix (Slim Fast)**
	95210020	Nutritional powder mix, high protein (Slim Fast)**
	95220000	Nutritional powder mix, NFS**
	95220010	Nutritional powder mix, high protein, NFS**
	95230000	Nutritional powder mix, whey based, NFS**
	95230010	Nutritional powder mix, protein, soy based, NFS**
	95230020	Nutritional powder mix, protein, light, NFS**
	95230030	Nutritional powder mix, protein, NFS**
2c	PediaSure	
	Food code	Food description
	11710800	Infant formula, NS as to form (PediaSure)
	11710801	Infant formula, ready-to-feed (PediaSure)
	11710806	Infant formula, with fiber, ready-to-feed (PediaSure Fiber)
5a	RTE and cooked, regular	
	Food code	Food description
	56201360	Grits, instant, made with non-dairy milk, fat added
	56201540	Cornmeal, Puerto Rican Style
	56202905	Oatmeal, from fast food, maple flavored
	56202910	Oatmeal, from fast food, fruit flavored
	56202920	Oatmeal, from fast food, other flavors
	56203075	Oatmeal, regular or quick, made with non-dairy milk, NS as to fat

External Memorandum
Revised Cumulative Estimated Daily Intake of Allulose
September 8, 2023, Page 5

56203076	Oatmeal, regular or quick, made with non-dairy milk, no added fat
56203077	Oatmeal, regular or quick, made with non-dairy milk, fat added
56203106	Oatmeal, instant, plain, made with non-dairy milk, no added fat
56203125	Oatmeal, instant, maple flavored, NS as to fat
56203130	Oatmeal, instant, maple flavored, no added fat
56203135	Oatmeal, instant, maple flavored, fat added
56203150	Oatmeal, instant, fruit flavored, NS as to fat
56203155	Oatmeal, instant, fruit flavored, no added fat
56203160	Oatmeal, instant, fruit flavored, fat added
56203175	Oatmeal, instant, other flavors, no added fat
56203180	Oatmeal, instant, other flavors, fat added
56205080	Rice, creamed, made with milk and sugar, Puerto Rican style
56207027	Cream of wheat, regular or quick, made with non-dairy milk, fat added
56207030	Cream of wheat, instant, made with water, no added fat
56207060	Cream of wheat, instant, made with water, fat added
56207094	Cream of wheat, instant, made with milk, fat added
56207095	Cream of wheat, instant, made with milk, no added fat
56207102	Cream of wheat, instant, made with non-dairy milk, no added fat
57100100	Cereal, ready-to-eat, NFS
57101000	Cereal (Kellogg's All-Bran)
57103000	Cereal (Post Alpha-Bits)
57103100	Cereal (General Mills Cheerios Apple Cinnamon)
57104000	Cereal (Kellogg's Apple Jacks)
57106050	Cereal (Post Great Grains Banana Nut Crunch)
57106060	Cereal (General Mills Cheerios Banana Nut)
57106100	Cereal (General Mills Basic 4)
57106250	Cereal (General Mills Kix Berry Berry)
57106260	Cereal (General Mills Cheerios Berry Burst)
57107000	Cereal (General Mills Boo Berry)
57110000	Cereal (Kellogg's All-Bran Bran Buds)
57117000	Cereal (Quaker Cap'n Crunch)
57117500	Cereal (Quaker Christmas Crunch)
57119000	Cereal (Quaker Cap'n Crunch's Crunchberries)
57120000	Cereal (Quaker Cap'n Crunch's Peanut Butter Crunch)
57124030	Cereal (General Mills Chex Chocolate)
57124050	Cereal (General Mills Chex Cinnamon)
57124100	Cereal (General Mills Cheerios Chocolate)
57124200	Cereal, chocolate flavored, frosted, puffed corn
57124300	Cereal (General Mills Lucky Charms Chocolate)
57125000	Cereal (General Mills Cinnamon Toast Crunch)
57125900	Cereal (General Mills Honey Nut Clusters)
57126000	Cereal (Kellogg's Cocoa Krispies)
57127000	Cereal (Post Cocoa Pebbles)
57128000	Cereal (General Mills Cocoa Puffs)
57130000	Cereal (General Mills Cookie Crisp)
57132000	Cereal (General Mills Chex Corn)
57134000	Cereal, corn flakes
57135000	Cereal (Kellogg's Corn Flakes)

External Memorandum
Revised Cumulative Estimated Daily Intake of Allulose
September 8, 2023, Page 6

57137000	Cereal, corn puffs
57139000	Cereal (General Mills Count Chocula)
57143000	Cereal (Kellogg's Cracklin' Oat Bran)
57143500	Cereal (Post Great Grains, Cranberry Almond Crunch)
57148000	Cereal (Kellogg's Crispix)
57148500	Cereal, crispy brown rice
57151000	Cereal, crispy rice
57201900	Cereal (General Mills Dora The Explorer)
57206710	Cereal (General Mills Fiber One Honey Clusters)
57206715	Cereal (General Mills Fiber One Raisin Bran Clusters)
57207000	Cereal, bran flakes
57208000	Cereal (Kellogg's All-Bran Complete Wheat Flakes)
57209000	Cereal (Post Bran Flakes)
57211000	Cereal (General Mills Frankenberry)
57213000	Cereal (Kellogg's Froot Loops)
57213010	Cereal (Kellogg's Froot Loops Marshmallow)
57213850	Cereal (General Mills Cheerios Frosted)
57214000	Cereal (Kellogg's Frosted Mini-Wheats)
57218000	Cereal (Kellogg's Frosted Krispies)
57221700	Cereal, fruit rings
57221810	Cereal (General Mills Cheerios Fruity)
57223000	Cereal (Post Fruity Pebbles)
57224000	Cereal (General Mills Golden Grahams)
57227000	Cereal, granola
57228000	Granola, homemade
57229000	Cereal (Kellogg's Low Fat Granola)
57229500	Cereal (Kellogg's Low Fat Granola with Raisins)
57231000	Cereal (Post Grape-Nuts Flakes)
57231200	Cereal (Post Great Grains Raisins, Dates, and Pecans)
57231250	Cereal (Post Great Grains Double Pecan Whole Grain Cereal)
57237100	Cereal (Post Honey Bunches of Oats Honey Roasted)
57237200	Cereal (Post Honey Bunches of Oats with Vanilla Bunches)
57237300	Cereal (Post Honey Bunches of Oats with Almonds)
57237900	Cereal (Post Honey Bunches of Oats Just Bunches)
57238000	Cereal (Post Honeycomb)
57240100	Cereal (General Mills Chex Honey Nut)
57241000	Cereal (General Mills Cheerios Honey Nut)
57241200	Cereal (Post Shredded Wheat Honey Nut)
57243000	Cereal (Kellogg's Honey Smacks)
57301505	Cereal (Kashi Autumn Wheat)
57301510	Cereal (Kashi GOLEAN)
57301511	Cereal (Kashi GOLEAN Crunch)
57301512	Cereal (Kashi GOLEAN Crunch Honey Almond Flax)
57301530	Cereal (Kashi Heart to Heart Honey Toasted Oat)
57303100	Cereal (General Mills Kix)
57303105	Cereal (General Mills Honey Kix)
57303200	Cereal (Kellogg's Krave)
57304100	Cereal (Quaker Life)

External Memorandum
Revised Cumulative Estimated Daily Intake of Allulose
September 8, 2023, Page 7

57305100	Cereal (General Mills Lucky Charms)
57305150	Cereal, frosted oat cereal with marshmallows
57305160	Cereal (Malt-O-Meal Blueberry Muffin Tops)
57305165	Cereal (Malt-O-Meal Cinnamon Toasters)
57305170	Cereal (Malt-O-Meal Coco-Roos)
57305174	Cereal (Malt-O-Meal Colossal Crunch)
57305175	Cereal (Malt-O-Meal Cocoa Dyno-Bites)
57305180	Cereal (Malt-O-Meal Corn Bursts)
57305200	Cereal (Malt-O-Meal Crispy Rice)
57305210	Cereal (Malt-O-Meal Frosted Flakes)
57305215	Cereal (Malt-O-Meal Frosted Mini Spooners)
57305300	Cereal (Malt-O-Meal Fruity Dyno-Bites)
57305400	Cereal (Malt-O-Meal Honey Graham Squares)
57305500	Cereal (Malt-O-Meal Honey Nut Toasty O's)
57305600	Cereal (Malt-O-Meal Marshmallow Mateys)
57306130	Cereal (Malt-O-Meal Raisin Bran)
57306500	Cereal (Malt-O-Meal Golden Puffs)
57306800	Cereal (Malt-O-Meal Tootie Fruities)
57308190	Cereal, muesli
57308400	Cereal (General Mills Cheerios Multigrain)
57309100	Cereal (Nature Valley Granola)
57316300	Cereal (Health Valley Oat Bran Flakes)
57316380	Cereal (General Mills Cheerios Oat Cluster Crunch)
57316385	Cereal (General Mills Cheerios Protein)
57316450	Cereal (General Mills Oatmeal Crisp with Almonds)
57316710	Cereal (Quaker Honey Graham Oh's)
57320500	Cereal (Quaker Granola with Oats, Honey, and Raisins)
57321900	Cereal (Nature's Path Organic Flax Plus)
57326000	Cereal (Barbara's Puffins)
57327450	Cereal (Quaker Toasted Oat Bran)
57327500	Cereal (Quaker Oatmeal Squares)
57329000	Cereal, raisin bran
57330000	Cereal (Kellogg's Raisin Bran)
57330010	Cereal (Kellogg's Raisin Bran Crunch)
57331000	Cereal (Post Raisin Bran)
57332050	Cereal (General Mills Total Raisin Bran)
57332100	Cereal (General Mills Raisin Nut Bran)
57335550	Cereal (General Mills Reese's Puffs)
57336000	Cereal (General Mills Chex Rice)
57337000	Cereal, rice flakes
57339000	Cereal (Kellogg's Rice Krispies)
57339500	Cereal (Kellogg's Rice Krispies Treats Cereal)
57341200	Cereal (Kellogg's Smart Start Strong)
57341300	Cereal (Kellogg's Smorz)
57344000	Cereal (Kellogg's Special K)
57344001	Cereal (Kellogg's Special K Blueberry)
57344005	Cereal (Kellogg's Special K Chocolatey Delight)
57344007	Cereal (Kellogg's Special K Low Fat Granola)

External Memorandum
 Revised Cumulative Estimated Daily Intake of Allulose
 September 8, 2023, Page 8

	57344010	Cereal (Kellogg's Special K Red Berries)
	57344015	Cereal (Kellogg's Special K Fruit & Yogurt)
	57344020	Cereal (Kellogg's Special K Vanilla Almond)
	57344025	Cereal (Kellogg's Special K Cinnamon Pecan)
	57347000	Cereal (Kellogg's Corn Pops)
	57348000	Cereal, frosted corn flakes
	57349000	Cereal (Kellogg's Frosted Flakes)
	57355000	Cereal (Post Golden Crisp)
	57406100	Cereal (General Mills Total)
	57407100	Cereal (General Mills Trix)
	57411000	Cereal (General Mills Chex Wheat)
	57416010	Cereal, puffed wheat, sweetened
	57418000	Cereal (General Mills Wheaties)
5b	RTE and cooked, low calorie, reduced calorie, sugar-free	
	Food code	Food description
	56203510	Oatmeal, reduced sugar, plain, no added fat
	56203550	Oatmeal, reduced sugar, flavored, NS as to fat
	56203555	Oatmeal, reduced sugar, flavored, no added fat
	56203560	Oatmeal, reduced sugar, flavored, fat added
	57125010	Cereal (General Mills 25% Less Sugar Cinnamon Toast Crunch)
	57128005	Cereal (General Mills 25% Less Sugar Cocoa Puffs)
	57407110	Cereal (General Mills 25% Less Sugar Trix)
5d	Grain-free, no sugar, high protein RTE cereal	
	Food code	Food description
	57206700	Cereal (General Mills Fiber One)
	57230000	Cereal (Post Grape-Nuts)
	57301500	Cereal (Kashi 7 Whole Grain Puffs)
	57307500	Cereal, millet, puffed
	57340000	Cereal, puffed rice
	57341000	Cereal (Post Shredded Wheat'n Bran)
	57408100	Cereal (Uncle Sam)
	57416000	Cereal, puffed wheat, plain
	57417000	Cereal (Post Shredded Wheat)
9	Frozen dairy (ice cream, soft serve, and sorbet), low calorie, reduced calorie, sugar-free	
	Food code	Food description
	13110000	Ice cream, NFS
	13110320	Ice cream, no sugar added, flavors other than chocolate
	13110330	Ice cream, no sugar added, chocolate
	13120740	Ice cream cone, NFS
	13121000	Ice cream sundae, NFS
	13130300	Light ice cream, vanilla
	13130310	Light ice cream, chocolate
	13130320	Light ice cream, no sugar added, NS as to flavor
	13130330	Light ice cream, no sugar added, flavors other than chocolate
	13130340	Light ice cream, no sugar added, chocolate
	13135000	Light ice cream sandwich, vanilla
	13135010	Light ice cream sandwich, chocolate
	13136000	Ice cream sandwich, made with light, no sugar added ice cream

External Memorandum
Revised Cumulative Estimated Daily Intake of Allulose
September 8, 2023, Page 9

	13140000	Light ice cream bar, vanilla
	13140100	Light ice cream bar, vanilla, chocolate coated
	13140115	Light ice cream bar, chocolate
	13140575	Light ice cream, no sugar added, cone, flavors other than chocolate
	13140580	Light ice cream, no sugar added, cone, chocolate
	13142100	Light ice cream cone, vanilla, prepackaged
	13142110	Light ice cream cone, chocolate, prepackaged
	13160160	Fat free ice cream, no sugar added, flavors other than chocolate
	13161600	Fudgesicle, light
	13161630	Light ice cream, bar or stick, with low-calorie sweetener, chocolate coated
11	Nutrition bars	
	Food code	Food description
	53710800	Cereal or granola bar (Kashi Chewy)
	53710802	Cereal or granola bar (Kashi Crunchy)
	53720100	Nutrition bar (Balance Original Bar)
	53720200	Nutrition bar (Clif Bar)
	53720210	Nutrition bar (Clif Kids Organic Zbar)
	53720300	Nutrition bar (PowerBar)
	53720400	Nutrition bar (Slim Fast Original Meal Bar)
	53720500	Nutrition bar (Snickers Marathon Protein Bar)
	53720600	Nutrition bar (South Beach Living Meal Bar)
	53720610	Nutrition bar (South Beach Living High Protein Bar)
	53720700	Nutrition bar (Tiger's Milk)
	53720800	Nutrition bar (Zone Perfect Classic Crunch)
	53729000	Nutrition bar or meal replacement bar, NFS
16	Ketchup and barbecue sauces	
	Food code	Food description
	21304210	Beef, shortribs, barbecued, with sauce, lean and fat eaten*
	21304220	Beef, shortribs, barbecued, with sauce, lean only eaten*
	22701030	Pork, spareribs, barbecued, with sauce, NS as to fat eaten*
	22701040	Pork, spareribs, barbecued, with sauce, lean and fat eaten*
	22701050	Pork, spareribs, barbecued, with sauce, lean only eaten*
	24103070	Chicken, NS as to part, grilled with sauce, NS as to skin eaten*
	24103075	Chicken, NS as to part, grilled with sauce, skin eaten*
	24103080	Chicken, NS as to part, grilled with sauce, skin not eaten*
	24123310	Chicken breast, grilled with sauce, skin eaten*
	24123311	Chicken breast, grilled with sauce, skin not eaten*
	24134150	Chicken leg, drumstick and thigh, grilled with sauce, skin eaten*
	24134151	Chicken leg, drumstick and thigh, grilled with sauce, skin not eaten*
	24142510	Chicken drumstick, grilled with sauce, skin eaten*
	24142511	Chicken drumstick, grilled with sauce, skin not eaten*
	24154020	Chicken thigh, grilled with sauce, skin eaten*
	24154021	Chicken thigh, grilled with sauce, skin not eaten*
	24164010	Chicken wing, grilled with sauce*
	24168001	Chicken "wings" with other sauces or seasoning, from fast food / restaurant*
	24168011	Chicken "wings" with other sauces or seasoning, from precooked*
	24168021	Chicken "wings" with other sauces or seasoning, from other sources*
	24168030	Chicken "wings", boneless, with hot sauce, from fast food / restaurant*

External Memorandum
Revised Cumulative Estimated Daily Intake of Allulose
September 8, 2023, Page 10

24168031	Chicken "wings", boneless, with hot sauce, from other sources*
24209000	Turkey with barbecue sauce, skin eaten*
24209001	Turkey with barbecue sauce, skin not eaten*
27111500	Beef sloppy joe, no bun*
27116200	Beef with barbecue sauce*
27116300	Beef with sweet and sour sauce*
27120030	Ham or pork with barbecue sauce*
27120060	Sweet and sour pork*
27146011	Chicken, shredded or pulled, with barbecue sauce*
27150170	Sweet and sour shrimp*
27160010	Meat with barbecue sauce, NS as to type of meat*
27315250	Stuffed cabbage rolls with beef and rice*
27510145	Cheeseburger, 1 miniature patty, with condiments, on miniature bun, from fast food / restaurant*
27510165	Cheeseburger, 1 small patty, with condiments, on bun, from fast food / restaurant*
27510170	Cheeseburger (Burger King)*
27510171	Whopper Jr with cheese (Burger King)*
27510175	Cheeseburger, 1 small patty, with condiments, on bun, from fast food / restaurant (Wendy's Jr. Cheeseburger Deluxe)*
27510205	Cheeseburger, 1 small patty, with condiments, on white bun*
27510206	Cheeseburger, 1 small patty, with condiments, on wheat bun*
27510207	Cheeseburger, 1 small patty, with condiments, on whole wheat bun*
27510225	Cheeseburger, 1 medium patty, with condiments, on bun, from fast food / restaurant*
27510251	Cheeseburger, 1 medium patty, with condiments, on white bun*
27510252	Cheeseburger, 1 medium patty, with condiments, on wheat bun*
27510253	Cheeseburger, 1 medium patty, with condiments, on whole wheat bun*
27510266	Cheeseburger, 1 large patty, with condiments, on bun, from fast food / restaurant*
27510276	Bacon cheeseburger, 1 small patty, with condiments, on bun, from fast food / restaurant*
27510312	Bacon cheeseburger, 1 medium patty, with condiments, on bun, from fast food / restaurant*
27510341	Bacon cheeseburger, 1 medium patty, with condiments, on white bun*
27510342	Bacon cheeseburger, 1 medium patty, with condiments, on wheat bun*
27510343	Bacon cheeseburger, 1 medium patty, with condiments, on whole wheat bun*
27510346	Bacon cheeseburger, 1 large patty, with condiments, on bun, from fast food / restaurant*
27510376	Double cheeseburger, 2 small patties, with condiments, on bun, from fast food / restaurant*
27510386	Double cheeseburger (Burger King)*
27510406	Double cheeseburger, 2 medium patties, with condiments, on bun, from fast food / restaurant*
27510431	Double bacon cheeseburger, 2 small patties, with condiments, on bun, from fast food / restaurant (Burger King Bacon Double Cheeseburger)*
27510451	Double bacon cheeseburger, 2 medium patties, with condiments, on bun, from fast food / restaurant*
27510465	Double bacon cheeseburger, 2 medium patties, with condiments, on bun, from fast food / restaurant (Wendy's Baconator)*
27510475	Double bacon cheeseburger, 2 large patties, with condiments, on bun, from fast food / restaurant*

External Memorandum
 Revised Cumulative Estimated Daily Intake of Allulose
 September 8, 2023, Page 11

	27510486	Triple cheeseburger, 3 medium patties, with condiments, on bun, from fast food / restaurant*
	27510506	Hamburger, 1 miniature patty, with condiments, on miniature bun, from fast food / restaurant*
	27510511	Hamburger, 1 miniature patty, on miniature bun, from school*
	27510536	Hamburger, 1 small patty, with condiments, on bun, from fast food / restaurant*
	27510551	Hamburger (Burger King)*
	27510552	Whopper Jr (Burger King)*
	27510555	Hamburger, 1 small patty, with condiments, on bun, from fast food / restaurant (Wendy's Jr. Hamburger)*
	27510565	Hamburger, from school cafeteria*
	27510585	Hamburger, 1 small patty, with condiments, on white bun*
	27510587	Hamburger, 1 small patty, with condiments, on whole wheat bun*
	27510606	Hamburger, 1 medium patty, with condiments, on bun, from fast food / restaurant*
	27510641	Hamburger, 1 medium patty, with condiments, on white bun*
	27510642	Hamburger, 1 medium patty, with condiments, on wheat bun*
	27510643	Hamburger, 1 medium patty, with condiments, on whole wheat bun*
	27510667	Double hamburger, 2 small patties, with condiments, on bun, from fast food / restaurant*
	27510676	Double hamburger, 2 medium patties, with condiments, on bun, from fast food / restaurant*
	27510681	Double hamburger, 2 medium patties, with condiments, on bun, from fast food / restaurant (Burger King Double WHOPPER)*
	27510682	Double hamburger, 2 medium patties, with condiments, on bun, from fast food / restaurant (Wendy's 1/2 lb Double)*
	27520500	Pork sandwich, on white roll, with onions, dill pickles and barbecue sauce*
	27520510	Pork barbecue sandwich or Sloppy Joe, on bun*
	27545010	Turkey or chicken burger, with condiments, on bun, from fast food / restaurant*
	27545200	Turkey or chicken burger, with condiments, on white bun*
	27545210	Turkey or chicken burger, with condiments, on wheat bun*
	27545220	Turkey or chicken burger, with condiments, on whole wheat bun*
	28110620	Beef short ribs, boneless, with barbecue sauce, potatoes, vegetable, frozen meal*
	28160650	Stuffed green pepper, frozen meal*
	74401010	Ketchup
	74406010	Barbecue sauce
	81308100	Fry sauce*
19	Cranberries, dried	
	Food code	Food description
	42500000	Trail mix, NFS*
	42501000	Trail mix with nuts and fruit*
	42501500	Trail mix with chocolate*
	42502100	Trail mix with pretzels, cereal, or granola*
	53710810	Cereal or granola bar (KIND Fruit and Nut Bar)*
	53713010	Cereal or granola bar, fruit and nut*
	62101000	Fruit, dried, NFS, uncooked
	62101050	Fruit mixture, dried*
	62109100	Cranberries, dried
20	Jerky (meat or poultry based)	
	Food code	Food description

External Memorandum
Revised Cumulative Estimated Daily Intake of Allulose
September 8, 2023, Page 12

	21602100	Beef jerky
	22002800	Pork jerky
	23321900	Venison/deer jerky

* Only the component of the food (by weight) with existing or proposed use of allulose was included in the analysis

** Non-reconstituted dry powder was adjusted to the reconstituted/prepared amount

Question #12 Attachment

Literature search documentation

Allulose GRAS

Last search conducted 9/1/23

Dates limited from 1/1/20 to current (9/1/23)

150 total results after deduplication (combination of PubMed and Embase searches below)

PubMed:

(Allulose OR "DL-Psicose" OR Psicose OR 23140-52-5[rn])

AND

(safe OR safety OR toxic OR toxicity OR NOAEL OR LD50 OR "consumer product safety"[MeSH Terms] OR "Toxicity Tests"[MeSH Terms] OR "body weight" OR "weight gain" OR "mortality rate" OR microbiota OR microbial OR microflora OR intestinal OR digest* OR liver OR absorption OR distribution OR metabolism OR excretion OR ADME[tiab] OR allergy OR allergen OR allergenicity OR allergic OR allergens[MeSH Terms] OR sensitiz* OR "hypersensitivity"[MeSH Terms] OR "hypersensitivity"[All Fields] OR "allergy and immunology"[MeSH Terms] OR atopic[All Fields] OR LLNA OR "Local Lymph Node Assay"[MeSH Terms] OR "Local Lymph Node Assay" OR (toxicity AND (development OR developmental OR reproductive)) OR "Teratogenesis"[MeSH Terms] OR teratogen OR teratogenic OR "Reproductive and Urinary Physiological Phenomena"[MeSH Terms] OR neoplastic OR cancer OR carcinogen* OR carcinoma OR tumor OR tumors OR "animal bioassay" OR oncogenic* OR malignant OR malignancy OR malignancies OR genotoxic OR genotoxicity OR clastogen* OR mutagen OR mutagenic OR mutation* OR "cytogenetic aberration" OR "chromosome aberrations"[MeSH Terms] OR micronucle* OR "DNA damage" OR "DNA fragmentation"[Mesh] OR "Mutagenicity Tests"[MeSH Terms] OR "comet assay")

Results = 354

Results (limited from 2020 – current) = 116

Embase:

(allulose OR 'psicose'/exp OR psicose OR 23140-52-5:rn)

AND

('risk assessment'/exp OR 'safety'/exp OR 'toxic substance'/exp OR 'toxicity'/exp OR 'ld50'/exp OR 'lc50'/exp OR 'product safety'/exp OR 'toxicity testing'/exp OR 'drug toxicity'/exp OR 'toxicity assay'/exp OR 'adverse drug reaction'/exp OR 'pharmacokinetics'/exp OR 'metabolism'/exp OR 'excretion'/exp OR 'hypersensitivity'/exp OR 'allergen'/exp OR 'sensitization'/exp OR 'local lymph node assay'/exp OR 'developmental toxicity'/exp OR 'reproductive toxicity'/exp OR 'teratogenicity'/exp OR 'teratogenic agent'/exp OR 'teratogenesis'/exp OR 'malignant neoplasm'/exp OR 'carcinogen'/exp OR 'oncogenesis and malignant transformation'/exp OR 'carcinoma'/exp OR 'genotoxicity'/exp OR 'genotoxicity assay'/exp OR 'mutagenesis'/exp OR 'chromosome aberration'/exp OR 'genetic damage'/exp OR 'mutagenic agent'/exp)

Results = 351

Results (limited from 2020 – current) = 107

Year	Author	Title	Journal	DOI
2023	S. Wulansari, S. Heng, P. Ketbot, S. Baramée, R. Waeonukul, P. Pason, K. Ratanakhanokchai, A. Uke, A. Kosugi and C. Tachaapaikoon	A Novel D-Psicose 3-Epimerase from Halophilic, Anaerobic <i>Locasia fonsfrigidae</i> and Its Application in Coconut Water	Int J Mol Sci	10.3390/ijms24076394
2023	K. Fukunaga, T. Yoshimura, H. Imachi, T. Kobayashi, T. Saheki, S. Sato, N. Saheki, W. Jiang and K. Murao	A Pilot Study on the Efficacy of a Diabetic Diet Containing the Rare Sugar D-Allulose in Patients with Type 2 Diabetes Mellitus: A Prospective, Randomized, Single-Blind, Crossover Study	Nutrients	10.3390/nu15122802
2023	S. Duan, Y. Chen, G. Wang, Z. Li, S. Dong, Y. Wu, Y. Wang, C. Ma and R. Wang	A study of targeted mutation of l-rhamnose isomerase to improve the conversion efficiency of D-allose	Enzyme Microb Technol	10.1016/j.enzymictec.2023.110259
2023	T. Yuma, M. Tokuda, N. Nishimoto, H. Yokoi and K. Izumori	Allulose for the attenuation of postprandial blood glucose levels in healthy humans: A systematic review and meta-analysis	PLoS ONE	10.1371/journal.pone.0281150
2023	Y. Gao, F. Li, Y. Wang, Z. Chen and Z. Li	An artificial multienzyme cascade for the whole-cell synthesis of rare ketoses from glycerol	Biotechnol Lett	10.1007/s10529-023-03415-6
2023	H. Samreen and S. Dhaneshwar	Artificial Sweeteners: Perceptions and Realities	Current Diabetes Reviews	10.2174/1573399818666220429083052
2023	M. Akiyama, T. Akiyama, D. Saigusa, E. Hishinuma, N. Matsukawa, T. Shibata, H. Tsuchiya, A. Mori, Y. Fujii, Y. Mogami, C. Tokorodani, K. Kuwahara, Y. Numata-Uematsu, K. Inoue and K. Kobayashi	Comprehensive study of metabolic changes induced by a ketogenic diet therapy using GC/MS- and LC/MS-based metabolomics	Seizure	10.1016/j.seizure.2023.03.014
2023	A. Scalfani, A. Castillo, I. Carata, R. Pines, E. Berglas, S. Joseph, J. Sarker, M. Nashed, M. Roland, S. Arzayus, N. Williams, J. I. Glendinning and R. J. Bodnar	Conditioned preference and avoidance induced in mice by the rare sugars isomaltulose and allulose	Physiol Behav	10.1016/j.physbeh.2023.114221

Year	Author	Title	Journal	DOI
2023	M. Yamazaki, M. Okito, A. Harada, K. Miyake, T. Tamiya and T. Nakamura	d-Allulose Supplementation Prevents Diet-Induced Hepatic Lipid Accumulation via miR-130-Mediated Regulation in C57BL/6 Mice	Molecular nutrition & food research	10.1002/mnfr.202200748
2023	L. Stefanie, M. Sophie, W. Judith, L. Ilona and P. Püschel Gerhard	Different impact of the ketoses fructose and allulose on hepatocyte glucose metabolism	Zeitschrift für Gastroenterologie	10.1055/s-0042-1759987
2023	H. Pullmann-Lindsley, A. Bartlett-Miller and R. J. Pitts	Diols and sugar substitutes in attractive toxic sugar baits targeting <i>Aedes aegypti</i> and <i>Aedes albopictus</i> (Diptera: Culicidae) mosquitoes		10.1101/2023.02.09.527878
2023	Y. Kohara, S. Ikai, A. Yoshihara, K. Murao and Y. Sugiyama	Effect of chronic exposure to ketohexoses on pancreatic β -cell function in INS-1 rat insulinoma cells	Bioscience, biotechnology, and biochemistry	10.1093/bbb/zbac190
2023	J. Tak, M. Bok, H. Rho, J. H. Park, Y. Lim, S. Chon and H. Lim	Effect of diabetes-specific oral nutritional supplements with allulose on weight and glycemic profiles in overweight or obese type 2 diabetic patients	Nutr Res Pract	10.4162/nrp.2023.17.2.241
2023	F. Teyseire, V. Bordier, A. Budzinska, N. Weltens, C. Beglinger, L. Van Oudenhove, B. K. Wölnerhanssen and A. Meyer Gerspach	Efficacy and safety of acute administration of D-allulose and erythritol in healthy participants	Obesity Facts	10.1159/000530456
2023	H. Zhang, A. Zhao, L. Qu, W. Xiong, M. A. Alam, J. Miao, W. Wang, J. Xu and Y. Lv	Engineering an efficient whole-cell catalyst for d-allulose production from glycerol	Biotechnology Journal	10.1002/biot.202200600

Year	Author	Title	Journal	DOI
2023	L. Wang, K. Chen, P. Zheng, X. Huo, F. Liao, L. Zhu, M. Hu and Y. Tao	Enhanced production of D-psicose from D-fructose by a redox-driven multi-enzyme cascade system	Enzyme and Microbial Technology	10.1016/j.enzmitec.2022.110172
2023	K. D. Medak, A. J. Weber, H. Shamshoum, G. L. McKie, M. K. Hahn and D. C. Wright	Enhancing endogenous levels of GLP1 dampens acute olanzapine induced perturbations in lipid and glucose metabolism	Frontiers in Pharmacology	10.3389/fphar.2023.1127634
2023	Y. Chen, Y. Chen, D. Ming, L. Zhu and L. Jiang	Highly efficiency production of D-allulose from inulin using curli fiber multi-enzyme cascade catalysis	International Journal of Biological Macromolecules	10.1016/j.ijbiomac.2023.124468
2023	Y. Gao, Z. Chen, H. Nakanishi and Z. Li	Highly Efficient Synthesis of Rare Sugars from Glycerol in Endotoxin-Free ClearColi by Fermentation	Foods	10.3390/foods12163078
2023	K. Kishida, T. Iida, T. Yamada and Y. Toyoda	Intestinal absorption of D-fructose isomers, D-allulose, D-sorbose, and D-tagatose, via glucose transporter type 5 (GLUT5) but not sodium-dependent glucose cotransporter 1 (SGLT1) in rats	British Journal of Nutrition	10.1017/S0007114523001113
2023	Y. Guo, Z. Zhu, J. Lv, Y. Li, J. Chen, X. Cheng, N. Li and J. Liu	Irreversible biosynthesis of D-allulose from D-glucose in Escherichia coli through fine-tuning of carbon flux and cofactor regeneration engineering	Journal of the science of food and agriculture	10.1002/jsfa.12623
2023	J. Li, Q. Dai, Y. Zhu, W. Xu, W. Zhang, Y. Chen and W. Mu	Low-calorie bulk sweeteners: Recent advances in physical benefits, applications, and bioproduction	Critical reviews in food science and nutrition	10.1080/10408398.2023.2171362

Year	Author	Title	Journal	DOI
2023	F. Teysseire, V. Bordier, A. Budzinska, L. Van Oudenhove, N. Weltens, C. Beglinger, B. K. Wölnerhanssen and A. C. Meyer-Gerspach	Metabolic Effects and Safety Aspects of Acute D-allulose and Erythritol Administration in Healthy Subjects	Nutrients	10.3390/nu15020458
2023	P. Zarza Reynoso	New Nutritional Strategies for Reducing Sugar and Calorie Intake	Annals of Nutrition and Metabolism	10.1159/000526958
2023	Q. Jia, H. Zhang, A. Zhao, L. Qu, W. Xiong, M. A. Alam, J. Miao, W. Wang, F. Li, J. Xu and Y. Lv	Produce D-allulose from non-food biomass by integrating corn stalk hydrolysis with whole-cell catalysis	Front Bioeng Biotechnol	10.3389/fbioe.2023.1156953
2023	M. Miyoshi, A. Yoshihara, S. Mochizuki, S. Kato, H. Yoshida, T. Matsuo, Y. Kishimoto, T. Inazu, I. Kimura, K. Izumori and K. Akimitsu	Safety evaluation and maximum use level for transient ingestion in humans of allitol	Bioscience, biotechnology, and biochemistry	10.1093/bbb/zbad087
2023	C. Lambré, J. M. Barat Baviera, C. Bolognesi, P. S. Coconcelli, R. Crebelli, D. M. Gott, K. Grob, E. Lampi, M. Mengelers, A. Mortensen, G. Rivière, I. L. Steffensen, C. Tlustos, H. Van Loveren, L. Vernis, H. Zorn, B. Glandorf, L. Herman, M. Andryszkiewicz, A. Gomes, Y. Liu, S. Peluso and A. Chesson	Safety evaluation of the food enzyme d-tagatose 3-epimerase from the genetically modified Escherichia coli strain PS-Sav-001	Efsa j	10.2903/j.efsa.2023.7752
2023	L. Preechasuk, C. Luksameejaroenchai, W. Tangjittipokin and T. Kunavisarut	Short-term effects of allulose consumption on glucose homeostasis, metabolic parameters, incretin levels, and inflammatory markers in patients with type 2 diabetes: a double-blind, randomized, controlled crossover clinical trial	European Journal of Nutrition	10.1007/s00394-023-03205-w
2023	J. H. Tan, A. Chen, J. Bi, Y. H. Lim, F. T. Wong and D. S. Ow	The Engineering, Expression, and Immobilization of Epimerases for D-allulose Production	Int J Mol Sci	10.3390/ijms241612703

Year	Author	Title	Journal	DOI
2023	T. Feng, Z. Wang, H. Li, Q. Li, Y. Guo, J. Zhao and J. Liu	Whole-cell biotransformation for simultaneous synthesis of allitol and D-gluconic acid in recombinant <i>Escherichia coli</i>	Journal of Bioscience and Bioengineering	10.1016/j.jbiosc.2023.03.004
2022	S. Japar, K. Fukunaga, T. Kobayashi, H. Imachi, S. Sato, T. Saheki, T. Ibata, T. Yoshimura, K. L. Soh, S. L. Ong, Z. Muhamed and K. Murao	A pilot study on the effect of D-allulose on postprandial glucose levels in patients with type 2 diabetes mellitus during Ramadan fasting	Diabetol Metab Syndr	10.1186/s13098-022-00856-3
2022	S. H. Jeong, M. Kwon and S. W. Kim	Advanced Whole-cell Conversion for D-allulose Production Using an Engineered <i>Corynebacterium glutamicum</i>	Biotechnology and Bioprocess Engineering	10.1007/s12257-022-0057-1
2022	X. Wen, H. Lin, Y. Ren, C. Li, C. Zhang, J. Lin and J. Lin	Allitol bioproduction by recombinant <i>Escherichia coli</i> with NADH regeneration system co-expressing ribitol dehydrogenase (RDH) and formate dehydrogenase (FDH) in individual or in fusion	Electronic Journal of Biotechnology	10.1016/j.ejbt.2021.11.007
2022	J. E. Kim, E. Y. Kwon and Y. Han	Allulose Attenuated Age-Associated Sarcopenia via Regulating IGF-1 and Myostatin in Aged Mice	Molecular nutrition & food research	10.1002/mnfr.202100549
2022	H. Daniel, H. Hauner, M. Hornef and T. Clavel	Allulose in human diet: The knowns and the unknowns	British Journal of Nutrition	10.1017/S0007114521003172
2022	W. C. Tseng, Y. C. Chen, H. C. Chang, C. J. Lin and T. Y. Fang	Altering the substrate specificity of recombinant l-rhamnose isomerase from <i>Thermoanaerobacterium saccharolyticum</i> NTOU1 to favor d-allose production	J Biotechnol	10.1016/j.jbiotec.2022.08.015
2022	Z. Liu, Y. Wang, S. Liu, X. Guo, T. Zhao, J. Wu and S. Chen	Boosting the Heterologous Expression of d-Allulose 3-Epimerase in <i>Bacillus subtilis</i> through Protein Engineering and Catabolite-Responsive Element Box Engineering	Journal of agricultural and food chemistry	10.1021/acs.jafc.2c04800

Year	Author	Title	Journal	DOI
2022	S. J. Kim, M. S. Choi and C. S. Park	Characterization of a Recombinant I-rhamnose Isomerase from <i>Paenibacillus baekrokdamisoli</i> to Produce d-allose from d-allulose	Biotechnology and Bioprocess Engineering	10.1007/s12257-021-0341-5
2022	T. Suzuki and K. Morimoto	Characterization of d-xylose isomerase from <i>Shinella zoogloeoides</i> NN6 and its application for producing d-allulose and two d-ketopentoses in a one-pot multi-step transformation	Journal of General and Applied Microbiology	10.2323/jgam.2022.01.004
2022	T. Tsuzuki, R. Suzuki, R. Kajun, T. Yamada, T. Iida, B. Liu, T. Koike, Y. Toyoda, T. Negishi and K. Yukawa	Combined effects of exercise training and D-allulose intake on endurance capacity in mice	Physiological Reports	10.14814/phy2.15297
2022	T. Suzuki, Y. Sato, S. Kadoya, T. Takahashi, M. Otomo, H. Kobayashi, K. Aoki, M. Kantake, M. Sugiyama and R. P. Ferraris	Comparative Effects of Allulose, Fructose, and Glucose on the Small Intestine	Nutrients	10.3390/nu14153230
2022	J. Chen, D. Chen, Q. Chen, W. Xu, W. Zhang and W. Mu	Computer-Aided Targeted Mutagenesis of <i>Thermoclostridium caenicola</i> d-Allulose 3-Epimerase for Improved Thermostability	Journal of agricultural and food chemistry	10.1021/acs.jafc.1c07256
2022	M. R. Mora, Z. Wang, J. M. Goddard and R. Dando	Consumers Respond Positively to the Sensory, Health, and Sustainability Benefits of the Rare Sugar Allulose in Yogurt Formulations	Foods	10.3390/foods11223718
2022	X. Wen, H. Lin, Y. Ning, G. Liu, Y. Ren, C. Li, C. Zhang, J. Lin, X. Song and J. Lin	D-Allulose (D-Psicose) Biotransformation From Allitol by a Newly Found NAD(P)-Dependent Alcohol Dehydrogenase From <i>Gluconobacter frateurii</i> NBRC 3264 and the Enzyme Characterization	Frontiers in Microbiology	10.3389/fmicb.2022.870168
2022	H. Y. Lee, G. H. Lee, T. H. Hoang, S. A. Park, J. Lee, J. Lim, S. Sa, G. E. Kim, J. S. Han, J. Kim and H. J. Chae	D-Allulose Ameliorates Hyperglycemia Through IRE1 α Sulfonation-RIDD-Sirt1 Decay Axis in the Skeletal Muscle	Antioxidants and Redox Signaling	10.1089/ars.2021.0207

Year	Author	Title	Journal	DOI
2022	R. Yermek, L. Wang, K. Kaneko, W. Han, Y. Seino, D. Yabe and T. Yada	D-Allulose cooperates with glucagon-like peptide-1 and activates proopiomelanocortin neurons in the arcuate nucleus and central injection inhibits feeding in mice	Biochem Biophys Res Commun	10.1016/j.bbrc.2022.04.027
2022	B. Liu, Y. Gou, T. Tsuzuki, T. Yamada, T. Iida, S. Wang, R. Banno, Y. Toyoda and T. Koike	D-Allulose Improves Endurance and Recovery from Exhaustion in Male C57BL/6J Mice	Nutrients	10.3390/nu14030404
2022	Y. Rakhat, K. Kaneko, L. Wang, W. Han, Y. Seino, D. Yabe and T. Yada	d-Allulose Inhibits Ghrelin-Responsive, Glucose-Sensitive and Neuropeptide Y Neurons in the Arcuate Nucleus and Central Injection Suppresses Appetite-Associated Food Intake in Mice	Nutrients	10.3390/nu14153117
2022	M. Niibo, A. Kanasaki, T. Iida, K. Ohnishi, T. Ozaki, K. Akimitsu and T. Minamino	D-allulose protects against diabetic nephropathy progression in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes	PLoS ONE	10.1371/journal.pone.0263300
2022	S. Higaki, R. Inai, S. Mochizuki, A. Yoshihara and T. Matsuo	Dietary Dried Sweetspire (Itea) Powder Reduces Body Fat Accumulation in Rats Fed with a High-fat Diet	J Oleo Sci	10.5650/jos.ess22111
2022	K. Jürkenbeck, T. Haarhoff, A. Spiller and M. Schulze	Does Allulose Appeal to Consumers? Results from a Discrete Choice Experiment in Germany	Nutrients	10.3390/nu14163350
2022	P. Ding, Z. Ming, J. Liu, I. Erill and Z. Zhang	Editorial: Microbiome and microbial informatics	Frontiers in Microbiology	
2022	S. Higaki, R. Inai and T. Matsuo	Effects of Dietary Allitol on Body Fat Accumulation in Rats	Journal of Nutritional Science and Vitaminology	10.3177/jnsv.68.348
2022	W. Liao, S. Liu, Y. Chen, Y. Kong, D. Wang, Y. Wang, T. Ling, Z. Xie, I. Khalilova and J. Huang	Effects of Keemun and Dianhong Black Tea in Alleviating Excess Lipid Accumulation in the Liver of Obese Mice: A Comparative Study	Front Nutr	10.3389/fnut.2022.849582
2022	M. Hu, Y. Wei, R. Zhang, M. Shao, T. Yang, M. Xu, X. Zhang and Z. Rao	Efficient D-allulose synthesis under acidic conditions by auto-inducing expression of the tandem D-allulose 3-epimerase genes in Bacillus subtilis	Microbial Cell Factories	10.1186/s12934-022-01789-2

Year	Author	Title	Journal	DOI
2022	J. Li, J. Chen, W. Xu, W. Zhang, Y. Chen and W. Mu	Efficient Utilization of Fruit Peels for the Bioproduction of D-Allulose and D-Mannitol	Foods	10.3390/foods11223613
2022	L. J. Zheng, Q. Guo, Y. X. Zhang, C. Y. Liu, L. H. Fan and H. D. Zheng	Engineering of Escherichia coli for D-allulose fermentative synthesis from D-glucose through izumoring cascade epimerization	Front Bioeng Biotechnol	10.3389/fbioe.2022.1050808
2022	Y. Feng, Z. Pu, L. Zhu, M. Wu, L. Yang, H. Yu and J. Lin	Enhancing the thermostability of D-allulose 3-epimerase from Clostridium cellulolyticum H10 via a dual-enzyme screening system	Enzyme and Microbial Technology	10.1016/j.enzmictec.2022.110054
2022	F. A. Laksmi, R. Nirwantono, I. Nuryana and E. Agustriana	Expression and characterization of thermostable D-allulose 3-epimerase from Arthrobacter psychrolactophilus (Ap DAEase) with potential catalytic activity for bioconversion of D-allulose from D-fructose	International Journal of Biological Macromolecules	10.1016/j.ijbiomac.2022.06.117
2022	W. Zhang, M. Wei, X. Sun, F. Lu, L. Guan, S. Mao and H. M. Qin	Fine-Tuning of Carbon Flux and Artificial Promoters in Bacillus subtilis Enables High-Level Biosynthesis of d-Allulose	Journal of agricultural and food chemistry	10.1021/acs.jafc.2c05585
2022	J. Wang, J. Sun, H. Qi, L. Wang, J. Wang and C. Li	High production of d-psicose from d-fructose by immobilized whole recombinant Bacillus subtilis cells expressing d-psicose 3-epimerase from Agrobacterium tumefaciens	Biotechnology and Applied Biochemistry	10.1002/bab.2115
2022	K. Xue, C. L. Liu, Y. Yang, X. Liu, J. Zhan and Z. Bai	Immobilization of D-allulose 3-epimerase into magnetic metal-organic framework nanoparticles for efficient biocatalysis	World journal of microbiology & biotechnology	10.1007/s11274-022-03330-4

Year	Author	Title	Journal	DOI
2022	K. Takao, M. Suzuki, R. Miyazaki, M. Miyake, K. Akimitsu and K. Hoshino	Immunomodulatory effects of D-allose on cytokine production by plasmacytoid dendritic cells	Biochemical and Biophysical Research Communications	10.1016/j.bbrc.2022.08.037
2022	H. Wang, J. Chen, J. Zhao, H. Li, X. Wei and J. Liu	Improved thermostability of D-allulose 3-epimerase from <i>Clostridium bolteae</i> ATCC BAA-613 by proline residue substitution	Protein expression and purification	10.1016/j.pep.2022.106145
2022	M. J. Haas, S. Parekh, P. Kalidas, A. Richter, F. Warda, N. C. W. Wong, M. Tokuda and A. D. Mooradian	Insulin mimetic effect of D-allulose on apolipoprotein A-I gene	J Food Biochem	10.1111/jfbc.14064
2022	D. Nagarajan, C. Y. Chen, T. U. Ariyadasa, D. J. Lee and J. S. Chang	Macroalgal biomass as a potential resource for lactic acid fermentation	Chemosphere	10.1016/j.chemosphere.2022.136694
2022	Q. Guo, C. Y. Liu, L. J. Zheng, S. H. Zheng, Y. X. Zhang, S. Y. Zhao, H. D. Zheng, L. H. Fan and X. C. Lin	Metabolically Engineered <i>Escherichia coli</i> for Conversion of D-Fructose to D-Allulose via Phosphorylation-Dephosphorylation	Front Bioeng Biotechnol	10.3389/fbioe.2022.947469
2022	Q. Guo, M. M. Liu, S. H. Zheng, L. J. Zheng, Q. Ma, Y. K. Cheng, S. Y. Zhao, L. H. Fan and H. D. Zheng	Methanol-Dependent Carbon Fixation for Irreversible Synthesis of d-Allulose from d-Xylose by Engineered <i>Escherichia coli</i>	Journal of agricultural and food chemistry	10.1021/acs.jafc.2c06616
2022	W. Pratchayasakul, K. Jinawong, W. Pongkan, T. Jaiwongkam, B. Arunsak, T. Chunchai, M. Tokuda, N. Chattipakorn and S. C. Chattipakorn	Not only metformin, but also D-allulose, alleviates metabolic disturbance and cognitive decline in prediabetic rats	Nutritional Neuroscience	10.1080/1028415X.2020.1840050

Year	Author	Title	Journal	DOI
2022	Z. Liu, S. Liu, J. Jia, L. Wang, F. Wang, X. Pan, J. Wu and S. Chen	Optimization of Ultrahigh-Throughput Screening Assay for Protein Engineering of d-Allulose 3-Epimerase	Biomolecules	10.3390/biom12111547
2022	Y. Guo, T. Feng, Z. Wang, H. Li, X. Wei, J. Chen, D. Niu and J. Liu	Phosphorylation-Driven Production of d-Allulose from d-Glucose by Coupling with an ATP Regeneration System	Journal of agricultural and food chemistry	10.1021/acs.jafc.2c06920
2022	A. Ahmed, T. A. Khan, D. D. Ramdath, C. W. C. Kendall and J. L. Sievenpiper	Rare sugars and their health effects in humans: a systematic review and narrative synthesis of the evidence from human trials	Nutrition Reviews	10.1093/nutrit/nuab012
2022	A. Smith, A. Avery, R. Ford, Q. Yang, A. Goux, I. Mukherjee, D. C. A. Neville and P. Jethwa	Rare sugars: Metabolic impacts and mechanisms of action: A scoping review	British Journal of Nutrition	10.1017/S0007114521003524
2022	Z. Chen, X. D. Gao and Z. Li	Recent Advances Regarding the Physiological Functions and Biosynthesis of D-Allulose	Frontiers in Microbiology	10.3389/fmicb.2022.881037
2022	J. Zhao, Y. Guo, Q. Li, J. Chen, D. Niu and J. Liu	Reconstruction of a Cofactor Self-Sufficient Whole-Cell Biocatalyst System for Efficient Biosynthesis of Allitol from d-Glucose	J Agric Food Chem	10.1021/acs.jafc.2c00440
2022	Y. S. Jung, H. G. Kim, M. C. Lim, J. S. Park, S. Sa and M. Yoo	Synthesis of a New Glycoconjugate with Di--Psicose Anhydride Structure	International Journal of Molecular Sciences	10.3390/ijms232112827
2022	S. Sa, Y. Seol, A. W. Lee, Y. Heo, H. J. Kim and C. J. Park	Teratogenicity of D-allulose	Toxicology Reports	10.1016/j.toxrep.2022.03.028
2022	X. Tang, Y. An, M. W. Iqbal, H. Cong, G. Zhang, Y. Zhang, Y. Ravikumar, H. M. Zayed, M. Zhao, H. Zhou and X. Qi	The Characterization of a Novel D-allulose 3-Epimerase from <i>Blautia producua</i> and Its Application in D-allulose Production	Foods	10.3390/foods11203225

Year	Author	Title	Journal	DOI
2022	F. Teysseire, V. Bordier, A. Budzinska, N. Weltens, J. F. Rehfeld, J. J. Holst, B. Hartmann, C. Beglinger, L. Van Oudenhove, B. K. Wölnerhanssen and A. C. Meyer-Gerspach	The Role of D-allulose and Erythritol on the Activity of the Gut Sweet Taste Receptor and Gastrointestinal Satiation Hormone Release in Humans: A Randomized, Controlled Trial	J Nutr	10.1093/jn/nxac026
2021	A. S. Machado, A. Dias-Amaral, A. Silva and R. Grangeia	[Psychosis Associated with Herbal Products: Iatrogenic Delusional Disorder]	Acta Med Port	10.20344/amp.13135
2021	C. Li, Z. Lu, M. Wang, S. Chen, L. Han and W. Han	A Possible Mechanism of Graphene Oxide to Enhance Thermostability of D-Psicose 3-Epimerase Revealed by Molecular Dynamics Simulations	Int J Mol Sci	10.3390/ijms221910813
2021	M. Z. Mohsin, R. Omer, J. Huang, A. Mohsin, M. Guo, J. Qian and Y. Zhuang	Advances in engineered Bacillus subtilis biofilms and spores, and their applications in bioremediation, biocatalysis, and biomaterials	Synth Syst Biotechnol	10.1016/j.synbio.2021.07.002
2021	S. Govindarajan, S. N. Babu, M. A. Vijayalakshmi, P. Manohar and A. Noor	Aloe vera carbohydrates regulate glucose metabolism through improved glycogen synthesis and downregulation of hepatic gluconeogenesis in diabetic rats	Journal of Ethnopharmacology	10.1016/j.jep.2021.114556

Year	Author	Title	Journal	DOI
2021	D. Chen, J. Chen, X. Liu, C. Guang, W. Zhang and W. Mu	Biochemical identification of a hyperthermostable L-ribulose 3-epimerase from <i>Labeledella endophytica</i> and its application for D-allulose bioconversion	International Journal of Biological Macromolecules	10.1016/j.ijbiomac.2021.08.131
2021	M. Hu, M. Li, B. Jiang and T. Zhang	Bioproduction of D-allulose: Properties, applications, purification, and future perspectives	Comprehensive Reviews in Food Science and Food Safety	10.1111/1541-4337.12859
2021	S. J. Hofer, S. Davinelli, M. Bergmann, G. Scapagnini and F. Madeo	Caloric Restriction Mimetics in Nutrition and Clinical Trials	Frontiers in Nutrition	10.3389/fnut.2021.717343
2021	J. Chen, D. Chen, M. Ke, S. Ye, X. Wang, W. Zhang and W. Mu	Characterization of a Recombinant d-Allulose 3-epimerase from <i>Thermoclostridium caenicola</i> with Potential Application in d-Allulose Production	Molecular Biotechnology	10.1007/s12033-021-00320-z
2021	Y. Wei, X. Zhang, M. Hu, Y. Shao, S. Pan, M. Fujita and Z. Rao	Construction and immobilization of recombinant <i>Bacillus subtilis</i> with D-allulose 3-epimerase	Sheng wu gong cheng xue bao = Chinese journal of biotechnology	10.13345/j.cjb.210005
2021	C. Li, W. Zhang, C. Wei, X. Gao, S. Mao, F. Lu and H. M. Qin	Continuous Spectrophotometric Assay for High-Throughput Screening of Predominant d-Allulose 3-Epimerases	Journal of Agricultural and Food Chemistry	10.1021/acs.jafc.1c04716
2021	H. Yoshida, A. Yoshihara, S. Kato, S. Mochizuki, K. Akimitsu, K. Izumori and S. Kamitori	Crystal structure of a novel homodimeric l-ribulose 3-epimerase from <i>Methylomonas</i> sp	FEBS Open Bio	10.1002/2211-5463.13159

Year	Author	Title	Journal	DOI
2021	S. N. Patel, G. Kaushal and S. P. Singh	D-Allulose 3-epimerase of Bacillus sp. origin manifests profuse heat-stability and noteworthy potential of D-fructose epimerization	Microb Cell Fact	10.1186/s12934-021-01550-1
2021	G. H. Lee, C. Peng, H. Y. Lee, S. A. Park, T. H. Hoang, J. H. Kim, S. Sa, G. E. Kim, J. S. Han and H. J. Chae	D-allulose ameliorates adiposity through the AMPK-SIRT1-PGC-1 α pathway in HFD-induced SD rats	Food and Nutrition Research	10.29219/fnr.v65.7803
2021	Y. Gou, B. Liu, M. Cheng, T. Yamada, T. Iida, S. Wang, R. Banno and T. Koike	d-Allulose Ameliorates Skeletal Muscle Insulin Resistance in High-Fat Diet-Fed Rats	Molecules (Basel, Switzerland)	10.3390/molecules26206310
2021	W. Pongkan, K. Jinawong, W. Pratchayasakul, T. Jaiwongkam, S. Kerdphoo, M. Tokuda, S. C. Chattipakorn and N. Chattipakorn	d-allulose provides cardioprotective effect by attenuating cardiac mitochondrial dysfunction in obesity-induced insulin-resistant rats	European Journal of Nutrition	10.1007/s00394-020-02394-y
2021	W. Zhang, D. Chen, J. Chen, W. Xu, Q. Chen, H. Wu, C. Guang and W. Mu	D-allulose, a versatile rare sugar: recent biotechnological advances and challenges	Crit Rev Food Sci Nutr	10.1080/10408398.2021.2023091
2021	A. Kanasaki, M. Niibo and T. Iida	Effect of D-allulose feeding on the hepatic metabolomics profile in male Wistar rats	Food & function	10.1039/d0fo03024d
2021	I. S. Surono, A. A. Wardana, P. Waspodo, B. Saksono and K. Venema	Effect of Taro Starch, Beet Juice, Probiotic, and/or Psicose on Gut Microbiota in a Type 2 Diabetic Rat Model: A Pilot Study	J Nutr Metab	10.1155/2021/1825209

Year	Author	Title	Journal	DOI
2021	J. Zhao, H. Wei, J. Chen, L. Li, K. Li and J. Liu	Efficient biosynthesis of D-allulose in <i>Bacillus subtilis</i> through D-psicose 3-epimerase translation modification	International Journal of Biological Macromolecules	10.1016/j.ijbiomac.2021.07.093
2021	L. Yu, W. Zhou, Y. She, H. Ma, Y. S. Cai, M. Jiang, Z. Deng, N. P. J. Price and W. Chen	Efficient biosynthesis of nucleoside cytokinin angustmycin A containing an unusual sugar system	Nat Commun	10.1038/s41467-021-26928-y
2021	Q. Guo, L. J. Zheng, X. Luo, X. Q. Gao, C. Y. Liu, L. Deng, L. H. Fan and H. D. Zheng	Engineering <i>Escherichia coli</i> for d-Allulose Production from d-Fructose by Fermentation	Journal of agricultural and food chemistry	10.1021/acs.jafc.1c05200
2021	J. Zhao, J. Chen, H. Wang, Y. Guo, K. Li and J. Liu	Enhanced thermostability of d-psicose 3-epimerase from <i>Clostridium boltea</i> through rational design and engineering of new disulfide bridges	International Journal of Molecular Sciences	10.3390/ijms221810007
2021	Y. Huang, L. Li, Y. Chi, Y. Sha, R. Wang, Z. Xu, X. Xu, S. Li, Z. Gao and H. Xu	Fusion and secretory expression of an exo-inulinase and a d-allulose 3-epimerase to produce d-allulose syrup from inulin	Journal of the science of food and agriculture	10.1002/jsfa.10682
2021	W. C. Tseng, C. T. Hsu, H. C. Chang, M. J. Wang and T. Y. Fang	Fusion of the peptide derived from the acidic tail of alpha-synuclein improves the thermostability and soluble expression of recombinant <i>Agrobacterium</i> sp. D-allulose 3-epimerase	Biochemical Engineering Journal	10.1016/j.bej.2020.107828
2021	D. K. Ingram and G. S. Roth	Glycolytic inhibition: an effective strategy for developing calorie restriction mimetics	GeroScience	10.1007/s11357-020-00298-7
2021	Y. Bu, T. Zhang, B. Jiang and J. Chen	Improved Performance of D-Psicose 3-Epimerase by Immobilisation on Amino-Epoxy Support with Intense Multipoint Attachment	Foods	10.3390/foods10040831
2021	Z. Zhu, L. Li, W. Zhang, C. Li, S. Mao, F. Lu and H. M. Qin	Improving the enzyme property of D-allulose 3-epimerase from a thermophilic organism of <i>Halanaerobium congolense</i> through rational design	Enzyme and Microbial Technology	10.1016/j.enzmictec.2021.109850

Year	Author	Title	Journal	DOI
2021	Z. J. Wei, L. Sun, Y. L. Li, J. S. H. Muhammad, Y. Wang, Q. W. Feng, Y. Z. Zhang, H. Inadera, Z. G. Cui and C. A. Wu	Low-calorie sweetener d-psicose promotes hydrogen peroxide-mediated apoptosis in c2c12 myogenic cells favoring skeletal muscle cell injury	Molecular Medicine Reports	10.3892/MMR.2021.12175
2021	C. Li, J. Wang, Y. Li, B. Chen, J. Tao, X. Wang, H. Yang, Y. Liu, Y. Tong and W. Han	Molecular mechanisms of metal ions in regulating the catalytic efficiency of D-psicose 3-epimerase revealed by multiple short molecular dynamic simulations and free energy predictions	Journal of Biomolecular Structure and Dynamics	10.1080/07391102.2020.1737232
2021	D. X. Jia, C. Y. Sun, Y. T. Jin, Z. Q. Liu, Y. G. Zheng, M. Li, H. Y. Wang and D. S. Chen	Properties of D-allulose 3-epimerase mined from <i>Novibacillus thermophilus</i> and its application to synthesis of D-allulose	Enzyme and Microbial Technology	10.1016/j.enzmictec.2021.109816
2021	A. D. E. Van Laar, C. Grootaert and J. Van Camp	Rare mono- and disaccharides as healthy alternative for traditional sugars and sweeteners?	Crit Rev Food Sci Nutr	10.1080/10408398.2020.1743966
2021	Y. Xia, Q. Cheng, W. Mu, X. Hu, Z. Sun, Y. Qiu, X. Liu and Z. Wang	Research Advances of d-allulose: An Overview of Physiological Functions, Enzymatic Biotransformation Technologies, and Production Processes	Foods	10.3390/foods10092186
2021	C. Lambré, J. M. Barat Baviera, C. Bolognesi, P. S. Cocconcelli, R. Crebelli, D. M. Gott, K. Grob, E. Lampi, M. Mengelers, A. Mortensen, G. Rivière, I. L. Steffensen, C. Tlustos, H. Van Loveren, L. Vernis, H. Zorn, B. Glandorf, L. Herman, Y. Liu, J. Maia, E. Nielsen and A. Chesson	Safety evaluation of the food enzyme d-psicose 3-epimerase from the genetically modified <i>Corynebacterium glutamicum</i> strain FIS002	Efsa j	10.2903/j.efsa.2021.6870
2021	C. Lambré, J. M. Barat Baviera, C. Bolognesi, P. S. Cocconcelli, R. Crebelli, D. M. Gott, K. Grob, E. Lampi, M. Mengelers, A. Mortensen, G. Rivière, I. L. Steffensen, C. Tlustos, H. van Loveren, L. Vernis, H. Zorn, B. Glandorf, L. Herman, M. Andryszkiewicz, A. Gomes, Y. Liu, J. Maia, S. Rainieri and A. Chesson	Safety evaluation of the food enzyme d-psicose 3-epimerase from the genetically modified <i>Escherichia coli</i> strain K-12 W3110 (pWKLP)	Efsa j	10.2903/j.efsa.2021.6565

Year	Author	Title	Journal	DOI
2021	C. Li, L. Li, Z. Feng, L. Guan, F. Lu and H. M. Qin	Two-step biosynthesis of D-allulose via a multienzyme cascade for the bioconversion of fruit juices	Food Chemistry	10.1016/j.foodchem.2021.129746
2021	C. Somjai, T. Siriwoharn, K. Kulprachakarn, S. Chaipoot, R. Phongphisutthinant and P. Wiriyacharee	Utilization of Maillard reaction in moist-dry-heating system to enhance physicochemical and antioxidative properties of dried whole longan fruit	Heliyon	10.1016/j.heliyon.2021.e07094
2020	S. N. Patel, G. Kaushal and S. P. Singh	A Novel d-Allulose 3-Epimerase Gene from the Metagenome of a Thermal Aquatic Habitat and d-Allulose Production by <i>Bacillus subtilis</i> Whole-Cell Catalysis	Applied and Environmental Microbiology	10.1128/AEM.02605-19
2020	Y. Han, H. Park, B. R. Choi, Y. Ji, E. Y. Kwon and M. S. Choi	Alteration of microbiome profile by d-allulose in amelioration of high-fat-diet-induced obesity in mice	Nutrients	10.3390/nu12020352
2020	Y. Han, E. Y. Kwon and M. S. Choi	Anti-Diabetic Effects of Allulose in Diet-Induced Obese Mice via Regulation of mRNA Expression and Alteration of the Microbiome Composition	Nutrients	10.3390/nu12072113
2020	A. Trincone	Application-Oriented Marine Isomerases in Biocatalysis	Mar Drugs	10.3390/md18110580
2020	Y. Wang, Y. Ravikumar, G. Zhang, J. Yun, Y. Zhang, A. Parvez, X. Qi and W. Sun	Biocatalytic Synthesis of D-Allulose Using Novel D-Tagatose 3-Epimerase From <i>Christensenella minuta</i>	Front Chem	10.3389/fchem.2020.622325
2020	Z. Chen, Z. Li, F. Li, M. Wang, N. Wang and X. D. Gao	Cascade synthesis of rare ketoses by whole cells based on L-rhamnulose-1-phosphate aldolase	Enzyme and Microbial Technology	10.1016/j.enzmictec.2019.109456
2020	Z. Chen, Z. Li, F. Li, N. Wang and X. D. Gao	Characterization of alditol oxidase from <i>Streptomyces coelicolor</i> and its application in the production of rare sugars	Bioorganic and Medicinal Chemistry	10.1016/j.bmc.2020.115464
2020	D. Lee, Y. Han, E. Y. Kwon and M. S. Choi	d-allulose Ameliorates Metabolic Dysfunction in C57BL/KsJ-db/db Mice	Molecules (Basel, Switzerland)	10.3390/molecules25163656

Year	Author	Title	Journal	DOI
2020	A. Kanasaki, T. Iida, K. Murao, B. Shirouchi and M. Sato	d-Allulose enhances uptake of HDL-cholesterol into rat's primary hepatocyte via SR-B1	Cytotechnology	10.1007/s10616-020-00378-8
2020	C. R. Braunstein, J. C. Noronha, T. A. Khan, S. B. Mejia, T. M. Wolever, R. G. Josse, C. W. Kendall and J. L. Sievenpiper	Effect of fructose and its epimers on postprandial carbohydrate metabolism: A systematic review and meta-analysis	Clinical Nutrition	10.1016/j.clnu.2020.03.002
2020	I. S. Surono, A. A. Wardana, P. Waspodo, B. Saksono, J. Verhoeven and K. Venema	Effect of functional food ingredients on gut microbiota in a rodent diabetes model	Nutr Metab (Lond)	10.1186/s12986-020-00496-2
2020	J. E. Nijesh, R. Srudhy and P. E. Chaly	Effect of various sweeteners on cariogenicity features ostreptococcus mutans: In-vitro study	Medico-Legal Update	10.37506/mlu.v20i4.2189
2020	X. Wen, H. Lin, Y. Ren, C. Li, C. Zhang, X. Song, J. Lin and J. Lin	Efficient Allitol Bioproduction from d-Fructose Catalyzed by Recombinant E. coli Whole Cells, and the Condition Optimization, Product Purification	Applied Biochemistry and Biotechnology	10.1007/s12010-020-03359-x
2020	J. Zhang, C. Xu, X. Chen, X. Ruan, Y. Zhang, H. Xu, Y. Guo, J. Xu, P. Lv and Z. Wang	Engineered Bacillus subtilis harbouring gene of d-tagatose 3-epimerase for the bioconversion of D-fructose into D-psicose through fermentation	Enzyme and Microbial Technology	10.1016/j.enzmictec.2020.109531
2020	S. Mao, X. Cheng, Z. Zhu, Y. Chen, C. Li, M. Zhu, X. Liu, F. Lu and H. M. Qin	Engineering a thermostable version of D-allulose 3-epimerase from Rhodospirellula baltica via site-directed mutagenesis based on B-factors analysis	Enzyme and Microbial Technology	10.1016/j.enzmictec.2019.109441
2020	G. Fu, S. Zhang, H. Dong, J. Chen, R. Tu and D. Zhang	Enhanced production of d-psicose 3-epimerase in Bacillus subtilis by regulation of segmented fermentation	Biotechnology and Applied Biochemistry	10.1002/bab.1831
2020	X. Zhang, X. Xu, X. Yao, R. Wang, H. Tang, X. Ju and L. Li	Exploring Multifunctional Residues of Ribose-5-phosphate Isomerase B from Ochrobactrum sp. CSL1 Enhancing Isomerization of d-Allose	Journal of agricultural and food chemistry	10.1021/acs.jafc.9b07855

Year	Author	Title	Journal	DOI
2020	S. R. Dedania, V. K. Patel, S. S. Soni and D. H. Patel	Immobilization of <i>Agrobacterium tumefaciens</i> D-psicose 3-epimerase onto titanium dioxide for bioconversion of rare sugar	Enzyme and Microbial Technology	10.1016/j.enzmictec.2020.109605
2020	S. J. Lee, W. K. Yu, H. R. Park, H. Kim, J. H. Kim, J. Park and K. S. Shin	Improved effect of palatinose syrup bioconverted from sucrose on hyperglycemia and regulation of hepatic lipogenesis in male C57BL/6J mice	Journal of food biochemistry	10.1111/jfbc.13201
2020	S. Moon, Y. H. Kim and K. Choi	Inhibition of 3T3-L1 Adipocyte Differentiation by D-allulose	Biotechnology and Bioprocess Engineering	10.1007/s12257-019-0352-7
2020	A. D. Mooradian, M. J. Haas, L. Onstead-Haas, Y. Tani, T. Iida and M. Tokuda	Naturally occurring rare sugars are free radical scavengers and can ameliorate endoplasmic reticulum stress	International Journal for Vitamin and Nutrition Research	10.1024/0300-9831/a000517
2020	W. Zhou, Y. Hong, A. Yin, S. Liu, M. Chen, X. Lv, X. Nie, N. Tan and Z. Zhang	Non-invasive urinary metabolomics reveals metabolic profiling of polycystic ovary syndrome and its subtypes	Journal of Pharmaceutical and Biomedical Analysis	10.1016/j.jpba.2020.113262
2020	K. Kakleas, F. Christodouli and K. Karavanaki	Nonalcoholic fatty liver disease, insulin resistance, and sweeteners: a literature review	Expert Review of Endocrinology and Metabolism	10.1080/17446651.2020.1740588
2020	X. Wen, H. Lin, Y. Ren, C. Li, C. Zhang, X. Song, J. Lin and J. Lin	Optimization for allitol production from D-glucose by using immobilized glucose isomerase and recombinant <i>E. coli</i> expressing D-psicose-3-epimerase, ribitol dehydrogenase and formate dehydrogenase	Biotechnology letters	10.1007/s10529-020-02917-x
2020	K. Kishida, K. Yoshikawa, T. Taguchi, R. Tamaoki, T. Iida, T. Yamada and Y. Toyoda	Plasma Rare Sugar Levels and the Effect on Plasma Glucose Levels in GLUT5-induced Rats Gavigated with Rare Sugar D-Sorbose, D-Tagatose, or D-Allulose	FASEB Journal	10.1096/fasebj.2020.34.s1.02055

Year	Author	Title	Journal	DOI
2020	C. Li, L. Gao, K. Du, H. Lin, Y. Ren, J. Lin and J. Lin	Production of D-allose from D-fructose using immobilized L-rhamnose isomerase and D-psicose 3-epimerase	Bioprocess Biosyst Eng	10.1007/s00449-019-02262-y
2020	D. EdyLiani, Y. Yurnaliza and B. Saksono	Purification and Characterization of D-psicose 3 Epimerase (DPEase) From <i>Escherichia coli</i> BL21 (DE3) pET21b-dpe	Pakistan journal of biological sciences : PJBS	10.3923/pjbs.2020.561.566
2020	V. W. K. Tan, M. S. M. Wee, O. Tomic and C. G. Forde	Rate-All-That-Apply (RATA) comparison of taste profiles for different sweeteners in black tea, chocolate milk, and natural yogurt	Journal of food science	10.1111/1750-3841.15007
2020	S. Jiang, W. Xiao, X. Zhu, P. Yang, Z. Zheng, S. Lu, S. Jiang, G. Zhang and J. Liu	Review on D-Allulose: In vivo Metabolism, Catalytic Mechanism, Engineering Strain Construction, Bio-Production Technology	Front Bioeng Biotechnol	10.3389/fbioe.2020.00026
2020	Z. Zhang, M. Yang, A. Yin, M. Chen, N. Tan, M. Wang, Y. Zhang, H. Ye, X. Zhang and W. Zhou	Serum metabolomics reveals the effect of electroacupuncture on urinary leakage in women with stress urinary incontinence	Journal of Pharmaceutical and Biomedical Analysis	10.1016/j.jpba.2020.113513
2020	M. F. Mabanglo, J. P. Huddleston, K. Mukherjee, Z. W. Taylor and F. M. Raushel	Structure and Reaction Mechanism of YcjR, an Epimerase That Facilitates the Interconversion of d-Gulosides to d-Glucosides in <i>Escherichia coli</i>	Biochemistry	10.1021/acs.biochem.0c00334
2020	J. Franceus and T. Desmet	Sucrose phosphorylase and related enzymes in glycoside hydrolase family 13: Discovery, application and engineering	International Journal of Molecular Sciences	10.3390/ijms21072526
2020	A. Scalfani, N. Williams and J. I. Glendinning	The avidity of C57BL/6 mice for two rare sugars: Allulose (D-Psicose) and isomaltulose (Palatinose)	Chemical Senses	10.1093/chemse/bjaa061
2020	Y. Han, J. Yoon and M. S. Choi	Tracing the Anti-Inflammatory Mechanism/Triggers of d-Allulose: A Profile Study of Microbiome Composition and mRNA Expression in Diet-Induced Obese Mice	Mol Nutr Food Res	10.1002/mnfr.201900982

Year	Author	Title	Journal	DOI
2020	Y. Liu, J. Liu, A. Abozeid, K. X. Wu, X. R. Guo, L. Q. Mu and Z. H. Tang	UV-B radiation largely promoted the transformation of primary metabolites to phenols in <i>Astragalus mongholicus</i> seedlings	Biomolecules	10.3390/biom10040504

From: [Kolberg, Lore](#)
To: [Hice, Stephanie](#)
Subject: [EXTERNAL] Re: GRN 001057 - Questions for Notifier_Addendum to Notifier response
Date: Thursday, September 28, 2023 12:29:49 PM
Attachments: [image009.png](#)
[image011.png](#)
[image012.png](#)
[image013.png](#)
[image014.png](#)
[image015.png](#)
[image016.png](#)
[image017.png](#)
[image018.png](#)
[image019.png](#)
[image020.png](#)
[image021.png](#)
[image022.png](#)
[image023.png](#)
[image002.png](#)
[2023 Tate & Lyle GRAS statement GENSWREET IGI-VHF 27SEP2023.pdf](#)

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Hice,

The attached document is intended as an addendum to Tate & Lyle's response to question #3 regarding GRN 1057. We received this document yesterday from the supplier of the glucoisomerase. The document includes an expert opinion statement regarding the GRAS status of the enzyme and thus provides additional rationale for the supplier's GRAS statement, which we shared with you previously. The supplier has given us permission to share the attached document.

Best regards,
Lore

Lore Kolberg
Director, Regulatory & Scientific Affairs
Innovation and Commercial Development
Tate & Lyle
Mob. +1 224 355 9013

TATE & LYLE

Science \ Solutions \ Society



External use permitted

From: Don Schmitt <dschmitt@toxstrategies.com>
Sent: Friday, September 15, 2023 4:53 PM
To: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>
Cc: Kolberg, Lore <lore.kolberg@tateandlyle.com>
Subject: Re: [EXTERNAL] Re: GRN 001057 - Questions for Notifier

Hi Stephanie,

Attached are Tate & Lyle's responses to FDA's questions regarding GRN 1057.

Sincerely,

Don

Donald F. Schmitt, M.P.H.
Senior Managing Scientist



ToxStrategies

739 Thornapple Drive
Naperville, IL 60540
phone: 630.352.0303
email: dschmitt@toxstrategies.com

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please immediately notify ToxStrategies, Inc. at (832) 868-7729 and permanently delete the original and any copy of any e-mail and any printout thereof.

From: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>
Date: Wednesday, August 23, 2023 at 1:07 PM
To: Don Schmitt <dschmitt@toxstrategies.com>

Cc: Kolberg, Lore <lore.kolberg@tateandlyle.com>

Subject: RE: [EXTERNAL] Re: GRN 001057 - Questions for Notifier

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Mr. Schmitt,

Thank you for the update. Yes, an extension until September 15, 2023, is fine.

Sincerely,

Stiffy Hice

Stephanie (Stiffy) Hice, Ph.D. (they/them/their)

Regulatory Review Scientist & Microbiology Reviewer

**Division of Food Ingredients
Office of Food Additive Safety
Center for Food Safety and Applied Nutrition
U.S. Food and Drug Administration
stephanie.hice@fda.hhs.gov**

Pronouns: They-Them-Their ([what is this?](#))



From: Don Schmitt <dschmitt@toxstrategies.com>

Sent: Wednesday, August 23, 2023 12:59 PM

To: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>

Cc: Kolberg, Lore <lore.kolberg@tateandlyle.com>

Subject: [EXTERNAL] Re: GRN 001057 - Questions for Notifier

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Stephanie,

We are working on responses to the list of questions you provided on August 14. One of the questions requires that the intake assessment be revised and this will take Exponent a few weeks to complete, given their previous commitments. Therefore, Tate & Lyle is requesting a 3-week extension of the time to reply to all 12 questions. That would be Friday, September 15.

Thank you for considering this extension request.

Best regards,

Don

Donald F. Schmitt, M.P.H.
Senior Managing Scientist



ToxStrategies

739 Thornapple Drive
Naperville, IL 60540
phone: 630.352.0303
email: dschmitt@toxstrategies.com

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please immediately notify ToxStrategies, Inc. at (832) 868-7729 and permanently delete the original and any copy of any e-mail and any printout thereof.

From: Don Schmitt <dschmitt@toxstrategies.com>

Date: Monday, August 14, 2023 at 9:46 AM

To: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>

Subject: Re: GRN 001057 - Questions for Notifier

Hi Stephanie,

I will speak with Tate & Lyle and be back in touch shortly.

Don

Donald F. Schmitt, M.P.H.
Senior Managing Scientist



ToxStrategies

739 Thornapple Drive
Naperville, IL 60540
phone: 630.352.0303
email: dschmitt@toxstrategies.com

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please immediately notify ToxStrategies, Inc. at (832) 868-7729 and permanently delete the original and any copy of any e-mail and any printout thereof.

From: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>

Date: Monday, August 14, 2023 at 8:07 AM

To: Don Schmitt <dschmitt@toxstrategies.com>

Subject: GRN 001057 - Questions for Notifier

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Mr. Schmitt,

During our evaluation of GRAS Notice No. 001057, we noted questions that need to be addressed and are attached to this email.

We respectfully request a response within **10 business days**. If you are unable to complete the response within that time frame, please contact me to discuss further options. Please do not include any confidential information in your response.

If you have questions or need further clarification, please feel free to contact me. Thank you in advance for your attention to our comments.

Sincerely,

Stiffy Hice

Stephanie (Stiffy) Hice, Ph.D. (they/them/their)

Regulatory Review Scientist & Microbiology Reviewer

Division of Food Ingredients

Office of Food Additive Safety
Center for Food Safety and Applied Nutrition
U.S. Food and Drug Administration
stephanie.hice@fda.hhs.gov

Pronouns: They-Them-Their ([what is this?](#))



***** This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not the intended recipient or the person responsible for delivering the email to the intended recipient, be advised that you have received this email in error that any use, dissemination, forwarding, printing, or copying of this email is strictly prohibited. If you have received this email in error please notify the sender immediately. Please note that we reserve the right to monitor and read any emails sent and received by the Company in accordance with and to the extent permitted by applicable legal rules.

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not the intended recipient or the person responsible for delivering the email to the intended recipient, be advised that you have received this email in error that any use, dissemination, forwarding, printing, or copying of this email is strictly prohibited. If you have received this email in error please notify the sender immediately. Please note that we reserve the right to monitor and read any emails sent and received by the Company in accordance with and to the extent permitted by applicable legal rules.

From: [Kolberg, Lore](#)
To: [Hice, Stephanie](#)
Subject: [EXTERNAL] GRN 1057 glucoisomerase
Date: Tuesday, October 3, 2023 3:56:44 PM
Attachments: [image001.png](#)
[image004.png](#)
[image005.png](#)
[image006.png](#)
[image007.png](#)
[image008.png](#)
[image003.png](#)
[2023 GRAS Statement_GENSWEET IGI-VHF_A10022.pdf](#)

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Stiffy,

IFF responded regarding my request for the GRAS Expert Opinion document, in a version not marked Confidential. They will not/cannot share the GRAS Expert Opinion with us except the version I shared with you that's marked Confidential. The only related document they could share as non-Confidential is the attached GRAS statement.

I hope you can use the attached document. Please let me know if there are other issues.
Best regards,
Lore

Lore Kolberg
Director, Regulatory & Scientific Affairs
Innovation and Commercial Development
Tate & Lyle
Mob. +1 224 355 9013



***** This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not the intended recipient or the person responsible for delivering the email to the intended recipient, be advised that you have received this email in error that any use, dissemination, forwarding, printing, or copying of this email is strictly prohibited. If you have received this email in error please notify the sender immediately. Please note that we reserve the right to monitor and read any emails sent and received by the Company in accordance with and to the

extent permitted by applicable legal rules.

External use permitted

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not the intended recipient or the person responsible for delivering the email to the intended recipient, be advised that you have received this email in error that any use, dissemination, forwarding, printing, or copying of this email is strictly prohibited. If you have received this email in error please notify the sender immediately. Please note that we reserve the right to monitor and read any emails sent and received by the Company in accordance with and to the extent permitted by applicable legal rules.

From: [Kolberg, Lore](#)
To: [Hice, Stephanie](#)
Subject: [EXTERNAL] Re: GRN 001057 - Questions for Notifier_Addendum to Notifier response
Date: Thursday, September 28, 2023 12:29:49 PM
Attachments: [image009.png](#)
[image011.png](#)
[image012.png](#)
[image013.png](#)
[image014.png](#)
[image015.png](#)
[image016.png](#)
[image017.png](#)
[image018.png](#)
[image019.png](#)
[image020.png](#)
[image021.png](#)
[image022.png](#)
[image023.png](#)
[image002.png](#)
[2023 Tate & Lyle GRAS statement GENSWEET IGI-VHF 27SEP2023.pdf](#)

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Hice,

The attached document is intended as an addendum to Tate & Lyle's response to question #3 regarding GRN 1057. We received this document yesterday from the supplier of the glucoisomerase. The document includes an expert opinion statement regarding the GRAS status of the enzyme and thus provides additional rationale for the supplier's GRAS statement, which we shared with you previously. The supplier has given us permission to share the attached document.

Best regards,
Lore

Lore Kolberg
Director, Regulatory & Scientific Affairs
Innovation and Commercial Development
Tate & Lyle
Mob. +1 224 355 9013

TATE & LYLE

Science \ Solutions \ Society



External use permitted

From: Don Schmitt <dschmitt@toxstrategies.com>
Sent: Friday, September 15, 2023 4:53 PM
To: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>
Cc: Kolberg, Lore <lore.kolberg@tateandlyle.com>
Subject: Re: [EXTERNAL] Re: GRN 001057 - Questions for Notifier

Hi Stephanie,

Attached are Tate & Lyle's responses to FDA's questions regarding GRN 1057.

Sincerely,

Don

Donald F. Schmitt, M.P.H.
Senior Managing Scientist



ToxStrategies

739 Thornapple Drive
Naperville, IL 60540
phone: 630.352.0303
email: dschmitt@toxstrategies.com

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please immediately notify ToxStrategies, Inc. at (832) 868-7729 and permanently delete the original and any copy of any e-mail and any printout thereof.

From: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>
Date: Wednesday, August 23, 2023 at 1:07 PM
To: Don Schmitt <dschmitt@toxstrategies.com>

Cc: Kolberg, Lore <lore.kolberg@tateandlyle.com>

Subject: RE: [EXTERNAL] Re: GRN 001057 - Questions for Notifier

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Mr. Schmitt,

Thank you for the update. Yes, an extension until September 15, 2023, is fine.

Sincerely,

Stiffy Hice

Stephanie (Stiffy) Hice, Ph.D. (they/them/their)

Regulatory Review Scientist & Microbiology Reviewer

**Division of Food Ingredients
Office of Food Additive Safety
Center for Food Safety and Applied Nutrition
U.S. Food and Drug Administration
stephanie.hice@fda.hhs.gov**

Pronouns: They-Them-Their ([what is this?](#))



From: Don Schmitt <dschmitt@toxstrategies.com>

Sent: Wednesday, August 23, 2023 12:59 PM

To: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>

Cc: Kolberg, Lore <lore.kolberg@tateandlyle.com>

Subject: [EXTERNAL] Re: GRN 001057 - Questions for Notifier

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Stephanie,

We are working on responses to the list of questions you provided on August 14. One of the questions requires that the intake assessment be revised and this will take Exponent a few weeks to complete, given their previous commitments. Therefore, Tate & Lyle is requesting a 3-week extension of the time to reply to all 12 questions. That would be Friday, September 15.

Thank you for considering this extension request.

Best regards,

Don

Donald F. Schmitt, M.P.H.
Senior Managing Scientist



ToxStrategies

739 Thornapple Drive
Naperville, IL 60540
phone: 630.352.0303
email: dschmitt@toxstrategies.com

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please immediately notify ToxStrategies, Inc. at (832) 868-7729 and permanently delete the original and any copy of any e-mail and any printout thereof.

From: Don Schmitt <dschmitt@toxstrategies.com>

Date: Monday, August 14, 2023 at 9:46 AM

To: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>

Subject: Re: GRN 001057 - Questions for Notifier

Hi Stephanie,

I will speak with Tate & Lyle and be back in touch shortly.

Don

Donald F. Schmitt, M.P.H.
Senior Managing Scientist



ToxStrategies

739 Thornapple Drive
Naperville, IL 60540
phone: 630.352.0303
email: dschmitt@toxstrategies.com

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please immediately notify ToxStrategies, Inc. at (832) 868-7729 and permanently delete the original and any copy of any e-mail and any printout thereof.

From: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>

Date: Monday, August 14, 2023 at 8:07 AM

To: Don Schmitt <dschmitt@toxstrategies.com>

Subject: GRN 001057 - Questions for Notifier

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Mr. Schmitt,

During our evaluation of GRAS Notice No. 001057, we noted questions that need to be addressed and are attached to this email.

We respectfully request a response within **10 business days**. If you are unable to complete the response within that time frame, please contact me to discuss further options. Please do not include any confidential information in your response.

If you have questions or need further clarification, please feel free to contact me. Thank you in advance for your attention to our comments.

Sincerely,

Stiffy Hice

Stephanie (Stiffy) Hice, Ph.D. (they/them/their)

Regulatory Review Scientist & Microbiology Reviewer

Division of Food Ingredients

Office of Food Additive Safety
Center for Food Safety and Applied Nutrition
U.S. Food and Drug Administration
stephanie.hice@fda.hhs.gov

Pronouns: They-Them-Their ([what is this?](#))



***** This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not the intended recipient or the person responsible for delivering the email to the intended recipient, be advised that you have received this email in error that any use, dissemination, forwarding, printing, or copying of this email is strictly prohibited. If you have received this email in error please notify the sender immediately. Please note that we reserve the right to monitor and read any emails sent and received by the Company in accordance with and to the extent permitted by applicable legal rules.

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not the intended recipient or the person responsible for delivering the email to the intended recipient, be advised that you have received this email in error that any use, dissemination, forwarding, printing, or copying of this email is strictly prohibited. If you have received this email in error please notify the sender immediately. Please note that we reserve the right to monitor and read any emails sent and received by the Company in accordance with and to the extent permitted by applicable legal rules.

Date: August 17, 2023



Where science
& creativity meet

GRAS STATEMENT

RE: **GENSWEET® IGI-VHF** (A10022)ⁱ

To Whom It May Concern,

GENSWEET® IGI-VHF consists of consists of glucose isomerase (also known as xylose isomerase) produced using a *Streptomyces rubiginosus* production strain that has been genetically engineered. The glucose isomerase protein is not protein engineered. The glucose isomerase enzyme is not a genetically modified organism (GMO).

GENSWEET® IGI-VHF is Generally Recognized as Safe (GRAS) for use as processing aid in High Fructose Corn Syrup (HFCS) manufacture when the enzyme product is used within the product dose guidelines described in IFF's product literature. The glucose isomerase enzyme produced with *Streptomyces rubiginosus* is affirmed to be Generally Recognized as Safe ('GRAS'), under 21 CFR 184.1372.

GENSWEET® IGI-VHF also meets or exceeds the Joint FAO/WHO Expert Committee on Food Additives (JECFA)/Food Chemical Codex (FCC) specifications for microbial and metal contaminants in food enzymes.

IFF is committed to help our customers maximize the benefits of our technology, and we want to ensure successful use and safety of our products. Please contact your account manager if you should have further questions.

IFF Health & Biosciences



Liane Grieco

Global Regulatory Affairs

Global Regulatory Strategy Leader, Grain Processing

liane.m.grieco@iff.com

Health & Biosciences

200 Powder Mill Road
Wilmington, DE 19803

T +1.302.332.8420

iff.com

This certificate is valid for one year from date of issue.



Where science
& creativity meet

ⁱ Copyright © 2023 International Flavors & Fragrances Inc. All rights reserved. IFF, the IFF logo and all products denoted with ® or ™ are trademarks of the affiliates of International Flavors & Fragrances Inc. The information contained herein is subject to change without further notice, is provided "as is" and without charge to our customers. This is business-to-business information and technical advice that is intended for use by persons having appropriate technical expertise and is based upon data and studies IFF believes to be reliable based upon IFF's present knowledge and experience. Conditions and methods of use of IFF's products are beyond our control, and nothing contained herein shall be construed as a representation or warranty on use or of non-infringement of intellectual property, regulatory or legal compliance. Use of the information and advice contained herein is at the recipient's sole discretion and risk and IFF assumes no liability for its use. Recipient should conduct their own tests to determine suitability of IFF products for their own specific purposes.

iff.com

From: [Kolberg, Lore](#)
To: [Hice, Stephanie](#)
Cc: [Santa Maria, Juan Cristian](#)
Subject: [EXTERNAL] GRN 001057 - Questions for Notifier
Date: Friday, October 13, 2023 1:53:52 PM
Attachments: [image007.png](#)
[image009.png](#)
[image010.png](#)
[image011.png](#)
[image012.png](#)
[image013.png](#)
[image014.png](#)
[image015.png](#)
[image016.png](#)
[image017.png](#)
[image018.png](#)
[image019.png](#)
[image002.png](#)
[GRN 001057 - questions for notifier and responses to FDA 101323.pdf](#)

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Stephanie,

Attached are Tate & Lyle's responses to FDA's additional questions regarding GRN 1057.

Sincerely,
Lore

Lore Kolberg
Director, Regulatory & Scientific Affairs
Innovation and Commercial Development
Tate & Lyle
Mob. +1 224 355 9013

TATE & LYLE
Science \ Solutions \ Society



Internal Use Only

From: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>
Sent: Wednesday, October 4, 2023 2:51 PM
To: Kolberg, Lore <lore.kolberg@tateandlyle.com>
Subject: [EXTERNAL] GRN 001057 - Questions for Notifier

Dear Lore,

During our evaluation of GRAS Notice No. 001057, we noted additional questions that need to be addressed and are below.

1. In the September 15, 2023, amendment (response to question 9), the notifier provides a revised copy of Table 6, with the specifications for mold listed as " ≤ 10 CFU/g" and states that the revised specifications align with the COAs presented in Appendix B of the notice. On pages 58-59, the units for mold for "Dolcia Prima DS" is listed as "CFU/10 g", while on page 60 it is listed as "CFU/g". For the administrative record, please confirm the units and specification for mold for crystalline allulose.
2. In the September 15, 2023, amendment (response to question 11), the notifier provides a revised cumulative eaters-only dietary exposure to D-psicose of 14.5 g/person (p)/d at the mean and 29 g/p/d at the pseudo 90th percentile (Table 3), based on the summation of the following:

The *per capita* mean estimate from background sources (reported as the cumulative *per capita* mean estimate in Table 1 of the January 19, 2023, amendment to GRN 001024), and the *per capita* mean estimate from the proposed uses in GRN 001057 (reported in Table 2 of the September 15, 2023, amendment).

The notifier further notes that the resulting cumulative *per capita* mean estimate is divided by the percent eaters (77%) to derive the revised cumulative eaters-only mean estimate of 14.5 g/p/d and that the revised cumulative eaters-only pseudo 90th percentile estimate of 29 g/p/d is derived by multiplying the eaters-only mean estimate by 2.

Please provide revised cumulative estimates derived using a fraction of eaters of any or all the foods in which D-psicose is used calculated based on the percent eaters reported in both GRN 001024 (77% eaters) and GRN 001057 (62.3% eaters). Information on how to calculate the fraction of eaters is available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-estimating-dietary-intake-substances-food>.

We respectfully request a response within **10 business days**. If you are unable to complete the response within that time frame, please contact me to discuss further options. Please do not include any confidential information in your response.

If you have questions or need further clarification, please feel free to contact me. Thank you in advance for your attention to our comments.

Sincerely,

Stiffy Hice

Stephanie (Stiffy) Hice, Ph.D. (they/them/their)

Regulatory Review Scientist & Microbiology Reviewer

Division of Food Ingredients
Office of Food Additive Safety
Center for Food Safety and Applied Nutrition
U.S. Food and Drug Administration
stephanie.hice@fda.hhs.gov

Pronouns: They-Them-Their ([what is this?](#))



***** This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not the intended recipient or the person responsible for delivering the email to the intended recipient, be advised that you have received this email in error that any use, dissemination, forwarding, printing, or copying of this email is strictly prohibited. If you have received this email in error please notify the sender immediately. Please note that we reserve the right to monitor and read any emails sent and received by the Company in accordance with and to the extent permitted by applicable legal rules.

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not the intended recipient or the person responsible for delivering the email to the intended recipient, be advised that you have received this email in error that any use, dissemination, forwarding, printing, or copying of this email is strictly prohibited. If you have received this email in error please notify the sender immediately. Please note that we reserve the right to monitor and read any emails sent and received by the Company in accordance with and to the extent permitted by applicable legal rules.

October 13, 2023

GRN 1057 Questions for Notifier and Notifier Responses

1. In the September 15, 2023, amendment (response to question 9), the notifier provides a revised copy of Table 6, with the specifications for mold listed as “≤10 CFU/g” and states that the revised specifications align with the COAs presented in Appendix B of the notice. On pages 58-59, the units for mold for “Dolcia Prima DS” is listed as “CFU/10 g”, while on page 60 it is listed as “CFU/g”. For the administrative record, please confirm the units and specification for mold for crystalline allulose.

Response:

The correct unit of measure in the specification and analyses for mold for DS (crystalline) allulose is CFU/g.

There was a typo in two of the original COAs that were submitted for crystalline allulose, for sample numbers LO19F90351 and LO18J90596, in which the unit of measure for mold was erroneously reported as CFU/10g. The results for mold in all three sample lots of crystalline allulose should have been reported as CFU/g, as shown in revised Table 6.

Revised Table 6 (below, which we submitted in our September 15 response to questions) contains the correct units of measure and specification for mold for crystalline allulose.

Table 6. Analytical results for three non-consecutive lots of crystalline allulose

Specification		Lot No. LO18J90596	Lot No. LO19F90351	Lot No. LO18J90294
Allulose (% dry basis)	>99.1	99.4	99.8	99.2
Total non-allulose saccharides (%)	<0.9	0.27	0.06	0.29
Moisture (%)	<0.5	0.14	0.12	0.10
Ash (%)	<0.5	<0.1	<0.1	<0.1
Sulfur dioxide (ppm)	<10	<10	<10	<10
Total plate count	≤200 cfu/g	<10	10	10
Yeast	≤10 cfu/g	<10	10	<10
Mold	≤10 cfu/g	<10	10	<10
Arsenic (ppm)	<0.1	<0.005	<0.005	<0.005
Cadmium (ppm)	<0.1	<0.005	<0.005	<0.005
Lead (ppm)	<0.1	<0.005	<0.005	<0.005
Mercury (ppm)	<0.01	<0.005	<0.005	<0.005

Likewise, in Table 4 of our original submission there was a typo in the unit of measure for mold in the specifications for crystalline allulose (Crystalline Granules). Table 4 should read as corrected below.

Table 4. Specifications for allulose

Parameter	Liquid Syrup	Crystalline Granules
Mold	≤ 10 CFU/10g	≤ 10 CFU/g

- In the September 15, 2023, amendment (response to question 11), the notifier provides a revised cumulative eaters-only dietary exposure to D-psicose of 14.5 g/person (p)/d at the mean and 29 g/p/d at the pseudo 90th percentile (Table 3), based on the summation of the following:

The *per capita* mean estimate from background sources (reported as the cumulative *per capita* mean estimate in Table 1 of the January 19, 2023, amendment to GRN 001024), and the *per capita* mean estimate from the proposed uses in GRN 001057 (reported in Table 2 of the September 15, 2023, amendment).

The notifier further notes that the resulting cumulative *per capita* mean estimate is divided by the percent eaters (77%) to derive the revised cumulative eaters-only mean estimate of 14.5 g/p/d and that the revised cumulative eaters-only pseudo 90th percentile estimate of 29 g/p/d is derived by multiplying the eaters-only mean estimate by 2.

Please provide revised cumulative estimates derived using a fraction of eaters of any or all the foods in which D-psicose is used calculated based on the percent eaters reported in both GRN 001024 (77% eaters) and GRN 001057 (62.3% eaters). Information on how to calculate the fraction of eaters is available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-estimating-dietary-intake-substances-food>.

Response:

Revised Table 3 is below.

Revised Table 3. CEDI of allulose from background uses and Tate and Lyle’s proposed uses by the U.S. 2+ y and subpopulations (g/day); NHANES 2017-2018

Sub-population	Background EDI (g/day) (GRN 001024)		EDI (g/day) from Proposed Uses GRN 001057		Cumulative Estimated Daily Intake (g/day)			
	% Users	Mean per capita	%Users	Mean per capita	% Users***	Mean per capita	Mean per user*	Pseudo 90 th ** Per user
US 2+ y	77.0	7.8	62.3	3.4	91.33	11.2	12.3	24.5
2-12 y	70.5	4.2	77.1	3.3	93.24	7.5	8.0	16.1
13-18 y	62.9	3.6	64.3	3.3	86.76	6.9	8.0	15.9
19+ y	81.2	8.9	59.4	3.4	92.37	12.3	13.3	26.6

* Mean per capita divided by % users to derive mean per user

** Pseudo 90th is derived based on 2 x mean (FDA 2006 guidance)¹

***calculated per FDA 2006 Guidance

From: [Santa Maria, Juan Cristian](#)
To: [Hice, Stephanie](#)
Subject: [EXTERNAL] RE: GRN 001057 - Questions for Notifier
Date: Thursday, December 7, 2023 2:15:21 PM
Attachments: [image007.png](#)
[image009.png](#)
[image010.png](#)
[image011.png](#)
[image012.png](#)
[image013.png](#)
[image014.png](#)
[image015.png](#)
[image016.png](#)
[image017.png](#)
[image018.png](#)
[image019.png](#)
[image001.png](#)

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Mrs. Hice,

I hope this message finds you well. Please be aware that Lore Kolberg retired on November 1st. I am therefore responding on behalf of Tate & Lyle to your message below. You can direct any subsequent communication related to GRN 1057 directly to me.

In response to your questions:

1. I hereby confirm the intended use of D-psicose does not include use in infant formula.
2. I hereby confirm Tate & Lyle concurs with FDA's approach to estimating the dietary exposure to allulose and the resulting estimate of 24.0 g/p/d.

Please do not hesitate to contact me should you need any additional information.

Kind regards,

Juan Cristián

Juan Cristián Santa María
Senior Director, Global Regulatory & Scientific Affairs
Innovation and Commercial Development
Tate & Lyle
Mob. +1 (470) 373-7122

TATE & LYLE

Science \ Solutions \ Society



External use permitted

From: Hice, Stephanie <Stephanie.Hice@fda.hhs.gov>
Sent: Thursday, December 7, 2023 9:59 AM
To: Kolberg, Lore <lore.kolberg@tateandlyle.com>
Cc: Santa Maria, Juan Cristian <JuanCristian.SantaMaria@tateandlyle.com>
Subject: [EXTERNAL] GRN 001057 - Questions for Notifier

Dear Lore,

During our evaluation of GRAS Notice No. 001057, we noted additional questions that need to be addressed and are below. For your awareness, I received an automated undeliverable message when transmitting question one on Tuesday, December 5, 2023, and Wednesday, December 6, 2023. As such, I've CC'd your colleague, who you included on your last correspondence to us, dated October 13, 2023.

1. For the administrative record, please state whether the intended use of D-psicose includes use in infant formula.
2. In the amendment dated October 13, 2023, we note that the notifier's cumulative mean "per capita" dietary exposure to allulose was obtained by summing the mean per capita dietary exposures from GRN 001024 (background) and GRN 001057 (intended uses). This exposure was then converted to an "eaters-only" mean dietary exposure by dividing the calculated percent (%) eaters of at least one food containing allulose. The cumulative eaters-only dietary exposure of 24.5 g/person (p)/d at the pseudo-90th percentile was obtained by multiplying the cumulative eaters-only mean dietary exposure to allulose by two.

We have independently confirmed the notifier's dietary exposure estimate using a method described in FDA's Guidance for Industry: Estimating Dietary Intake of Substances in Food (2006). Unlike in the notifier's approach, we estimated the cumulative total sample mean (cumulative mean per capita) dietary exposure to allulose by multiplying the eaters-only mean dietary exposures from GRN 001024 (background) and GRN 001057 (intended uses) by the corresponding percent (%) eaters and summing the resulting total sample mean dietary exposures. The cumulative eaters-only mean dietary exposure to allulose was obtained by dividing the cumulative total sample mean dietary exposure by the calculated percent (%) eaters of at least one food containing allulose. The cumulative eaters-only dietary exposure of 24.0 g/p/d at the pseudo-90th percentile was obtained by multiplying the cumulative eaters-only mean dietary exposure by two. We note that our estimate is slightly lower than your estimate of 24.5 g/p/d.

-

For the administrative record, we request that the notifier please confirm that they concur with our approach to estimating the dietary exposure to allulose and the resulting estimate of 24.0 g/p/d.

FDA's Guidance for Industry: Estimating Dietary Intake of Substances in Food, 2006.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-estimating-dietary-intake-substances-food>

We respectfully request a response within **10 business days**. If you are unable to complete the response within that time frame, please contact me to discuss further options. Please do not include any confidential information in your response.

If you have questions or need further clarification, please feel free to contact me. Thank you in advance for your attention to our comments.

Sincerely,

Stiffy Hice

Stephanie (Stiffy) Hice, Ph.D. (they/them/their)

Regulatory Review Scientist & Microbiology Reviewer

Division of Food Ingredients
Office of Food Additive Safety
Center for Food Safety and Applied Nutrition
U.S. Food and Drug Administration
stephanie.hice@fda.hhs.gov

Pronouns: They-Them-Their ([what is this?](#))



***** This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not the intended recipient or the person responsible for delivering the email to the intended recipient, be advised that you have received this email in error that any use, dissemination, forwarding, printing, or copying of this email is strictly prohibited. If you have received this email in error please notify the sender immediately. Please note that we reserve the right to monitor and read any emails sent and received by the Company in accordance with and to the extent permitted by applicable legal rules.

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not the intended recipient or the person responsible for delivering the email to the intended recipient, be

advised that you have received this email in error that any use, dissemination, forwarding, printing, or copying of this email is strictly prohibited. If you have received this email in error please notify the sender immediately. Please note that we reserve the right to monitor and read any emails sent and received by the Company in accordance with and to the extent permitted by applicable legal rules.

